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Resumen Tesis  
 
Los carbohidratos junto a los ácidos nucleícos, las proteínas y los lípidos, son las 
macromoléculas fundamentales que constituyen todas las células. Antiguamente los 
carbohidratos eran considerados únicamente como moléculas proveedoras de energía 
(glucosa y glicógeno) o como elementos estructurales (celulosa, quitina). Hoy en día, se 
conoce que participan en numerosos procesos celulares y que codifican una gran cantidad 
de información, debido a su gran diversidad estructural. La superficie de las células está 
cubierta de una densa capa de carbohidratos que se denomina glicocálix. En esta capa los 
carbohidratos se encuentran formando glicoconjugados, como glicoproteínas, glicolípidos o 
proteoglicanos.  
 
La expresión de macromoléculas glicosiladas es específica de cada tipo de célula o tejido y 
puede verse alterada por su estado de desarrollo o diferenciación. Los perfiles de 
glicosilación de las células también varían en diversas patologías. Por ello, patrones 
anormales de glicosilación pueden ser empleados como biomarcadores de enfermedades 
tan importantes como el cáncer o enfermedades autoinmunes. Adicionalmente, los 
carbohidratos juegan un papel muy importante en la activación de la respuesta inmune ya 
que los receptores de sistema inmunitario pueden ser activados por la presencia de 
carbohidratos exógenos en la superficie de patógenos. Por otro lado, muchos patógenos 
emplean la adhesión a los carbohidratos del huésped como el primer paso hacia la infección 
o incluso, expresan carbohidratos que mimetizan a los del huésped como estrategia para 
evadir al sistema inmunitario.  
 
La glicosilación es una de las modificaciones postraduccionales más abundantes en las células 
eucariotas, se estima que alrededor del cincuenta por ciento de las proteínas se encuentran 
modificadas por carbohidratos en su superficie, cuya presencia modula de manera 
importante las propiedades como la solubilidad y la vida media. Los carbohidratos se unen a 
distintos aminoácidos mediante enlaces N- y O-glicosídicos. En concreto, las estructuras de 
 
 
tipo N-glicano objeto de estudio de la presente Tesis doctoral se unen de manera covalente 
al nitrógeno de la amida de ciertos residuos de asparagina (Asn).  
La composición del glicoma, repertorio de carbohidratos presentes en cada organismo, varía 
de manera muy significativa entre las diferentes especies. En el caso de los N-glicanos, a pesar 
de compartir una estructura de pentasacárido central, el número y la composición de las 
antenas así como la sustitución en la quitobiosa central varía de manera importante entre 
los distintos organismos. Algunas de estas estructuras han sido identificadas como 
inmunogénicas y se encuentran en plantas, invertebrados y en parásitos helmintos como 
Schistosoma mansoni. En la presente Tesis doctoral se pretende abordar la síntesis de N-
glicanos que presentan epítopos supuestamente inmunogénicos y evaluar su posible función 
biológica, mediante el empleo de microarrays de carbohidratos y ensayos in vitro con células 
dendríticas. 
 
En el primer capítulo de la Tesis se recoge la preparación de manera quimio-enzimática de 
39 estructuras de tipo N-glicano que presentan todas ellas el epítopo β-1,2-xilosa. Para ello 
se aborda la síntesis orgánica de seis estructuras que posteriormente se modificarán 
empleando glicosiltransferasas recombinantes para instalar diferentes sustituyentes como 
pueden ser fucosas en la quitobiosa central (core α-1,6/core α-1,3) y diferentes elementos 
en las antenas como LDN (GalNAcβ-1,4-GlcNAc), Lewis X (Galβ-1,4(Fucα-1,3)GlcNAc)o LDNF 
(GalNAcβ-1,4(Fucα-1,3)GlcNAc).  
 
El segundo capítulo de la Tesis se centra en la preparación de microarrays de carbohidratos 
para el estudio de interacciones carbohidrato-proteína. En las últimas décadas, los 
microarrays de carbohidratos han surgido como una herramienta altamente eficaz para el 
estudio de interacciones carbohidrato-proteína, así como para el estudio de enzimas que 
modifican carbohidratos. Las ventajas de esta metodología se centran en la evaluación 
simultánea de múltiples posibles interacciones (High-Throughput Screening) empleando 
cantidades mínimas de analitos. Las estructuras de tipo N-glicano previamente sintetizadas 
se inmovilizan de manera covalente sobre portas de vidrio y se incuban con disoluciones de 
las proteínas o anticuerpos a estudiar. La presencia de interacciones positivas se estudiará 
 
 
empleando fluorescencia bien mediante el marcaje directo de la proteína o mediante la 
detección con un anticuerpo secundario marcado fluorescentemente.   
El conjunto de proteínas que reconocen de manera específica a los carbohidratos sin 
modificarlos se denominan lectinas. Muchas de estas proteínas se aíslan de diferentes 
plantas y hongos, donde juegan un papel en la defensa frente a insectos y herbívoros, a través 
del reconocimiento de estructuras no presentes en los organismos que las producen. La 
especificidad hacia los carbohidratos de muchas de estas lectinas es conocida y hoy en día se 
han convertido en herramientas muy útiles en glicobiología. En la presente Tesis doctoral, se 
ha empleado un pequeño panel de lectinas para demostrar la funcionalidad de los 
microarrays de N-glicanos preparados. A pesar de que su especificidad se encuentra 
ampliamente documentada, se observó una importante influencia por la presencia de β-1,2-
xilosa en los N-glicanos, que reduce el reconocimiento de Concanavalina A y completamente 
impide el reconocimiento de la aglutinina de Galanthus nivalis. Estos resultados demuestran 
el gran potencial de los microarrays de carbohidratos en el estudio y caracterización de 
interacciones carbohidrato-proteína.  
Las lectinas de tipo C (C-type lectins) son una importante familia de receptores que se 
expresan en la superficie de las células dendríticas (CD) capaces de reconocer de manera 
específica a los carbohidratos que expresan diferentes patógenos en su superficie. Estas 
proteínas colaboran en la internalización de los antígenos por parte de las células dendríticas, 
que posteriormente los procesan y presentan los fragmentos como péptidos antigénicos a 
los linfocitos T. Una selección de lectinas de tipo C recombinantes de origen murino y 
humano se incubaron en el microarray de N-glicanos pudiendo observar el patrón de 
reconocimento de tres de ellas. En el caso particular de DC-SIGN, la presencia de la β-1,2-
xilosa en los N-glicanos impide por completo el reconocimiento. 
 
La esquistosomiasis es una enfermedad aguda y crónica causada por gusanos parásitos del 
género Schistosoma que según la Organización Mundial de la Salud, afecta a más de 
doscientos millones de personas. La principal fuente de contagio es el contacto con aguas 
 
 
contaminadas, donde las personas se infectan cuando las larvas del parásito, liberadas por 
caracoles de agua dulce, penetran en la piel intacta. En el interior del organismo, las larvas 
se convierten en gusanos adultos, que viven en los vasos sanguíneos, donde las hembras 
depositan sus huevos. Algunos de esos huevos salen del organismo con las heces o la orina y 
continúan el ciclo vital del parásito infectado a caracoles de agua dulce. Otros quedan 
atrapados en los tejidos corporales, donde activan la respuesta inmune del huésped y 
producen un daño progresivo de los órganos. Durante su ciclo de vida, el parásito expresa un 
gran número de carbohidratos específicos en las distintas fases de su desarrollo y la 
estructura de muchos de ellos difiere marcadamente de los humanos. Está descrito que 
durante la infección se generan un gran número de anticuerpos anti-carbohidratos pero su 
papel en la protección del huésped o en el escape del parásito del sistema inmune no se 
conoce en detalle. En el tercer capítulo de la presente Tesis doctoral se emplearon 
microarrays de N-glicanos para caracterizar la especificidad de anticuerpos monoclonales 
generados a partir del suero de ratones infectados con S. mansoni. Posteriormente, se 
estudió la presencia de inmunoglobulinas G (IgG) y M (IgM) en el suero de pacientes 
infectados por S. mansoni que viven en una comunidad endémica en Butiaba, Uganda. Se 
observan marcadas diferencias en la respuesta de IgGs en el suero de pacientes de dos 
grupos de edad diferentes. La mayor respuesta en el suero de niños infectados, se observa 
hacia estructuras que contienen tanto β-1,2-xilosa como α-1,3-fucosa en las estructuras de 
N-glicano. Sin embargo, la respuesta de los adultos se centra sólo frente a N-glicanos 
sustituidos con β-1,2-xilosa, no reconociendo las estructuras que contienen α-1,3-fucosa. 
Parece indicar que el sistema inmune de los niños es capaz de reaccionar frente a un número 
mayor de epítopos inmunogénicos mientras que los adultos no muestran tal reacción 
probablemente por la exposición previa a dichos epítopos en infecciones pasadas.  
 
El capítulo 4 de la Tesis Doctoral, se estudió la dirección de antígenos a células dendríticas 
murinas mediada por carbohidratos empleando glicoconjugados sintéticos. Basados en los 
resultados de unión del receptor DC-SIGN en el microarray de N-glicanos, donde se 
observaba que una pequeña modificación estructural como la presencia de β-1,2-xilosa en 
 
 
los N-glicanos impedía la interacción con el receptor, se pretende estudiar la influencia de 
esta modificación en ensayos in vitro. Para ello se han sintetizado glicoconjugados de N-
glicanos con la proteína antigénica modelo ovoalbúmina (OVA). El estudio de la diferente 
interacción de estos glicoconjugados con lectinas de tipo C se llevó a cabo mediante 
microarrays de proteínas, observándose una importante diferencia en el reconocimiento de 
dichos glicoconjugados por parte de la lectina de origen murino SignR3, proteína homologa 
al DC-SIGN humano. Adicionalmente, se han llevado a cabo ensayos de captación directa de 
los glicoconjugados en células dendríticas de origen murino, observándose una 
internalización más efectiva cuando el N-glicano no contiene el epítopo β-1,2-xilosa. Tras la 
internalización en las CDs, los antígenos son procesados y los distintos fragmentos peptídicos 
se presentan en el complejo principal de histocompatibilidad (MHC-II) a las células T, 
causando su activación y posterior diferenciación en células efectoras. Para cuantificar la 
distinta activación de las células T por parte de los glicoconjugados, se llevó a cabo un ensayo 
de co-cultivo de CDs y células T. Se cuantificó la expresión del marcador CD69 por citometría 
de flujo y la expresión de interleuquina 2 (IL-2) e interferon gamma (IFNγ) mediante ELISA 
(Enzyme-Linked ImmunoSorbent Assay), mostrando una mayor activación de las células T 
debido a la presencia del N-glicano que no contiene el epítopo β-1,2-xilosa, promoviendo la 
diferenciación hacia un fenotipo Th1. 
 
Finalmente, se ha explorado la preparación de glicoconjugados de ovoalbúmina 
funcionalizados con nanoclusters de oro fluorescentes. Hoy en día los nanomateriales 
encuentran numerosas aplicaciones en campos como la biología y la medicina. Los 
nanoclusters de oro están formados por un número limitado de átomos de oro y poseen 
propiedades como alta solubilidad en agua, baja toxicidad y emisión de fluorescencia en el 
espectro del infrarrojo cercano, lo que posibilita su empleo en bioimagen tanto in vitro como 
in vivo. La preparación de nanoclusters de oro fluorescentes se ha llevado a cabo empleando 
los glicoconjugados previamente sintetizados como estabilizantes del núcleo de oro. La 
preparación de estos derivados se basa en la idea de combinar las propiedades antigénicas 
de la ovoalbúmina, la capacidad de dirección de antígenos del carbohidrato junto con las 
 
 
propiedades de bioimagen del cluster de oro. Se ha llevado a cabo la completa 
caracterización de los nanoclusters de oro por diferentes técnicas físico/químicas y un ensayo 
inicial de captación directa de los nanoclusters en células dendríticas murinas. 
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GENERAL INTRODUCTION  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Introduction and Objectives  
 
 
1 
General Introduction 
 
Glycosylation is one of the most common post-translational modifications in eukaryotic cells. 
Glycoproteins together with other glycoconjugates decorate cell surface and form the so-
called glycocalyx1 (Figure 1, A-B). Glycosylation is species and tissue specific and changes 
during cell development and differentiation. Aberrant glycosylation profiles can also be 
found in many pathologies highlighting the potential of glycans as disease markers for 
example in cancer or autoimmune diseases.2 Additionally, glycosylation can have an 
important role in cell-cell interactions, immune response and in pathogen recognition.3,4 
 
 
 
Figure 1. A. The erythrocyte glycocalyx visualized by electron microscopy (Taken from Voet and Voet, 
Biochemistry5); B. Glycans attached to the cell surface and inside the cell; C. Classification of N-glycans 
found in mammalian cells (B and C taken from Essentials of Glycobiology, Second Edition 20096). 
 
Around 50 % of mammalian proteins are glycosylated.7 Carbohydrates can be attached to 
protein backbone either by N- or O-glycosidic bonds. N-glycans are covalently linked to the 
amide nitrogen of asparagine (Asn) residues present as part of the protein Asn-X-Ser/Thr 
  
  
 
2 
consensus sequence (where X is every amino acid except proline). O-glycans are attached to 
side chains of serine or threonine.8 The presence of glycans in glycoproteins modulates their 
properties such as solubility and circulatory half-life and facilitates protein folding and 
trafficking. Mammalian N-glycans are generally composed of N-Acetyl-D-glucosamine 
(GlcNAc), D-mannose (Man), D-galactose (Gal), sialic acid (Neu5Ac), D-glucose (Glc) and L-
fucose (Fuc). They share a common pentasaccharide core, Manα-1,6(Manα-1,3)Manβ-
1,4GlcNAcβ-1,4GlcNAcβ-1,Asn- and can be classified into three types depending on the 
different substitution of pentasaccharide core: high mannose N-glycans in which only Man 
residues are attached to the core, complex N-glycans with GlcNAc substituted antennaes and 
hybrid N-glycans, a mixture of high-mannose and complex type N-glycans (Figure 1, C).  
The biosynthetic pathway of N-glycans in eukaryotes is highly conserved and begins at the 
cytosolic part of the endoplasmic reticulum (ER) with the common precursor Man5GlcNAc2 
transferred to a lipid dolichol phosphate (P-P-Dol).8,9 Man5GlcNAc2-P-P-Dol is translocated 
across the ER membrane bilayer and is further extended in the ER lumen by 
glycosyltransferases (GTs). The intermediate Gluc3Man9GlcNAc2-P-P-Dol is transferred onto 
Asn residues of the protein by the action of oligosaccharyltransferase (OST) (Figure 2). Before 
transport of a glycoprotein to the Golgi apparatus (GA) Gluc3Man9GlcNAc2 is trimmed and N-
glycans with eight or nine mannose residues are generated. At this point, quality control of 
misfolded protein takes place, once it is identified it is marked for further ER degradation. In 
the GA further glycan processing take place, glycan chains are differentiated with 
glycosyltransferases and glycosidases. Usually, in the early GA (Cis-Golgi) mannose moieties 
are trimmed while in the late GA (Medial-Golgi) the biosynthesis of complex and hybrid N-
glycans is initiated. Addition of terminal GlcNAc moieties occurs which may result in 
branching of complex N-glycans. The final maturation of N-glycans take place in trans-Golgi 
where oligosaccharides can be further decorated with terminal galactose, N-acetyl 
galactosamine, sialic acid and core fucose moieties. In fact, there are over 250 
glycosyltransferases present in the mammalian GA which catalyze transfer of activated 
sugars (glycan donor) to a glycan acceptor.10 The high energy nucleotide glycan donors are 
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synthesized in the cytoplasm by nucleotide synthases and are imported to the Golgi lumen 
by nucleotide sugars transporters. Depending on the cell type or development stage, 
glycosylation is controlled by the transcription factors which regulate expression levels of 
glycosyltransferases, nucleotide sugars transporters and synthases creating overall huge 
heterogeneity of glycosylation.9,10 
 
Figure 2. Processing and maturation of N-glycans (taken from Essentials of Glycobiology, Second 
Edition, 20098) 
 
N-glycosylation differs largely between species (Figure 3). In yeast only high oligomannose 
N-glycans structures are formed. The N-glycan precursor which enters the cis-Golgi is not 
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trimmed but instead, additional mannose residues are added. Another feature that often 
distinguishes N-glycans of different organisms is the degree of fucosylation.11 In mammals 
fucose can be linked α-1,2 to terminal Gal, α-1,3 or α-1,4 to GlcNAc of the antennae and core 
α-1,6 to the inner GlcNAc of the chitobiose core. The α-1,2-fucosyltransferase (FucT) activity 
is necessary for the biosynthesis of AB0 blood group antigens, while α-1,3 and α-1,4 FucT 
produce Lewis X (Galβ-1,4(Fucα-1,3)GlcNAc) related compounds. Core α-1,6-linked fucose of 
the inner GlcNAc on the other hand, is a typical mammalian feature, which is required for 
polysialylation of N-glycans12 and which effects the properties of protein to which is linked, 
for example by blocking the hydrolytic activity of human asparaginase which cleaves the N-
glycosidic linkage between protein and the N-glycan13 or influencing the effector function of 
the IgG antibody.14,15 The presence of core α-1,6-fucose substitution in the inner GlcNAc can 
be also found in the glycome of insects or invertebrates, but never in plants.12  
 
Figure 3. N-glycans commonly found in glycoproteins of different organisms (taken from New England 
BioLabs, https://www.neb.com) 
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Most of the plant-derived N-glycans are decorated with core α-1,3-fucose and/or core β-1,2- 
xylose. In mammals, both modifications are believed to be at least partially responsible for 
immunogenicity of plant-glycoproteins16 and to be involved in the pathophysiology of several 
food allergens.17 Core α-1,3-fucose and core β-1,2-xylose can be also found in the glycome 
of some invertebrates, such as insects and parasites and may have an important role in the 
induction of immune responses in parasites infected hosts.17 These organisms express also 
smaller high mannose (paucimanosidic) N-glycans and bis-fucosylated structures presenting 
both core α-1,6-Fuc/α-1,3-Fuc modifications. 
The complexity of glycans is tremendous. Nowadays it is understood that unlike RNA, DNA 
or proteins, glycosylation does not operate with templates as information about glycan 
structures is not genetically encoded. This is essential from the evolutionary point of view. In 
order to survive fast mutating pathogens, long-live hosts have to develop defense strategies, 
a feature known as Red Queen Effect- it takes all the running you can to keep in the same 
place.1,18 It is well known that pathogens can attach to the host cells through certain glycans 
of the glycocalyx coating cell surface. Hence hosts may evade the pathogens invasion by 
changing of glycosylation patterns on their cell surface. This process can be achieved rapidly 
by the biosynthesis of various heterogenic glycostructures without DNA mutation. At the end 
this process results in huge diversity of glycans, what might be essential for the survival but 
this makes Glycobiology a challenging field of research. 
In order to decode the information carried by a glycan structure, it is necessary to analyze 
and characterize the interactions with carbohydrate recognizing macromolecules. Glycan 
binding proteins (GBPs) and carbohydrate-binding antibodies play crucial roles in essential 
biological processes. Pathogens attach to host cells via GBPs which facilitate their further 
invasion.19,20 On the other hand, GBPs expressed on host cells bind to non-self glycans, 
promote pathogen recognition and initiate activation of immune responses. The generation 
of anti-carbohydrate antibodies can be induced as a response to the glycan antigens 
presented on the pathogen, and can lead to their neutralization. The first HIV broadly 
neutralizing antibody (bnAbs) isolated from an asymptomatic HIV-positive patient is directed 
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towards high mannose type N-glycans presented with a high density on its viral 
envelope.21,22,23 Interestingly, anti-carbohydrate antibodies are also found in the sera of all 
healthy individuals in the absence of the pathogens or immunization factors. So called natural 
antibodies (nAbs) are directed against structures found in normal human tissues and many 
of them are directed towards carbohydrate motifs. One of the first identified and well-known 
nAbs are directed against blood group antigens A and B.24,25 Evaluation of glycan specificity 
of antibodies induced in bacterial, viral or parasitic infections became a crucial step towards 
development of carbohydrate-based vaccines.  
The biggest challenge in the study of carbohydrate-protein interactions is the limited 
availability of glycan structures and their enormous complexity. Unlike proteins, 
carbohydrates cannot be cloned and their isolation from natural sources is very often 
laborious and time consuming, providing only low quantities of sugars and heterogeneous 
mixtures. Furthermore, the monovalent interaction between a carbohydrate moiety and a 
carbohydrate recognition domain (CRD) of GBPs is typically very weak. In nature to increase 
the binding affinity, proteins possess multiple CRDs or create assembles which results in 
multivalent complexes26 whereas sugars are presented in multiple copies at the cell surface. 
To overcome these issues, new efficient and fast carbohydrate synthetic strategies have to 
be developed together with high throughput screening methods allowing for a simultaneous 
analysis of numerous carbohydrate-sugar interactions with minimization of the required 
amount of both carbohydrate and GBPs and the multivalent presentation of the former.  
The development of chemoenzymatic synthesis towards complex carbohydrates has 
become the most promising method towards well defined and highly pure 
compounds.27,28,29,30 In this strategy, conserved N-glycan structures are chemically 
synthesized and further diversify with recombinant glycosyltransferases (Figure 4, A). Use of 
glycan processing enzymes reduces amount of synthetic steps to minimum and allows for 
generation of glycan libraries containing highly defined glycans in relatively short times.  
Together with the development of chemoenzymatic strategies, glycan microarrays have 
emerged as a high throughput screening method for carbohydrate-protein interactions 
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(Figure 4, B).31,32,33,34 Based on the DNA microchips and subsequently protein array 
technology,35 in 2002, the first glycan microarray was developed.33 Typically, the sugar 
ligands are immobilized on the activated surface of glass slides and screened with solutions 
of GBPs. After incubation, the array is washed to remove any unbound material and binding 
events are measured and analyzed. 
 
 
Figure 4. A. Chemoenzymatic synthesis of N-glycans, beginning with conserved, synthetic structure for 
its further differentiation with GTs; B. Schematic representation of glycan microarray.  
 
The most common detection method used for the microarray screening is fluorescence read-
out which involves the use of fluorescently labeled proteins or antibody directed against the 
analyte. The biggest advantage of the glycan microarray as a screening tool is the reduction 
of valuable material necessary to study carbohydrate-protein interactions and the capacity 
of simultaneous screening of hundreds glycans and multiple proteins.  
Glycan microarrays have been successfully applied for the characterization of the sugar 
binding specificities of various GBPs, like plant lectins and C-type lectins receptors (CLR) and 
have provided important information about the role of glycans in different biological 
processes.  
Plant lectins, are believed to play an important role in plant defense and act as storage 
proteins.36,37 By the recognition of specific carbohydrates of predators, including plant eating 
insects or herbivores, plants lectins may assure the survival of tissues in which they are 
located. Today, many plant lectins are commercially available and they have become 
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important tools in glycobiology research.38 Lectin affinity chromatography (Figure 5, A) is 
widely used for purifying glycoproteins while screening of glycan arrays with plant lectins is 
used as a functionality test to evaluate the correct immobilization of ligands on the array 
surface (Figure 5, B).  
 
Figure 5. A. Schematic representation of lectin affinity chromatography; B. Schematic representation 
of glycan microarray functionality test applying fluorescently labeled plant lectin specific for terminal 
GlcNAc residues. Non-bound ligand shows complete lack of fluorescent.  
 
C-type lectin receptors belong to the largest superfamily of animal lectins (over 1000 
proteins).39,40,41 CLRs contain one or more carbohydrate recognizing domain (CRDs) which 
mediates sugar binding, in most cases, in coordination with Ca2+. CLRs can be found in either 
soluble or in transmembrane form and can be further classified depending on their 
carbohydrate specificity determined by certain amino acids present in the CRD. It has been 
reported that CLRs expressing EPN amino acid motif are specific to mannose-derived ligands 
while CLRs expressing QPD sequence are specific for galactose. Some of the transmembrane 
CLRs expressed on the cells of immune system play an important role, acting as pattern 
recognizing receptors (PRR). PRR on the antigen presenting cells (APC) can recognize self- 
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and non-self-carbohydrates of pathogens42, capture and present them to lymphocytes. The 
most well-known and described APCs are dendritic cells (DCs) which express on their surface 
various C-type lectin receptors or even more extensively studied Toll like receptors (TLRs).43  
APCs act as a link between innate and adaptive immune system when the innate immune 
system alone cannot prevent from further pathogen invasion. Innate immune system is a 
first line of defense, which acts immediately in response to infection. Phagocytic cells of the 
innate immune system, like macrophages and neutrophils are constantly circulating in the 
organism ready to fight pathogens.44 Adaptive immunity is normally silent and in order to be 
activated, foreign, antigenic substance has to be recognized and captured by APCs. The main 
family of adaptive immune cells are lymphocytes. B lymphocytes (which are also APC) 
produce antibodies and as a part of so called humoral immunity, defending against 
extracellular microbes. The whole microbes can be recognized by the B cells through their 
antigen receptors which are membrane-bound antibodies. Upon antigen recognition B 
lymphocytes are activated and differentiated into plasma cells producing and secreting 
antibodies directed against encountered pathogen. However, if the pathogen antigen is a 
protein, the effective antibody responses required second type of lymphocytes, called T cells. 
T cells are part of the cellular immunity and are mostly specialized to combat intracellular 
pathogens. T lymphocytes can be divided into helper T cells, (TH, expressing CD4+ surface 
protein), cytotoxic T lymphocytes (CTLs, CD8+) and regulatory T calls (Treg). CD4+ Th cells help 
B cells to produce antibodies45 and macrophages to kill ingested microbes, CTLs eliminate 
infected and tumor host cells whereas Treg control immune responses. 
Once DCs recognize the pathogen through C-type lectin receptors, the antigen is internalized 
and processed into smaller peptide fragments. Depending on the origin of the antigen, they 
are further presented on either major histocompatibility complex (MHC) molecule class-I or 
MHC-II which are recognized by CD8+ T or CD4+ T cells respectively. The processed peptide 
antigens (as well as glycopeptides) are presented by MHC-II and MHC-II/peptide complex are 
recognized by T cell receptors (TCRs) expressed by CD4+ T cells. The activation of T cells 
requires not only recognition of MHC-II/peptide complex but also binding of co-stimulatory 
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molecules CD80 or CD86 of DCs by CD28 of T cells. Upon stimulation, CD4+ T cells expand in 
number and begin to differentiate into effector T cells which secret soluble proteins called 
cytokines (Figure 6).  
 
Figure 6. Schematic representation of DCs T cells interactions. Uptake, processing and presentation of 
antigen by DCs to CD4+ T cells leads to it activation and differentiation into effector T cells. 
 
Cytokines which mediate communication between leukocytes are called interleukins (IL). 
Depending on cytokines which are produced by CD4+ T cells and activated DCs, T cells can 
further differentiate into Th1, Th2, Th17 cells or induced regulatory T cells (Treg)46(Figure 6). 
Th1 cells are involved mostly in the cell-mediated immunity against viruses and intracellular 
bacteria and produce predominantly inflammatory cytokines, such as IL-2, interferon- γ (IFN-
γ) and tumor necrosis factor-α (TNF-α). Unlike Th1, Th2 cells promote humoral immunity and 
are important for the defense against parasite infections but also play a role in allergic 
responses. Th2 cells secrete IL-4, IL-5 and IL-13. More recently, a third type of effector T 
helper cells was identified and named Th17. CD4+ T cells differentiate into Th17 cells and 
further produce cytokine IL-17. Th17 elicit strong inflammatory response, play a role in the 
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host defense against extracellular bacteria and fungi but also can stimulate autoimmunity. 
Finally, Treg regulate Th1 and Th2 responses. 
Finally, upon exposure to antigen the effector T cells proliferate and increase in number. Part 
of them are employed to clear the infection, however, the majority of these cells die. The 
remaining effector T cells become the memory cells and provide quick protection upon re- 
exposure to the same pathogen. Similarly, certain amount of antibody producing plasma cells 
migrate to the bone marrow where they can live for many years as memory cells. Half of our 
circulating IgGs are produced from these cells and reflect history of antigen exposure. The 
production of long live memory cells against pathogens is the main goal of effective 
vaccination. 
In the last decades, the development of new vaccines preventing from bacterial infections 
emerged together with appearance antibiotic resistance. Carbohydrate based vaccines have 
a long history, already in 1923 Heidelberg and Avery identified a soluble polysaccharide from 
Streptococcus pneumoniae47, which few years later after intradermal injection induced the 
development of anti-carbohydrate specific antibodies.48 
Nowadays, the most successful carbohydrate-based vaccines are produced against bacterial 
infections and they are composed of the pathogen lipopolysaccharide or capsular 
polysaccharides coupled to protein carrier, which can elicit antibody responses in their host. 
Nowadays, the Food and Drug Administration of the United States (USFDA) has approved 
several polysaccharide-based vaccines preventing of infections caused by Streptococcus 
pneumoniae, Haemophilus influenza type b (Hib) and Salmonella typhi.49  
The identification of the minimal bacterial carbohydrate antigen and their further 
conjugation to protein carriers is a crucial step in the design and construction of valuable 
synthetic carbohydrate based vaccines.50 Carbohydrates alone are considered to activate B 
cells without involvement of T cells and thus do not stimulate effective immune protection. 
In conjugation with antigenic proteins, glycoproteins induce T-cell dependent immune 
responses which may provide long lasting protection and antibodies class switching.51 The 
immunogenicity of glycoproteins is enhanced compared to polysaccharide as such. The first 
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large scale synthesis of conjugate vaccines composed of a fully synthetic capsular 
polysaccharide antigen coupled to tetanus toxoid (TT) was described and evaluated by Verez-
Bencomo and colleagues and it was directed against Haemophilus influenza.52  
The development of anti-parasitic vaccines is far more complicated than anti-bacterial 
vaccines. Parasites are biologically and genetically complex organisms, expressing thousands 
of different sugar structures, which change with the development stage of the parasite.53  
The identification of glycan antigens for us in conjugate vaccine development is extremely 
challenging. Thus fundamental studies regarding the parasite glycome, identification of 
antigenic structures or the analysis of possible mechanisms of evading the host of immune 
system are needed.  
In recent years, shotgun glycan microarrays composed of the whole glycome of parasites 
have become an attractive tool for the evaluation of possible roles of glycans during parasitic 
infection and identification of antigenic structures. Hokke and colleagues constructed natural 
shotgun microarrays which comprise N-glycans and lipid-glycans directly isolated from 
various life stages of Schistosoma mansoni parasites.54,55 Extracts containing very complex 
sugars were isolated, subjected to detailed glycomic mass spectrometric analysis, purified 
and printed on the array. This natural microarray was further used for profiling anti-
carbohydrate polyclonal antibodies from sera of S. mansoni infected patients. Natural glycan 
arrays are an excellent way to gain structural information about the specificity of glycan 
binding antibodies and GBP, especially when no prior knowledge about the potential ligands 
is available. One of the greatest benefit of the shotgun glycan microarrays is the presence of 
very complex structures which synthesis could be difficult and time consuming. However, 
because of difficult isolation, some of the fractions printed on the shotgun arrays are rather 
a mixture of different glycan structures than a single ligand. In this context, glycan arrays 
containing well defined and characterized glycans synthesized chemoenzymatically, could be 
an excellent complementary tool towards evaluation of the biological role of glycan 
structures in S. mansoni infections and to determine lead antigenic structures for the 
development of vaccines against S. mansoni (Figure 7).   
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Figure 7. Use of synthetic glycan microarrays towards identification of antigenic glycans of S. mansoni; 
A. S. mansoni eggs and adult worms; B. Spectrometry analysis of parasite glycome; C. Chemoenzymatic 
synthesis of parasitic glycan structures; D. Design and preparation of glycan array containing 
previously synthesized compounds; E. Sera obtained from S. mansoni infected patients; F. Profiling of 
anti-carbohydrate polyclonal antibodies from sera of S. mansoni infected patients.  
 
In recent years, beside the tremendous effort in the identification and synthesis of antigenic 
glycans towards design of carbohydrate-based vaccines, sugars have also received attention 
as molecules for DC targeting.56 Targeting antigens to dendritic cells (DC) through CLRs is a 
promising strategy to enhance the efficacy of vaccines.56 CLR targeting offers some 
advantages compared to antibody-mediated targeting57, the most commonly employed 
strategy, such as, low immunogenicity, possibility to target several CLRs simultaneously and 
potentially a more favorable pharmacokinetic profile when compared to large protein drugs.  
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Objectives 
 
The glycome differs largely between species. In particular, N-glycosylation in plants and 
invertebrates vary from the mammalian structures in terms of fucosylation degree and type, 
2-O-xylosylation or the complete lack of sialylated structures which can be replaced by other 
terminal motifs. These differences have been found to have profound impact on the immune 
responses in mammals infected with parasites or being allergic to certain plants or insects. 
S. mansoni is a parasitic worm which infects significant number of people in developing 
countries. S. mansoni expresses thousands of different sugar structures, which change with 
the developmental stage of the parasite. Some of these structures share common glycan 
elements with major plant allergens. The fundamental studies regarding the parasite 
glycome, the identification of antigenic structures or the analysis of host immune system 
evasion is a work in progress, which gather together parasitologists, chemists and 
immunologists to better understand S. mansoni infection, with the final goal of improved 
treatments or vaccines. 
 
Drawing upon published antigenic carbohydrate structures identified by spectrometric 
analysis of the most infective stages of the parasite (cercariae and eggs), we will prepare 
chemoenzymatically library of non-mammalian, 2-O-xylosylated N-glycans. We aim to create 
a large set of defined N-glycans, with α-1,3 and α-1,6 core fucosylation and diverse terminal 
structural elements, including LN (Galβ-1,4-GlcNAc), LDN (GalNAcβ-1,4-GlcNAc), Lewis X 
(Galβ-1,4-(Fucα-1,3)GlcNAc), and LDNF (GalNAcβ-1,4-(Fucα-1,3)GlcNAc) and study their 
interactions with relevant glycan binding proteins (GBPs) and anti-carbohydrate antibodies 
induced in patients suffering from S. mansoni infection. 
 
In Chapter 1 the chemical synthesis of six conserve N-glycan structures will be presented, 
followed by their enzymatic diversification using a set of recombinant glycosyltransferases 
(Figure 8).  
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Figure 8. General strategy for the chemoenzymatic synthesis of xylosylated N-glycans; A. Target 
structures with a common xylosylated tetrasaccharide core (G1-G6); B. Exemplified enzymatic 
diversifications of core structures shown for the example of biantennary glycan G6. 
 
In recent years, glycan microarrays have been successfully applied as a miniaturized, high 
throughput screening method for the characterization of sugar binding specificities of various 
GBPs, like plant lectins and C-type lectins receptors providing important information about 
the role of glycans in different biological processes.  
In Chapter 2, the design and preparation of glycan microarrays which included the 
xylosylated N-glycans prepared in Chapter 1 will be described. Initially, the array functionality 
will be interrogated with plant lectins of known, general specificity, to be subsequently 
probed with set of human and murine CLRs. To better understand the role of parasite N-
glycans in the interactions with the CLRs present on the surface of dendritic cells (DCs), we 
will pay special attention on the specificity of DC-SIGN, MGL-1 and Dectin-2 which were 
previously shown to internalize specific glycoproteins of parasites.     
 
The majority of antibodies generated during the course of S. mansoni infection are directed 
against certain antigenic glycan elements. Their identification and characterization can be 
essential for the development of potential carbohydrate-based vaccines or to better 
understand the role of certain parasitic sugars during the infection, like the evasion of 
parasite from the host immune system. 
  
  
 
16 
In Chapter 3, glycan microarrays will be employed for the screening of antibodies raised 
against S. mansoni. First, the utility of glycan microarray towards the characterization of anti-
carbohydrate antibodies will be tested using monoclonal antibodies produced against sera 
of infected mice. Second, the glycan microarray will be used to detect and characterize 
polyclonal antibodies from sera of S. mansoni infected patients from an endemic community. 
As control, sera from healthy individuals will be also screened and their natural carbohydrate 
antibodies will be characterized. Based on the glycan microarray screening of sera from 
patient infected with Schistosomiasis we aim to, first identify major antigenic N-glycans 
structures in a context of structures available on our synthetic glycan and secondly, propose 
their biological role in the host-parasite interactions. 
 
In Chapter 4 we want to explore the use of specific N-glycans as DCs targeting molecules. 
Based on the microarray-assisted screening of different C-type lectin receptors (CLRs) 
present on the surface of DCs we want to design an in vitro assay and study the correlation 
of microarray data with cellular trials.  
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1.1 Introduction 
 
N-glycans have multiple roles in various biological processes thus their synthesis has been 
extensively studied over the years. However, due to polyhydroxyl nature of carbohydrates, 
the development of general and efficient chemical strategies of their synthesis is not trivial. 
The major challenge in the carbohydrate synthesis relies on the modification of a specific 
hydroxyl group in the presence of others and this task is usually solved by multiple 
protection/deprotection strategy. Moreover, the enormous complexity of oligosaccharides 
synthesis come from their similar chemical sequence: monosaccharide building blocks can 
adopt either α or β anomeric configuration (stereoisomers) and can be coupled by different 
linkages to the next monosaccharide unite (regioisomers). Improvement of synthetic 
methodology has been addressed by several research groups during the years, both in 
solution1 and on solid phase.2–4 One important contribution in the synthesis of N-glycans 
was made in mid-eighties by groups of Paulsen5 and Ogawa6–8 who used independent 
approaches to synthesized complex, N-glycans of glycoproteins.  
Nevertheless, despite the big progress in synthetic carbohydrate chemistry, the preparation 
of complex N-glycans is still time consuming and often leads to low yields and high costs. As 
an alternative to purely organic synthesis, chemoenzymatic preparation of N-glycans have 
been developed in recent years.9–12 It combines carbohydrate chemistry of a common 
scaffold with enzymatic glycosylation, taking advantage of the flexibility of the chemical 
approach and of the efficiency and selectivity of the modifications performed by enzymes. 
The chemoenzymatic strategy reduces the amount of necessary synthetic, structures to 
minimum and utilizes glycosyltransferases (GTs) or glycosidases to further diversify 
previously prepared structures. One of the first example of use glycosyltransferases 
towards synthesis of a simple glycan, N-acetyllactosamine was given by Whitesides and co-
workers.13 They designed the recycling system that generated UDP-galactose from 
inexpensive UDP-glucose by UDP-galactose epimerase. So created donor was used by 
galactosyltransferase (GalT) to elongate glucosamine acceptor whereas the hydrolyzed UDP 
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cofactor was further regenerated to UDP-glucose and UDP-galactose. The proposed 
enzymatic strategy overcame the biggest limitation of enzymatic glycosylation at that time, 
which was the high cost of sugar nucleotides. Few years later Paulson and co-workers 
described the efficient, fully enzymatic synthesis of sialyllactosamine,14 based on the earlier 
study on the specificity of the sialyltransferase purified from bovine colostrum which 
transfers sialic acid to β-D-galactosides.15 Finally, the chemoenzymatic approach was 
successfully applied for the generation of more complex N-glycans, in mid-nineties 
Unverzagt described the preparation of sialylated biantennary N-glycan with the help of 
two glycosyltransferases.16 The terminal galactose and sialic acid residues were 
enzymatically introduced at the end onto a chemically prepared deprotected 
heptasaccharide with overall high yield of 87%.  
In recent years, the use of glycosyltransferases for oligosaccharide synthesis has become a 
complementary approach to the chemical synthesis, and offers many advantages over 
traditional methods.17 The use of enzymes results in the formation of defined products with 
complete regio- and stereoselectivity, without involvement of laborious 
protection/deprotection steps. Glycosyltransferases are known to be very specific towards 
both, glycosyl donor and acceptor but may also exhibit some flexibility, especially in vitro, 
when the substrates are externally provided. These features make glycosyltransferases very 
attractive tools for carbohydrate chemistry.18,9 Beside glycosyltransferases, the glycosidic 
bond formation can be also achieved using glycosidase. In vivo these carbohydrate 
processing enzymes catalyze the hydrolysis of glycosidic linkage, however, they can also 
synthesize glycosides in vitro. Reaction with glycosidases gives the glycosyl-enzyme complex 
which can be intercepted either by water resulting in hydrolysed product or by a glycosyl 
acceptor in order to form new glycoside. The formation of new oligosaccharide in vitro can 
be achieved using appropriate glycosyl donors which are rapidly and irreversibly cleaved by 
the enzyme, for example p-nitrophenyl glycosides.19  
In this Chapter, the chemoenzymatic synthesis of non-mammalian β-1,2-xylosylated N-
glycans will be described. Some of these structures were identified in the glycome of 
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parasite helminths and trematodes such as S. mansoni or they are part of plant allergens. In 
the first part of this Chapter, we will focus on the chemical synthesis of six conserved core 
structures G1-G6 (Figure 1, 1) with ready installed core β-1,2-xylosylation. Taking into 
account that in plants β-1,2-xylosylation has been suggested to occurs prior to other core 
modifications20 the xylose containing N-glycans could be employed as starting point for 
further enzymatic diversifications. The introduction of β-1,2-xylose enzymatically will not be 
evaluated because it has been reported that the β-1,2-xylosyltransferase isolated from 
Arabidopsis thaliana (XYLT) always requires the presence of β-1,2-linked GlcNAc at the non-
reducing terminus of the α-1,3-branched mannose residue (GlcNAcβ-1,2Manα-1,3Man) and 
does not tolerate α-1,3-linked fucose in the chitobiose core or β-1,4-linked terminal 
galactose residues of GlcNAcβ-1,2Manα-1,3Man branching.  
In the second section of the Chapter, we will describe the expression of glycosyltransferases 
and enzymatic reactions performed on synthetic, deprotected structures (Figures 1, 2). We 
will introduce α-1,3-fucose or/and α-1,6-fucose core modifications using different 
fucosyltransferases. Our target structures are also decorated with terminal structural 
elements including LN (Galβ-1,4GlcNAc), LDN (LacdiNAc, GalNAcβ-1,4GlcNAc) or Lewis X 
(Galβ-1,4(Fucα-1,3)GlcNAc) motifs (Figure 1, 3). LN is the most common structural element 
of mammalian complex-type N-glycans, it decorates the terminal GlcNAc residues which 
can be additionally substituted with fucose, sialic acid and sulfate groups. LDN and Lewis X 
are an alternative type of nonreducing terminal glycan structures which are shared by both 
various parasites and their human host. 21,22 Both motifs seem to be highly abundant in 
helminths, including S. mansoni which express Lewis X, LDN and its fucosylated derivative 
LDNF within the different life stages.23 In mammals, expression of Lewis X and LDN is only 
restricted to certain glycoproteins.24 These both glycan moieties are commonly capped by 
sialic acid and are much lower abundant than LN element. Lewis X plays a role in the 
development of the nervous system of the vertebrates while the sialyl Lewis X mediates 
human sperm binding during fertilization.25 Both structural elements are overexpressed on 
the surface of cancer cells. LDN-type glycans, on the other hand have been found on the N- 
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and O-glycans decorating certain hormons and other mammalian glycoproteins. 
Interestingly, it has been described that the humoral immune response of the host infected 
with S.mansoni is potentially directed towards LDN and Lewis X structural elements. Both 
motifs, are linked to the recognition of parasite by the host immune system26 and might 
have a role in the modulation of immune responses.  
 
 
Figure 1. General strategy for the chemoenzymatic synthesis of xylosylated N-glycans; 1. Target 
structures with a common xylosylated tetrasaccharide core prepared chemically; 2. Exemplified 
enzymatic diversifications on the example of biantennary glycan G6; 3. Library of final compounds 
obtained after chemoenzymatic synthesis. 
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1.1.1 Chemical synthesis 
 
The chemical synthesis of carbohydrates requires sophisticated methodologies based on 
protecting group strategy and the modular assembly of carbohydrate building blocks. The 
formation of a glycosidic linkage between two carbohydrate units, known as glycosylation 
reaction, involves the coupling of activated OH-group of glycosyl donor with an OH-group of 
the glycosyl acceptor. Because carbohydrates contain more than one hydroxyl group, the 
differentiation between them is only possible by using protecting groups (PGs) masking all 
non-reacting hydroxyl functions except the one to be glycosylated (Scheme 1). One of the 
key aspects for the success in carbohydrate synthesis is a design of an orthogonal 
protecting group strategy. This means that the removal of a desired PG can be performed 
under conditions which do not affect the other set of protecting groups.  
 
 
Scheme 1. Reaction of glycosylation between the glycosyl donor and acceptor catalyzed by the 
promoter. 
 
In general, the protecting groups are divided into two types: permanent and temporary 
groups. Permanent PGs are used for the protection of functional groups which are not 
manipulated until the end of the synthesis; they mask the positions in which they are 
installed and prevent them from interfering in the synthetic steps. Permanent protecting 
groups are usually introduced in the first steps of synthesis and are removed at the end as 
for example benzyl ether. On the other hand, temporary protecting groups are much more 
easy and selective to remove without affecting permanent PGs and other temporary 
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groups. The nature of the protecting groups can have a profound effect on the overall 
reactivity of a carbohydrate building block and can also affect the stereochemical outcome 
of glycosylation reaction. 
In general, glycosylation reaction involves the nucleophilic displacement of a leaving group 
installed at the anomeric carbon by a sugar acceptor following a SN1 or SN2 type pathway 
(Scheme 2). In most cases, the departure of this leaving group is assisted with an activator 
(promoter) and results on the formation of a glycosyl cation27 that can be stabilized by 
resonance with the lone pairs of the adjacent oxygen forming an oxocarbenium ion.  
 
 
Scheme 2. Glycosylation mechanism depending on the presence of A. non-participating group -ONP 
at C-2; B. participating group –OP and the different outcomes ,1,2-trans or 1,2-cis glycoside. 
 
If the glycosyl donor carries a non-participating protecting group (Scheme 2, A) on the 2-
hydroxyl group, this oxocarbenium ion could be attacked by the glycosyl acceptor from 
both top and bottom face of the ring following a SN1 mechanism and allowing the possible 
CHAPTER 1 Chemoenzymatic synthesis 
 
 
29 
formation of both β and α anomers. One of the most successful ways to control the 
stereochemistry of the 1,2-trans glycosidic bond is the presence of a neighboring 
participating group, such as acetate or benzoate, on the 2-hydroxyl position of glycosyl 
donor (Scheme 2, B). In this case, the glycosyl cation is stabilized by the action of the 
adjacent carbonyl oxygen forming a cyclic oxonium ion, which is attacked by the 
nucleophile acceptor from the top face of the ring following a SN2 mechanism. This results 
in the major formation of 1,2-trans glycosidic linkage. 
Unlike 1,2-trans glycosides, the stereoselective formation of 1,2-cis glycosidic linkages, like 
β-mannoside requires an alternative synthetic strategy than the participating/non-
participating group strategy and is a classical problem in the carbohydrates synthesis. In 
1975 Lemieux reported so called halide-assisted or in situ anomerization strategy, which 
allows for the generation of 1,2-cis glycosides applying glycosyl bromide donor and the 
tetraethylammonium bromide as additive.28 
The addition of halide salts results in the establishment of the quick equilibrium between 
the α and β bromide of the donor, without forcing of its departure, as the regular promoter 
does. The α-bromide is too stable to react with the acceptor, unlike the β-anomer which 
can be displaced by the nucleophile following the SN2 pathway and resulting formation of 
the α-product. Once entire amount of the available β-bromide donor is turned into the 
product, new equilibrium between both anomers is established, more of the β-bromide is 
created and finally all the donor is used to form the 1,2-cis glycoside. Another typical 
approach of the β-mannosyl linkage formation was demonstrated by Stork and co-workers. 
They have described the intramolecular glycosylation (intramolecular aglycon delivery) 
performed on the temporarily tied glycosyl acceptor to the 2-OH group of glycosyl donor 
via a silicon ether tether.29  
 
As mentioned before, the choice of protecting groups not only influence the 
stereoselectivity of the glycosylation as described above, but also can have an effect on the 
overall reactivity of a carbohydrate building block. Lemieux30 and Fletcher31,32 first linked 
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the reactivity and the selectivity of glycosyl halides and the armed/disarmed terminology 
was introduced. Carbohydrates substituted with strong electron-withdrawing groups like 
esters (-OCOR,) are called disarmed donors, they have a destabilizing effect on the 
oxocarbenium ion and they are less reactive that so called armed-donors. Armed-donors 
have as substituent electrodonating groups such as benzyl groups (-OBn) that reacts faster 
than disarmed donors. 
 
During the years, development in carbohydrate synthesis was focused mostly on the design 
of new anomeric leaving groups and promoters. The first glycosylation was made by 
Michael and Fischer, who performed the reaction of anomeric position of glucose in the 
presence of methanol under acidic conditions.33,34 Later on, Köenigs and Knorr35 described 
the nucleophilic replacement of chlorine and bromine at the anomeric center using Ag2CO3 
as a promoter. Subsequently Zemplen and Gerecs36 improved the leaving-group ability by 
changing of promoter, into mercury (II) salt catalysts. For many decades halogen activated 
glycosyl donors and later hemiacetals and acetals were exclusively used as leaving groups in 
carbohydrate synthesis. Later, more elaborated leaving groups were introduced and 
nowadays, thioglycosides, O-acetimidates and fluorides are the most commonly sugar 
donors employed in complex carbohydrate chemistry.  
 
1.1.2 Retrosynthetic analysis of target structures  
 
Our synthetic strategy for the modular assembly of N-glycans is illustrated on Scheme 3, it 
is based on previously developed approach in our group37 and utilizes a tetrasaccharide 4 as 
a starting point for further diversification into target structures (G1-G6). The synthesis of 
trisaccharide 1 has been described previously.38 Trisaccharide 1 is protected by a set of 
orthogonal temporary protecting groups at OH-2, OH-3, OH-4 and OH-6, differentiated with 
acetate, 2-naphthyl methyl ether and benzylidene acetal protecting groups respectively. 
Moreover, the introduction of C5 azide containing linker at the anomeric position of the 
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first N-acetylglucosamine, gives us the possibility for conjugation of N-glycans on 
microarray surfaces and proteins. 
 
Scheme 3. Retrosynthesis of G1-G6 N-glycans.  
 
The synthesis of N-glycans from the trisaccharidic core 1 starts with the selective 
deprotection of an acetate group at the axial position of terminal mannose, followed by 
glycosylation with xylose donor 3 to form the common tetrasaccharide scaffold. With 
tetrasaccharide 4 in hands, glycosylations on (G1, G2) or both (G3-G6) branching sites OH-3 
and/or OH-6 will produce the desired compounds. In order to synthesize compounds G2-
G6, tetrasaccharide 4 was treated with 2,3-dichloro-5,6-dicyano-p-benzoquinone (DDQ), to 
liberate OH-3. This glycosyl acceptor was subsequently substituted with donor 5 (final 
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compound G2) or 7 (G3). In the next steps, the benzylidene acetal ring was cleaved and in 
regio- and stereoselective fashion the primary hydroxyl group OH-6 is glycosylated with 
donor 7 (G4) or 6 (G6). In order to synthesize compound G1 we directly performed the 
reductive benzylidene acetal ring opening of tetrasaccharide 4 followed by the glycosylation 
with donor 5.  
 
1.1.3 Glycosyl imidates as donors in carbohydrate synthesis 
 
Synthesis of donors used during the generation of target structures (Scheme 3) was 
described previously by several groups,6,39,40 thus their detailed preparation and 
characterization will not be further discussed in this Chapter. However, because all of them 
are activated as O-imidates, we will shortly comment on the preparation and reactivity of 
trichloro- and trifluoroacetimidate donors. 
In 1980 Schmidt and Michel introduced trichloroacetimidates (TCA) as donors41 and they 
have fast become one of the most widely used glycosyl donors for the oligosaccharides 
synthesis.42,43,44 Trichloroacetimidates are rapid and easy to prepare by treatment of 
hemiacetal with trichloroacetonitrile under basic conditions (Scheme 4, A).  
 
Scheme 4. Preparation of O-imidates donors; A. Trichloroacetimidate; B. N-phenyl-
trifluoroacetimidate.  
CHAPTER 1 Chemoenzymatic synthesis 
 
 
33 
Depending on the type of base used either the α-glycosyl (NaH/Cs2CO3) or β-glycosyl 
(K2CO3) trichloroacetimidates can be obtained, which while glycosylated under mild 
activation conditions can help to control the stereoselective outcome of the reaction 
following SN2-like pathway. 42 The preparation of TCA under mild, basic conditions tolerates 
the use of almost all kind of protecting group patterns and glycosidic linkages in the donor 
molecule. Nevertheless, one of the biggest advantage of TCA over traditional glycosyl 
donors, like halides or thioglycosides, is the requirement of only catalytic amount of 
promoter for their activation, which can be achieve using Lewis acids, such as trimethylsilyl 
trifluoromethanesulfonate (TMSOTf) or boron trifluoride diethyletherate (BF3.Et2O). Some 
years after the trichloroacetimidate synthesis, Schmidt reported the analogues, 
trifluoroacetimidates45 and in 2010, Yu and Tao reviewed the use of N-
phenyltrifluoroacetimidates (PTFAI) as donors in glycosylation reactions.46 Similarly to TCA, 
PTFAI glycozyl donors are easy to prepare, starting from hemiacetals by treatment with N-
phenyl trifluoroacetimidoyl chloride under mild, basic conditions. Compared to 
trichloroacetimidates, PTFAIs are reported to be less reactive and to generally require a 
higher amount of catalyst or higher temperatures for activation. The main advantage of 
PTFAIs over TCAs is the lower probability to undergo side reactions during glycosylation. 
When trichloroacetimidates donors are used, the trichloroacetamide liberated from the 
donor can react with the oxocarbenium ion and form a N-glycoside by-product. Particularly, 
this reaction takes place when the acceptor is low nucleophilic or sterically hindered. In the 
case of PTFAI, the lower N-basicity and the present of N-substitution help to avoid the 
formation of N-glycoside byproducts and thus the trifluoroacetimidates have become an 
alternative for a wide range of oligosaccharide synthesis, including preparation of β-
mannosides. 
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1.2. Chemical synthesis of xylose containing N-glycans G1-G6 
 
1.2.1. Assembly of β-1,2-xylosylated precursor 4 
 
For the introduction of β-1,2-xylose moiety, we investigated the deprotection of the 2-O-
acetyl group on the β-mannose moiety. Unexpectedly, standard Zemplén conditions 
employing sodium methoxide (NaOMe) treatment did not provide the deacetylated 
compound 2 and only unreacted starting material was recovered. The different trials in 
order to optimize this reaction are summarized in Table 1.  
 
 
ENTRY Base Reagents and conditions Comments 
 
1 
 
NaOMe 
0.1 eq. NaOMe, MeOH:DCM (1:1) No reaction 
1 eq NaOMe, MeOH:DCM (1:1) SM+ product + byproduct 
2 Bu2SnO 1 eq. Bu2SnO, DCM:MeOH (1:1) No reaction 
3 tBuOK 1 eq tBuOK, tBuOH:DCM (1:1) No reaction 
4 K2CO3 1eq K2CO3, MeOH:DCM (3:1), MW 90 °C (1 hour) 40% of producta 
5 Cs2CO3 1 eq Cs2CO3, MeOH:DCM (3:1), MW 90 °C (1 hour) 57% of product, 17% BP, 
26% SMa 
6 KCN 3 eq. of KCN, MeOH, MW 80 °C (30 min) 50% of producta 
7 Mg(OMe)2 50 eq. Mg(OMe)2 in DCM MW 80 °C (3x30 min) 82% of productb 
 
Table 1. Different conditions of compound 1 2-O-acetate deprotection of trisaccharide 1. aYield 
determine by UPLC. bIsolated yield. 
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Forcing the reaction condition by increasing the amount of sodium methoxide up to one 
equivalent resulted in the opening of the phthalimide groups (Table 1, entry 1). The 
opening of phthalimide groups under harsh basic conditions was confirmed by ultra-
performance liquid chromatography-mass spectrometry (UPLC-MS). A new peak was 
detected corresponding to the m/z of the desired product plus 18 suggested addition of the 
water to the molecule. After several trials, using different bases, the 2-O-deacetylation was 
achieved by treatment of 1 with magnesium methoxide (Table 1, entry 7) under microwave 
heating at 80°C in three cycles of thirty minutes. The deacetylated compound 2 was 
obtained with a very good yield (86%) and no byproduct formation was observed. Next the 
determination of optimal conditions for the xylosylation on trisaccharide acceptor 2 was 
performed. 
 
Only few examples describing the xylosylation of carbohydrates have been reported. One of 
the first was published in 1990 by Ogawa and coworkers when a series of synthetic 
mollusks glycosphingolipids were prepared6 (Scheme 6, A). Few years later, Kerekgyarto et 
al.47(Scheme 6, B) and van der Ven et al.36 (Scheme 6, C) synthesized simple, protected tri- 
and tetrasaccharide N-glycan fragments. More recently Nakano et al. focused on the 
preparation of xylose containing N-glycans, common for the S. mansoni and S. japonicum 
parasites. The xylosylation was performed on the orthogonally protected disaccharide 
Manβ-1,4-GlcNAc (Scheme 6, D), showing a similar protecting group scheme as the 
trisaccharide acceptor 2 we were going to employ in our synthesis. The glycosylation was 
reported using a trichloroacetimidate xylose donor, 2 equivalents of TMSOTf to give the 
overall trisaccharide with a good yield of 67%.  
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Scheme 6. Previous examples of xylosylation reaction; A. Synthesis of glycosyl ceramides. Reagents 
and conditions: a) 0.3 eq. BF3.Et2O, 1.6 eq. xylose donor, -20°C to room temp. mixture of three 
compounds (28%), (26%), (20%); B. Synthesis of xylosylated carbohydrates from glycoproteins of 
plant and animal origin. Reagents and conditions: b) 1.2 eq. TMSOTf, 1.2 eq. xylose donor, -40°C, 
yield 79%; C. Synthesis of xylosylated carbohydrates from N-glycoproteins Reagents and conditions: 
c) 0.25 eq. TMSOTf, 1.3 eq. xylose donor, -40°C, yield 89%; D. Synthesis of complex-type glycans 
derived from parasitic helminths Reagents and conditions: d) 2 eq. TMSOTf, 3 eq. xylose donor, -
40°C, yield 67%. 
 
Based on these previous results, we chose the peracetylated xylose trichloroacetimidate 3 
and trimethylsilyl trifluoromethanesulfonate (TMSOTf) as promoter for the first trials of 
xylosylation. We investigated several reaction conditions (Table 2) and experienced that 
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this particular glycosylation requires strong acidic conditions in order to achieve the 
formation of the desired product and to avoid the formation of orthoester 8 which was the 
main obstacle of this reaction (Figure 2).  
 
ENTRY Donor [eq] TMSOTf [eq] Temperature  Concentration [M] Product (yield)* 
1 1.5 0.1 0 oC to RT 0.02 4 (40%) 
2 2.2 0.1 0 oC to RT 0.02 4 (50%) 
3 3 0.5 -40 oC 0.01 8 (70%) 
4 3 0.1 -40 oC to RT 0.07 8 (85%) 
5 3 0.4 -40 oC to RT 0.07 4 (75%) 
 
Table 2. Reaction conditions for the xylosylation of the trisaccharide 2 (*conversion determined by 
UPLC). 
 
When xylosylation was performed at room temperature with 1.5 or 2 equivalents of donor 
and catalytic amount of promoter (Table 2, entries 1 and 2) the starting material was 
converted into tetrasaccharide 4 in 40-50% of yield, estimated on the basis of the UPLC 
chromatogram recorded after quenching of the reaction with triethylamine.  
By lowering the reaction temperature and simultaneously increasing the amount of 
promoter and donor added (Table 2, entry 3), we observed the formation of the orthoester 
8, which sluggishly rearranges into acetylated or hydrolyzed starting material. The 
formation of orthoester 8, was monitored by TLC and could be distinguished from the 
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reaction product 4 by a different retention time in UPLC-MS analysis (Figure 2). In order to 
avoid the formation of 8, we have further increased the concentration of the reaction (0.07 
M) and subsequently warmed it up to room temperature after addition of promoter. 
Unfortunately, again orthoester 8 was formed with very high yield (Table 2, entry 4). Finally, 
we kept previous conditions, but using an increased amount of promoter adding up to 0.4 
equivalents (Table 2, entry 5). Under these conditions, the starting material was converted 
into the desired product with 75% of yield as determined by UPLC-MS. Unfortunately, the 
high amount of TMSOTf promoter favored the formation of the trimethylsilylated 
trisaccharide (see Figure 2B) byproduct, which complicated the isolation of the desired 
tetrasaccharide 4. After the purification by flash column chromatography, the final 
compound was isolated in a 65% of yield.  
 
Figure 2. UPLC-chromatogram of the reaction crude after quenching with Et3N under A. not 
optimized conditions with an orthoester 8 as a main product (Table 2, entry 3); B. optimized 
conditions (Table 2, entry5). 
 
To avoid formation of trimethylsilyl substituted acceptor, we investigated alternative 
promoters such as trifluoromethanesulfonic acid (TfOH), copper (II) 
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trifluoromethanesulfonate Cu(OTf)2 and ytterbium(III) trifluoromethanesulfonate Yb(OTf)3 
(Table 3).  
 
Catalysts Donor Catalyst [eq.] Temperature [oC] 4 [%] 
TfOH 3 0.4 0 to r.t. 73 
Cu(OTf)2 3 2.5 0 to r.t. 55 
Yb(OTf)3 3 3 0 to r.t. 41 
TfOH 9 0.4 0 to r.t. 50 
NIS/TfOH 10 3.2/0.1 r.t. 60 
Table 3. Different catalysts and donors used during xylosylation reaction.  
We also investigated different donors such as thioglycoside 10 or N-
phenyltrifluoroacetimidate 9 (Figure 3) but unfortunately, product formation was not 
improved and the xylose trichloroacetimidate was used in the reaction (Table 3).  
 
Figure 3. Three donors tested in the xylosylation of trisaccharide.  
Under previously optimized conditions (Table 2, entry 5) and using TfOH as promoter the 
xylosylated tetrasacchride 4 was obtained in 73% yield after purification. 
Finally, we could establish the optimal conditions for the synthesis of tetrasaccharide 4 as 
summarized in Scheme 7. The removal of 2-OH acetate was achieved in high yield (86%) by 
using Mg(OMe)2 under microwave irradiation. For the introduction β-1,2-xylose, we 
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employed xylose trichloroacetimidate 3 activated with TfOH as acid catalyst to form the 
tetrasaccharide 4 in high yield (73%). 
 
Scheme 7. Synthesis of tetrasaccharide 4; Reagents and conditions: a) Mg(OMe)2, DCM, MeOH, 80°C, 
MW, 86%; b) TfOH, DCM, 0°C to r.t, 73%.  
1.2.2 Assembly of N-glycans. Glycosylation of 4 with glycosidic donors 
 
With the tetrasaccharide 4 in hands, we started to investigate glycosylation reactions with 
different glycosidic donors in one (G1, G2) or both (G3-G6) branching sites OH-3 and/or OH-
6 to produce the final xylosylated N-glycans. In order to deprotect OH-3 position, 
tetrasaccharide 4 was treated with 2,3-dichloro-5,6-dicyano-p-benzoquinone (DDQ) to 
remove 2-naphthylmethyl ether (Nap) group48,49,50 (Scheme 8). The desired tetrasaccharide 
acceptor 11 was obtained in modest yields between 50 to 60% while recovering part of the 
starting material. It was observed that increasing reaction time results in the loose of benzyl 
groups which hampered the isolation of the final product. Therefore, the optimal 
conditions were established by quenching the reaction before complete deprotection of 
Nap group to both maintain a reasonable yield and maximize the recovery of unmodified 
starting material. The tetrasaccharide acceptor 11 was subsequently glycosylated with 
disaccharide 7 or mannose donor 5 under TMSOTf activation to produce both 
hexasaccharide 12 (82%) and pentasaccharide 13 (94%) in excellent yields (Scheme 8). 
Removal of benzylidene acetal protecting group to liberate OH-4 and OH-6 was achieved by 
acid hydrolysis catalyzed by BF3OEt2 in the presence of ethanethiol to afford the 
corresponding diol acceptors 14 (79%) and 15 (86%) in good yields.  
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The glycosyl acceptors 14 and 15 were reacted with disaccharide donor 7 under TMSOTf 
activation to produce octasaccharide 16 (73%) and heptasaccharide 17 (73%) with 
complete stereo- and regio-selectivity in good yields (Scheme 8, e). A strict control of low 
temperature as well as high dilution of reaction mixture (250 mL/mmol) helped preventing 
the formation of regioisomers.39 
The initial attempt for the preparation of hybrid N-glycan G5 employed a similar strategy as 
for the biantennary compound 16, starting with acceptor 14 and coupling with 
peracetylated mannose trichloroacetimidate donor 18 (Scheme 9).  
 
Scheme 9. Synthesis of the heptasaccharide G5; Reagents and conditions; a) TMSOTf, DCM, 4Å MS, -
30oC. Yields determined by UPLC before chromatographic purification of desired compound 20. 
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Unfortunately, during this reaction an unusually stable orthoester 19 was formed as major 
reaction product, which after rearrangement under acidic conditions afforded a complex 
mixture of both OH-4 and OH-6 substituted regioisomers and unreacted starting material 
14 (ratio 1:1:1, as determined by UPLC). In order to avoid the orthoester formation, we 
synthesized the mannose donor 6, fully substituted with benzyl ester groups that are 
bulkier than acetates. Glycosylation with acceptor 14 was conducted under activation with 
TMSOTf and even though we could observe the presence of a regioisomer OH-4 21 and a 
bis-substituted by-product 22 (Scheme 9, b) we could isolate the desired heptasaccharide 
20 in a moderate isolated yield (50%). 
Finally, we attempted the synthesis of the truncated N-glycan G1. We assumed that 
glycosylation of acceptor 23 with armed mannose donor 5 would preferable lead to 
substitution of the less sterically hindered and more reactive primary OH-6 position 
providing the desired pentasaccharide in a regioselective manner (Scheme 10, route A, 
donor 5). Unfortunately, detailed analysis of HSQC and comparison of 13C and 1H chemical 
shift values at C-4 and C-6 attachment sites between starting material and product revealed 
formation mainly of the undesired regioisomer OH-4 24 (Figure 4). We observed a 
downfield shift for the C-4 13C resonance from 66 ppm in 23 to 71 ppm for compound 24. 
Likewise, a downfield shift was observed for the H-4 1H resonance from 3.7 ppm to 4.1 ppm 
in 2451 while the C-6 13C resonance remained unaltered between starting material 23 and 
product 24. Both were in the range of 60-65 ppm, which is a characteristic value for 
unsubstituted derivatives (Figure 4). A similar result was obtained when disarmed donor 6 
was employed (Scheme 10, route A, 24b). 
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Scheme 10. Synthesis of compound 28. Reaction and conditions: a) BF3.Et2O, EtSH in DCM; b) 
TMSOTf, 4Å MS in DCM; c) DDQ, DCM:MeOH (4:1); d) butane-2,3-dione, (MeO)3CH, BF3Et2O or CSA, 
MeOH; e) 2,2,3,3-tetramethoxybutane, (MeO)3CH, CSA, MeOH; f) BH3.THF, n-Bu2BOTf, 0oC, 2h; g) 
15% TMSOTf, 4Å MS in DCM, -20oC. 
 
Fairbanks and coworkers observed similar phenomena on the set of a 4,6-diol disaccharide 
acceptors that were glycosylated with a different glycosidic donors.52 They demonstrated 
that the regioselectivity of the glycosylation reaction is strongly dependent on the 
functionalization of the neighboring OH-3 group of the acceptor  and that the OH-4 
regioisomer is preferably formed when OH-3 is protected with benzyl ether and when 
donor possesses an ester participating group at C-2. Similar to our findings, they also 
demonstrated the preferential formation of OH-6 regioisomer when the OH-3 position had 
been previously glycosylated. Later our group have reported further experimental 
observation regarding the role of the glycosyl donor on the regiochemical outcome of the 
glycosylation reaction performed on the 4,6-diol system of OH-3 glycosylated acceptor.53 
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Figure 4. HSQC spectra comparison of starting material 23 (red) and product 24 (blue). 
 
In the next attempt (Scheme 10, route B) we removed Nap and benzylidene acetal 
protecting groups from tetrasaccharide 4 and we tried the selective protection of the two 
equatorial hydroxyl groups OH-3 and OH-4 of compound 25 via a butane-2,3-diacetal. Even 
though these reaction conditions has been applicable in the synthesis of several 6-
substituted sugars54,55, in our case we the conversion of triol into protected sugar was not 
achieved. 
Finally, we could selectively perform the reductive ring opening of the benzylidene acetal in 
tetrasaccharide 4 employing borane tetrahydrofuran complex (BH3.THF) to yield acceptor 
with primary alcohol OH-6 26 (Scheme 10, route C). When TMSOTf or Cu(OTf)2 were used 
as a catalyst in this reduction, conversion into desired product was low (20-30%). In these 
reactions, different byproducts lacking acetates or with a reduced azide group were 
formed, as monitored by UPLC-MS. Changing the catalyst into n-Bu2BOTf, provided free OH-
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6 acceptor 26 with excellent selectivity56,57 and good isolated yield (65%). Nevertheless, the 
formation of a byproduct 27 with the azido group reduced to a primary amine could not be 
completely abolished (15% as detected by UPLC-MS). After purification, tetrasaccharide 
acceptor 26 was reacted with mannose donor 5 under TMSOTf activation to provide 
desired pentasaccharide 28 with a moderate yield (52%). 
 
1.2.3 Final deprotection of N-glycans 
 
The N-glycan precursors 12, 13, 16, 17, 20 and 28 were deprotected to yield the target N-
glycans G1-G6 either in a three or four step sequence (Scheme 11, Table 4). 
 
 
Scheme 11. Two ways of deprotection of final compounds on the example of biantennary compound 
G6; Method A. Three steps deprotection. Reagents and conditions; a: NH2CH2CH2NH2:nBuOH, MW 
(120oC, 3x30'); b) Ac2O, pyridine.; c) Na, NH3(liquid), -78ºC; Method B. Four steps deprotection 
Reagents and conditions: a, b), d) NaOMe, MeOH; e) H‐cube®, 10% Pd/C CatCart®, MeOH, 0.1% TFA. 
In both cases, we initially performed the aminolysis of phtalimide protecting groups by 
treatment with ethanolamine in nBuOH under heating, followed by acetylation of free 
amino and hydroxyl groups generated after aminolysis with acetic anhydride in pyridine. In 
the three steps deprotection, we have subsequently removed O-acetates, O-benzyl groups 
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and reduced the azido group of the linker to a primary amine in a single step applying Birch 
reaction using metallic sodium in liquid ammonia (Scheme 11, method A). 
For other glycans the dissolving metal conditions, led to the formation of a side product 
with a mass loss 18Da compared to the target compounds, presumably formed by the 
elimination of an acetate group. This side reaction was avoided by deprotection of O-
acetate groups by methanolysis using sodium methoxide, followed by the removal of 
remaining benzyl ether and the reduction of azido group by palladium catalyzed 
hydrogenation (Scheme 11, method B). Following this procedure, the fully deprotected 
target glycans G1, G3, G5, and G6, were obtained in good yields (Table 4).  
 
 
 
 
 
 
 
                      
Table 4. Deprotection of glycans followed by two strategies, A and B. 
The final compounds were easily purified using reverse phase C18 cartridges. With G1-G6 in 
hand we focused on the preparation of a library of core-xylosylated compounds by 
enzymatic diversification employing recombinant glycosyltransferases. 
 
 
Entry N-glycan Precursor Method Total yield [%] 
1 G1 28 B 49 
2 G2 13 A 69 
3 G3 12 B 65 
4 G4 17 A 56 
5 G5 20 B 58 
6 G6 16 B 69 
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1.3. Conformational changes of xylose moiety in synthetic N-glycans 
 
During the synthesis of xylose donor 3 and tetrasaccharide 4, we have encountered an 
atypical conformational behavior of D-xylose compared to other sugars. In this section we 
will discuss the conformational changes of the xylose moiety observed during the synthesis 
of β-1,2-xylosylated N-glycans in detail.  
D-xylose is an aldopentaose analogue of the aldohexose D-glucose that lack the 
hydroxymethyl group at position C5. In solution, D-xylose exists predominantly in the 4C1 
chair pyranose form as an α- or β- anomer in a ratio of 35 to 65% respectively.58 
Interestingly, the derivatives of β-xylopyranose can also adopt 1C4 chair conformation 
(Figure 5) depending on the nature of the substituents.59  
 
Figure 5. Open and cyclic form of D-xylose, with 4C1 and 1C4 chair conformations present as an α- or 
β- anomers. 
 
We have therefore closely investigated the structure of trichloroacetimidate xylose donor 3 
by Nuclear Magnetic Resonance (NMR), in order to establish which anomer (α- or β-) and in 
which conformation (4C1 or 1C4) was favored. 
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The α- and β- anomers of xylose have in principle distinguishable NMR spectra, vicinal 
proton–proton coupling constants (JH1-H2) in NMR depend on the dihedral angle between 
them and this is described by the Karplus equation (Figure 6).60 It states that vicinal proton-
proton coupling constant are maximal for protons with 0° and 180° dihedral angles and that 
coupling will be minimal for protons that are 90° from each other. In general, coupling 
constants will be larger for the protons in axial-axial orientation, followed by an axial-
equatorial, equatorial-axial and with lowest couplings constants values for equatorial-
equatorial protons positions (Figure 6).  
 
 
Figure 6. Schematic of coupling constants in nuclear magnetic resonance following Karplus equation. 
 
In xylose pyranose ring, the anomeric configuration is assigned based on the basic 1H NMR 
spectra with coupling constant, values between 3JH1-H2= 7–9 Hz are typical for the diaxial 
protons coupling and 3JH1-H2= 2–4 Hz indicative of the equatorial–axial coupling. Beside the 
three bond proton-proton H1-H2 coupling constant, the anomeric configuration can be also 
determined based on the single-bond 1H–13C coupling constant.61 This information can be 
easily obtained from an undecoupled 1H–13C heteronuclear single quantum correlation 
spectrum (HSQC), where the value of coupling constants 1JC1-H1 above or equal to 170Hz 
indicates an equatorial proton at C-1, while 1JC1-H1 160 Hz indicates an axial orientation of 
the anomeric proton. 
The evaluation of 1H-NMR spectrum of 2,3,4-tri-O-acetyl-xylopyranosyl trichloroacetimidate 
3 revealed the presence of two species (A and B) with coupling constants of 3JH1-H2 = 3.6 and 
3JH1-H2 = 4.4 Hz for anomeric protons (AH-1, BH-1), respectively (Figure 7). Taking into 
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account the values of 3JH4-H5’ and 3JH4-H5’’ we assumed, that xylose donor B adopted the 
standard 4C1 chair conformation, as α anomer. This finding was confirmed by the HSQC 
experiment coupling constants 1JH1-C1 value 174 Hz, which is indicative of axial glycosides.  
 
Figure 7. NMR studies of the conformations of 2,3,4-tri-O-acetyl-xylopyranosyl trichloroacetimidate 
3, showing two species A and B; I. Fragment of the 1H NMR spectrum with peaks corresponding to an 
axial and equatorial H5 protons of compounds A and B; II. undecoupled 1H-13C HSQC spectrum 
showing coupling constants between H1 at the anomeric carbon of A and B; III. Ilustration of β 1C4 
(A) and α 4C1 (B) conformation of xylose donor 3. 
 
On the other hand, xylose donor A revealed smaller values of coupling constants than 
donor B in the entire molecule, with a value of 3JH4-H5’’=3.8 Hz, which could be explained by 
the equatorial-equatorial orientation of vicinal protons H-4 and H-5’’ present in the 
inverted chair conformation 1C4. Moreover, coupling constant 3JH1-H2 =3.6 Hz is inconsistent 
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with the β-anomer of the 4C1 D-xylose conformation but is in a good agreement with the β 
anomer of a 1C4 chair conformation, where vicinal protons H-1 and H-2 have equatorial-
equatorial orientation. The observation can be also supported by the high coupling 
constant 1JH1-C1=180 Hz which is characteristic again for axial glycosides. The ratio between 
both conformations α and β was 4:1.  
These findings were in agreement with data reported previously in the literature. Durette 
and Horton investigated the conformational equilibria of peracetylated and perbenzoylated 
D-xylose halides.62 They demonstrated that α anomer of both D-xylose chloride and 
bromide exist mainly in the 4C1 form while the β anomer exist in the inverted chair 
conformation 1C4. Later, Kerekgyarto47 and Crich63 reported the conformational changes of 
xylose moiety, which always produce deviations in J values between the protons on the 
xylose skeleton. These conformational changes were explained by a possible compensation 
of sterically unfavored axial oriented O-acetyl groups destabilizing effect by the favorable 
dipolar interactions in the anomeric effect.64 
After having determined the possible conformations of xylose donor 3, we investigated the 
preferential conformation of the xylose moiety on the tetrasaccharide 4 (Figure 8). We 
expected the glycosylation of xylose trichloroacetimidate 3 with trisaccharide 2 to produce 
a single β-1,2-xylose glycoside due to the O-2 acetyl neighboring group participation in 
donor 3. In the analysis of HSQC experiment of tetrasaccharide 4, we could observe 
presence of anomeric carbon C1 at δ 99.4 ppm, with a coupling constant of 1JC1-H1 =171 Hz 
characteristic for axial glycosides. Due to the overlapping of signals in 1H NMR spectra of 
tetrasaccharide 4, additional NMR experiments were required to determine all coupling 
constants between the different protons in the xylose moiety. We employed 
monodimensional-TOCSY (Total Correlation Spectroscopy) experiments, in which anomeric 
proton of xylose is irradiated to produce a 1H-NMR spectra of the xylose unit (Figure 8). 
With this experiment, we were able to measure the coupling constants between H-1 and H-
2 (3JH1-H2=3.6 Hz) as well as between H-4 and H-5 (3JH4-H5'=3.68 Hz and 3JH4-H5"=4.1 Hz) which 
are consistent with H-4 and H-5 protons adopting a equatorial-equatorial conformation. 
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Based on these findings, we could assign a 1C4 chair conformation for the β-1,2-xylose 
moiety. 
 
Figure 8. Analysis of the xylose conformation in the tetrasaccharide 4; A. Possible β-conformations of 
xylose in tetrasaccharide; B. Values of 3JH5-H4 coupling constants predicted based on Karplus equation;  
C. 1H-1H TOCSY (Total Correlated Spectroscopy) spectrum of tetrasaccharide 4 showing J values in 
agreement with a 1C4 conformation of β-xylose. 
 
During the synthesis of N-glycans G1-G6, we observed protecting group dependent 
conformational changes for the β-D-xylose residue in various intermediates, most of which 
have been assigned and are listed in the Table 5. Generally, removal of the benzylidene 
acetal on the β-1,4-core mannose moiety of protected N-glycans results in the flipping of 
the xylose residue into the 4C1 configuration (15) persisted after glycosylation of position 
OH-6 (17). Surprisingly, the reductive opening of the benzylidene acetal and the presence of 
benzyl ethers in the position OH-4 (20), showed no influence on xylose conformation 
maintained the conformation adopted in tetrasaccharide (4), even after glycosylation of 
position OH-6 (28). Importantly, after final deprotection of N-glycans, β-D-xylose residue 
always adopts a “standard” 4C1 configuration, with 3JH1-H2 values between 7.4-7.6 Hz. 
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Protected compounds (NMR data, CDCl3) 
Compound 3JH1-H2 3JH2-H3 3JH3-H4 3JH4-H5a 3JH4-H5b 3JH5a-H5b 1JC1-H1 δC1 Conformation 
3 A 4.4 5.9 5.9 3.8 5.8 12.86 180 93.1 1C4 
B 3.6 9.9 9.9 5.9 12.7 11.3 174 94.8 4C1 
4 3.63 5.45 - 3.7 4.1 13 171 99.4 1C4 
11 6.7 8.4 8.4 - - - 168 100.9 4C1 
12 - - - 4.2 - 12.4 171 99.6 1C4 
13 4.4 6.6 6.6 3.9 5.7 12.6 171 99.7 1C4 
15 6.6 8.4 8.4 5.1 8.5 11.8 168 99.5 4C1 
26 3.35 5.06 5.06 - - - 171 98.9 1C4 
Table 5. Coupling constants (J, Hz) between the skeleton protons of the xylose residue and the 1JC1H1 
values in the protected and deprotected synthesized compounds. 
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1.4 Glycosyltransferases. Introduction 
 
In the second part of this Chapter the expression and use of recombinant 
glycosyltransferases for the enzymatic diversification of the synthetic compounds G1-G6 
will be described.  
Glycosyltransferases (GTs) (EC 2.4.1.-) are the family of carbohydrate-processing enzymes 
which catalyze glycosidic bond formation by transferring of a sugar moiety from an 
activated donor to an acceptor substrate (Scheme 13).  
 
 
Scheme 13. Representation of the glycosyltransferases mechanism of action on the example of 
nucleotide monosphosphate NMP/ nucleotide diphosphate NDP activated glycosyl donor. 
The majority of glycosyl donors are activated as a nucleoside mono- or di- phosphates 
(Leloir donors), however, the mono phosphates (non-Leloir donor) substituted donors can 
be also found (Figure 9). Non-activated sugars in form of sucrose or starch are also utilized 
by some GTs, however their action is limited to a use of a glucose or fructose donors. 
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Figure 9. Different donors utilized by GTs divided into two categories: I. Leloir donors II. non-Leloir 
donors A. activated with phosphate B. non-activated sucrose and starch. 
 
The majority of mammalian GTs found in Golgi apparatus and endoplasmic reticulum 
belongs to so called GT-A superfamily (Figure 10), with the catalytic domain being able to 
bind both, nucleotide sugar donor and acceptor, generally in a divalent metal-ion-
dependent matter.65,66 Mn2+ or Mg2+ ions are coordinated in the enzyme active site and 
further facilitate the departure of leaving group by stabilization of negative charge of 
phosphate group of sugar donor. Unlike GT-A enzymes, GT-B proteins possess two distinct 
domains and do not required metal ion for their correct action.67 More recently a third 
superfamily of glycosyltransferases, GT-C was identified and the first full length crystal 
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structure of bacterial oligosaccharyltransferase PgIB from Campylobacter lari has been 
resolved.68 GT-C utilizes lipid phosphate-linked sugars as sugar donors.  
 
Figure 10. Representative structures of glycosyltransferases type GT-A, GT-B and GT-C. (Gloster et al. 
201465) 
 
Depending on the stereochemical outcome of glycosyltransferase action, their mechanism 
can be further classified as an inverting (α-->β) or retaining (α-->α) (Figure 11). 
 
Figure 11. Proposed mechanism of GTs action; A. Inverting and B. Retaining mechanism. 
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The inversion of configuration at C1 of glycosyl donor is usually explained as a direct 
displacement SN2-like mechanism (Figure 11, A). The carboxylate residue from aspartic acid 
(Asp) or glutamic acid (Glu) in the enzyme catalytic site deprotonates the glycosyl acceptor, 
which subsequently attacks the C1 atom of the glycosyl donor (SN2). An oxocarbenium like 
transition state is formed which rearrange to the glycoside bond with an inversion of 
configuration at C1. The divalent metal ion facilitates a leaving group departure. 
 
The retaining mechanism is far less understood, however the double-displacement theory 
has been proposed (Figure 11, B). In this mechanism, after the direct SN2 nucleophile attack 
of carboxylic residue on the C1 of glycosyl donor the β linked enzyme-donor intermediate is 
formed followed by reaction with the glycosyl acceptor with a second inversion of 
stereochemistry.69 
 
1.4.1 Expression of recombinant glycosyltransferases 
 
The glycosyltransferases are powerful tools for the synthesis of oligosaccharides. However, 
it is difficult to obtain them in a sufficient amount by direct isolation from tissues, fluids or 
natural extracts. Recent progress in molecular biology allows for the recombinant 
expression of proteins in host organisms such as bacteria, yeast, insect cells or mammalian 
cells.70 This methodology can provide pure enzymes in large quantities that find application 
in the enzymatic preparation of glycoconjugates. In our N-glycan synthesis, we have 
employed GTs expressed in bacterial cultures (E. coli) and in yeast cultures (P. pastoris). In 
the next section, the advantages and limitations of both expressions will be briefly 
discussed. 
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1.4.1.1 E. coli expression system 
 
Escherichia coli host organism is usually the first choice when expressing heterologous 
proteins, due to its simplicity and easy manipulation. E. coli culture is inexpensive and can 
be performed in standard laboratories. Moreover, proteins are produced very rapidly and 
in large quantities. There are many commercial expression vectors available with different 
N- and C-terminal tags and several strains optimized for special applications. Nevertheless, 
the biggest drawback of using E. coli as expression system is the inability to form disulfide 
bonds and post-translational modifications. Therefore, many eukaryotic proteins do not 
fold properly in E. coli and form insoluble aggregates, called inclusion bodies. Inclusion 
bodies are biologically inactive and need to be further processed to recover their biological 
function. The protein folding from inclusion bodies is an empirical process that need to be 
optimized for each individual protein.71–77 The process involves several steps such as the 
isolation of inclusion bodies from the bacterial pellet, solubilization in the appropriate 
chaotrophic reagent, optimization of refolding buffer and finally the 
purification/concentration of the desired protein. Folding buffers usually contain a large 
number of components, including oxidized/reduced thiol pairs, such as glutathione 
(GSH/GSSG) or cysteamine/cystamine. Both oxidizing/reducing agents help the formation 
of disulfide bonds, which are crucial in the process of refolding. Several additives can be 
present in the folding buffer, like L-arginine, detergents, low molecular concentration of 
chaotrophic reagents such as urea or sugars. Nevertheless, there are some advantages of 
protein expressed as inclusion bodies production, including their lower degradability, 
resistance to proteolytic attack or very high level of expression. 
 
1.4.1.2 Pichia pastoris expression system 
 
Pichia pastoris is frequently used as an expression system for the production of 
recombinant proteins. Yeasts are easy to cultivate, they grow on inexpensive media without 
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any special requirement and they are considered to be simpler to handle compared to 
other host such as insect and mammalian cell cultures.  
P. pastoris is a single-cell eukaryotic microorganism, capable to perform several 
posttranslational modifications typical of eukaryotic organisms including folding, disulfide 
bond formation and glycosylation of proteins. Thus, proteins produced in the system, either 
intracellular or secreted into medium are directly biological active, and beside purification, 
do not required further manipulations. P. pastoris is a methylotrophic yeast capable to 
utilize methanol as only carbon source. It has a specialized organelle, called peroxisome, 
where the methanol is oxidized to form formaldehyde and hydrogen peroxide by a set of 
specialized enzymes called alcohol oxidases (AOX). There are two genes encoding AOX 
enzymes in P. pastoris, AOX1 and AOX2, however it is the AOX1 which is the principal 
responsible for alcohol oxidase activity and whose expression is strictly regulated and 
induced by the presence of methanol. 
In order to express a recombinant protein in P. pastoris, the foreign cDNA sequence 
encoding the target protein has to be introduced into the yeast genome, in a process called 
transformation. There are several expression vectors specially designed for P. pastoris, 
sharing variety of common characteristics, including the presence of a foreign gene 
expression cassette. The expression cassette is composed of P. pastoris AOX1 promoter 
gene, followed by the unique restriction sites for the insertion of the recombinant protein 
sequence and transcriptional termination sequence. The expression vectors might 
additionally carry drug resistance markers, which allow for the enrichment of strains with 
multiple copies of foreign gene. Once the foreign gene encoding the recombinant protein is 
introduced into the genome of P. pastoris, the yeasts are cultivated and protein expression 
is simply induced by addition of methanol to the growing media. In general, proteins in P. 
pastoris are expressed extracellularly and the protein is secreted to the expression media 
being in many cases the major component of the media facilitating subsequent isolation 
and/or purification. 
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1.5 Expression of GTs used for diversification of synthetic N-glycans 
 
Recombinant glycosyltransferases which were used for the diversification of the target N-
glycans (G1-G6) were produced in Pichia pastoris and E. coli expression systems as 
summarized in Table 6. 
Table 6. Glycosyltransferases (GTs) expressed and used during the chemo-enzymatic preparation   of 
N-glycans structures. 
 
1.5.1 Expression of glycosyltransferases in P. pastoris 
 
The target N-glycan library in this study differs significantly from the mammalian set of N-
glycan structures. The synthetic compounds G1-G6 contain β-1,2-linked xylose which is 
typically found in invertebrates and plants but never in mammalian organisms. We want to 
further diversify the synthetic structures and introduce other modifications which will 
resembles antigenic structures presented in some pathogens, like S. mansoni or in plant 
allergens.78,79 We therefore focused on the preparation of multiple core α-fucose decorated 
N-glycans and structures with terminal LDN, LDNF or Lewis X-motifs. We centered our 
attention in glycosyltransferases available for recombinant expression that come from two 
Enzyme Expression system 
Bovine milk β-1,4 GalT86,87 Escherichia coli 
C. elegans β-1,4-GalNAcT82 Pichia pastoris 
C. elegans α-1,3-FucT (CeFUT6)90,84 Pichia pastoris 
C. elegans α-1,3-FucT core type (CeFUT1)90,84 Pichia pastoris 
C. elegans α-1,6-FucT core type (CeFUT8)79 Pichia pastoris 
A. thaliana α-1,3-FucT core type (AtFucTA)83 Pichia pastoris 
  
CHAPTER 1 Chemoenzymatic synthesis 
 
 
61 
model organisms, such as the nematode Caenorhabditis elegans and the plant Arabidopsis 
thaliana. 
C. elegans express a high number of fucose containing N-glycans, and it is able to 
accommodate up to three fucose residues in the chitobiose core of N-glycans.80,81 
Moreover, the β-1,4-galactosaminyltransferase activity involved in the LDN synthesis as 
well as the α-1,3-fucosyltransferase able to prepare Lewis X like structures have been 
identified.82 On the other hand, A. thaliana express core α-1,3-fucose83 and β-1,2-xylose 
modifications on its N-glycans. Our group has participated in the characterization of some 
of these enzymes using glycan microarrays84 and therefore, expression of these and some 
other enzymes has been set up in our laboratory. 
In this thesis P. pastoris strains encoding four different fucosyltransferases: AtFucTA, 
CeFUT1, CeFUT6, CeFUT8 and one N-acetylgalactosaminetransferase GalNAcT were used. 
The gene encoding AtFucTA was originally identified and isolated from the Arabidopsis 
thaliana plant.83,85 The enzyme possesses core α-1,3-fucosyltransferase activity and is 
involved in the synthesis of N-glycans specific to plants and invertebrates which have at 
least one non-reducing terminal N-acetylglucosamine residue on the 3-arm (Figure 12, A-I). 
CeFUT1, CeFUT6 and CeFUT8 were identified in C. elegans. CeFUT1 exhibit core α-1,3-
fucosyltransferase activity similar to AtFucTA, however its substrate requirement differs.79 
Unlike the plant enzyme, the nematode CeFUT1 accepts paucimannose N-glycans lacking 
terminal GlcNAc residues (Figure 12, A-II). Nematode CeFUT6 exhibits dual activity. It has 
been described to synthesize Lewis X type motifs in vitro but the C. elegans glycome does 
not contain these type of structures and the in vivo activity of the enzyme has been 
established recently, CeFUT6 is capable to introduce α-1,3-fucose in the distal GlcNAc of 
truncated N-glycans lacking 6-arm (Figure 12, C).84 CeFUT8 is a homologue of mammalian 
core α-1,6-fucosyltransferase, with the typical substrate specificity for this type of enzyme, 
requiring the presence of a non-reducing terminal N-acetylglucosamine residue (Figure 12, 
B).80 The N-acetylgalactosaminetransferase from C. elegans decorates terminal, non-
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reducing GlcNAc moieties with β-1,4-GalNAc residues creating LDN epitopes (Figure 12, 
D).82 
 
Figure 12. Schematic representation of recombinant glycosyltransferases activities and their 
substrate specificity; A-I. α-1,3-fucosyltransferase activity of AtFucTA; A-II. α-1,3-fucosyltransferase 
activity of CeFUT1 towards paucimannose N-glycans; B. α-1,6-fucosyltransferase activity of CeFUT8; 
C-I. α-1,3-fucosyltransferase activity of CeFUT6 towards distal GlcNAc of truncated N-glycans; C-II. 
Lewis X type α-1,3-fucosyltransferase activity of CeFUT6; D. β-1,4-N-acetylgalactosaminetransferase 
activity. 
The protein expression in P. pastoris is summarized in Figure 13, the frozen glycerol stocks 
of recombinant P. pastoris were inoculated into agar plates containing ZeocinTM as selection 
marker. The agar plates were incubated at 30°C until yeast colonies appeared. A single 
colony was selected and inoculated in a pre-culture medium containing glycerol as carbon 
source. The generation of the biomass was monitored by measuring the absorbance at 600 
nm (OD600nm=1 corresponds to 3x107 cells/mL).  
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Figure 13. Schematic representation of the recombinant proteins expression in P.pastoris system; 1. 
Frozen glycerol stock is inoculated on the agar plate; 2. A single colony is selected and introduced to 
the pre-culture medium; 3. The growth of the yeast is controlled by the OD600 measurement; 4. Cells 
are seeded in medium for protein expression; 5. The protein expression is induced by the methanol 
(1%) addition; 6. The protein expression is monitored by the gel electrophoresis or Western Blot and 
the cell growth by OD measurements: a. absorbance at 600 nm at different time points after CeFUT1 
protein induction by MeOH addition, b. image of CeFUT1 protein expression taken at different time 
points monitored by Western blot detected with Anti-His tag antibody; 7. Collection of the soluble 
proteins; 8. Purification of the His-tagged proteins on the NTA-Ni cartridge; 9. Purified recombinant 
protein. 
 
After the initial step for biomass generation, cells were collected by centrifugation and 
seeded to OD600nm=1 in medium for protein expression, in this case containing methanol as 
sole carbon source. The induction of protein was maintained by the addition of methanol 
(1%) every 24 hours and protein expression in the medium supernatant was monitored by 
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gel electrophoresis and/or by Western Blot. In our case, the optimal time for yeast 
harvesting was 72 hours after protein induction. At this point, the P. pastoris culture 
reaches the steady state of growth and the amount of protein expressed reaches a plateau 
as shown by Western Blot analysis (Figure 13). After 72h of protein expression the culture is 
centrifuged and the protein presented in the medium was purified by immobilized metal 
affinity chromatography (IMAC) or used directly after concentration by ultracentrifugation. 
 
All expressed fucosyltransferases contain a hexahistidine tag (6xHis tag) on their N-
terminus and they were purified using Ni-NTA (nitrilotriacetic acid) columns (Figure 14, A).  
 
Figure 14. Purification of the recombinant proteins using immobilized metal affinity chromatography 
(IMAC); A. Ni-NTA loaded column and the Ni-His complex; B. Chromatogram showing loading, 
washing and elution steps of the recombinant protein purification; C. Collected fractions monitored 
by gel electrophoresis; D. Collected fractions monitored by the Western Blot with the anti-His 
antibody. 
His-tagged recombinant proteins expressed high affinity towards nickel and forming stable 
complexes which could be trapped on the column. At the end, each Ni2+ coordinates with 
one nitrilotriacetic acid and two histidines from the recombinant protein. The protein is 
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eluted from the column by using an imidazole gradient which competes for binding to Ni-
NTA and causes protein elution from the column (Figure 14, B). Protein fractions were 
analyzed by gel electrophoresis and/or by Western Blot (Figure 14, C-D) and dialyzed to 
remove imidazole and/or concentrated by ultracentrifugation. Purified recombinant 
fucosyltransferases were stored at -4ºC and were highly stable. 
 
1.5.2 Expression of bovine milk β1,4- galactosyltransferase in E. coli 
 
Bovine milk galactosyltransferase (β1,4-GalT) is a well-studied enzyme which catalytic 
domain has been successfully cloned and expressed in E. coli, as previously described.86,87 
This enzyme catalyzes the transfer of galactose from UDP-galactose to terminal N-
acetylglucosamine residues and it is used for elongation of oligosaccharide chains (Figure 
15, A).  
                                                                     
 
Figure 15. β-1,4-GalT;  
A. Specificity of enzyme; 
B. SDS-PAGE analysis of 
protein expression present 
in the soluble fraction and in 
pellet after 1h, 2h and 3h; 
C. Purification of GalT on the 
Ni-NTA column;  
D. SDS-PAGE of collected 
fractions A1-A5. 
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E. coli cell line containing the catalytic domain of β-1,4-GalT gene was seeded in Luria 
Bertani (LB) agar plates containing the appropriate antibiotic and incubated at 37°C 
overnight. A single colony was inoculated in liquid LB and incubated overnight. The initial 
culture was diluted and bacterial growth was maintained at 37ºC until cells reached the 
OD600nm value of 0.6-0.7. At this point, protein expression was induced by the addition of 
isopropyl β-D-1-thiogalactopyranoside (IPTG) and monitored at different time points by gel 
electrophoresis (Figure 15, B).  
Protein expression was analyzed both in the cell lysate supernatant and in the bacterial 
pellet. An over expressed protein of around 37 kDa was found in the bacterial pellet 
expressed as inclusion bodies. The washed inclusion bodies were folded as previously 
described in the literature and purified by NiNTA affinity chromatography to yield the 
functional β1,4-GalT.86 
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1.6 Diversification of G1-G6 N-glycans with recombinant glycosyltransferases 
 
Having fully characterized N-glycans G1-G6 (Chapter 1 Section 1.2) and purified, active 
recombinant glycosyltransferases (Chapter 1 Section 1.5) we have further performed the 
enzymatic diversification of the synthetic structures in solution. The key aspect of this 
strategy is based on previous knowledge of substrate specificity of enzymes used during the 
study, mentioned in the Sections 1.5.1 and 1.5.2 (Figure 12, Figure 15). Taking into account 
the previously described substrate specificity of glycosyltransferases and the ‘order’ of their 
action in vivo, GTs can be easily translated into the in vitro situation, and be further used as 
a synthetic tool for the substrate diversification.  
Glycosyltransferases are very specific both for the sugar-nucleotide glycosyl donor and the 
acceptor sugar. For example, in mammals up to seven fucosyltransferases act on the 
disaccharide substrate Galα-1,3/4-GlcNAc but their specificities differ. A common feature of 
the family of enzymes transferring fucose onto the GIcNAc residue is that they do not 
tolerate substitution on position-6 of the galactose residue, indicating that the 
corresponding hydroxyl group is involved in substrate binding to the active site.  
In our study, xylose containing synthetic N-glycans G1-G6 have been used as a starting 
point for their further diversification by the action of recombinant glycosyltransferases. 
First the fucosyltransferases were applied. Based on the microarray-assisted probing of 
CeFUT8 and AtFucTA performed in our laboratory88 and the earlier literature80 it was 
shown, that core α-1,6-fucosylation occurs prior to α-1,3-fucosylation and that the α-1,3- 
fucosylated compounds are no longer substrate for the CeFUT8. Fucosylated or 
bisfucosylated compounds can be treated with GalT or GalNAcT resulting in the installation 
of terminal β-1,4-linked LN and LDN elements on the non-reducing GlcNAc of glycans 
antennae. When the terminal β-1,4-Gal and β-1,4-GalNAc are introduced prior the core 
fucosylation, the subsequent installation of α-1,6-fucose moieties in the reducing GlcNAc is 
impeded. At the end, LN or LDN decorated glycans can be further diversify with CeFUT6, 
which introduces α-1,3-fucose to the GlcNAc of antennae, creating corresponding Lewis X 
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compounds. As mentioned in the Section 1.5.1 of this Chapter, besides the Lewis X type 
fucosyltransferase activity of CeFUT6, the enzyme can also catalyze the fucosylation of the 
distal GlcNAc of truncated N-glycans, both paucimannose and with non-reducing GlcNAc on 
the 3-arm (See Figure 17, G41 and G48).84 In both cases, only glycans without further 
substituents in O-6 of the central β-mannose are tolerated. Here, as an additional 
constraint, we found that the presence of a core xylose impedes the fucosylation with 
CeFUT6 on glycans which are otherwise good substrates for the enzyme.89 This behavior 
was demonstrated in solution followed by MALDI-TOF MS and on glycan arrays, prepared 
by the printing the synthetic structures G1-G6 and the corresponding N-glycans lacking β-
1,2-xylose available in the lab on NHS-activated glass slides (Figure 16). A further 
description of the microarray technique will be given in Chapter 2, here it is only important 
to mention that glycan arrays can be a suitable and fast tool for the screening of enzyme 
specificity.  
 
Figure 16. Screening for CeFUT6 substrates on the glycan array; A. Enzymatic on-chip elongation 
with CeFUT6 (a); the N-glycan microarray image after incubation with fucose-recognizing AAL-555 
lectin (b); B. Mean fluorescence intensities of the CeFUT6-incubated (fucosylated) array after 
incubation with AAL-555 lectin.  
The structures immobilized on the microarray surface were incubated with C. elegans α-1,3 
fucosyltransferase CeFUT6 in the presence of GDP-fucose. The presence of enzymatically 
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extended structures was verified by incubation with fluorescently tagged fucose specific 
Aleuria aurantia lectin (Figure 16). As a result of the CeFUT6 fucosyltransferase action on 
the xylosylated compounds G1-G6, only Lewis X or LDNF element can be introduced, never 
α-1,3 fucose of the innermost GlcNAc of chitobiose core. 
 
In general, the synthesis of target compounds involves up to 4 subsequent elongations with 
recombinant glycosyltransferases starting with core fucosylation/s (α-1,6 prior α-1,3; 
CeFUT8, AtFucTA, CeFUT1), followed by terminal β-1,4 GalT or β-1,4 GalNAcT modifications 
and the final introduction of Lewis X type element. 
In addition, the paucimannose compounds G35-G39 were accessible by incubation of 
several enzymatically diversified N-glycans or biantennary compound G6 (see Figure 17, 
orange arrows) with a commercially available β-N-acetyl-glucosaminidase from Canavalia 
ensiformis, which cleaves glycosidic bonds at terminal GlcNAc moieties of N-glycan 
antennae. Enzymatic reaction could be easily followed by MALDI-TOF mass spectrometry 
and reaction was continued until a single product was formed. After each enzymatic 
elongation, the reaction product was purified on the reverse phase C18 cartridges and fully 
characterized by NMR and mass spectrometry.  
At this point, it is necessary to point out the great effectiveness of enzymatic preparation of 
carbohydrates. Starting from six synthetic N-glycan structures and by the combine action of 
6 recombinant glycosyltransferases and 1 commercially available glycosyl hydrolase, we 
could achieve the formation of 33 new fully characterized N-glycan structures. The 
enzymatic reactions proceeded with complete stereo- and regioselectivity leading to the 
formation of desired products in high yields. 
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1.7 Summary 
 
In this chapter, the chemoenzymatic synthesis of 39 β-1,2-xylosylated N-glycans carrying 
core and terminal modifications, including α-1,3- or/and α-1,6-core fucosylation, LN, LDN 
and Lewis X elements (Figure 18) was described. In the first part, we have focused on the 
modular assembly of carbohydrates leading to the six synthetic structures G1-G6. Later we 
have described the expression of recombinant glycosyltransferases available in our 
laboratory and finally, their use as complementary tool to the carbohydrate synthesis 
towards diversification of synthetic structures (compounds G7-G39).  
Some of the chemoenzymatically prepared structures are of biological relevance in the field 
of helminth infections as well as in food allergies. Therefore, in the next chapters we will 
describe the preparation of glycan arrays including above mentioned compounds and 
glycan array-based screenings of C-type lectin receptors which might be involved in the 
pathogen recognition, as well as monoclonal and polyclonal antibodies of mice and humans 
suffering from S. mansoni infections.  
 
Figure 18. List of the total number of xylosylated N-glycans prepared chemoenzymatically. 
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1.8 Experimental Part 
 
General Methods 
 
Materials: Chemicals were purchased from Sigma-Aldrich or Acros Organics and were used 
without further purification. All reaction solvents were dried over activated 4Å or 3Å 
molecular sieves. Thin layer chromatography was carried out using Merck aluminium sheets 
silica gel 60 F254 and visualized by UV irradiation (254 nm) or by staining with vanillin 
solution The recombinant enzymes α-1,3-fucosyltransferases (AtFucTA) from Arabidopsis 
Thaliana, α-1,6-fucosyltransferase, (CeFUT8), core α-1,3-fucosyltransferases 
(CeFUT6/CeFUT1) and β-1,4-N-acetylgalactosaminyltransferase from C. elegans, bovine 
milk β-1,4-galactosyltransferase were expressed as described previously.90,79,82,83,84,85,86,87 β-
N-acetylglucosaminidase from Canavalia ensiformis (Jack bean) was purchased from Sigma 
Aldrich. Uridine 5’-diphosphogalactose disodium salt (UDP-Gal), uridine 5’-diphospho-N-
acetylgalactosamine disodium salt (UDP-GalNAc) and guanosine 5’-diphospho-β-L-fucose 
sodium salt (GDP-Fuc) were purchased from Carbosynth (San Diego, USA). Aleuria aurantia 
lectin (AAL) lectin was purchased from VectorLabs and was labeled with Hilyte PlusTM 555 
protein labeling kits from AnaSpec, Freemont, USA.  
Microwave irradiation was performed on Biotage Initiator monomode oven, (Biotage AB, 
Uppsala, Sweden). Hydrogenation reactions were performed in continuous-flow 
hydrogenation reactor H-Cube® and CatCarts® 10% Pd/C from ThalesNano Nanotechnology 
Inc. (Budapest, Hungary). Purifications of compounds were performed on: size-exclusion 
chromatography using LP2 gel from Biorad (Hercules, USA), SampliQ high performance 
graphitized carbon cartridges (1 mL) from Agilent Technologies (Santa Clara, CA, USA), C18 
Sep-Pak Cartridges (1 mL) from Waters (Milford, Massachusetts, USA), flash 
chromatography using Merck 62Å 230-400 mesh silica gel or on a Biotage SP4 automated 
flash chromatography system, (Biotage AB, Uppsala Sweden) employing prepacked silica 
cartridges. All aqueous solutions were prepared from nanopure water produced with a 
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Diamond UV water purification system (Branstead International, IA, Madrid, Spain). Pooled 
glycan containing fractions were lyophilized on an ALPHA-2-4 LSC freeze-dryer from Christ, 
Osterode, Germany. All compounds in organic solvents were concentrated using rotary 
evaporator.  
1H and 13C spectra were acquired on Bruker 500 MHz spectrometer or on Bruker BioSpin 
GmbH 800 MHz. 13C-HSQC spectra recorded with Bruker BioSpin GmbH 800 MHz use a 
folded window in the F1(13C) dimension (with a sweepwidth value of 40 ppm). Chemical 
shifts were reported in ppm (δ) and referenced to the residual signal of the solvent used 
(MeOD 4.87 ppm; CDCl3 7.26ppm; D2O 4.79 ppm). Plitting patterns are designated as s, 
singlet; d, doublet; t, triplet; m, multiplet. Coupling constants (J) are reported in Hz. High 
resolution mass spectra were acquired on a Waters LCT Premier XE instrument, (Waters, 
Manchester, UK) equipped with a standard ESI source by direct injection. The instrument 
was operated with a capillary voltage of 1.0 kV and a cone voltage of 200 V. Cone and 
desolvation gas flow were set to 50 and 600 L/h, respectively; source and desolvation 
temperatures were 100 ºC. MALDI-TOF mass analyses were performed on an 
Ultraflextreme III time-of-flight mass spectrometer equipped with a pulsed N2 laser (337 
nm) and controlled by FlexControl 3.3 software (Bruker Daltonics). The acquisitions were 
carried out in positive ion reflectron mode at a laser frequency of 500 Hz. Microarrays were 
printed employing a robotic non-contact piezoelectric SciFLEXARRAYER spotter S11 
(Scienion, Berlin, Germany). Fluorescence measurements were performed in an Agilent 
G2565BA microarray scanner system (Agilent Technologies, Santa Clara, USA) with 10 µm 
resolution, using 2 lasers (532 nm, 633 nm). Quantification of fluorescence was achieved by 
ProScanArray® Express software from Perkin Elmer, Shelton, USA.  
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Chemical synthesis of N-glycans G1-G6: 
 
5-azidopentyl 4,6-O-benzylidene-3-O-(2-naphthylmethyl)-β-D-mannopyranosyl)-(14)-
3,6-di-O-benzyl-2-deoxy-2-phthalimido-β-D-glucopyranosyl-(14)-3,6-di-O-benzyl-2-
deoxy-2-phthalimido-β-D-gluco-pyranoside (2): To a solution of trisaccharide 1 (200 mg, 
132.9 µmol) in CH2Cl2 (3 mL) 12 mL of Mg(OMe)2 were added. The reaction mixture was 
heated to 80 ºC by microwave irradiation (4 cycles of 30 minutes). The suspension was 
filtered through a pad of Celite® and the filtrate was neutralized with 10% acetic acid. The 
organic layer was washed with saturated NaHCO3, water, saturated NaCl, dried over MgSO4 
and concentrated. The crude product was purified by flash column chromatography (SiO2, 
Hexane:EtOAc, 3:1 to 2:1) to afford the title compound as a white foam (167 mg, 86%); 
[α]20589= +14.2 (c, 0.5, CHCl3); 1H NMR (500 MHz, CDCl3) δ 7.87–7.66 (m, 12H, Ar), 7.48–7.46 
(m, 5H, Ar), 7.39–7.29(m, 8H, Ar), 7.24–7.14 (m, 5H, Ar), 7.02-7.00 (m, 2H, Ar), 6.97-6.88 
(m, 5H, Ar), 6.78-6.74 (m, 3H, Ar), 5.51 (s, 1H, OCHPh), 5.27 (d, J= 8.7 Hz, 1H, H-1Aβ), 4.93–
4.90 (m, 2H, H-1Bβ, CH2Ph), 4.87–4.82 (m, 3H, CH2Ph ), 4.65 (s, 1H, H-1Cβ), 4.54-4.35 (m, 
7H, H-3A, CH2Ph), 4.24-4.20 (m, 2H, H-2A, H-4B), 4.14-4.09 (m, 4H, H-2B, H-6aC, H-3B, H-
4A), 4.05-4.00 (m, 2H, H-2C, H-4C), 3.69-3.62 (m, 2H, H-6aA, OCHH(CH2)4N3), 3.58-3.48 (m, 
4H, H-6bA, H-6aB, H-6bC, H-3C), 3.41 (dd, J6a-6b= 11.1 Hz, J6b-5= 3.7 Hz, 1H, H-6bB), 3.34-3.22 
(m, 3H, H-5A, H-5B, OCHH(CH2)4N3), 3.14-3.09 (m, 1H, H-5C), 2.91-2.81 (m, 2H,-CH2N3), 
1.40-1.28 (m, 4H, OCH2CH2CH2CH2CH2N3), 1.10-1.02 (m, 2H, O(CH2)2CH2(CH2)2N3); 13C NMR 
(126 MHz, CDCl3) δ 138.7-123.3, 101.7, 100.8, 98.2, 97.1, 79.1, 78.3, 75.8, 74.8, 74.6, 74.5, 
74.5, 73.4, 72.7, 72.6, 69.9, 69.0, 68.6, 68.3, 67.9, 66.8, 56.7, 55.8, 51.2, 29.8, 28.4, 23.1; 
HRMS (MALDI-Tof) m/z [M+Na]+ calculated for C85H83N5O18 1484.5625, found 1484.5649.  
 
5-azidopentyl (2,3,4-tri-O-acetyl-β-D-xylopyranosyl)-(12)-(4,6-O-benzylidene-3-O-(2-
naphthylmethyl)-β-D-mannopyranosyl)-(14)-(3,6-di-O-benzyl-2-deoxy-2-phthalimido-β-
D-glucopyranosyl)-(14)-3,6-di-O-benzyl-2-deoxy-2-phthalimido-β-D-glucopyranoside 
(4): A mixture of 2 (172 mg, 117.6 µmol) and 3 (125 mg, 297.1 µmol) was dried under high 
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vacuum overnight. The mixture was dissolved in anhydrous CH2Cl2 (1.1 mL) and freshly 
activated molecular sieves (3Å) were added. After stirring for 40 minutes at room 
temperature, the mixture was cooled to 0oC and 5% solution of trifluoromethanesulfonic 
acid (50 µL, 0.28 eq) in CH2Cl2 was slowly added. The mixture was allowed to warm up to 
room temperature and stirred for 2h. The reaction mixture was then quenched with Et3N, 
filtered through a pad of Celite® and concentrated. The crude product was purified by 
automated flash column chromatography (toluene:acetone 10:1) to afford the title 
compound (128 mg, 68%) as a white foam; [α]20589= -4 (c, 0.5, CHCl3); 1H NMR (500 MHz, 
CDCl3) δ 7.87-7.78 (m, 4H, Ar), 7.74-7.63 (m, 7H, Ar), 7.51-7.43 (m, 5H, Ar), 7.40-7.28 (m, 
9H, Ar), 7.23-7.16 (m, 2H, Ar), 7.15-7.09 (m, 3H, Ar), 7.06-7.02 (m, 2H, Ar), 6.99-6.93 (m, 4H, 
Ar), 6.91-6.86 (m, 1H, Ar), 6.80-6.73 (m, 3H, Ar), 5.46 (s, 1H, OCHPh), 5.30 (d, J = 8.4 Hz, 1H, 
H-1Aβ), 5.10-5.07 (m, 2H, H-1Xβ, H-3X), 5.04 (dd, J=3.47Hz, J=5.4Hz, 1H, H-2X), 4.94-4.92 
(m, 1H, H-1Bβ), 4.90-4.82 (m, 5H, H-4X, OCH2Ph), 4.60 (dd, J5xa-5xb=13Hz, J5xa-4=3.4Hz, 1H, H-
5Xa) 4.58-4.48 (m, 4H, OCH2Ph, H-1Cβ), 4.43 (d, J= 12.1 Hz, 1H, OCH2Ph), 4.38-4.32 (m, 2H, 
H3A ,OCH2Ph), 4.26-4.19 (m, 3H, OCH2Ph, H-4B, H-2A), 4.14-4.06 (m, 4H, H-2C, H-3B, H-2B, 
H-6aC ), 4.03-3.99 (m, 1H, H-4A), 3.89 (t, J= 9.5 Hz, 1H, H-4C), 3.70-3.62 (m, 2H, 
OCHH(CH2)4N3, H-6aB), 3.55 (d, J= 10.6 Hz, 1H, H-6bB), 3.52-3.35 (m, 5H, H-5Xb, H-6bC, H-
3C, H-6aA, H-6bA), 3.34-3.28 (m, 2H, H-5A, H-5B), 3.27-3.21 (m, 1H, OCHH(CH2)4N3), 3.12-
3.05 (m, 1H,H-5C), 2.93-2.80 (m, 2H, -CH2N3), 2.10 (s, 3H, CH3CO), 2.02, 1.99 (2 s, 2x3H, 
CH3CO), 1.41-1.28 (m, 4H, OCH2CH2CH2CH2CH2N3), 1.12-1.01 (m, 2H, O(CH2)2CH2(CH2)2N3); 
13C NMR (126 MHz, CDCl3) δ 170.1, 169.5, 169.1, 167.7, 138.8-131.8, 129.9-123.3, 102.0, 
101.7, 99.4, 98.2, 97.2, 80.6, 78.4, 75.9, 76.0, 75.8, 75.2, 74.8, 74.6, 74.5, 73.5, 73.4, 72.8, 
72.1, 69.1, 69.0, 68.7, 68.5, 68.4, 68.3, 68.3, 67.4 60.3,  56.7, 55.9, 51.2, 28.8, 28.4, 23.1, 
21.1- 20.8; HRMS (ESI) m/z [M+NH4]+ calculated for C96H97N5O25NH4 1737.6811, found 
1737.6862.  
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5-azidopentyl (2,3,4-tri-O-acetyl-β-D-xylopyranosyl)-(12)-(4,6-O-benzylidene-β-D-
mannopyranosyl)-(14)-(3,6-di-O-benzyl-2-deoxy-2-phthalimido-β-D-glucopyranosyl)-
(14)-3,6-di-O-benzyl-2-deoxy-2-phthalimido-β-D-glucopyranoside (11): Tetrasaccharide 
4 (110 mg, 63.9 µmol) was dissolved in a mixture of CH2Cl2:MeOH (0.6 ml, 4:1) and treated 
with 2,3-dichloro-5,6-dicyano-1,4-benzoquinone (DDQ) (35 mg, 154 µmol). After 90 min. of 
stirring at room temperature, the reaction was quenched with saturated NaHCO3 and 
extracted with EtOAc (3x). The combined organic layers were washed with saturated 
NaHCO3, water, saturated NaCl, dried over MgSO4 and concentrated. The crude product was 
purified by flash column chromatography (SiO2, hexane:EtOAc 4:2 to 2:2) to afford the title 
compound (60 mg, 60%) as a white solid; [α]20589= -8.6o , (c, 0.5, CHCl3); 1H NMR (500 MHz, 
CDCl3) δ 7.85-7.28 (m, 23H, Ar), 7.04-6.78 (m, 10H, Ar), 5.41 (s, 1H, OCHPh), 5.28 (d, J= 8.1 
Hz, 1H, H-1Aβ), 5.24 (t, 1H, J=8.4 Hz, H-3X), 5.02-4.95 (m, 2H, H-2X, H-4X), 4.94-4.92 (m, 1H, 
H-1Bβ), 4.86 (d, 1H, J=12.8 Hz, OCHHPh), 4.81– 4.78 (m, 2H, J1-2=6.7 Hz, J=11.9 Hz, OCHHPh, 
H-1Xβ), 4.66 (s, 1H, H-1Cβ), 4.61-4.44 (m, 5H, 3x OCH2Ph), 4.32 (d, 1H, J=12.2Hz, OCHHPh), 
4.29-4.20 (m, 4H, H-4A, H-3B, H-5aX, H-2A), 4.15-4.11 (m, 2H, H-2B, H-4B), 4.05-4.00 (m, 2H, 
H-6aC, H-3A), 3.91 (d, J= 2.7 Hz, 1H, H-2C), 3.70-3.65 (m, 2H, H-6aA, OCHH(CH2)4N3), 3.59-
3.47 (m, 4H, H-6aB, H-6bA, H-4C, H-3C), 3.38-3.35 (m, 3H, H-5X, H-6bC, H-6bB), 3.34-3.28 
(m, 2H, H-5A, H-5B), 3.27-3.21 (m, 1H, OCHH(CH2)4N3), 3.12-3.05 (m, 1H, H-5C), 2.93-2.80 
(m, 2H, -CH2N3), 2.10, 2.02, 1.99 (3 s, 3x3H, CH3CO), 1.41-1.28 (m, 
4H,OCH2CH2CH2CH2CH2N3), 1.12-1.01 (m, 2H, O(CH2)2CH2(CH2)2N3); 13C NMR (126 MHz, 
CDCl3) δ 170.0, 169.9, 169.4, 138.8, 138.6, 137.7, 137.3, 134.0, 131.5, 129.2-126.5, 123.3, 
102.2, 102.0, 101.0, 98.3, 97.2, 80.9, 79.0, 78.9, 76.1, 74.7, 74.6, 74.5, 73.7, 72.7, 71.1, 70.8, 
70.4, 69.0, 68.6, 68.5, 68.3, 68.1, 67.5, 62.1, 56.6, 55.9, 51.2, 29.8, 29.8, 29.7, 28.8, 28.4, 
23.1, 21.1, 20.9, 20.9; HRMS (ESI) m/z [M+NH4]+ calculated for C96H97N5O25 1737.6811, 
found 1737.6862.  
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5-azidopentyl (3,4,6-tri-O-acetyl-2-deoxy-2-phthalimido-β-D-glucopyranosyl)-(12)-
(3,4,6-tri-O-acetyl-α-D-mannopyranosyl)-(13)-[2,3,4-tri-O-acetyl-β-D-xylopyranosyl-
(12)]-(4,6-O-benzylidene-β-D-mannopyranosyl)-(14)-(3,6-di-O-benzyl-2-deoxy-2-
phthalimido-β-D-glucopyranosyl)-(14)-3,6-di-O-benzyl-2-deoxy-2-phthalimido-β-D-
glucopyranoside (12): A mixture of 11 (55 mg, 34.79 µmol) and 7 (50 mg, 57.6 µmol) was 
dried under high vacuum overnight, then dissolved in anhydrous CH2Cl2 (1.1 mL) and freshly 
activated ground molecular sieves (3Å) were added. After 1h of stirring at room 
temperature, the mixture was cooled to -40oC and TMSOTf (1 µL, 5.52 µmol) was added. 
After 1h the reaction mixture was quenched with Et3N, filtered through a pad of Celite® and 
concentrated. The crude product was purified by flash column chromatography (hexane: 
EtOAc, 3:2 to 2:3) to afford the title compound as a white foam (63 mg, 82%); [α]20589= -21 
(c, 0.5, CHCl3); 1H NMR (500 MHz, CDCl3) δ 7.86-7.53 (m, 12H, Ar), 7.77-7.29 (m, 15H, Ar), 
7.02-6.79 (m, 10H, Ar), 5.49 (dd, J3-2= 10.9 Hz, J3-4= 9.3 Hz, 1H, H-3G), 5.36 (s, 1H, OCHPh), 
5.31 (d, J1-2= 8.4 Hz, 1H, H-1Aβ), 5.09-5.06 (m, 2H, H-3M, H-3X), 5.01 (t, J = 10.01, J =11.1 Hz, 
1H, H-4M), 4.98-4.95 (m, 2H, H-4G, H-2X), 4.95-4.87(m, 5H, H-1Bβ, H-1Mα, H-1Xβ, OCHHPh, 
H-1Gβ), 4.85-4.80 (m, 2H, H-4X, OCHHPh), 4.66 (d, J=11.8 Hz,1H, OCH2Ph), 4.57-4.48 (m, 3H, 
OCH2Ph), 4.43 (s, 1H, H-1Cβ), 4.41-4.36 (m, 2H, H-5aX, H-3A), 4.31-4.24 (m, 3H, OCH2Ph, H-
2G), 4.24-4.18 (m, 2H, H-2A, H-4B), 4.14-4.09 (m, 2H, H-2B, H-3B), 4.07-4.02 (m, 3H, H-6aC, 
H-2M, H-4A), 3.95 (dd, J6a-6b= 12.4 Hz, J6a-5= 3.7 Hz, 1H, H-6aG), 3.90-3.87 (m, 1H, H-5M), 
3.79 (d, J= 3.4 Hz, 1H, H-2C), 3.72-3.63 (m, 6H, H-6bG, OCHH(CH2)4N3, H-6aA, H4C, H-6a,bM), 
3.59 (dd, J5a-5b= 12.4 Hz, J5b-4= 4.2 Hz, 1H, H-5bX), 3.55-3.50 (m, 2H, H-6bA, H-6aB), 3.45-3.41 
(m, 2H, H-3C, H-6bB), 3.36-3.29 (m, 3H, H-5A, H-5B, H-6bC), 3.27– 3.22 (m, 1H, 
OCHH(CH2)4N3), 2.94– 2.90 (m, 1H, H-5C), 2.89-2.81 (m, 2H, -CH2N3), 2.11-2.10 (m, 1H, H-
5G), 2.07, 2.05, 2.03, 1.98, 1.97, 1.94, 1.87, 1.86 (9 s, 9x3H, CH3CO), 1.38-1.29 (m, 4H, 
OCH2CH2CH2CH2CH2N3), 1.10-1.03 (m, 2H, O(CH2)2CH2(CH2)2N3); 13C NMR (126 MHz, CDCl3) δ 
170.7, 170.5, 170.4, 170.3, 169.8, 169.5, 169.3, 169.0, 138.9, 138.8, 138.6, 137.9, 137.6, 
134.35, 133.8, 131.5, 130.3, 129.1, 128.9, 128.7, 128.7, 128.6, 128.3, 128.2, 128.0, 127.8, 
127.5, 127.5, 127.1, 127.0, 123.7, 123.3, 102.5, 101.3, 99.6, 98.4, 98.2, 97.2, 95.8, 79.8, 
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78.4, 76.6, 76.1, 74.6, 74.6, 73.6, 72.8, 72.7, 71.2, 70.5, 69.2, 69.0, 68.8, 68.7, 68.5, 68.3, 
67.9, 66.7, 66.2, 65.5, 63.2, 61.1, 60.3, 56.6, 55.8, 54.2, 51.2, 29.8, 28.8, 28.4, 23.1, 21.1, 
21.0, 20.9, 20.8, 20.8, 20.7, 20.6; HRMS (MALDI-Tof) m/z [M+Na]+ calculated for 
C117H124N6O42 2307.7644, found 2307.7554.  
 
5-azidopentyl [2,3,4-tri-O-acetyl-β-D-xylopyranosyl-(12)]-[2-O-acetyl-3,4,6-tri-O-benzyl-
α-D-mannopyranosyl-(13)]-(4,6-O-benzylidene- β-D-mannopyranosyl)-(14)-(3,6-di-O-
benzyl-2-deoxy-2-phthalimido-β-D-glucopyranosyl)-(14)-3,6-di-O-benzyl-2-deoxy-2-
phthalimido-β-D-glucopyranoside (13): A mixture of 11 (43mg, 27.2 µmol) and 5 (25mg, 
37.6 µmol) was dried under high vacuum overnight. The mixture was dissolved in 
anhydrous CH2Cl2 (0.6 mL) and freshly activated molecular sieves (3Å ) were added. After 
stirring for 40 minutes at room temperature, the mixture was cooled to -20oC and 0.1 eq of 
trimethylsilyl trifluoromethanesulfonate TMSOTf (10% in CH2Cl2, 4.5 µL, 2.75 µmol) was 
slowly added. After stirring for 45 min the suspension was quenched with Et3N, filtered 
through a pad of Celite® and concentrated. The crude product was purified by flash column 
chromatography (SiO2; hexane:EtOAc, 4:2 to 3:2) to afford the pentasaccharide as a white 
solid (52 mg, 94%); [α]20589= -5 (c, 0.5, CHCl3); 1H NMR (500 MHz, CDCl3) δ 7.91 -7.66 (m, 
12H, Phth), 7.44-7.16 (m, 30H, Ar), 7.18-6.76 (m, 10H, Ar), 5.60-5.55 (m, 1H, H-2M), 5.42 (s, 
1H, OCHPh), 5.28 (d, 1H, J1-2= 8.3 Hz, H-1Aβ), 5.24-5.20 (m, 1H, H-1Mα), 5.09 (t, J3,2/4 = 6.6 
Hz, 1H, H-3X), 5.03-4.97 (m, J2-3 = 6.6Hz, J2-1= 4.4 Hz, 1H, H-2X), 4.95 (d, 1H, J1-2 = 4.4 Hz, H-
1Xβ), 4.93-4.88 (m, 2H, H-1B, CH2O), 4.84 (dd, J= 12.5 Hz, J=5.3 Hz, 2H, OCH2Ph), 4.80-4.74 
(q, 1H, J4-3= 6.6 Hz, J4-5b= 5.7 Hz, H-4X), 4.72 (d, J= 11.3 Hz, 1H, OCHHPh), 4.63 (d, 2H, 
OCHHPh, H-1Cβ), 4.59-4.44 (m, 8H, 4xOCH2Ph), 4.41-4.30 (m, 3H, OCH2Ph, H-3A), 4.26 (dd, 
J5a-5b= 12.6 Hz, J5a-4= 3.9 Hz, 1H, H-5Xa,) 4.23-4.19 (m, 2H, H-2A, H-4B), 4.11-4.09 (m, 2H, H-
2B, H-3B), 4.05-3.96 (m, 5H, H-6aC, H-2C,H-4A, H-3C, H-3M), 3.87-3.72 (m, 4H, H-4M, H-
4C,H-5M, H-6aM), 3.69-3.63 (m, 3H, H-6bM, H-6aA, OCHH(CH2)4N3), 3.54 (d, J= 10.9 Hz, 1H, 
H-6bA), 3.47-3.39 (m, 2H, H-6abB), 3.38-3.27 (m, 4H, H-6bC,H-5bX, H-5A, H-5B), 3.27-3.21 
(m, 1H, OCHH(CH2)4N3), 3.05-2.99 (m, J5-6= 9.5 Hz, J5-4= 4.7 Hz, 1H, H-5C), 2.92-2.82 (m, 2H,-
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CH2N3), 2.11, 2.03, 2.01, 1.93( 4 s, 4x3H, CH3CO), 1.37-1.27 (m, 4H, OCH2CH2 CH2CH2 CH2N3), 
1.10-1.03 (m, 2H, OCH2CH2 CH2CH2 CH2N3); 13C NMR (126 MHz, CDCl3) δ 170.1, 169.7, 169.6, 
169.2, 168.6, 167.7, 138.8, 138.7, 138.5, 138.3, 138.1, 137.8, 137.2, 133.7, 131.8, 131.5, 
128.9-127.0, 126.0, 123.8, 123.3, 102.1, 101.2, 99.7, 99.1, 98.2, 97.1, 80.6, 78.2, 77.8, 76.7, 
76.0, 75.2, 74.7, 74.6, 74.6, 74.5, 74.5, 74.3, 73.6, 73.5, 73.4, 72.7, 72.1, 71.7, 69.6, 69.1, 
69.0, 68.5, 68.4, 68.3, 68.3, 68.1, 67.2, 60.7, 56.6, 55.8, 51.2, 28.8, 28.4, 23.1, 21.2-21.0; 
HRMS (MALDI-Tof) m/z [M+Na]+ calculated for  C114H119N5O31 2076.7781, found 2076.7880. 
 
5-azidopentyl (3,4,6-tri-O-acetyl-2-deoxy-2-phthalimido-β-D-glucopyranosyl)-(1 2)-
(3,4,6-tri-O-acetyl-α-D-mannopyranosyl)-(13)-[2,3,4-tri-O-acetyl-β-D-xylopyranosyl-
(12)]-(β-D-mannopyranosyl)-(14)-(3,6-di-O-benzyl-2-deoxy-2-phthalimido-β-D-
glucopyranosyl)-(14)-3,6-di-O-benzyl-2-deoxy-2-phthalimido-β-D-glucopyranoside (14): 
Hexasaccharide 12 (69 mg, 30.18 µmol) was dissolved in dry CH2Cl2 (0.32 mL) and EtSH 
(13.5 µL) and a 10% solution of BF3.Et2O in CH2Cl2 (7.4 µL, 0.2 eq) were added. After 2h of 
stirring at room temperature, the reaction mixture was quenched with Et3N and 
concentrated. The crude product was purified by flash column chromatography (SiO2, 
hexane: EtOAc, 2:1 to 1:2) to afford the title compound as a white solid (52 mg, 79%); 
[α]20589= -3.5 , (c, 0.5, CHCl3); 1H NMR (500 MHz, CDCl3) δ 7.86-7.55 (m, 12H, Ar), 7.38-7.23 
(m, 10H, Ar), 7.06-6.78 (m, 10H, Ar), 5.78 (dd, J3-2= 10.75 Hz, J3-4= 9.21 Hz, 1H, H-3G), 5.42 
(d, J1-2= 8.4 Hz, 1H, H-1Gβ), 5.27 (d, J1-2= 8.5 Hz, 1H, H-1Aβ), 5.19-5.09 (m, 3H, H-4G, H-3X, 
H-4M), 5.05-5.02 (m, 2H, H-2X, H-3M), 4.95 (d, 1H, J1-2= 1.4Hz, H-1Mα), 4.93-4.84 (m, 5H, H-
1Bβ, H-4X, H-1Xβ, OCH2Ph), 4.59-4.48 (m, 5H, 2xOCH2Ph, H-1Cβ), 4.43-4.37 (m, 4H, OCH2Ph, 
H-2G, H-3A), 4.32 (dd, 1H, J6a-6b= 12.4Hz, J6a-5= 4.8Hz, H-6aG), 4.28 (t, 1H, J2-4= 3.6Hz, J2-3= 2.4 
Hz, H-2M), 4.24-4.17 (m, 3H, H-2A, H-5aX, H-4B), 4.14-4.08 (m, 3H, H-2B, H-3B, H-6bG), 3.99-
3.97 (m, 1H, H-4A), 3.95-3.90 (m, 2H, H-5M, H-5G), 3.84 (d, 1H, J= 2.9Hz, H-2C), 3.78 (dd, 
1H, J6a-6b= 12.1Hz, J6a-5= 2.6 Hz , H-6aM), 3.73-3.64 (m, 4H, H-6bM, H-4C, H-6aA, 
OCHH(CH2)4N3), 3.61 (dd, 1H, J6a-6b= 12.0 Hz, J6a-5= 2.7 Hz, H-6aC), 3.54-3.46 (m, 3H, H-6bA, H-
6aB, H-6bC), 3.43-3.39 (m, 2H, H-6bB, H-5bX), 3.33– 3.29 (m, 2H, H-5A, H-5B), 3.26– 3.19 (m, 
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2H, OCHH(CH2)4N3, H-3C), 2.96-2.93 (m, 1H, H-5C), 2.92-2.81 (m, 2H, -CH2N3), 2.11, 2.07, 
2.04, 2.02, 1.94, 1.91, 1.86 (9 s, 9x3H, CH3CO), 1.35-1.29 (m, 4H, OCH2CH2CH2CH2CH2N3), 
1.09-1.04 (m, 2H, O(CH2)2CH2(CH2)2N3); 13C NMR (126 MHz, CDCl3) δ 170.9, 170.6, 170.5, 
170.3, 169.8, 169.6, 169.5, 138.8, 138.5, 137.7, 134.4, 134.1, 133.8, 131.8, 131.5, 128.8-
127.0, 123.7, 123.3, 101.2, 99.8, 98.2, 97.8, 97.1, 96.9, 80.1, 79.9, 76.5, 76.1, 75.9, 74.7, 
74.6, 74.6, 74.3, 74.2, 73.5, 72.7, 71.9, 70.7, 70.3, 69.9, 69.9, 69.1, 69.0, 68.7, 68.6, 68.3, 
67.7, 66.3, 66.1, 63.1, 62.3, 62.2, 61.1, 56.6, 55.8, 54.6, 51.2, 29.8, 28.8, 28.4, 23.1, 21.1-
20.6; HRMS (MALDI-Tof) m/z [M+ Na]+ calculated for C110H120N6O42 2219.7331, found 
2219.7351. 
 
5-azidopentyl [2,3,4-tri-O-acetyl-β-D-xylopyranosyl-(12)]-[2-O-acetyl-3,4,6-tri-O-benzyl-
α-D-mannopyranosyl-(13)]-(β-D-mannopyranosyl)-(14)-(3,6-di-O-benzyl-2-deoxy-2-
phthalimido-β-D-glucopyranosyl)-(14)-3,6-di-O-benzyl-2-deoxy-2-phthalimido-β-D-
glucopyranoside (15): Pentasaccharide 13 (51 mg, 24.81 µmol) was dissolved in dry CH2Cl2 
(0.24 mL) and EtSH (10 µL, 5.7 eq) and a 10% solution of BF3.Et2O in CH2Cl2 (8.5 µL, 0.27 eq) 
were added. After 3h of stirring at room temperature the reaction mixture was quenched 
with Et3N and concentrated. The crude product was purified by flash column 
chromatography (SiO2, hexane: EtOAc, 2:1 to 1:1) to afford the title compound as a white 
solid (42 mg, 86%); [α]20589= +0.8 ,(c, 0.35, CHCl3); 1H NMR (500 MHz, CDCl3) δ 7.84 -7.64 (m, 
6H, Ar), 7.39-7.24 (m, 25H, Ar), 7.19-7.17 (m, 2H, Ar), 7.04-7.02 (m, 2H, Ar), 6.99-6.97 (m, 
2H, Ar), 6.92-6.86 (m, 3H, Ar), 6.78-6.767 (m, 2H, Ar),  5.57 (dd, 1H, J2-3= 3.2 Hz, J2-1= 1.8 Hz, 
H-2M), 5.43 (d, 1H, J1-2= 1.8 Hz, H-1Mα), 5.26 (d, J1-2= 8.3 Hz, 1H, H-1Aβ), 5.21 (t, 1H, J3-4/2= 
8.4 Hz, H-3X), 5.04 (dt, 1H, J4-3 = 8.4 Hz, J4-5a = 5.1 Hz, H-4X), 4.95 (d, 1H, J1-2= 6.6 Hz, H-1Xβ), 
4.94-4.91 (m, 1H, H-1Bβ), 4.90-4.77 (m, 5H, H-2X, 2x OCH2Ph), 4.69 (d, 1H, J1-2= 8.4 Hz, H-
1Bβ), 4.56-4.41 (m, 10H, 5xOCH2Ph), 4.28 (dd, J= 10.6 Hz, J= 8.6 Hz, 1H, H-3A), 4.22-4.10 (m, 
7H, H-5Xa, H-5M, H-2A, H-2C, H-4B, H-3B, H-2B), 4.0-3.94 (m, 2H, H-3M, H-4A), 3.85 (t, 1H, 
J4-3/5= 9.7 Hz, H-4C), 3.74 (dd, 1H, J6a-6b= 10.3 Hz, J6a-5= 1.7 Hz, H-6Ma), 3.68-3.57 (m, 5H, H-
6Ca, H-4M, OCHH(CH2)4N3, H-6Mb, H-6Ba), 3.53-3.46 (m, 3H, H-6Aab, H-6Cb), 3.44 (dd, 1H, J3-
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4= 9.7 Hz, J3-2=3.1 Hz, H-3C), 3.40 (dd, 1H, J6a-6b= 10.9 Hz, J6-5= 4.1 Hz, H-6Bb), 3.31-3.22 (m, 
4H, H-5A, H-5B, H-5Xb, OCHH(CH2)4N3), 3.08-3.04 (m, 1H, H-5C), 2.91-2.81 (m, 2H, -CH2N3), 
2.17, 2.07, 2.01, 1.79 (4 s, 4x3H, CH3CO), 1.37-1.24 (m, 4H, OCH2CH2 CH2CH2 CH2N3), 1.19-
1.03 (m, 2H, OCH2CH2CH2CH2CH2N3); 13C NMR (126 MHz, CDCl3) δ 170.4, 170.0, 169.8, 
169.6, 138.7, 138.6, 138.5, 138.3, 138.1, 137.7, 134.1, 133.9, 133.8, 131.8, 131.5, 128.7-
127.0, 123.7, 123.3, 101.9, 99.5, 98.2, 97.1, 96.9, 80.5, 79.7, 77.9, 76.1, 76.1, 75.3, 75.1, 
74.8, 74.7, 74.7, 74.6, 74.6, 73.6, 73.5, 72.7, 71.8, 71.4, 71.0, 70.8, 69.7, 69.1, 69.0, 68.6, 
68.3, 67.8, 62.9, 62.1, 56.6, 55.8, 51.2, 29.8, 28.8, 28.4, 23.1, 21.2, 21.0, 20.8, 20.7; HRMS 
(MALDI-Tof) m/z [M+ Na]+ calculated for C107H115N5O31 1988.7468, found 1988.7417. 
 
5-azidopentyl (3,4,6-tri-O-acetyl-2-deoxy-2-phthalimido-β-D-glucopyranosyl)-(12)-
(3,4,6-tri-O-acetyl-α-D-mannopyranosyl)-(13)-[2,3,4-tri-O-acetyl-β-D-xylopyranosyl-
(12)]-[(3,4,6-tri-O-acetyl-2-deoxy-2-phthalimido-β-D-glucopyranosyl)-(12)-(3,4,6-tri-
O-acetyl-α-D-mannopyranosyl)-(16)]-(β-D-mannopyranosyl)-(14)-(3,6-di-O-benzyl-2-
deoxy-2-phthalimido-β-D-glucopyranosyl)-(14)-3,6-di-O-benzyl-2-deoxy-2-phthalimido-
β-D-glucopyranoside (16): A mixture of 14 (28 mg, 12.73 µmol) and 7 (14.3 mg, 16.5 µmol) 
was dried under high vacuum overnight. The mixture was dissolved in anhydrous CH2Cl2 (3 
mL, 250 mL/mmol) in the presence of freshly activated ground 3Å MS. After 1h at room 
temperature, the mixture was cooled to -45oC and TMSOTf (3.4 µL, 0.15 eq, 1.9 µmol) was 
slowly added. After 2h the reaction mixture was quenched with Et3N, filtered through a pad 
of Celite and concentrated. The crude product was purified by flash chromatography (SiO2, 
hexane: acetone, 3:2) to afford the title compound as a wihte solid (25 mg, 70%); [α]20589= 
+8.2 , (c, 0.5, CHCl3); 1H NMR (500 MHz, CDCl3) δ 5.76-5.69 (m, 2H, H-3G, H-3G’), 5.45 (d, 
1H, J1-2 = 8.5 Hz, H-1Gβ), 5.29 (d, 1H, J1-2= 8.8 Hz, H-1G’β), 5.25 (d, 1H, J1-2= 8.4 Hz, H-1Aβ), 
5.20-5.11 (m, 5H, H-4M, H-4G, H-4M’, H-4G’, H-3X), 5.07 (dd, 1H, J3-4= 10.1 Hz, J3-2=3.3 Hz, 
H-3M), 4.96-4.86 (m, 6H, H-3M’,H-2X, H-1Bβ, H-1Mα, H-1Xβ, H-4X), 4.84 (d, 1H, J = 12.8 Hz, 
OCHHPh), 4.72 (d, 1H, J = 12.5 Hz, OCHHPh), 4.58 (d, 1H, J= 12.0 Hz, OCH2Ph), 4.52-4.43 (m, 
4H, OCH2Ph, H-1Cβ), 4.41-4.30 (m, 7H, H-1M’α, H-2G, H-2G’, OCH2Ph, H-2C, H-6Ga) 4.27-
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4.21 (m, 3H, H-6G’a, H-5Xa, H-3A), 4.17-4.08 (m, 6H, H-4B, H-2M’, H-3B, H-2A, H-2B, H-
6Gb), 3.97-3.93 (m, 4H, H-5G, H-5Xb, H-4A, H-5M), 3.83-3.71 (m, 5H, H-6Mab, H-6M’ab, H-
2C), 3.68-3.55 (m, 6H, H-5G’, H-5M’, H-6Cab, H-4C, OCHH(CH2)4N3), 3.51-3.36 (m, 4H, H-
6Aab, H-6Ba, H-5Xb), 3.29-3.21 (m, 4H, H-5A, H-5B, H-6Bb, OCHH(CH2)4N3), 3.15 (dd, 1H, J3-
4= 9.6 Hz, J3-2= 3.0 Hz, H-3C), 3.04-3.00 (m, 1H, H-5C), 2.91-2.81 (m, 2H, -CH2N3), 2.08 , 2.06 
(2 s, 2x3H, CH3CO), 2.04-2.03 (3 s, 3x3H, CH3CO), 2.00-1.96 (m, 21H, CH3CO), 1.84 (s, 6H, 
CH3CO), 1.81 (s, 3H, CH3CO), 1.37– 1.27 (m, 4H, OCH2CH2CH2CH2CH2N3), 1.09-1.02 (m, 2H, 
O(CH2)2CH2(CH2)2N3); 13C NMR (126 MHz, CDCl3) δ 171.0-168.4, 138.8, 138.6, 137.8, 134.4, 
133.8, 131.5, 128.8-127.0, 123.7, 123.3, 101.2, 99.6, 99.1, 98.2, 98.0, 97.4, 97.2, 79.9, 79.6, 
76.0, 75.4, 74.7-74.4, 73.6, 73.5, 72.7, 71.8, 71.7, 70.8, 70.2, 70.1, 69.9, 69.9, 69.7, 69.4, 
69.0, 68.9, 68.7, 68.2, 67.7, 66.1, 65.6, 62.9, 62.4, 61.9, 61.7, 61.1, 56.7, 55.8, 54.7, 54.6, 
51.2, 29.8, 28.8, 28.4, 23.1, 20.8-20.7; HRMS (MALDI-Tof) m/z [M+Na]+ calculated for 
C142H155N7O59 2924.9236, found 2924.9144.  
 
5-azidopentyl (3,4,6-tri-O-acetyl-2-deoxy-2-phthalimido-β-D-glucopyranosyl)-(12)-
(3,4,6-tri-O-acetyl-α-D-mannopyranosyl)-(16)-[2,3,4-tri-O-acetyl-β-D-xylopyranosyl-
(12)]-[2-O-acetyl-3,4,6-tri-O-benzyl-α-D-mannopyranosyl)-(13)]-(β-D-
mannopyranosyl)-(14)-(3,6-di-O-benzyl-2-deoxy-2-phthalimido-β-D-glucopyranosyl)-
(14)-3,6-di-O-benzyl-2-deoxy-2-phthalimido-β-D-glucopyranoside (17): A mixture of 15 
(40 mg, 20.33 µmol) and 7 (21 mg, 24.19 µmol) was dried under high vacuum overnight. 
The mixture was dissolved in anhydrous CH2Cl2 (5 mL, 250 mL/mmol) in the presence of 
freshly activated ground 3Å MS. After stirring for 1h, the reaction mixture was cooled to -45 
oC and TMSOTf (7 µL, 0.2 eq, 4.06 µmol) was slowly added. After 2h of stirring the 
suspension was quenched with Et3N, filtered through a pad of Celite® and concentrated. 
The crude product was purified by flash chromatography (SiO2, hexane: acetone, 3:2) to 
afford the tittle compound as a white solid (40 mg, 73%); [α]20589= -0.6 (c, 0.35, CHCl3); 1H 
NMR (500 MHz, CDCl3) δ 7.79 -7.55 (m, 12H, Ar), 7.38-7.27 (m, 24H, Ar), 7.16-7.15 (m, 2H, 
Ar), 7.04-7.03 (m, 2H, Ar), 6.94-6.93 (m, 2H, Ar), 6.81-6.74(m, 5H, Ar),  δ 5.66 (t, 1H, J = 9.9 
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Hz, H-3G), 5.59 (s, 1H, H-2M), 5.36 (s, 1H, H-1Mα), 5.24 (t, 2H, J= 7.9 Hz, H-1Aβ, H-1Gβ), 
5.19 (t, J= 8.4 Hz, H-3X), 5.14 (t, 1H, J= 9.9 Hz, H-4M), 5.08 (t, 1H, J= 9.7 Hz, H-4G), 5.02-4.99 
(m, 1H, H-4X), 4.98-4.93 (m, 2H, H-3M’, H-1Xβ), 4.91-4.83 (m, 4H, H-2X, H-1Bβ, OCH2Ph), 
4.78 (d, 1H, J= 11.3 Hz, OCHHPh), 4.67 (d, 1H, J= 12.6 Hz, OCHHPh), 4.59-4.54 (m, 5H, H-
C1β, 2xOCH2Ph), 4.51-4.33 (m, 8H, H-1M’α, H-2G, 3xOCH2Ph), 4.23-4.06 (m, 10H, H-5Xa, H-
6aG, H-3A, H-5M, H-2A, H-2B, H-2M’, H-2C, H-3B, H-4B), 4.00 (dd, 1H, J3-4= 9.9Hz, J3-2= 3.4 
Hz, H-3M), 3.95 (t, 1H, J=9.0 Hz, H-4A), 3.87 (d, 1H, J= 12.0 Hz, H-6Gb), 3.80 (dd, 1H, J6a-6b= 
12.2 Hz, J6a-5= 4.3 Hz, H-6M’a), 3.72-3.61 (m, 8H, H-4C, H-4M, H-5M’, H-6M’b, 
OCHH(CH2)4N3, H-6Mab, H-6Aa), 3.56-3.35 (m, 7H, H-5G, H-3C, H-6Ab, H-6Bab, H-6Cab), 
3.30-3.22 (m, 4H, H-5A, H-5B, H-5Xb, OCHH(CH2)4N3), 3.13-3.10 (m, 1H, H-5C), 2.91-2.80 (m, 
2H, -CH2N3), 2.16, 2.05, 2.02, 2.00, 1.99, 1.98, 1.93, 1.92, 1.82, 1.71 (10 s, 10x3H, CH3CO), 
1.41-1.29 (m, 4H, OCH2CH2CH2CH2CH2N3), 1.107-1.03 (m, 2H, OCH2CH2CH2CH2CH2N3); 13C 
NMR (126 MHz, CDCl3) δ 170.9-167.4, 138.8, 138.5, 138.1, 138.0, 134.4, 134.0, 133.7, 
131.9, 131.7, 131.5, 128.7-127.0, 123.6, 123.3, 101.8, 99.6, 98.2, 97.8, 97.7, 97.2, 80.7, 
79.5, 77.8, 76.1, 75.1, 75.1, 74.8, 74.7, 74.6, 74.4, 73.5, 73.4, 72.7, 71.8, 71.7, 71.6, 71.0, 
70.7, 70.0, 69.4, 69.1, 69.0, 68.9, 68.7, 68.6, 68.4, 68.3, 68.0, 66.8, 65.6, 62.5, 62.0, 61.7, 
56.5, 55.8, 54.5, 51.2, 29.8, 28.8, 28.4, 23.1, 21.2-20.6; HRMS (ESI) m/z [M+Na]+ calculated 
for C139H150N6O48 2693.9373, found 2693.9343. 
 
5-azidopentyl (3,4,6-tri-O-acetyl-2-deoxy-2-phthalimido-β-D-glucopyranosyl)-(12)-
(3,4,6-tri-O-acetyl-α-D-mannopyranosyl)-(13)-[2,3,4-tri-O-acetyl-β-D-xylopyranosyl-
(12)]-[(2,3,4,6-tetra-O-benzoyl-α-D-mannopyranosyl)-(16)]-(β-D-mannopyranosyl)-
(14)-(3,6-di-O-benzyl-2-deoxy-2-phthalimido-β-D-glucopyranosyl)-(14)-3,6-di-O-
benzyl-2-deoxy-2-phthalimido-β-D-glucopyranoside (20): A mixture of 14 (21 mg, 9.55 
µmol) and 6 (8.5 mg, 11.47 µmol) was dried under high vacuum overnight. The mixture was 
dissolved in anhydrous CH2Cl2 (2.2 mL, 250 mL/mmol) and in the presence of freshly 
activated ground 3Å MS. After 1h at room temperature, the mixture was cooled to -45 oC 
and TMSOTf (6.5 µL, 0.4 eq, 3.82 µmol) was added. After 5 hours stirring at -45 ºC, the 
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reaction mixture was quenched with Et3N, filtered through a pad of Celite® and 
concentrated. The crude product was purified by preparative HPLC (acetonitrile:H2O; initial 
condition 85:15; 2 min 90:10, 35min 99:1, 36min 85:15) to afford the tittle compound as a 
white solid (12.4 mg, 47%); [α]20589= -8.8 (c, 0.52, CHCl3); 1H NMR (500 MHz, CDCl3) δ 8.12– 
8.11 (m, 2H, Ar), 7.99-7.97(m, 2H, Ar), 7.91-7.89 (m, 2H ,Ar), 7.83-7.71 (m, 5H, Ar), 7.66-
7.61(m, 5H, Ar), 7.57-7.47 (m, 6H, Ar), 7.43-7.39 (m, 3H, Ar), 7.35-7.28 (m, 12H, Ar), 7.24-
7.21 (m, 4H, Ar), 7.05 (d, J= 7.9 Hz, 2H, Ar), 6.98-6.96 (m, 2H, Ar), 6.83 (t, J=7.92Hz,  2H, Ar), 
6.78-6.76 (m, 3H, Ar), 6.74-6.71 (m, 1H, Ar), 6.09 (t, J= 10.0 Hz, H-4M’), 5.83-5.79 (m, 2H, H-
3M’, H-3G), 5.66-5.64 (m, 1H, H-2M’), 5.49 (d, J2-1/3= 8.5 Hz, 1H, H-1Gβ), 5.27 (d, J1-2= 8.4 Hz, 
1H, H-1Aβ), 5.21-5.08 (m, 4H, H-3X, H-4M, H-4G, H-3M), 5.04-5.02 (m, 3H, H-2X, H-1M, H-
1M’), 4.95-4.90 (m, 4H, H-1Xβ, H-1Bβ, H-4X, OCHHPh), 4.87 (d, J= 12.9 Hz, 1H, OCHHPh), 
4.80-4.77 (m, 1H, H-6M’a), 4.61-4.33 (m, 12H, 6xOCH2Ph, H-1Cβ, H-5M’, H-2G, H-2M, H-3A, 
H-6M’b), 4.25-4.20 (m, 3H, H-2A, H-6Ga, H-5Xa), 4.18-4.09 (m, 3H, H-4B, H-3B, H-2B), 4.04 
(t, J= 9.2 Hz, 1H, H-4A), 3.99- 3.96 (m, 2H, H-5M, H-6Gb), 3.91-3.84 (m, 3H, H-6Ca, H-2C, H-
5G), 3.80-3.64 (m, 6H, H-6Cb, H-4C, H-6Mab, H-6Aa, OCHH(CH2)4N3), 3.56-3.47 (m, 2H, 
H6Ab, H6Ba), 3.42-3.33 (m, 2H, H6Bb, H5Xb), 3.35-3.22 (m, 4H, OCHH(CH2)4N3, H-3C, H-5A, 
H-5B), 3.18-3.15 (m, 1H, H-5C) 2.90-2.81 (m, 2H, CH2N3 ), 2.06, 2.04, 2.03, 2.015, 2.01, 1.93, 
1.91, 1.85 (9 s, 3x3H, CH3CO), 1.41-1.29 (m, 4H, OCH2CH2CH2CH2CH2N3), 1.06-1.05 (m, 2H, 
OCH2CH2CH2CH2CH2N3); 13C NMR (126 MHz, CDCl3) δ 170.9, 170.6, 170.5, 170.3, 169.9, 
169.8, 169.6, 169.5, 169.2, 166.5, 165.6, 165.5, 165.2, 138.8, 138.7, 138.5, 137.8, 134.3, 
133.7, 133.4, 133.4, 133.2, 131.6, 130.0, 129.9 129.9, 129.4, 129.3, 129.2, 128.9, 128.8, 
128.6, 128.6, 128.5, 128.3, 128.3, 128.2, 128.1, 128.0, 128.0, 128.0, 127.8, 127.5, 127.4, 
127.1, 127.0, 101.9, 100.1, 98.8, 98.3, 98.2, 97.2, 97.0, 80.5, 79.3, 76.1, 75.9, 74.8, 74.7, 
74.6, 74.5, 74.2, 73.4, 72.7, 71.8, 70.9, 70.7, 70.5, 70.4, 70.3, 70.2, 69.9, 69.4, 69.0, 69.0, 
68.7, 68.3, 67.9, 67.8, 66.7, 66.2, 63.1, 62.4, 62.0, 61.4, 56.7, 55.8, 54.7, 51.2, 32.0, 28.8, 
28.4, 23.1, 20.9-20.6; HRMS (ESI) m/z [M+ Na]+ calculated for C144H146N6O51Na 1410.4399, 
found 1410.4358. 
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5-azidopentyl 2,3,4-tri-O-acetyl-β-D-xylopyranosyl-(12)-4-O-benzyl-3-O-(2-
naphthylmethyl)- β-D-mannopyranosyl)-(14)-(3,6-di-O-benzyl-2-deoxy-2-phthalimido-
β-D-glucopyranosyl)-(14)-3,6-di-O-benzyl-2-deoxy-2-phthalimido-β-D-glucopyranoside 
(26): A solution of BH3·THF (310 µL, 310 µmol, 1.0 M in THF) was added to the 
tetrasaccharide 4 (50 mg, 29.0 µmol) and the reaction mixture cooled to 0oC. n-Bu2BOTf (92 
µL of 1.0 M solution in Et2O, 92 µmol) were then added, and the reaction mixture was 
stirred at 0oC for 2 h, quenched with Et3N/MeOH and concentrated in vacuo. The crude 
mixture was coevaporated with MeOH (2 times) and purified by flash column 
chromatography (SiO2, toluene:EtOAc, 3:1) to afford the title compound as a white solid (32 
mg, 65%); [α]20589= + 9.6 (c, 0.52, CHCl3); 1H NMR (500 MHz, CDCl3) δ 7.85-7.77 (m, 5H, Ar), 
7.73-7.61 (m, 7H, Ar), 7.49-7.45 (m, 3H, Ar), 7.36-7.27 (m, 11H, Ar), 7.14-7.10 (m, 3H, Ar), 
7.10-7.07(m, 2H, Ar), 7.02-6.91 (m, 6H, Ar), 6.77-6.75 (m, 3H, Ar), 5.29 (d, J1-2 = 8.3 Hz, 1H, 
H-1Aβ), 5.09 (d, J1-2 = 3.35 Hz, 1H, H-1Xβ), 5.07 (t, J3-2/1 = 5.06 Hz, 1H, H-3X), 5.01 (q, 1H, J2-1= 
3.40 Hz, J2-3=4.82Hz, H-2X), 4.98 (d, J= 12.5 Hz, 1H, OCHHPh), 4.94-4.92 (m, 1H, H-1Bβ), 4.90 
(d, J= 11.0 Hz, 1H, OCHHPh), 4.85-4.82 (m, 3H, OCH2Ph, H-4X), 4.68 (d, J= 11.9 Hz, 1H, 
OCHHPh), 4.58-4.49 (m, 6H, H-5Xa, H-1Cβ, 2xOCH2Ph), 4.42 (d, J= 12.5 Hz, 2H, OCH2Ph), 
4.38-4.36 (m, 1H, H-3A), 4.28 (d, J= 12.1 Hz, 1H, OCHHPh ), 4.24-4.17 (m, 2H, H-2A, H-4B), 
4.11-4.07 (m, 3H, H-2B, H-3B, H-2C), 3.96 (t, 1H, J= 9.3 Hz, H-4A), 3.75-3.54 (m, 5H, H-4C, H-
6Ca, H-6Aa, H-6Ba, OCHH(CH2)4N3 ), 3.49-3.38 (m, 5H, H-5Xb, H-6Ab, H-6Bb, H-6Cb, H-3C), 
3.33-3.22 (m, 3H, H-5A, H-5B, OCHH(CH2)4N3), 3.12-3.08 (m, 1H, H-5C), 2.92-2.82 (m, 2H, -
CH2N3), 2.11, 2.04, 1.99 (3 s, 3x3H, CH3CO), 1.43-1.31 (m, 4H, OCH2CH2CH2CH2CH2N3), 1.12-
1.01 (m, 2H, O(CH2)2CH2(CH2)2N3); 13C NMR (126 MHz, CDCl3) δ 170.1, 169.6, 169.2, 138.9, 
138.8, 138.6, 138.3, 137.8, 135.5, 133.7, 133.4, 133.1, 128.6, 128.5, 128.4, 128.3, 128.3, 
128.1, 128.0, 127.9, 127.8, 127.7, 127.6, 127.6, 127.1, 127.0, 126.7, 126.6, 126.4, 126.2, 
125.9, 123.3, 101.2, 98.9, 98.2, 97.2, 81.1, 80.3, 76.0, 75.7, 75.2, 74.6, 74.6, 74.4, 74.0, 73.8, 
73.4, 72.8, 71.7, 70.7, 69.0, 68.8, 68.4, 68.3, 68.1, 62.1, 59.9, 56.7, 55.8, 51.2, 29.8, 28.8, 
28.4, 23.1, 21.1, 21.1, 20.9; HRMS (ESI) m/z [M+ Na]+ calculated for C96H99N5O25Na 
1744.6521, found 1744.6563. 
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5-azidopentyl 2-O-acetyl-3,4,6-tri-O-benzyl-α-D-mannopyranosyl-(16)-[2,3,4-tri-O-
acetyl-β-D-xylopyranosyl-(12)]-4-O-benzyl-3-O-(2-naphthylmethyl)- β-D-
mannopyranosyl)-(14)-(3,6-di-O-benzyl-2-deoxy-2-phthalimido-β-D-glucopyranosyl)-
(14)-3,6-di-O-benzyl-2-deoxy-2-phthalimido-β-D-glucopyranoside (28): A mixture of 26 
(24 mg, 13.93 µmol) and 5 (13.4 mg, 20.19 µmol) was dried under high vacuum overnight. 
The mixture was dissolved in anhydrous CH2Cl2 (0.4 mL) and freshly activated, ground 
molecular sieves (3Å) were added. After 30 minutes of stirring at room temperature, the 
mixture was cooled to -20oC and TMSOTf (3.6 µL, 0.15 eq, 2.08 µmol) was slowly added. 
After 1h stirring at -20 ºC, the reaction was quenched with Et3N, filtered through a pad of 
Celite® and concentrated. The crude product was purified by preparative thin layer 
chromatography (TLC) on Silica gel 60 F254, Merck KGaA, Germany (hexane: EtOAc 3:1 to 
3:2) to afford product in 52% yield (16 mg); [α]20589= +2.1 (c, 0.45, CHCl3); 1H NMR (500 
MHz, CDCl3) δ 7.83-7.76 (m, 4H, Ar), 7.71-7.62 (m, 7H, Ar), 7.48– 7.44 (m, 3H, Ar), 7.33-7.29 
(m, 7H, Ar), 7.24-7.15 (m, 20H, Ar), 7.17-7.11 (m, 2H, Ar), 7.07-7.04 (m, 2H, Ar), 7.04-6.98 
(m, 2H, Ar), 6.93-6.92 (m, 2H, Ar), 6.77-6.68 (m, 6H, Ar), 5.38-5.37 (dd, J2-3= 3.3 Hz, J2-1= 1.8 
Hz, 1H, H-2M), 5.26-5.22 (m, 2H, H-3X, H-1Aβ), 5.10-5.06 (m, 2H, H-1X, H-2X), 4.98-4.89 (m, 
4H, H-4X, H-1Bβ, OCH2Ph), 4.82-4.75 (m, 4H, H1M-α, OCH2Ph), 4.62-4.26 (m, 16H, H-1Cβ, 
OCH2Ph, H-5Xa, H-3A), 4.21-4.15 (m, 3H, H-2A, H-2C, H-4B), 4.09-4.06 (m, 2H, H-2B, H-3B), 
4.01 (t, J4-3/5=9.1 Hz, 1H, H-4A), 3.91 (dd, J3-4= 9.6 Hz, J3-2= 3.3 Hz, 1H, H-3M), 3.77 (t, J4-3/5= 
9.6 Hz, 1H, H-4M), 3.73-3.63 (m, 5H, H-4C, H-6Ca, H-6Aa, H-6Ba, OCHH(CH2)4N3), 3.60-3.54 
(m, 2H, H-5M, H-6Cb), 3.53-3.49 (m, 2H, H-6Ab, H-6Bb), 3.45-3.37 (m, 4H, H-5Xb, H-3C, H-
6Mab), 3.33-3-21 (m, 4H, H-5A, H-5B, H-5C, OCHH(CH2)4N3), 2.91-2.81 (m, 2H, -CH2N3 ), 
2.10, 1.98, 1.97, 1.97, (4 s, 4x3H, CH3CO), 1.38-1.29 (m, 4H, OCH2CH2CH2CH2CH2N3), 1.09– 
1.03 (m, 2H, O(CH2)2CH2(CH2)2N3); 13C NMR (126 MHz, CDCl3) δ 170.4-169.1, 138.7-133.1, 
128.4-123.2, 102.7, 99.8, 98.0, 97.4, 96.9, 81.3, 78.1, 76.5, 76.0, 75.0-74.1, 73.3, 72.9, 72.7, 
71.6, 71.3, 70.4, 69.0- 68.3, 66.7, 56.7, 55.8, 51.2, 28.8, 28.4, 23.1, 21.0, 20.9; HRMS (ESI) 
m/z [M+H+Na]2+ calculated for C125H129N5O31 1120.9227, found 1120.9224. 
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General procedure A: Deprotection of compounds G2 and G4 
 
A mixture of the glycans (1 eq.) and ethylenediamine:nBuOH (1:4; 42 mL/mmol) was heated 
at 120 ºC under microwave irradiation (3 cycles x 30 minutes). The reaction mixture was 
concentrated and coevaporated with toluene (3x) and EtOH (3x). The crude product was 
dissolved in anhydrous pyridine (60 µL/µmol), cooled to 0 ºC and Ac2O (28 µL/µmol) was 
added dropwise. The reaction was warmed to room temperature and stirred overnight. The 
mixture was concentrated and coevaporated with toluene (3 times). The crude product was 
purified by flash column chromatography (SiO2, EtOAc:MeOH, 99:1). Sodium (25 mg) was 
added to liquid ammonia (15 mL) at -78 ºC and the resulting blue colored solution was 
stirred for 5 minutes. A solution of the protected glycan in anhydrous THF (0.11 mL/µmol) 
was added dropwise and the resulting mixture was stirred at -78 ºC until the blue color 
disappeared (1 h). The reaction was quenched by adding solid NH4Cl until neutral pH and 
evaporated to dryness. The crude was purified by graphitized carbon cartridge and the 
deprotected N-glycans were eluted using H2O:MeOH (1:1). 
 
General procedure B: Deprotection of compounds G1, G3, G5 and G6. 
 
A mixture of the protected glycan (1 eq.) and ethylenediamine:nBuOH (1:4; 42 mL/mmol) 
was heated at 120 ºC under microwave irradiation (3 cycles x 30 minutes). The reaction 
mixture was concentrated and coevaporated with toluene (3 times) and EtOH (3 times). The 
crude product was dissolved in anhydrous pyridine (60 µL/µmol), cooled to 0 ºC and Ac2O 
(28 µL/µmol) was added dropwise. The reaction was warmed to rt and stirred overnight. 
The mixture was concentrated and co-evaporated with toluene (3 times) to remove 
pyridine. The crude product was purified by size exclusion chromatography (CH2Cl2:MeOH, 
1:2). The compound was dissolved in MeOH and 0.5 M NaOMe in MeOH was added (0.2 eq. 
per each acetate group). After 2 h of stirring at room temperature, the reaction mixture 
was quenched with Amberlite® IR120 (H), filtered and concentrated. The crude product was 
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dissolved in MeOH containing 0.1% of trifluoroacetic acid (TFA) and hydrogenated with H-
Cube® reactor on 10% Pd/C cartridge (full H2 mode; 0.5 mL/min; 50 ºC). The solution was 
quenched with NaHCO3, the crude was purified by graphitized carbon cartridge and the 
deprotected N-glycans were eluted using H2O:MeOH (1:1). 
 
5-Aminopentyl [α-D-mannopyranosyl]-(1→6),[-D-xylopyranosyl]-(1→2)--D-
mannopyranosyl-(1→4)-2-acetamido-2-deoxy--D-glucopyranosyl-(1→4)-2-acetamido-2-
deoxy--D-glucopyranoside (G1): Following the general procedure B, compound 28 (24.5 
mg, 11.17 μmol) was deprotected to give G1 as a white solid (5.3 mg, 49 % over 4 steps); 1H 
NMR (500 MHz, D2O) δ 4.93 (s, 1H), 4.87 (s, 1H), 4.62 (d, J= 7.5 Hz, 1H), 4.50 (d, J= 7.5 Hz, 
1H), 4.46 (d, J= 7.5 Hz, 1H), 4.28 (m, 1H), 3.99– 3.59 (m, 33H), 3.54-3.37 (m, 4H), 3.27 (t, J= 
11.1Hz, 1H), 2.94 (t, J= 7.5 Hz, 2H, CH2NH2), 2.09, 2.04 (2 s, 2x3H, -NHAc), 1.66-1.58 (m, 4H, 
CH2 linker), 1.43-1.37 (m, 2H, CH2 linker ); 13C NMR (126 MHz, D2O) δ 174.7, 174.4, 104.2, 
101.3, 101.0, 100.7, 99.7, 79.7, 79.3, 78.0, 75.3, 74.5, 74.4, 73.2, 72.7, 72.4, 72.1, 70.4, 70.1, 
69.8, 69.2, 67.0, 66.7, 65.8, 65.0, 60.9, 60.1, 55.0, 39.5, 28.1, 27.0, 22.2, 22.1; HRMS (ESI) 
m/z [M+H]+ calculated for C38H67N3O25H 966.4142, found 966.4161. 
5-Aminopentyl [α-D-mannopyranosyl]-(1→3),[-D-xylopyranosyl]-(1→2)--D-
mannopyranosyl-(1→4)-2-acetamido-2-deoxy--D-glucopyranosyl-(1→4)-2-acetamido-2-
deoxy--D-glucopyranoside (G2): Following the general procedure B, compound 13 (31 mg, 
15.08 μmol) was deprotected to give G2 as a white solid (7.43 mg, 50 % over 3 steps); 1H 
NMR (500 MHz, D2O) δ 5.14 (s, 1H), 4.86 (s, 1H), 4.60 (d, J= 7.6 Hz, 1H), 4.50 (d, J= 7.8 Hz, 
1H), 4.47(d, J= 7.6 Hz, 1H), 4.26 (d, J= 3.0 Hz, 1H), 4.06– 4.04 (m, 1H), 4.03-3.99 (m, 2H), 
3.93-3.57 (m, 27H), 3.52-3.43 (m, 3H), 3.38 (t, J= 8.6 Hz, 1H), 3.25 (t, J= 11.3 Hz, 1H), 2.93 (t, 
J= 7.2 Hz, 2H), 2.08, 2.04 (2 s, 2x3H, -NHAc), 1.67-1.56 (m, 4H, CH2 linker), 1.42-1.36 (m, 2H 
CH2 linker); 13C NMR (126 MHz, D2O, peaks assigned from HSQC) δ 104.8, 102.2, 101.3, 
101.0, 100.1, 79.3, 79.0, 78.7, 77.3, 76.2, 74.5, 74.5, 73.5, 73.2, 72.4, 72.0, 70.3, 70.3, 70.1, 
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70.0, 69.2, 66.8, 66.3, 64.9, 64.9, 60.3, 60.1, 60.1, 55.1, 55.0, 39.5, 28.2, 27.2, 22.3, 22.2, 
22.2; HRMS (ESI) m/z [M+Na]+ calculated for C38H67N3O25Na 988.3956, found 988.3972.  
5-Aminopentyl [2-acetamido-2-deoxy-β-D-glucopyranosyl-(1→2)-α-D-mannopyranosyl]-
(1→3),[-D-xylopyranosyl]-(1→2)- -D-mannopyranosyl-(1→4)-2-acetamido-2-deoxy--D-
glucopyranosyl-(1→4)-2-acetamido-2-deoxy--D-glucopyranoside (G3): Following the 
general procedure B, compound 12 (36 mg, 15.7 μmol) was deprotected to give G3 as a 
white solid (12.5 mg, 65% over 4 steps); 1H NMR (500 MHz, D2O) δ 5.15 (s, 1H, H1M), 4.86 
(s, 1H, H1M’), 4.60 (d, J= 7.7 Hz, 1H), 4.53-4.49 (m, 2H), 4.45 (d, J= 7.6 Hz, 1H, H1X), 4.25 (d, 
J= 2.8 Hz, 1H, H2M), 4.16 (m, 1H, H2M’), 4.04-4.00 (m, 1H), 3.93-3.85 (m, 10H), 3.80– 3.42 
(m, 28H), 3.42-3.39 (m, 1H), 3.27-3.23 (m, 1H), 2.92 (t, J= 7.6 Hz, 2H,-CH2NH2), 2.07, 2.06, 
2.04 (3 s, 3x3H, -NHAc), 1.66-1.57 (m, 4H, CH2 linker), 1.42-1.37 (m, 2H, CH2 linker); 13C NMR 
(126 MHz, D2O) δ 174.7, 174.6, 174.4, 104.9, 101.3, 101.0, 100.1, 99.7, 99.2, 79.3, 79.1, 
78.7, 77.1, 76.6, 76.3, 75.8, 75.3, 74.5, 73.6, 73.3, 73.2, 72.4, 71.9, 70.1, 69.9, 69.4, 69.3, 
67.2, 66.5, 64.9, 61.7, 60.6, 60.2, 60.1, 55.3, 55.1, 55.0, 39.5, 28.1, 27.3, 22.3, 22.1, 22.1, 
22.1; HRMS (ESI) m/z [M+H]+ calculated for C46H80N4O30H 1169.493, found 1169.4907. 
5-Aminopentyl [α-D-mannopyranosyl]-(1→3), [2-acetamido-2-deoxy-β-D-glucopyranosyl-
(1→2)-α-D-mannopyranosyl]- (1→6), [-D-xylopyranosyl]-(1→2)--D-mannopyranosyl-
(1→4)-2-acetamido-2-deoxy--D-glucopyranosyl-(1→4)-2-acetamido-2-deoxy--D-
glucopyranoside (G4): Following the general procedure A compound 17 (40 mg, 15.0 μmol) 
was deprotected to give G4 as a white solid (11.9 mg, 56 %); 1H NMR (500 MHz, D2O) δ 5.13 
(s, 1H), 4.91 (s, 1H), 4.88 (s, 1H), 4.60 (d, J= 7.8 Hz, 1H), 4.56 (d, J= 8.4 Hz, 1H), 4.50 (m, J= 
7.8 Hz, 1H), 4.45 (d, J= 7.5 Hz, 1H), 4.27 (d, J= 2.8 Hz, 1H), 4.12-4.11 (m, 1H), 4.06-4.04 (m, 
1H), 4.02-3.98 (m, 2H), 3.94-3.36 (m, 43H), 3.25 (t, J= 11.2 Hz, 1H), 2.92 (t, J= 7.5 Hz, 2H, 
CH2NH2), 2.09, 2.06, 2.04 (3 s, 3x3H, -NHAc), 1.65-1.58 (m, 4H, CH2 linker), 1.40-1.37 (m, 2H, 
CH2 linker); 13C NMR (126 MHz, D2O) δ 174.8, 174.6, 174.4, 105.1, 102.2, 101.3, 101.0, 
100.6, 99.6, 96.9, 79.5, 79.3, 77.3, 76.2, 75.8, 75.3, 74.5, 74.4, 74.3, 73.5, 73.3, 72.8, 72.4, 
72.0, 70.3, 70.1, 69.9, 69.9, 69.7, 69.5, 69.3, 67.3, 66.7, 66.4, 65.4, 64.9, 61.6, 61.2, 60.6, 
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60.1, 60.0, 55.3, 55.0, 39.5, 28.2, 28.1, 27.4, 27.2, 22.3, 22.2, 22.1; HRMS (ESI) m/z [M+H]+ 
calculated for C52H90N4O35H 1331.5458, found 1331.5494. 
5-Aminopentyl [2-acetamido-2-deoxy-β-D-glucopyranosyl-(1→2)-α-D-mannopyranosyl]- 
(1→3),[α-D-mannopyranosyl]-(1→6),[-D-xylopyranosyl]-(1→2)--D-mannopyranosyl-
(1→4)-2-acetamido-2-deoxy--D-glucopyranosyl-(1→4)-2-acetamido-2-deoxy--D-
glucopyranoside (G5): Following the general procedure B, compound 20 (24.8 mg, 8.9 
μmol) was deprotected to give G5 as a white solid (58% over 4 steps); 1H NMR (500 MHz, 
D2O) δ 5.15 (s, 1H), 4.93 (d, 1H, J= 1.7 Hz), 4.88 (s, 1H), 4.61 (d, J= 8.0 Hz, 1H), 4.53 (d, 1H, J= 
8.3 Hz), 4.50 (d, J= 8.2Hz, 1H), 4.45 (d, J= 7.6 Hz, 1H), 4.27 (d, J= 3.2 Hz, 1H), 4.20-4.15 (dd, 
J= 3.2, 1.4 Hz, 1H), 4.05-3.37 (m, 45H), 3.26 (t, J= 11.1 Hz, 1H), 2.99 (t, J= 7.8 Hz, 1H, linker), 
2.09, 2.06, 2.04 (3 s, 3x3H, -NHAc), 1.71-1.65 (m, 2H, linker), 1.64-1.58 (m, 2H, linker), 1.43-
1.39 (m, 2H, linker); 13C NMR (126 MHz, D2O) δ 105.1, 101.3, 101.0, 100.4, 99.7, 99.5, 99.1, 
79.5, 79.3, 79.2, 77.0, 76.5, 75.6, 74.5, 74.2, 73.7, 73.3, 73.2, 72.7, 72.4, 71.8, 70.3, 70.2, 
70.1, 69.8, 69.7, 69.7, 69.4, 69.2, 67.2, 66.6, 66.5, 65.2, 65.2, 64.9, 64.8, 61.7, 60.6, 60.6, 
60.1, 54.9, 55.1, 39.4, 28.1, 26.5, 22.3, 22.1; HRMS (ESI) m/z [M+H]+ calculated for 
C52H90N4O35H 1331.5458, found 1331.5502.  
 
5-Aminopentyl di[2-acetamido-2-deoxy-β-D-glucopyranosyl-(1→2)-α-D-mannopyranosyl]-
(1→3),(1→6)-[-D-xylopyranosyl]-(1→2)--D-mannopyranosyl-(1→4)-2-acetamido-2-
deoxy--D-glucopyranosyl-(1→4)-2-acetamido-2-deoxy--D-glucopyranoside (G6): 
Following the general procedure B, compound 16 (95 mg, 54.2 μmol) was deprotected to 
give G6 as a white solid (50.2 mg, 60 % over 4 steps);1H NMR (500 MHz, D2O) δ 5.13 (s, 1H), 
4.90 (s, 1H), 4.86 (s, 1H), 4.59 (d, J= 7.7 Hz, 1H), 4.57 (d, J= 8.4 Hz, 1H), 4.52 (d, J= 8.3 Hz, 
1H), 4.51 (d, J= 7.6 Hz, 1H), 4.45(d, J= 7.7 Hz, 1H), 4.26 (d, J= 2.6 Hz 1H), 4.15-4.12 (m, 1H), 
4.12-4.07 (m, 1H), 4.05 –3.35 (m, 51H), 3.24 (t, J= 11.2 Hz, 1H), 2.91 (t, J= 7.8 Hz, 2H), 2.07, 
2.05, 2.04, 2.02 (4 s, 4x3H, -NHAc), 1.65-1.55 (m, 4H, linker), 1.40-1.34 (m, 2H, linker); 13C 
NMR (126 MHz, D2O) δ 174.8, 174.7, 174.5, 105.1, 101.4, 101.0, 100.5, 99.7, 99.6, 99.2, 
96.9, 79.6, 79.4, 76.6, 76.3, 75.8, 75.4, 74.5, 74.4, 73.7, 73.4, 73.3, 72.9, 72.5, 72.1, 70.2, 
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69.9, 69.6, 69.5, 69.3, 67.3, 67.2, 66.5, 65.0, 61.8, 61.6, 60.7, 60.1, 55.4, 55.1, 39.6, 28.1, 
27.3, 22.4, 22.2, 22.2; HRMS (ESI) m/z [M+H]+ calculated for C60H103N5O40H 1534.6252, 
found 1534.6322. 
 
Screening of CeFUT6 specificity on the glycan array (more detailed description of glycan 
array preparation will be given in Chapter 2) 
 
50 µM solutions of N-glycans G1-G6 (and corresponding non-xylosylated structures) were 
prepared from stock solutions (1 mM in water) by dilution with sodium phosphate buffer 
(300 mM, pH 8.4, 0.005% Tween 20). 40 µl of each glycans solutions were pippeted into a 
384 well plate (Scienion, Berlin, Germany) that was used as a source plate for printing 
glycans onto NHS functionalized glass slides (each spot: 1.25 nL, 5 drops of 250 pL). N-
glycans were printed at a spot to spot distance of 350 µm (x and y axies). Ligands were 
printed in 6 replicates (3 different N-glycans/row). After printing, the slides were placed in a 
75 % humidity chamber (saturated NaCl solution) at 25 ºC for 18 hours. The unreacted NHS 
groups were quenched by placing the slides in a 50 mM solution of ethanolamine in sodium 
borate buffer 50 mM, pH 9.0, for 1h. The standard washing of the slides was performed 
with PBST (PBS solution containing 0.5% Tween 20), PBS and water. The slides were dried in 
a slide spinner. 
 
The array was used to predict possible enzymatic elongations of xylosylated compounds 
(G1-G6) and to compare enzyme specificities with corresponding, non-xylosylated 
structures. A solution (100 µL) containing 10 µL of CeFUT6 fucosyltransferase, GDP-Fuc (2 
mM), MnCl2 (20 mM) in MES buffer (80 mM, pH 6.5) was added to each well  and the slide 
was incubated at room temperature for 24 hours. The slide was then washed with PBS and 
water. To test efficient fucosylation one well was incubated with Aleuria aurantia lectin 
(AAL-555, 20 µg/mL) in PBS, 5mM CaCl2, 5 mM MgCl2 containing 0.1% Tween-20, for 1h at 
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room temperature. The slide was washed with PBST, PBS and water, dried under a stream 
of Ar and analyzed. 
 
Enzymatic synthesis of N-glycans 
 
Expression of bovine milk β-1,4-galactosyltransferase in E. coli. 
 
A single colony was inoculated in 10 mL of LB medium (1 % NaCl, 1 % peptone and 0.5 % 
yeast extract) containing kanamycin (50 µg/mL) and incubated at 37 ºC/250 rpm overnight. 
This culture was used to inoculate 400 mL of LB medium containing kanamycin (50 µg/mL). 
Cells were grown at 37ºC/250rpm until they reached OD600nm value of 0.6-0.7. Protein 
expression was induced by the addition of 1 mM isopropyl β-D-1-thiogalactopyranoside 
(IPTG) during 3 hours at 37ºC/250rpm. The culture was harvested by centrifugation (30000 
rpm, 4ºC, 10 minutes) and washed with Tris 50 mM, 150 mM NaCl, pH=8.5 twice. The pellet 
was resuspended in 10 mL of lysis buffer (Tris 50 mM, 150 mM NaCl, 1% Triton X-100, 10 
mM EDTA, 1 mM phenylmethylsulfonyl fluoride PMSF pH=8.5) and lysis was performed by 
sonication followed by centrifugation. The treatment with lysis buffer was performed twice 
and the inclusion bodies were washed once with water. The inclusion bodies were 
solubilized in 5M guanidine·HCl until OD280nm value of 1.9 to 2.0 (1 mg/mL). The protein 
solution was filtered through 0.22 µm filter and diluted ten times (100 µg/mL) in folding 
buffer containing Tris·HCl 50 mM pH=8.5, 10.56 mM NaCl, 0.44 mM KCl, 2.2 mM MgCl2, 2.2 
mM CaCl2, 0.5 M guanidine·HCl, 8 mM cysteamine, 4 mM cystamine, 0.055 % PEG-4000, 
0.55 M L-arginine. The protein was allowed to renature for 48 h at 4 ºC and then dialyzed 
against Tris 25 mM, 150 mM NaCl, pH 8.5 (24 h, 4 changes of buffer). The precipitated 
protein was removed by centrifugation at 5000 rpm, 10 mM imidazole was added to the 
supernatant and purified by HisTrap column (5 mL) controlled by an ÄKTATM protein purifier. 
The column was washed with 5 CV of binding buffer and the protein is eluted with Tris 25 
mM, 300 mM NaCl, 500 mM imidazole, pH =8.5. Elution fractions were analyzed by SDS-
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PAGE. SDS‐PAGE was performed in 12 % acrylamide gels that were stained with Coomassie 
Blue G‐250. Protein containing fractions were pooled and dialyzed against Tris 25 mM, 150 
mM NaCl, pH 7.5.  
 
Expression of glycosyltransferases in P. pastoris: 
 
Recombinant strains of Pichia pastoris were inoculated in 10 mL of MGYC medium (1% 
(w/v) yeast extract, 2% (w/v) peptone, 1% (w/v) casamino acid, 1.34% (w/v) yeast nitrogen 
base, 1% (v/v) glycerol, 0.00004% (w/v) biotin). The cultures were grown at 30 ºC with 
shaking at 250 rpm in baffled flasks for 24 h. The culture was centrifuged at 500g for 10 
minutes at 4 ºC and re‐suspended in 100 mL of MMYC (composition as for MGYC except 
that MeOH 1% (v/v) substitutes glycerol). The protein expression was carried out at 16 ºC 
for 72 hours, adding every 24 hours additional MeOH (to 1% (v/v)). After expression 
phenylmethylsulfonyl fluoride (PMSF, final concentration 0.1 mg/mL) was added to the 
culture medium and centrifuged at 1500x g for 10 minutes. The supernatant was 
concentrated in Vivaspin® 20 devices. C. elegans β-1,4-N-acetylgalactosaminyltransferase 
was employed in enzymatic reactions without further purification. The fucosyltransferases 
were further purified by affinity chromatography. The crude extracts were dialyzed against 
Tris 50 mM, 300 mM NaCl, 7 mM imidazole pH=8.5 and were loaded on nickel HistrapTM HP 1 
mL affinity columns controlled by an ÄKTA™ protein purifier. The column was washed with 
5 CV of binding buffer and the protein is eluted with a gradient from 0% to 100% of elution 
buffer (Tris 25 mM, 300 mM NaCl, 500 mM imidazole, pH =8.5). Elution fractions were 
analyzed by SDS-PAGE/Western Blot. SDS‐PAGE was performed in 12 % acrylamide gels 
that were stained with Coomassie Blue G‐250. For Western blotting, the polyacrylamide 
gel was rinsed with blotting solution (50 mM Tris, 40 mM glycine, 0.036% (w/v) SDS and 20 
% (v/v) MeOH) for 5 minutes and placed into the transfer sandwich soaked with blotting 
solution and proteins were transferred by semidry blotting to a nitrocellulose membrane. 
After the protein transfer, the membrane was rinsed with TBS buffer (10 mM Tris, 150 mM 
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NaCl, pH 7.4) for 5 minutes. The membrane was then blocked with TBST (10 mM Tris, 150 
mM NaCl, 0.05% (v/v) Tween 20, pH 7.4) containing 0.5% (w/v) of bovine serum albumin 
(BSA) during 1 hour. The membrane was incubated with anti-HIS monoclonal antibody 
raised in mouse (General Electrics) 1:3000 in TBST containing 0.5% (w/v) of BSA. After one 
hour of incubation, the membrane was washed three times with TBST and incubated with 
the secondary antibody anti‐Mouse IgG alkaline phosphatase conjugate (Sigma Aldrich), 
1:10000 in TBST containing 0.5% (w/v) BSA for one hour. After washing as above mentioned 
the membrane was immersed in staining solution FAST™BCIP/NBT (Sigma Aldrich). The 
reaction was stopped with 5% acetic acid. Protein fractions were pooled, concentrated with 
Vivaspin® 20 devices and dialyzed against Tris∙HCl 25 mM, 150 mM NaCl, pH 7.5. 
 
General procedure C: Reaction with bovine milk β-1,4-galactosyltransferase 
 
A solution (500 μL/mg) of glycan (1eq.), UDP-Gal (Uridine 5'-diphosphogalactose disodium 
salt) (1.2 eq.), bovine serum albumin BSA (0.5 mg), bovine milk β-1,4-galactosyltransferase, 
alkaline phosphatase and 10 mM MnCl2 in HEPES buffer (50 mM, pH=7.4) was incubated at 
37 ºC overnight. The resulting mixture was heated at 95ºC for 5 minutes to precipitate the 
enzyme. After centrifugation, the supernatant was purified on a C18 cartridge and the 
product was eluted using a mixture of ACN: aqueous 0.1% TFA (1:1). Fractions were 
analyzed by MALDI-TOF and the compound containing fractions were pooled and freeze 
dried to obtain the title compound.  
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General procedure D: Reaction with fucosyltransferases. 
 
A solution (500 μL/mg) of glycan (1 eq.), GDP-Fuc (guanosine 5′-diphospho-β-L-fucose 
sodium salt) (1.2eq.), CeFUT6, AtFucTA, CeFUT1 or CeFUT8 and 20 mM MnCl2 in MES buffer 
(40 mM, pH=6.5) was incubated at room temperature overnight. The resulting mixture was 
heated at 95ºC for 5 minutes to precipitate the enzyme. After centrifugation the 
supernatant was purified on a C18 cartridge and the product was eluted using a mixture of 
ACN: aqueous 0.1% TFA(1:1). Fractions were analyzed by MALDI-TOF and the compound 
containing fractions were pooled and freeze dried.  
 
General procedure E: Reaction with β-1,4-N-acetylgalactosaminyltransferase 
 
A solution (500 μL/mg) of glycan (1 eq.), UDP-GalNAc (Uridine 5′-diphospho-N-
acetylgalactosamine disodium salt) (1.2 eq.), concentrated P. pastoris extract containing β-
1,4-GalNAcT and 10 mM MnCl2 in HEPES buffer (40 mM, pH=7.4) was incubated at room 
temperature for 72h. The resulting mixture was heated at 95ºC for 5 minutes to precipitate 
the enzyme. After centrifugation the supernatant was purified on a C18 cartridge and the 
product was eluted using a mixture of ACN: aqueous 0.1% TFA(1:1). Fractions were analyzed 
by MALDI-TOF and the compound containing fractions were pooled and freeze dried.  
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General procedure F: Reaction with Jack bean β-N-acetylglucosaminidase. 
 
 A solution (500 μL/mg) of compound glycan (1 eq.), Jack bean β-N-acetylglucosaminidase 
in ammonium acetate buffer (50 mM, pH 4.9) was incubated at room temperature for 96 h. 
The resulting mixture was heated at 95ºC for 5 minutes to precipitate the enzyme. After 
centrifugation the supernatant was purified on a C18 cartridge and the product was eluted 
using a mixture of ACN: aqueous 0.1% TFA (1:1).. Fractions were analyzed by MALDI-TOF 
and the compound containing fractions were pooled and freeze dried.  
Heptasaccharide G7: Following the general procedure D, compound G7 (1.35 mg, 98.5%) 
was prepared from G3 (1.22 mg, 1.04 μmol) using CeFUT8 (30 μL, 1.1 mg/mL ) and GDP-Fuc 
(792 μg, 1.25 μmol). 1H NMR (500 MHz, D2O) δ 5.15 (s, 1H, H-1αMan), 4.91 (d, J= 4.0 Hz, 1H, 
H-1Fuc), 4.86 (s, 1H, H-1βMan), 4.68 (d, J= 7.6 Hz, 1H), 4.51 (t, J= 8.4 Hz, 2H), 4.46 (d, J= 7.6 Hz, 
1H), 4.26-4.25 (m, 1H, H-2Man), 4.17-4.16 (m, 1H, H-2Man), 4.16-4.12 (m, 1H, H-5Fuc), 4.02 (dd, 
J= 11.5, 5.4 Hz, 1H), 3.96-3.44 (m, 38H), 3.40-3.35 (m, 1H), 3.26 (t, J= 11.1 Hz, 1H), 2.99 (t, J= 
7.6 Hz, 2H, linker), 2.08, 2.06, 2.04 (3 s, 3x3H, NHAc), 1.69-1.65 (m, 2H, linker), 1.63-1.58 
(m, 2H, linker), 1.44-1.38 (m, 2H, linker), 1.24 (d, J= 6.7 Hz, 3H, CH3Fuc); 13C NMR (126 MHz, 
D2O) δ,105.0, 101.2, 101.0, 100.1, 99.7, 99.4, 99.2, 79.2, 78.7, 78.6, 77.17, 76.6, 76.3, 75.7, 
73.6, 73.4, 73.3, 73.1, 72.3, 72.0, 71.8, 70.0, 69.8,  69.6, 69.5, 69.5, 69.4, 69.3, 68.1, 68.0, 
67.2, 66.8, 66.5, 66.5, 64.9, 64.9, 61.7, 60.3, 60.3, 55.2, 55.1, 39.3, 28.1, 26.4, 22.3(x3), 22.1, 
15.4; HRMS (ESI) m/z [M+H]+ calculated for C52H90N4O34H 1315.5509, found 1315.5499. 
Octasaccharide G8: Following the general procedure D, compound G8 (1.24 mg, 99%) was 
prepared from G5 (1.03 mg, 0.76 μmol) using core α-1,6-fucosyltransferase CeFUT8 (30 μL, 
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1.1 mg/ml), and GDP-Fuc (589 μg, 0.93 μmol); 1H NMR (500 MHz, D2O) δ 5.15 (s, 1H, H-
1αMan), 4.93 (s, 1H, H-1αMan), 4.92 (d, J= 4.0 Hz, 1H, H-1Fuc), 4.88 (s, 1H), 4.68 (d, J= 8.1 Hz, 
1H), 4.53 (d, J= 8.1 Hz, 1H), 4.51 (d, J= 8.1 Hz, 1H), 4.45 (d, J= 7.6 Hz, 1H), 4.27-4.26 (m, 1H, 
H-2Man), 4.18-4.16 (m, 1H, H-2Man), 4.15-4.12 (m, 1H, H-5Fuc), 4.04-3.51 (m, 45H), 3.40-3.36 
(m, 1H), 3.26 (t, J= 11.3 Hz, 1H), 2.99 (t, J= 7.5 Hz, 2H, linker), 2.10, 2.06, 2.04 (3 s, 3x3H, 
NHAc), 1.71-1.65 (m, 2H, linker), 1.63-1.58 (m, 2H, linker), 1.43-1.38 (m, 2H, linker), 1.24 (d, 
J= 6.7 Hz, 3H, CH3Fuc); 13C NMR (126 MHz, D2O) δ 105.2, 101.1, 101.0, 100.6, 99.7, 99.5, 
99.1, 79.6, 79.6, 79.4, 78.6, 76.9, 76.5, 75.6, 74.4, 74.3, 73.6, 73.3, 73.3, 72.8, 72.6, 72.1, 
71.8, 70.2, 70.0, 69.9, 69.8, 69.6, 69.5, 69.3, 68.1, 68.0, 67.2, 66.8, 66.7, 66.6, 66.5, 65.4, 
65.3, 64.9, 64.9, 61.8, 60.7, 60.6, 55.20, 54.3, 54.8, 39.3, 28.1, 26.4, 22.3, 22.1, 22.1 (x2), 
15.3; HRMS (ESI) m/z [M+H]+ calculated for C58H100N4O39H 1477.6037, found 1477.6073. 
Nonasaccharide G9: Following the general procedure D, compound G9 (0.82 mg, 75%) was 
prepared from G6 (1 mg, 0.651 μmol) using core α-1,6-fucosyltransferase CeFUT8 (30 μL, 
1.1 mg/mL) and GDP-Fuc (589 μg, 0.93 μmol); 1H NMR (500 MHz, D2O) δ 5.16 (s, 1H, H-
1αMan), 4.92 (s, 2H, H-1αMan, H-1αFuc), 4.89 (s, 1H, H-1βMan), 4.68 (d, J= 7.9 Hz, 1H), 4.57 (d, J= 
8.3 Hz, 1H), 4.53 (d, J= 8.3 Hz, 1H), 4.51 (d, J= 8.0 Hz, 1H), 4.45 (d, J= 7.6 Hz, 1H), 4.27-4.25 
(m, 1H, H-2Man), 4.18-4.16 (m, 1H, H-2Man), 4.14-4.12 (m, 2H), 4.04-4.00 (m, 2H), 3.94-3.37 
(m, 49H), 3.26 (t, J= 11.1 Hz, 1H), 3.00 (t, J= 7.7 Hz, 2H, linker), 2.10, 2.07, 2.06, 2.04 (4 s, 
4x3H, NHAc), 1.69-1.66 (m, 2H, linker), 1.62-1.59 (m, 2H, linker), 1.42-1.38 (m, 2H, linker), 
1.24 (d, J= 6.6 Hz, 3H, CH3Fuc); 13C NMR (126 MHz, D2O) δ 105.2, 101.2, 101.1, 100.6, 99.7, 
99.3, 99.2, 99.2, 99.1, 81.8, 79.6, 79.6, 79.4, 79.2, 77.1, 76.6, 76.3, 76.2, 75.7, 74.3, 73.9, 
73.3, 73.3, 73.1, 73.0, 72.2, 71.8, 71.70, 71.1, 70.2, 69.8,69.5, 69.4, 68.2, 68.0, 67.1, 66.8, 
66.5, 66.3, 66.3, 65.5, 65.1, 64.9, 64.2, 61.7, 61.7, 60.1, 60.6, 60.3, 55.2, 55.1, 54.9, 53.5, 
39.3, 28.1, 26.5, 22.2, 22.2, 22.1, 15.4; HRMS (ESI) m/z [M+Na]+ calculated for 
C66H113N5O44Na 1702.6651, found 1702.6577.  
Hexasaccharide G10: Following the general procedure D, compound G10 (720 µg, 99%) was 
prepared from G2 (548 μg, 0.57 μmol) using core α-1,3-fucosyltransferase CeFUT1 (26 μL, 
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0.9 mg/mL), and GDP-Fuc (430 μg, 0.68 μmol); 1H NMR (500 MHz, D2O) δ 5.15 (s, 1H, H-
1Fuc), 5.14 (s, 1H, H-1αMan), 4.84 (s, 1H, H-1βMan), 4.74-4.70 (m, 1H, H-5Fuc), 4.55 (d, J= 7.9 Hz, 
1H), 4.49 (t, J= 7.6 Hz, 2H), 4.26 (d, J= 3.2 Hz, 1H, H-2Man), 4.06-3.39 (m, 29H), 3.26 (t, J= 11.2 
Hz, 1H), 2.95 (t, J= 7.7 Hz, 2H, linker), 2.06, 2.03 (2 s, 2x3H, NHAc), 1.68-1.57 (m, 4H, linker), 
1.41-1.37 (m, 2H, linker), 1.28 (d, J= 6.7 Hz, 3H, CH3Fuc); 13C NMR (126 MHz, D2O) δ 104.9, 
102.2, 100.9, 100.4, 100.1, 98.4, 79.9, 78.9, 77.4, 76.2, 75.3, 75.3, 74.7, 73.9, 73.5, 73.3, 
72.2, 72.0, 70.3, 70.3, 70.2, 69.9, 69.4, 69.1, 67.7, 66.8, 66.7, 66.3, 64.9, 64.7, 61.2, 61.0, 
60.1, 55.7, 55.2, 39.4, 28.1, 26.9(2x), 22.3, 22.2, 15.5; HRMS (ESI) m/z [M+H]+ calculated for 
C44H77N3O29 H 1112.4716 found 1112.4758. 
Heptasaccharide G11: Following the general procedure D, compound G11 (1.2 mg, 85 %) 
was prepared from G3 (1.27 mg, 1.08 μmol) using AtFucTA (50 μL, 0.55 mg/mL) and GDP-
Fuc (0.8 mg, 1.27 μmol); 1H NMR (500 MHz, D2O) δ 5.16 (s, 1H, H-1Fuc), 5.14 (d, J = 4.2 Hz, 
1H, H-1αMan), 4.72 (m, 1H, H-5Fuc), 4.85 (s, 1H, H-1βMan), 4.55 (d, J= 7.91 Hz, 1H), 4.53 (d, J= 
8.4 Hz, 1H), 4.50 (d, J= 7.91 Hz, 1H), 4.48 (d, J= 7.7 Hz, 1H), 4.25 (d, J= 2.27 Hz, 1H, H-2Man), 
4.19-4.17 (m, 1H, H-2Man), 4.03 (dd, J= 11.7, 5.5 Hz, 1H), 3.99 (dd, J= 10.5, 3.26 Hz, 1H), 3.94-
3.43 (m, 34H), 3.38 (dd, J= 9.8, 7.9 Hz, 1H), 3.27 (t, J= 11.1 Hz, 1H), 2.91 (t, J= 7.6 Hz, 2H, 
linker), 2.06, 2.05, 2.03 (3 s, 3x3H, NHAc), 1.66-1.57 (m, 4H, linker), 1.42-1.37 (m, 2H, 
linker), 1.28 (d, J= 6.9 Hz, 3H, CH3Fuc); 13C NMR (126 MHz, D2O) δ 104.9, 101.0, 100.4, 100.1, 
99.7, 99.1, 98.3,  79.9, 79.7, 79.1, 77.0, 76.6, 76.1, 75.9  75.4, 74.7, 73.3, 73.7, 73.2, 72.2, 
71.9, 70.2, 70.2, 69.8, 69.4, 69.3, 69.2, 67.8, 67.2, 66.8, 66.1, 64.9, 64.9, 61.8, 60.9, 60.5, 
60.3, 60.2, 55.6, 55.3, 55.3, 39.7, 28.1, 27.3, 22.2 (3x), 22.1, 15.5; HRMS (MALDI-tof) m/z 
[M+Na]+ calculated for C52H90N4O34Na 1337.5329, found 1337.5347. 
Octasaccharide G12: Following the general procedure D, compound G12 (470 µg, 84%) was 
prepared from G5 (560 µg, 0.38 μmol) using core α-1,3-fucosyltransferase AtFucTA (25 μL, 
0.25 mg/mL), and GDP-Fuc (291 μg, 0.46 μmol); 1H NMR (800 MHz, D2O) δ 5.15 (s, 1H, H-
1αMan), 5.13 (d, J= 3.9 Hz, 1H, H-1Fuc), 4.91 (d, J= 1.3 Hz, 1H, H1- HαMan), 4.85 (s, 1H, H1 βMan), 
4.71-4.69 (m, 1H, H-5Fuc), 4.54 (d, J= 8.3 Hz, 1H, H1- HGlcNAc), 4.52 (d, J= 8.7 Hz, 1H, H1- 
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HGlcNAc), 4.49 (d, J= 8.3 Hz, 1H, H1- HGlcNAc), 4.45 (d, J= 7.4 Hz, 1H, H1- Hxyl), 4.25 (d, J= 3.4 Hz, 
1H, H2- HMan), 4.16-4.15 (m, 1H, H2- HMan), 4.02 (dd, J= 11.6, 5.3 Hz, 1H), 3.98-3.95 (m, 2H), 
3.93-3.83 (m, 12H), 3.81-3.80 (m,1H), 3.80-3.72 (m, 9H), 3.68-3.43 (m, 17H), 3.37 (dd, J= 
9.4, 7.8 Hz, 1H), 3.26 (t, J= 11 Hz, 1H), 2.98 (t, J= 7.8 Hz, 2H, linker), 2.05, 2.05, 2.02 (3 s, 
3x3H, NHAc ), 1.68-1.64 (m, 2H, linker), 1.60-1.57 (m, 2H, linker), 1.41-1.37 (m, 2H, linker), 
1.27 (d, J= 6.6 Hz, 3H, CH3 Fuc); 13C NMR (201 MHz, D2O, peaks from HSQC experiment) δ 
107.8, 103.6, 103.2, 103.0, 102.3, 102.3, 101.7, 100.9, 83.3, 81.8, 79.6, 79.2, 78.4, 78.0, 
77.1, 77.1, 76.9, 76.5, 76.4, 75.9, 75.8, 75.4, 74.9, 74.7, 74.4, 73.1, 72.5, 72.4, 72.0, 71.9, 
71.8, 69.8, 69.4, 69.3, 69.1, 68.0, 67.8, 67.8, 64.4, 64.4, 63.5, 63.5, 63.0, 62.6, 62.4, 58.2, 
58.1, 57.7, 41.9, 30.7, 29.0, 24.8, 24.8, 24.8, 18.1; HRMS (ESI) m/z [M+Na+H]2+ calculated 
for C58H101N4O39Na 851.8362, found 851.8347. 
Nonasaccharide G13: Following the general procedure D, compound G13 (620 µg, 99%) 
was prepared from G6 (570 µg, 0.37 μmol) using AtFucTA (25 μL, 0.25 mg/mL), and GDP-
Fuc (267 μg, 0.42 μmol); 1H NMR (500 MHz, D2O) δ 5.16 (s, 1H, H-1αMan), 5.15 (d, J= 3.7 Hz, 
1H, H-1Fuc), 4.91 (s, 1H, H-1αMan), 4.87 (s, 1H, H-1βMan),4.75 (m, 1H, H-5Fuc), 4.55 (m, 3H), 4.50 
(d, J= 8.0 Hz, 1H), 4.46 (d, J= 7.6 Hz, 1H), 4.27-4.26 (m, 1H, H-2Manβ), 4.17-4.16 (m, 1H, H-
2Manα), 4.12-4.11 (m, 1H, H-2Manα), 4.05-3.43 (m, 47H), 3.40 (t, J= 8.8 Hz 1H), 3.27 (t, J= 11.5 
Hz, 1H), 3.00 (t, J= 7.8 Hz, 2H, linker), 2.07, 2.06, 2.03 (3 s, 4x3H, NHAc), 1.71- 1.58 (m, 4H, 
linker), 1.43-1.37 (m, 2H, linker), 1.28 (d, J= 6.5 Hz, 3H, CH3Fuc); 13C NMR(201 MHz, D2O) δ 
104.7, 100.5, 100.1, 99.9, 99.3, 99.1, 98.6, 97.8, 96.5, 80.2, 78.8, 76.6,76.0, 75.7, 75.3, 74.9, 
74.8, 74.1, 74.1, 73.8, 73.3, 72.8, 72.8, 72.4, 71.8, 71.5, 71.2, 69.7, 69.7, 69.4, 69.0, 68.9, 
68.8, 68.7, 68.0, 67.3, 66.7, 66.2, 65.9, 64.9, 64.5, 64.4, 61.2, 61.2, 61.1, 60.5, 60.5, 60.1, 
60.1, 60.1, 59.5, 59.4, 55.1, 54.8, 54.5, 38.9, 27.6, 26.0, 21.8, 21.7, 21.6, 15.0; HRMS 
(MALDI-tof) m/z [M+Na]+ calculated for C66H113N5O44Na 1702.6651, found 1702.6577. 
Heptasaccharide G14: Following the general procedure C, compound G14 (630 µg, 99%) 
was prepared from G3 (0.5 mg, 0.427 μmol) using 5mU of bovine milk β-1,4-
galactosyltransferase and UDP-Gal (390 µg, 0.64 μmol); 1H NMR (500 MHz, D2O) δ 5.16 (s, 
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1H, H-1αMan), 4.86 (s, 1H, H-1β-Man), 4.61 (d, J= 7.7 Hz, 1H), 4.55 (d, J= 7.6 Hz, 1H, H-1 βGal), 
4.51 (d, J= 8.0 Hz, 1H), 4.48 (d, J= 7.8 Hz, 1H), 4.46 (d, J= 7.7 Hz, 1H), 4.26 (d, J= 2.8 Hz, 1H, 
H-2Man), 4.18-4.17 (m, 1H, H-2Man), 4.04-3.98 (m, 2H), 3.94-3.43 (m, 37H), 3.40-3.36 (m, 1H) 
3.26 (t, J= 11.4 Hz, 1H), 2.95 (t, J= 7.4 Hz, 2H, linker), 2.08, 2.06, 2.04 (3 s, 3x3H,-NHAc), 
1.70-1.56 (m, 4H, linker)1.44-1.37 (m, 2H, linker); 13C NMR (126 MHz, D2O) δ 105.0, 102.9, 
101.3, 101.0, 100.2, 99.6, 99.2, 79.1, 78.5, 77.2, 76.5, 76.4, 75.3, 75.3, 74.7, 74.6, 74.5, 73.7, 
73.3, 72.4, 71.9, 71.0, 70.2, 70.2, 70.1, 69.4, 68.5, 67.2, 66.5, 65.0, 64.9, 61.8, 61.8, 60.9, 
60.3, 60.3, 60.2, 59.9, 59.9,58.3, 55.1, 54.9, 39.4, 28.0, 26.8, 22.2, 22.1; HRMS (ESI) m/z 
[M+Na]+ calculated for C52H90N4O35Na 1353.5278, found 1353.5264. 
Octasaccharide G15: Following the general procedure C, compound G15 (640 µg, 95%) was 
prepared from G5 (600 µg, 0.45 μmol) applying using 94 mU of bovine milk β-1,4-
galactosyltransferase and, UDP-Gal (590 µg, 0.98 μmol); 1H NMR (500 MHz, D2O) δ 5.16 (s, 
1H, H-1αMan),  4.93 (s, 1H, H-1αMan), 4.88 (s, 1H, H-1βMan), 4.61 (d, J= 7.7 Hz, 1H), 4.55 (d, J= 
7.7 Hz, 1H), 4.50 (d, J= 8.0 Hz, 1H), 4.48 (d, J= 8.0 Hz, 1H), 4.45 (d, J= 7.7 Hz, 1H), 4.27 (d, J= 
2.8 Hz, 1H, H-2Man), 4.18-4.17 (m, 1H, H-2Man), 4.04-3.43 (m, 46H), 3.26 (t, J= 11.3 Hz, 1H), 
2.96 (t, 2H, J= 7.5 Hz, linker), 2.09, 2.06, 2.04 (3 s, 3x3H, -NHAc), 1.67-1.59 (m, 4H, linker), 
1.43-1.39 (m, 2H, linker); 13C NMR(201 MHz, D2O, peaks from HSQC experiment) δ 107.8, 
105.5, 104.0, 103.7, 103.2, 102.3, 102.2, 101.8, 82.1, 82.0, 81.9, 81.1, 79.7, 79.1, 78.0, 77.9, 
77.1, 77.1, 77.0, 76.3, 75.3, 75.0, 74.5, 73.8, 73.1, 72.8, 72.4, 71.9, 71.2, 69.8, 69.4, 69.3, 
68.0, 67.6, 67.6, 64.4, 64.4, 63.6, 63.5, 62.6, 62.6, 62.6, 60.8, 57.6, 57.6, 57.5, 42.1, 30.7, 
29.5, 24.9, 24.8, 24.7, 24.7; HRMS (ESI) m/z [M+Na+H]2+ calculated for C58H101N4O40Na 
758.2939 found 758.2911. 
Octasaccharide G16: Following the general procedure C, compound G16 (0.65 mg, 99 %) 
was prepared from G4 (582 µg, 0.437 μmol) using 62.5 mU of bovine milk β-1,4-
galactosyltransferase and UDP-Gal (306 µg, 0.502 μmol); 1H NMR (500 MHz, D2O) δ 5.14 (s, 
1H, H-1αMan), 4.92 (s, 1H, H-1αMan), 4.89 (s, 1H, H-1βMan), 4.61 (d, J= 8.4 Hz, 1H), 4.59 (d, J= 
7.90 Hz, 1H), 4.51 (d J= 7.9 Hz, 1H), 4.49 (d, J= 7.9 Hz, 1H), 4.46 (d, J= 7.6 Hz, 1H), 4.29-4.27 
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(m, 1H, H-2Man), 4.13-4.11 (m, 1H, H-2Man), 4.06-4.05 (m, 1H, H-2Man), 4.02-3.50 (m, 45H), 
3.45 (t, J= 9.5 Hz, 1H), 3.41-3.36 (m,1H), 3.26 (t, J= 11.1 Hz, 1H), 3.00 (t, J= 7.6 Hz, 2H, 
linker), 2.09, 2.06, 2.04 (3 s, 3x3H, NHAc), 1.71 – 1.65 (m, 2H, linker), 1.63-1.58 (m, 2H, 
linker), 1.44-1.38 (m, 2H, linker); 13C NMR (126 MHz, D2O) δ 105.1, 102.9, 102.2, 101.4, 
101.0, 100.6, 99.4, 96.9, 79.7, 79.4, 79.2, 78.5, 78.3, 77.3, 76.2, 75.3, 74.5, 74.4, 73.6, 73.3, 
73.1, 72.9, 72.6, 72.3, 72.0, 70.9, 70.2, 70.09, 69.8, 69.9, 69.7, 69.6, 69.5, 69.2, 68.5, 66.6, 
66.3, 65.5, 65.1, 65.0, 61.5, 61.4, 61.1, 60.1, 60.0, 60.0, 55.0, 54.9, 39.3, 28.0, 26.3, 22.2, 
22.1, 22.1; HRMS (ESI) m/z [M+H]+ calculated for C58H101N4O40 1493.5987, found 
1493.6013. 
Decasaccharide G17: Following the general procedure C, compound G17 (700 µg, 99%) was 
prepared from G4 (470 µg, 0.306 μmol) using 88 mU of bovine milk β-1,4-
galactosyltransferase and, UDP-Gal (550 µg, 0.91 μmol); 1H NMR (800 MHz, D2O) δ 5.14 (s, 
1H, H-1αMan), 4.91 (s, 1H, H-1αMan), 4.87 (s, 1H, H-1βMan), 4.59 (dd, J= 8.6, 7.9 Hz, 2H), 4.54 (d, 
J= 7.9 Hz, 1H), 4.49 (d, J= 7.9 Hz, 1H), 4.47 (dd, J= 7.8, 4.7 Hz, 2H), 4.44 (d, J= 7.7 Hz, 1H), 
4.26-4.25 (d, J= 3.2 Hz, 1H, H-2Man), 4.16-4.15 (m, 1H, H-2Man), 4.11-4.10 (m, 1H, H-2Man), 
4.02-3.97 (m, 4H), 3.93-3.48 (m, 51H), 3.45-3.42 (m, J= 9.2, 2.3 Hz, 1H), 3.38-3.36 (m, 1H), 
3.25 (t, J= 11.3 Hz, 1H), 2.98 (t, 2H, J= 7.7 Hz, linker), 2.08, 2.05, 2.04, 2.03 (4 s, 4x3H, 
NHAc), 1.69-1.65 (m, 2H, linker), 1.61-1.57 (m, 2H, linker), 1.40-1.38 (m, 2H, linker); 13C 
NMR(201 MHz, D2O) δ 107.7, 105.6, 105.6, 104.0, 103.7, 103.2, 102.2, 102.1, 101.7, 99.7, 
82.1, 82.05, 81.9, 81.1, 79.7, 79.1, 78.9, 78.0, 77.9, 77.9, 77.4, 77.4, 77.1, 77.0, 76.3, 76.2, 
75.9, 75.5, 75.1, 74.7, 74.6, 74.4, 73.6, 73.5, 72.8, 72.7, 72.2, 72.1, 71.9, 71.9, 71.4, 71.2, 
69.8, 69.1, 68.0, 67.9, 67.6, 67.6, 64.3, 64.2, 63.6, 62.9, 62.7, 62.6, 62.6, 62.6, 62.6, 62.5, 
57.6, 57.6, 57.5, 41.9, 30.7, 29.0, 24.9, 24.9, 24.8, 24.7; HRMS (MALDI-tof) m/z [M+Na]+ 
calculated for C72H123N5O50Na 1880.7128, found 1880.7042. 
Heptasaccharide G18: Following the general procedure E, compound G18 (680 µg, 99%) 
was prepared from G3 (590 µg, 0.50 μmol) using concentrated P. pastoris extract 
containing β-1,4-GalNAcT (40 µL) and UDP-GalNAc (390 µg, 0.60 μmol); 1H NMR (500 MHz, 
  
 
 
102 
D2O) δ 5.15 (s, 1H, H-1αMan), 4.86 (s, 1H, H-1βMan), 4.61 (d, J= 7.5 Hz, 1H, H-1βGlcNAc), 4.54-4.50 
(m, 3H), 4.46 (d, J= 7.5 Hz, 1H, H-1βXyl), 4.26-4.24 (m, 1H, H-2Man), 4.18-4.16 (m, 1H, H-2Man), 
4.05-3.99 (dd, J= 11.4, 5.5 Hz, 1H), 3.96-3.43 (m, 38H), 3.40-3.36 (m, 1H), 3.26 (t, J = 11.1 
Hz, 1H), 2.98 (t, J= 7.7 Hz, 2H, linker), 2.08, 2.06, 2.04 (3 s, 3x3H, NHAc), 1.71-1.65 (m, 2H, 
linker), 1.62-1.58 (m, 2H, linker), 1.44-1.39 (m, 2H, linker); 13C NMR(201 MHz, D2O, peaks 
from HSQC experiment) δ 107.6, 104.4, 104.0, 103.7, 102.7, 102.2, 101.8, 81.9, 81.8, 81.7, 
81.3, 79.8, 79.1, 78.9, 78.0, 77.9, 77.2, 77.1, 76.3, 75.9, 75.0, 74.6, 74.4, 73.3, 72.8, 72.8, 
72.1, 72.0, 70.2, 69.8, 69.1, 67.6, 64.4, 64.4, 63.6, 63.0, 62.7, 62.7, 62.6, 57.8, 57.6, 57.2, 
55.1, 41.9, 30.7, 29.0, 24.8, 24.7, 24.7, 24.7; HRMS (ESI) m/z [M+H]+ calculated for 
C54H94N5O35 1372.5724, found 1372.5740. 
Octasaccharide G19: Following the general procedure E, compound G19 (500 µg, 99%) was 
prepared from G4 (450 µg, 0.34 μmol), using concentrated P. pastoris extract containing β-
1,4-GalNAcT (75 µL) and UDP-GalNAc (270 µg, 0.41 μmol); 1H NMR (800 MHz, D2O) δ 5.14 
(s, 1H, H-1αMan), 4.92 (s, 1H, H-1αMan), 4.87 (s, 1H, H-1βMan), 4.59 (d, J= 8.3 Hz, 1H), 4.52-4.50 
(m, 2H), 4.49 (d, J= 7.9 Hz, 1H), 4.44 (d, J= 7.6 Hz, 1H), 4.25 (d, J= 3.3 Hz, 1H, H-2Man), 4.14 
(m, 1H, H-2Man), 4.01 (dd, J= 11.7, 5.6 Hz, 1H), 3.99-3.98 (m, 1H), 3.97-3.54 (m, 39H), 3.52-
3.49 (m, 3H), 3.43 (t, J= 9.2 Hz, 1H), 3.37 (dd, J= 9.3, 7.6 Hz, 1H), 3.25 (t, J= 11.1 Hz, 1H), 
2.98 (t, J= 7.7 Hz, 2H, linker), 2.08, 2.07, 2.04, 2.03 (4 s, 4x3H, NHAc), 1.69-1.64 (m, 2H, 
linker), 1.62-1.57 (m, 2H, linker), 1.40-1.37 (m, 2H); 13C NMR (201 MHz, D2O, peaks from 
HSQC experiment) δ 105.0, 101.6, 101.2, 101.0, 100.4, 99.5, 99.4, 98.8, 82.2, 81.9, 81.9, 
81.8, 79.7, 79.1, 77.9, 77.9, 77.1, 77.0, 77.0, 76.3, 75.9, 75.3, 75.1, 74.6, 74.4, 73.3, 73.1, 
72.7, 72.7, 72.4, 72.2, 72.0, 71.9, 70.2, 69.8, 69.3, 68.0, 64.4, 64.4, 63.5, 63.5, 62.9, 62.7, 
62.7, 57.6, 57.6, 57.2, 55.1, 41.9, 30.7, 29.0, 24.9, 24.8, 24.8, 24.8, 24.7; HRMS (ESI) m/z 
[M+H]+ calculated for C60H104N5O40 1534.6252, found 1534.6299. 
Octasaccharide G20: Following the general procedure E, compound G20 (700 µg, 99 %) was 
prepared from G4 (610 µg, 0.46 μmol) using concentrated P. pastoris extract containing β-
1,4-GalNAcT (120 μL) and UDP-GalNAc (752 µg, 1.15 μmol); 1H NMR (500 MHz, D2O) δ 5.14 
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(s, 1H, H-1αMan), 4.91 (s, 1H, H-1αMan), 4.89 (s, 1H, H-1βMan), 4.61 (d, J= 7.9 Hz, 1H), 4.58-4.55 
(d, J= 7.8 Hz, 1H), 4.52 (d, J = 8.3 Hz, 1H), 4.51 (d, J= 7.8 Hz, 1H), 4.46 (d, J= 7.6 Hz, 1H), 4.28 
(d, J= 3.0 Hz, 1H, H-2Man), 4.12-4.10 (m, 1H, H-2Man), 4.05 (dd, J= 3.2, 1.4 Hz, 1H, H-2Man), 
4.03-3.58 (m, 40H), 3.53-3.49 (m, 3H), 3.45 (t, J = 9.26 Hz, 1H), 3.40-3.37 (m, 1H), 3.26 (t, J= 
11.1 Hz, 1H), 3.00 (t, J= 7.7 Hz, 2H, linker), 2.10, 2.09, 2.05, 2.04 (4 s, 4x3H, NHAc), 1.71-1.65 
(m, 2H, linker), 1.62-1.58 (m, 2H, linker), 1.44-1.38 (m, 2H, linker); 13C NMR(201 MHz, D2O, 
peaks from HSQC experiment) δ:107.6, 104.8, 104.4, 104.0, 103.7, 103.3, 102.1, 99.5, 82.3, 
82.2, 81.9, 79.9, 78.8, 78.0, 78.0, 77.1, 77.0, 76.2, 75.9, 75.5, 75.0, 74.7, 74.3, 73.3, 72.9, 
72.8, 72.7, 72.6, 72.2, 72.2, 71.9, 70.2, 69.9, 69.4, 69.0, 68.0, 67.6, 67.5, 64.2, 63.8, 63.7, 
62.8, 62.7, 62.7, 57.6, 57.6, 57.3, 55.1, 41.9, 30.7, 29.0, 24.9, 24.9, 24.8, 24.8, 24.7; HRMS 
(ESI) m/z [M+H]+ calculated for C60H104N5O40 1534.6252, found 1534.6201. 
Decasaccharide G21: Following the general procedure E, compound G21 (700 µg, 99%) was 
prepared from G6 (570 µg, 0.37 μmol), using concentrated P. pastoris extract containing β-
1,4-GalNAcT (150 µL) and UDP-GalNAc (960 µg, 1.48 µmol); 1H NMR (800 MHz, D2O) δ 5.15 
(s, 1H, H-1αMan), 4.91 (s, 1H, H-1αMan ), 4.88 (s, 1H, H-1βMan), 4.61 (d, J= 8.0 Hz, 1H), 4.58-4.50 
(m, 5H), 4.45 (d, J= 8.1 Hz, 1H), 4.28-4.26 (m, 1H, H-2Man), 4.16-4.14 (m, 1H, H-2Man), 4.01-
3.42 (m, 56H), 3.38 (s, 2H), 3.28-3.23 (m, 1H), 2.97 (t, J= 7.4 Hz, 2H), 2.10-2.07 (m, 9H, 
NHAc), 2.06-2.04 (m, 9H, NHAc), 1.69-1.63 (m, 2H, linker), 1.62-1.57 (m, 2H, linker), 1.42-
1.38 (m, 2H, linker); HRMS (MALDI-tof) m/z [M+Na]+ calculated for C76H129N7O50Na 
1962.7659, found 1962.7672. 
Octasaccharide G22: Following the general procedure D, compound G22 (650 µg, 99%) was 
prepared from G7 (470 µg, 0.36 μmol) using AtFucTA (25μL, 0.25 mg/mL), and GDP-Fuc 
(267 μg, 0.42 μmol); 1H NMR (500 MHz, D2O) δ 5.16 (s, 1H, H-1αMan), 5.14 (d, J= 4.1 Hz, 1H, 
H-1Fuc α1,3), 4.94 (d, J= 4.1 Hz, 1H, H-1Fuc α1,6), 4.84 (s, 1H, H-1βMan), 4.74-4.72 (m, 1H, H-5Fuc α1,3), 
4.69 (d, J= 7.9 Hz, 1H), 4.52 (d, J= 8.5 Hz, 1H), 4.49 (t, J= 8.9Hz, 2H), 4.25 (d, J= 3.17 Hz, 1H, 
H-2Man), 4.18-4.16 (m, 2H, H-2Man ,H-5Fuc α1,6), 4.03-3.46 (m, 39H), 3.40-3.35 (m, 1H), 3.27 (t, 
J= 11.3 Hz, 1H), 2.99 (t, J= 7.7 Hz, 2H, linker), 2.06, 2.05, 2.03 (3 s, 3x3H, NHAc ), 1.71-1.65 
  
 
 
104 
(m, 2H, linker), 1.62-1.57(m, 2H, linker), 1.41-1.36 (m, 2H, linker), 1.28 (d, J= 6.8 Hz, 3H, 
CH3Fuc α1,3), 1.24 (d, J= 6.7 Hz, 3H, CH3Fuc α1,6); 13C NMR (201 MHz, D2O) δ 107.6, 103.6, 102.7, 
102.7, 102.4, 101.8, 101.6, 100.9, 82.7, 81.8, 79.7, 79.2, 78.8, 78.5, 77.9, 77.7, 77.3, 76.6, 
76.3, 76.0,75.9, 75.9, 74.8, 74.4, 72.7, 72.5, 72.1, 72.0, 71.9, 71.8, 70.7, 70.4, 69.8, 69.4, 
69.4, 69.1, 67.6, 67.5, 65.3, 64.4, 64.3, 63.2, 63.0, 58.3, 57.9, 57.9, 42.0, 30.7, 29.2, 24.8, 
24.8, 24.8, 24.8, 18.1, 18.0; HRMS (ESI) m/z [M+Na]+ calculated for C58H100N4O38Na 
1483.5908 found 1483.5907. 
Nonasaccharide G23: Following the general procedure D, compound G23 (340 µg, 91.5%) 
was prepared from G8 (340 µg, 0.23 µmol) using AtFucTA (25 μL, 0.25 mg/mL) and GDP-Fuc 
(228 µg, 0.36 μmol); 1H NMR (500 MHz, D2O) δ 5.16 (s, 1H, H-1αMan), 5.14 (d, J= 3.9 Hz, 1H, 
H-1Fuc α1,3), 4.94 (d, J= 3.9 Hz, 1H, H-1Fuc α1,6), 4.9 (d, J= 1.6 Hz, 1H, H-1αMan), 4.87 (s, 1H, H-
1βMan), 4.74-4.72 (m, 1H, H-5Fuc α1,3), 4.70 (d, J= 7.9 Hz, 1H), 4.53 (d, J = 8.6 Hz, 1H), 4.50 (d, J 
= 8.2 Hz, 1H), 4.48 (d, J= 7.8 Hz, 1H), 4.27 (d, J= 3.1 Hz, 1H, H-2Man), 4.18-4.15 (m, 2H, H-2Man, 
H-5Fuc α1,6), 4.05-3.45 (m, 42H), 3.41-3.36 (m, 1H), 3.28 (t, J= 11.3 Hz, 1H), 3.00 (t, J= 7.5 Hz, 
2H, linker), 2.07, 2.06 ,2.03 (3 s, 3x3H, NHAc), 1.71-1.64 (m, 2H, linker), 1.63-1.58 (m, 2H, 
linker), 1.43-1.38 (m, 2H, linker), 1.29 (d, J= 6.5 Hz, 3H, CH3Fuc α1,3), 1.24 (d, J= 6.7 Hz, 3H, 
CH3Fucα1,6); 13C NMR (201 MHz, D2O) δ 107.8, 103.6, 103.2, 102.6, 102.4, 102.3, 101.8, 101.6, 
100.9, 83.6, 82.05, 79.6, 79.2, 78.4, 77.9, 77.3, 77.1, 77.0,  76.6, 76.3, 76.0, 75.9, 75.8, 75.3, 
75.00, 74.5, 73.1, 72.7, 72.4, 72.3, 72.1, 72.0, 71.9, 71.8, 70.7, 70.4, 70.0, 69.4, 69.4, 69.3, 
69.2, 68.0, 68.1, 67.6, 67.5, 64.4, 64.3, 63.5, 63.2, 58.3, 57.9, 57.7, 42.0, 30.7, 29.3, 24.9, 
24.8, 24.8, 24.8, 18.1, 18.0; HRMS (ESI) m/z [M+Na]+ calculated for C64H110N4O43Na 
1645.6436 found 1645.6415. 
Decasaccharide G24: Following the general procedure D, compound G24 (1.64 mg, 93 %) 
was prepared from G9 (1.62 mg, 0.96 μmol) using AtFucTA (30 μL, 0.25 mg/mL), and GDP-
Fuc (728 μg, 1.15 μmol); 1H NMR (800 MHz, D2O) δ 5.15 (s, 1H, H-1αMan), 5.13 (d, J= 3.6 Hz, 
1H, H-1Fucα1-3), 4.94 (d, J= 3.6 Hz, 1H, H-1Fucα1-6), 4.90 (s, 1H, H-1αMan), 4.86 (s, 1H, H-1βMan), 
4.68 (d, J= 8.3 Hz, 1H), 4.56 (d, J= 8.6 Hz, 1H), 4.51 (d, J= 8.6 Hz, 1H), 4.49-4.48 (m, 1H), 4.46 
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(d, J= 7.6 Hz, 1H), 4.26 (d, J= 3.2 Hz, 1H, H-2Man), 4.16-4.15 (m, 2H, H-2Man, H-5Fucα1-6), 4.11-
4.10 (m, 1H), 4.03-3.42 (m, 51H), 3.38 (dt, J= 9.8, 1.8 Hz, 1H), 3.27 (t, J= 11.3 Hz, 1H), 2.97-
2.94 (m, 2H, linker), 2.06 (s, 3H, NHAc), 2.05 (m, 6H, NHAc), 2.02 (s, 3H, NHAc), 1.67-1.63 
(m, 2H, linker), 1.60-1.57 (m, 2H, linker), 1.40-1.37 (m, 2H, linker), 1.27 (d, J= 6.6 Hz, 3H, 
CH3Fucα1-3), 1.23 (d, J= 6.5 Hz, 3H, CH3Fucα1-6); 13C NMR(201 MHz, D2O) δ 106.6, 102.4, 102.0, 
101.4, 101.3, 100.9, 100.5, 100.4, 99.7, 98.5, 82.3, 80.8, 78.4, 77.9, 77.5, 77.2, 76.6, 76.0, 
75.9, 75.8, 75.3, 75.0, 74.8, 74.7, 74.7, 74.2, 73.8, 73.3, 73.1, 71.4, 71.3, 70.9, 70.8, 70.6, 
70.5, 69.9, 69.5, 69.1, 68.6, 68.2, 68.1, 67.8, 67.4, 67.4, 66.9, 66.4, 66.3, 63.1, 63.1, 62.9, 
62.5, 62.4, 62.0, 62.0, 61.7, 57.0, 56.7, 56.4, 40.8, 29.5, 28.1, 23.7, 23.6, 23.6, 23.6, 23.5, 
16.9, 16.8; HRMS (ESI) m/z [M+Na+H]2+ calculated for C72H123N5O48 924.8651, found 
924.8627. 
Octasaccharide G25: Following the general procedure E, compound G25 (0.37 mg, 99%) 
was prepared from G11 (0.32 mg, 0.24 μmol) using concentrated P. pastoris extract 
containing β-1,4-GalNacT (50 μL) and UDP-GalNAc (189 μg, 0.291 μmol); 1H NMR (800 MHz, 
D2O) δ 5.14-5.13 (m, 2H, H-1αMan, H-1Fuc), 4.83 (s, 1H, H-1βMan), 4.71-4.69 (m, 1H, H-5Fuc), 4.54 
(d, 1H, J=8.5 Hz), 4.52-4.50 (m, 2H), 4.48 (d, J= 8.2 Hz, 1H), 4.45 (d, J= 7.8 Hz, 1H), 4.25-4.23 
(m, 1H, H-2Man), 4.15-4.14 (m, 1H, H-2Man ), 4.00 (dd, J= 11.4, 5.6 Hz, 1H), 3.97 (dd, J= 10.5, 
3.4 Hz, 1H), 3.94-3.43 (m, 40H), 3.37 (dd, J= 10.0, 7.8 Hz, 1H), 3.25 (t, J= 11.0 Hz, 1H), 2.98 
(t, J= 7.9 Hz, 2H, linker), 2.07, 2.04, 2.04, 2.02 (4 s, 4x3H, NHAc), 1.69-1.65 (m, 2H, linker), 
1.60-1.57 (m, 2H, linker), 1.41-1.38 (m, 2H, linker), 1.26 (d, J= 6.6 Hz, 3H, CH3Fuc); 13C 
NMR(201 MHz, D2O, peaks from HSQC experiment) δ 107.6, 104.4, 103.7, 103.1, 102.7, 
102.2, 101.7, 100.9, 82.5, 81.8, 81.7, 79.7, 79.0, 78.9, 78.0, 78.0, 77.9, 77.1, 76.4, 76.4, 75.9, 
74.8, 74.7, 74.4, 73.3, 72.8, 72.7, 72.1, 72.0, 71.9, 70.4, 70.2, 69.8, 69.4, 69.1, 67.6, 67.5, 
64.4, 64.4, 63.6, 63.6, 63.5, 62.9, 62.7, 62.7, 62.7, 58.2, 57.9, 57.2, 55.2, 30.7, 29.0, 24.9, 
24.8, 24.8, 24.7, 18.1; HRMS (MALDI-tof) m/z [M+Na]+ calculated for 1540.6122 
C60H103N5O39, found 1540.6124. 
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Octasaccharide G26: Following the general procedure C, compound G26 (830 µg, 89%) was 
prepared from G7 (830 µg, 0.63 μmol) using 87 mU of bovine milk β-1,4-
galactosyltransferase and UDP-Gal (464 μg, 0.76 μmol); 1H NMR (800 MHz, D2O) δ 5.14 (s, 
1H, H-1αMan), 4.91 (s, 1H), 4.85 (s, 1H), 4.66 (d, J= 8.3 Hz, 1H), 4.54 (d, J= 7.6 Hz, 1H), 4.50 (d, 
J= 8.6 Hz, 1H), 4.45 (dd, J= 7.9, 7.7 Hz, 2H), 4.24 (s, 1H, H-2Man), 4.16 (s, 1H, H-2Man), 4.14-
4.12 (m, 1H, H-5Fuc), 4.02-3.97 (m, 2H), 3.92-3.44 (m, 40H), 3.37 (t, J= 8.5 Hz, 1H), 3.24 (t, J= 
11.0 Hz, 1H), 2.98 (t, J= 7.9 Hz, 2H), 2.08, 2.05, 2.03 (3 s, 3x3H, NHAc), 1.68-1.65 (m, 2H, 
linker), 1.62-1.58 (m, 2H, linker), 1.41-1.37 (m, 2H, linker), 1.23 (d, J= 6.6 Hz, 3H, CH3Fuc); 13C 
NMR(201 MHz, D2O, peaks from HSQC experiment) δ 106.4, 104.3, 102.5, 102.5, 101.5, 
101.0, 100.8, 100.5, 80.5, 79.8, 78.5, 77.9, 77.7, 76.7, 76.6, 76.1, 75.9, 75.0, 74.9, 74.7, 73.3, 
73.1, 72.9, 72.3, 71.4, 70.9, 70.8, 70.7, 69.9, 69.5, 68.6, 68.2, 67.9, 67.8, 66.3, 66.3, 63.2, 
63.1, 62.4, 61.6, 61.4, 61.3, 61.3, 61.3, 56.6, 56.5, 56.4, 40.7, 29.5, 27.81, 23.7, 23.6, 23.5, 
23.5, 16.8; HRMS (MALDI-tof) m/z [M+Na]+ calculated for C58H100N4O39Na 1499.5857, found 
1499.5786. 
Octasaccharide G27: Following the general procedure D, compound G27 (380 µg, 99%) was 
prepared from G14 (350 µg, 0.26 μmol) using CeFUT6 (20 μL, 1.07 mg/mL) and GDP-Fuc 
(202 μg, 0.32 μmol); 1H NMR (800 MHz, D2O) δ 5.13 (s, 1H, H-1αMan), 5.13 (d, J= 4.1 Hz, 1H, 
H-1Fuc), 4.85(s, 1H, H-1βMan), 4.84-4.82 (m, 1H, H-5Fuc), 4.59 (d, J= 8.1 Hz, 1H), 4.55-4.53 (m, 
1H), 4.49 (d, J= 7.7 Hz, 1H), 4.44 (d, J= 8.2 Hz, 2H), 4.24 (d, J= 2.8 Hz, 1H, H-2Man ), 4.16-4.15 
(m, 1H, H-2Man), 4.03-3.99 (m, 2H), 3.96-3.84 (m, 14H), 3.80-3.56 (m, 21H), 3.52-3.46 (m, 
4H), 3.43 (t, J= 9.3 Hz, 1H), 3.37 (dd, J= 9.5, 7.7 Hz, 1H), 3.24 (t, J= 11.1 Hz, 1H), 2.98 (t, J = 
7.7 Hz, 2H, linker), 2.06, 2.04, 2.03 (3 s, 3x3H, NHAc), 1.69-1.64 (m, 2H, linker), 1.61-1.57 
(m, 2H, linker), 1.42-1.37 (m, 2H, linker), 1.17 (d, J= 6.6 Hz, 3H, CH3Fuc); 13C NMR(201 MHz, 
D2O, peaks from HSQC experiment) δ 106.4, 103.2, 102.8, 102.4, 101.3, 100.8, 100.5, 
99.93, 80.7, 80.5, 80.0, 78.5, 77.8, 77.7, 76.3, 75.9, 75.8, 75.1, 74.7, 74.6, 73.8, 73.3, 73.0, 
72.5, 71.5, 70.8, 70.7, 70.6, 69.8, 69.1, 68.6, 68.1, 67.8, 66.4, 66.3, 63.2, 63.1, 62.9, 61.7, 
61.6, 61.5, 61.4, 61.3, 61.1, 57.1, 56.6, 56.4, 40.7, 29.4, 27.8, 23.8, 23.6, 23.5, 23.4, 16.7; 
HRMS (ESI) m/z [M+H] calculated for C58H101N4O39 1477.6037, found 1477.6034. 
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Nonasaccharide G28: Following the general procedure D, compound G28 (380 µg, 99%) 
was prepared from G15 (325 µg, 0.22 μmol) using CeFUT6 (15 μL, 1.07 mg/mL) and GDP-
Fuc (164 μg, 0.26 μmol); 1H NMR (800 MHz, D2O) δ 5.13 (s, 1H, H-1αMan), 5.12(d, J = 3.9 Hz, 
1H, H-1Fuc), 4.92 (s, 1H, H-1αMan), 4.87 (s, 1H, H-1βMan), 4.60 (d, J= 8.0 Hz, 1H), 4.56-4.54 (m, 
1H), 4.5 (d, J = 7.8 Hz, 1H), 4.45-4.43 (m, 2H), 4.26 (d, J= 2.7 Hz, 1H, H-2Man), 4.16-4.15 (m, 
1H, H-2Man), 4.13-4.09 (m, 1H), 4.02-3.48 (m, 48H), 3.44 (t, J= 9.3 Hz, 1H), 3.37 (dd, J= 9.6, 
8.0 Hz, 1H), 3.25 (t, J= 11.0 Hz, 1H), 2.98 (t, J= 7.8 Hz, 2H, linker), 2.08, 2.04, 2.03 (3 s, 3x3H, 
NHAc), 1.68-1.65 (m, 2H, linker), 1.61-1.57 (m, 2H, linker), 1.41-1.38 (m, 2H, linker), 1.18 (d, 
J= 6.5 Hz, 3H, CH3Fuc); 13C NMR (201 MHz, D2O, peaks from HSQC experiment) δ 107.8, 
104.4, 104.0, 103.7, 103.2, 102.3, 101.9, 101.7, 101.2, 82.1, 82.0, 81.9, 79.7, 79.0, 77.9, 
77.9, 77.6, 77.2, 77.1, 77.0, 76.3, 75.9, 75.9, 75.3, 75.0, 75.0, 74.6, 74.6, 74.4, 73.7, 73.4, 
72.7, 72.7, 72.4, 72.0, 71.9, 71.7, 70.9, 70.3, 69.8, 69.5, 69.3, 69.2, 68.2, 67.6, 67.5, 64.8, 
64.1, 63.5, 62.9, 63.0, 62.3, 57.6, 57.6, 30.7, 29.1, 25.0, 24.8, 24.8, 24.7, 17.9; HRMS (ESI) 
m/z [M+Na+H]2+  calculated for C64H110N4O44 831.3229, found 831.3253. 
Nonasaccharide G29: Following the general procedure D, compound G29 (260 µg, 74%) 
was prepared from G16 (320 µg, 0.22 μmol) using CeFUT6 (15 μL, 1.07 mg/mL) and GDP-
Fuc (164 μg, 0.26 μmol); 1H NMR (800 MHz, D2O) δ 5.14-5.12 (m, 2H, H-1αMan, H-1Fucα-1,3), 
4.90 (s, 1H, H-1αMan), 4.88 (s, 1H, H-1βMan), 4.59-4.58 (m, 2H), 4.49 (d, J= 7.62 Hz, 1H), 4.44 
(dd, J= 7.91, 2.8 Hz, 2H), 4.27 (d, J= 2.8 Hz, 1H, H-2Man), 4.11-4.10 (m, 1H), 4.04-3.54 (m, 
45H), 3.51-3.47 (m, 3H), 3.44 (t, J= 9.4 Hz, 1H), 3.39-3.36 (m, 1H), 3.25 (t, J= 11.1 Hz, 1H), 
2.98 (t, J= 7.7 Hz, 2H, linker), 2.08, 2.04, 2.03 (3 s, 3x3H, NHAc), 1.68-1.63 (m, 2H, linker), 
1.61-1.57 (m, 2H, linker), 1.40-1.38 (m, 2H, linker), 1.17 (d, J= 6.6 Hz, 3H, CH3Fucα-1,3); 13C 
NMR(201 MHz, D2O, peaks from HSQC experiment) δ 107.7, 104.8, 104.4, 104.0, 103.7 
,103.3, 101.8, 101.2, 99.4, 82.2, 81.9, 81.9, 79.9, 78.7, 77.9, 77.9, 77.6, 77.3, 77.1, 77.0, 
76.2, 75.9, 75.9, 75.5, 75.1, 75.1, 74.7, 74.6, 74.3, 73.7, 72.9, 72.7, 72.6, 72.2, 71.8, 71.1, 
71.0, 70.3, 69.9, 69.4, 69.3, 69.1, 67.5, 64.1, 63.8, 63.0, 62.7, 62.7, 62.3, 62.1, 58.3, 57.6, 
57.6, 41.9, 30.7, 28.9, 25.0, 24.8, 24.8, 22.6, 17.9; HRMS (ESI) m/z [M+Na+H]2+  calculated 
for C64H111N4O44Na 831.3229, found 831.3199. 
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Dodecasaccharide G30: Following the general procedure D, compound G30 (400 µg, 99%) 
was prepared from G17 (360 µg, 0.19 μmol) using CeFUT6 (15 μL, 1.07 mg/mL) and GDP-
Fuc (291 μg, 0.46 μmol); 1H NMR (800 MHz, D2O) δ 5.13-5.11 (m, 3H, H-1αMan, H-1Fucα-1,3, H-
1Fucα-1,3), 4.89 (s, 1H, H-1αMan), 4.87(s, 1H, H-1βMan), 4.84 (m, 1H H-5Fucα-1,3), 4.60-4.58 (m, 2H), 
4.55-4.53 (m, 1H), 4.48 (d, J= 8.1 Hz, 1H), 4.45-4.43 (m, 3H), 4.25 (d, J= 3.1 Hz, 1H, H-2Man), 
4.16-4.15 (m, 1H, H-2Man), 4.11-4.10 (m, 1H, H-2Man), 4.02-3.55 (m, 57H), 3.50-3.47 (m, 5H), 
3.44-3.42 (m, 1H), 3.39-3.36 (m, 1H), 3.24 (t, J= 11.0 Hz, 1H), 2.98 (t, J= 7.7 Hz, 2H, linker), 
2.08, 2.04, 2.04, 2.03 (4 s, 4x3H, NHAc), 1.68-1.64 (m, 2H, linker), 1.61-1.57 (m, 2H, linker), 
1.41-1.38 (m, 2H, linker), 1.17 (m, 6H, CH3Fucα-1,3, CH3Fucα-1,3); 13C NMR(201 MHz, D2O, peaks 
from HSQC experiment) δ 108.0, 104.5, 104.4, 103.9, 103.7, 103.2, 101.9, 101.8, 101.7, 
101.2, 101.2, 99.5, 82.2, 82.0, 81.9, 79.9, 79.0, 78.7, 77.9, 77.9, 77.6, 77.2, 77.1, 76.9, 76.3, 
75.9, 75.9, 75.5, 75.1, 75.0, 75.0, 74.7, 74.5, 74.4, 73.7, 73.7, 72.7, 72.2, 72.2, 72.2, 72.1, 
71.9, 71.8, 71.7, 71.0, 70.3, 70.3, 69.8, 69.3, 69.3,  69.1, 68.3, 68.1, 67.6, 67.6, 64.4, 64.3, 
64.2, 64.1, 63.0, 62.8, 62.7, 62.7, 62.6, 62.4, 62.3, 58.3, 58.3, 57.6, 57.6, 41.9, 30.7, 29.0, 
25.0, 25.0, 24.8, 24.8, 24.7, 17.9, 17.9; HRMS (ESI) m/z [M+K]+ calculated for C84H143N5O57K 
2172.8286, found 2172.8364. 
Nonasaccharide G31: Following the general procedure D, compound G31 (420 µg, 79%) 
was prepared from G26 (480 µg, 0.32 μmol) using CeFUT6 (30 μL, 1.07 mg/mL) and GDP-
Fuc (297 μg, 0.47 μmol); 1H NMR (800 MHz, D2O) δ 5.13 (s, 1H, H-1αMan), 5.12 (d, J = 4.1 Hz, 
1H, H-1Fucα-1,3), 4.90 (d, J = 3.9 Hz, 1H, H-1Fucα-1,6), 4.85 (s, 1H, H-1βMan), 4.83-4.81 (m, 1H, H-
5Fucα-1,3), 4.65 (d, J= 8.0 Hz, 1H), 4.55-4.53 (m, 1H), 4.50 (d, J= 8.5, 1H), 4.44 (dd, J= 7.4, 3.9 
Hz, 2H), 4.24 (d, J= 2.94 Hz, 1H, H-2Manβ), 4.16-4.15 (m, 1H, H-2Manα), 4.12 (q, J= 6.7 Hz, 1H, 
H-5Fucα-1,6 ), 4.02-3.99 (m, 2H), 3.96-3.56 (m, 39H), 3.52-3.48 (m, 3H), 3.45 (t, J= 9.2 Hz, 1H), 
3.38-3.36 (m, 1H), 3.25 (t, J= 11.0 Hz, 1H), 2.98 (t, J= 7.7 Hz, 2H, linker), 2.08, 2.04, 2.03 (3 s, 
3x3H, NHAc), 1.69-1.65 (m, 2H, linker), 1.61-1.57 (m, 2H, linker), 1.41-1.37 (m, 2H, linker), 
1.22 (d, J= 6.6 Hz, 3H, CH3Fucα-1,3), 1.17 (d, J= 6.5 Hz, 3H, CH3Fucα-1,6); 13C NMR(201 MHz, D2O) 
δ 106.4, 103.2, 102.5, 102.4, 101.5, 100.8, 100.7, 100.4, 99.9, 80.6, 80.1, 78.5, 77.8, 77.7, 
76.7, 76.6, 76.0, 75.9, 75.1, 74.9, 74.7, 74.6, 73.8, 73.4, 73.3, 73.1, 72.5, 71.4, 71.4, 70.8, 
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70.8, 70.6, 69.7, 69.5, 69.1, 68.6, 68.2, 68.1, 67.9, 67.8, 66.3, 66.3, 63.1, 62.9, 61.6, 61.6, 
61.5, 61.1, 61.0, 57.1, 56.5, 56.4, 40.6, 29.4, 27.8, 23.7, 23.6, 23.5, 23.5, 16.7, 16.7; HRMS 
(ESI) m/z [M+Na]+ calculated for C64H110N4O43Na 1645.6436, found 1645.6499. 
Dodecasaccharide G32: Following the general procedure E, compound G32 (620 µg, 63% ) 
was prepared from G24 (900 µg, 0.49 μmol) using concentrated P. pastoris extract 
containing β-1,4-GalNAcT (210 μL) and UDP-GalNAc (320 µg, 1.97 μmol); 1H NMR (800 
MHz, D2O) δ 5.15-5.13 (m, 2H, H-1αMan, H-1Fucα1-3), 4.95, (m, 1H, H-1Fucα1-6), 4.90 (m, 1H, H-
1αMan), 4.86 (s, 1H, H-1βMan), 4.69 (m, 1H), 4.57-4.45 (m, 6H), 4.26-4.25 (m, 1H, H-2Man), 4.16-
4.15 (m, 2H, H-2Man, H-5Fucα1-6), 4.10-4.09 (m, 2H), 4.03-3.34 (m, 69H), 2.98 (m, 2H, linker), 
2.08, 2.07, 2.05, 2.02 (4 s, 4x3H, NHAc), 1.69-1.64 (m, 2H, linker), 1.62-1.55 (m, 2H, linker), 
1.42-1.36 (m, 2H, linker), 1.28 (d, J= 6.7 Hz, 3H, CH3Fucα1-3), 1.24 (d, J= 6.6 Hz, 3H, CH3Fucα1-6); 
HRMS (ESI) m/z [M+Na]+ calculated for C88H149N7O58 2254.8817, found 2254.885.  
Tetradecasaccharide G33: Following the general procedures C and D, compound G24 (1.2 
mg, 0.67 mmol) was first galactosylated employing bovine milk β-1,4-GalT (35 µL) and UDP-
Gal. The galactosylated intermediate (714 µg, 0.331 μmol) was purified and fucosylated 
using CeFUT6 (75 μL, 1.07 mg/mL) and GDP-Fuc (633 μg, 1.0 μmol) to produce compound 
G33 (800 µg, 99%); 1H NMR (500 MHz, D2O) δ 5.16-5.13 (m, 4H, H-1αMan, H-1Fucα-1,3, H-1Fucα-1,3, 
H-1Fucα-1,3), 4.95 (d, J = 3.61 Hz, 1H), 4.91 (s, 1H, H-1αMan,), 4.87-4.83 (m, 3H, H-1βMan, 2xH-
5Fucα1,3/LewisX,), 4.73-4.69 (m, 1H, H-5Fucα1,3), 4.69 (d, J= 8.0 Hz, 1H), 4.60 (d, J= 8.4 Hz, 1H), 4.56 
(d, J= 7.6 Hz, 1H), 4.50 (d, J=8.4 Hz, 1H), 4.48-4.45 (m, 3H), 4.27-4.26 (m, 1H, H-2Man), 4.17-
4.16 (m, 1H, H-2Man,), 4.11-4.10 (m, 1H, H-2Man,), 4.04 –3.47 (m, 70H), 3.42-3.37 (m, 1H), 
3.28 (t, J = 10.8 Hz, 1H), 3.01 (t, J= 7.7 Hz, 2H, linker), 2.08, 2.05, 2.03 (3 s, 3x3H, NHAc), 
1.70-1.57 (m, 4H, linker), 1.43-1.38 (m, 2H,linker), 1.29 (d, J = 6.54 Hz, 3H, CH3Fucα1,3), 1.24 
(d, J= 6.5 Hz, 3H, CH3Fucα1,6), 1.17 (m, 6H, 2xCH3Fuc/LewisX); HRMS (ESI) m/z [M+H]+ calculated 
for C96H164N5O66 1232.9759, found 1232.9803. 
Hexasaccharide G34: Following the general procedure F, compound G34 (670 µg, 99 %) was 
prepared from G6 (924 µg, 0.60 μmol) using 1.4 U of Jack bean β-N-acetylglucosaminidase; 
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1H NMR (800 MHz, D2O) δ 5.12 (d, J= 1.6 Hz, 1H, H-1αMan ), 4.91 (d, J= 1.8 Hz, 1H, H-1αMan), 
4.87 (s, 1H, H-1βMan), 4.60 (d, J= 8.2 Hz, 1H, H-1GlcNAc), 4.50 (d, J= 8.0 Hz, 1H, H-1GlcNAc), 4.45 
(d, J= 7.7, 1H, H-1Xyl), 4.27 (d, J= 3.1 Hz, 1H, H-2Manβ ), 4.04 (dd, J= 3.38 Hz, J =1.6 Hz, 1H, H-
2Manα), 4.01 (dd, J= 11.62 Hz, J =5.4 Hz, 1H), 4.00-3.94 (m, 3H), 3.92-3.58 (m, 27H), 3.51-3.49 
(m, 1H), 3.44 (td, J= 9.2Hz, J =2.3 Hz, 1H), 3.39-3.37 (m, 1H), 3.25 (t, J= 11.0 Hz, 1H), 2.98 (t, 
J= 7.9 Hz, 2H, linker), 2.08, 2.03 (2 s, 2x3H, NHAc), 1.69-1.65 (m, 2H, linker), 1.61-1.57 (m, 
2H, linker), 1.41-1.38 (m, 2H, linker); 13C NMR(201 MHz, D2O) δ 107.7, 104.8, 103.9, 103.7, 
103.2, 102.2, 82.2, 81.9, 81.9, 79.9, 77.9, 77.2, 77.1, 76.1, 75.9, 75.2, 75.0, 74.7, 73.1, 72.6, 
72.4, 72.2, 71.9, 69.1, 68.0, 67.6, 67.5, 63.9, 63.8, 63.5, 63.5, 62.8, 62.7, 62.7, 57.6, 57.6, 
41.9, 30.7, 28.9, 24.8, 24.7, 24.7; HRMS (MALDI-tof) m/z [M+Na]+ calculated for 
C44H77N3O30Na 1150.4484, found 1150.4433. 
 
Hexasaccharide G35: Following the general procedure F, compound G35 (1 mg, 90%) was 
prepared from G7 (1.3 mg, 0.99 μmol) using 0.5 U of jack bean β-N-acetylglucosaminidase; 
1H NMR (500 MHz, D2O) δ 5.14 (s, 1H, H-1αMan), 4.92 (d, J= 3.9 Hz, 1H, H-1αFuc), 4.87 (s, 1H, 
H-1βMan), 4.67 (d, J= 7.7 Hz, 1H), 4.51 (d, J= 7.7 Hz, 1H), 4.47 (d, J= 7.9 Hz, 1H), 4.25 (d, J= 3.1 
Hz, 1H, H-2Man), 4.14 (dd, J= 13.4 Hz, J= 6.22 Hz, 1H, H-5Fuc), 4.06 (dd, J= 3.3, 1.5 Hz, 1H, H-
2Man), 4.04-3.99 (m, 2H), 3.94-3.58 (m, 20H), 3.51-3.45 (m, 2H), 3.41-3.36 (m, 1H), 3.26 (t, J= 
11.4 Hz, 1H), 3.00 (t, J= 7.6 Hz, 2H, linker), 2.09, 2.05 (2 s, 2x3H, NHAc), 1.71-1.67 (m, 2H, 
linker), 1.64-1.58 (m, 2H, linker), 1.44-1.39 (m, 2H, linker), 1.24 (d, J= 6.7 Hz, 3H, CH3Fuc); 13C 
NMR (126 MHz, D2O) δ 104.9, 102.2, 101.2, 101.1, 100.1, 99.4, 79.1, 78.7, 77.3, 75.4, 74.5, 
73.5, 73.3, 72.4, 72.3, 72.0, 71.8, 71.7, 70.3, 70.0, 69.9, 69.6, 69.1, 68.1, 66.8, 66.7, 66.5, 
66.43, 64.90, 64.87, 61.7, 60.2, 60.2, 55.1, 55.1, 39.3, 28.1, 26.4, 22.2, 22.1, 22.1, 15.3; 
HRMS (ESI) m/z [M+H]+ calculated for C45H77N3O29 1112.4716, found 1112.4758. 
 
Heptasaccharide G37: Following the general procedure D, compound G37 (430 µg, 99%) 
was prepared from G34 (340 µg, 0.30 μmol) using CeFUT1 (20 μL, 0.9 mg/mL), and GDP-Fuc 
(272 μg, 0.43 μmol); 1H NMR (800 MHz, D2O) δ 5.13 (d, J= 3.7 Hz, 1H, H-1Fuc), 5.12 (s, 1H, H-
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1αMan), 4.91 (s, 1H, H-1αMan), 4.85 (s, 1H, H-1βMan), 4.72-4.70 (m, 1H, H-5Fuc), 4.54 (d, J= 8.3 Hz, 
1H), 4.49-4.46 (m, 2H), 4.26 (d, J= 3.1 Hz, 1H, H-2Manβ), 4.04-4.03 (m, 1H, H-2Manα), 4.03-3.44 
(m, 36H), 3.39-3.37 (m, 1H), 3.26 (t, J= 11.0 Hz, 1H), 2.98 (t, J= 7.8 Hz, 2H, linker), 2.05, 2.02 
(2 s, 2x3H, NHAc), 1.69-1.65 (m, 2H, linker), 1.59-1.57 (m, 2H, linker), 1.41-1.38 (m, 2H, 
linker), 1.27 (d, J = 6.7 Hz, 3H, CH3Fuc); 13C NMR(201 MHz, D2O, peaks from HSQC 
experiment) δ 106.4, 103.7, 102.4, 101.9, 101.8, 101.1, 99.7, 82.1, 80.6, 78.7, 76.7, 76.7, 
75.9, 75.9, 75.7, 75.2, 74.9, 74.7, 74.0, 73.7, 73.4, 73.1, 71.7, 71.7, 71.3, 71.2, 70.7, 70.5, 
69.1, 68.2, 68.1, 67.9, 66.6, 66.4, 62.6, 62.4, 62.3, 62.3, 61.7, 57.0, 56.5, 40.7, 29.5, 27.8, 
23.6, 23.5, 23.6, 16.8; HRMS (MALDI-tof) m/z [M+Na]+ calculated for C50H87N3O34 
1296.5063, found 1296.512. 
Heptasaccharide G38: Following the general procedure D, compound G38 (570 µg, 99%) 
was prepared from G35 (460 µg, 0.41 μmol) using CeFUT1 (20 μL, 0.9 mg/mL) and GDP-Fuc 
(310 μg, 0.49 μmol); 1H NMR (800 MHz, D2O) δ 5.13 (d, J= 3.8 Hz, 1H, H-1Fucα1,3), 5.12 (s, 1H, 
H-1αMan), 4.93 (d, J= 3.8 Hz, 1H, H-1Fucα1,6), 4.91 (s, 1H, H-1αMan), 4.85 (s, 1H. H-1βMan), 4.73-
4.71 (m, 1H, H-5Fucα1,3), 4.69 (d, J= 8.6 Hz, 1H), 4.48 (d, J = 8.9 Hz, 1H), 4.47 (d, J = 7.6 Hz, 
1H), 4.26 (d, J= 3.1 Hz, 1H, H-2Manβ), 4.15 (q, J= 6.8 Hz, 1H, H-5Fucα1,6), 4.04 (dd, J= 3.4, 1.4 Hz, 
1H, H-2Manα), 3.99-3.55 (m, 37H), 3.49 (t, J= 9.2 Hz, 1H), 3.46 (t, J= 8.9 Hz, 1H), 3.38 (dd, J = 
9.4, 7.5 Hz, 1H), 3.27 (t, J= 11.3 Hz, 1H), 2.98 (t, J= 7.9 Hz, 2H, linker), 2.06, 2.02 (2 s, 2x3H, 
NHAc), 1.68-1.64 (m, 2H, linker), 1.60-1.57 (m, 2H, linker), 1.40-1.36 (m, 2H, linker), 1.28 (d, 
J= 6.6 Hz, 3H, CH3Fucα1,3), 1.23 (d, J= 6.6 Hz, 3H, CH3Fucα1,6); 13C NMR(201 MHz, D2O, peaks 
from HSQC experiment) δ 104.5, 101.9, 100.6, 99.6, 99.6, 98.0, 97.9, 79.6, 78.7, 76.8, 75.8, 
74.8, 74.3, 74.2, 73.6, 73.0, 72.9, 71.5, 71.3, 69.8, 69.6, 69.5, 69.5, 69.1, 68.7, 67.6, 66.5, 
66.4, 65.7, 65.3, 64.9, 64.4, 64.4, 60.7, 59.9, 59.9, 58.7, 56.7, 55.3, 55.0, 38.9, 27.7, 26.1, 
21.8, 21.7, 21.7, 15.1, 14.9; HRMS (ESI) m/z [M+H]+ calculated for C50H88N3O33 1258.5295, 
found 1258.5330.  
Octasaccharide G39: Following the general procedure D, compound G39 (360 µg, 99%) was 
prepared from G36 (320 µg, 0.26 μmol) using CeFUT1 (20 μL, 0.9 mg/mL) and GDP-Fuc (190 
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μg, 0.31 μmol); 1H NMR (800 MHz, D2O) δ 5.13 (d, J = 3.8 Hz, 1H, H-1Fucα-1,3), 5.12 (s, 1H, H-
1αMan), 4.93 (d, J = 3.8 Hz, 1H, H-1Fucα1,6), 4.91 (s, 1H, H-1αMan), 4.85 (s, 1H. H-1βMan), 4.73-4.71 
(m, 1H, H-5Fuc1,3), 4.69 (d, J= 8.6 Hz, 1H), 4.48 (d, J= 8.9 Hz, 1H), 4.47 (d, J= 7.6 Hz, 1H), 4.26 
(d, J= 3.1 Hz, 1H, H-2Manβ), 4.15 (q, J= 6.8 Hz, 1H, H-5Fucα1,6), 4.04 (dd, J= 3.4, 1.4 Hz, 1H, H-
2Manα), 3.99-3.55(m, 37H), 3.49 (t, J= 9.2 Hz, 1H), 3.46 (t, J = 8.9 Hz, 1H), 3.38 (dd, J= 9.4, 7.5 
Hz, 1H), 3.27 (t, J= 11.3 Hz, 1H), 2.98 (t, J= 7.9 Hz, 2H, linker), 2.06, 2.02 (2 s, 2x3H, NHAc), 
1.68-1.64 (m, 2H, linker), 1.60-1.57 (m, 2H, linker), 1.40-1.36 (m, 2H, linker), 1.28 (d, J= 6.6 
Hz, 3H, CH3Fucα1,3), 1.23 (d, J= 6.6 Hz, 3H, CH3Fucα1,6); 13C NMR(201 MHz, D2O) δ: 106.5, 103.6, 
102.4, 102.0, 101.4, 101.1, 100.34, 99.71, 82.3, 80.8, 78.6, 76.6, 76.0, 75.9, 75.8, 75.4, 74.9, 
74.8, 74.7, 74.1, 73.7, 73.3, 71.8, 71.3, 71.3, 71.2, 70.9, 70.9, 70.6, 70.5, 69.4, 68.2, 68.2, 
68.1, 67.8, 67.5, 66.8, 66.8, 66.3, 62.6, 62.6, 62.4, 62.3, 62.3, 56.9, 56.4, 40.7, 29.5, 27.8, 
23.6, 23.6, 23.5, 16.9, 16.7; HRMS (ESI) m/z [M+H]+ calculated for C56H98N3O38 1420.5823, 
found 1420.5786.  
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2.1 Introduction 
 
2.1.1 Miniaturization of assay-glycan microarrays 
 
Cell surface glycans and glycan binding proteins (GBPs) have multiple functions and play 
important roles in numerous biological events such as cell proliferation, cell-cell recognition 
and the immune response.1 Pathogenic GBPs mediate attachment to glycans in host cells 
and facilitate its subsequent invasion2,3 whereas the host GBPs presented in immune cells 
promote pathogen recognition, immune activation and clearance of pathogens. 
In order to 'decode' the information carried by each glycan and to study their possible role 
in the organism, the interactions with GBPs have been extensively studied over past last 
years. Relatively weak affinities of proteins to a single carbohydrate ligand can be enforced 
by the multivalent interactions between multiple carbohydrate recognizing domains of 
protein and multiple glycans 4 or/and adjustment of their spatial orientations. To this end, 
the glycan multivalent presentation may be achieved by ligand clustering on proteins, 
dendrimers, nanoparticles or array surfaces. Taking into account the huge diversity of 
carbohydrate structures as well as the enormous complexity of the protein-carbohydrate 
interactions, the development of the miniaturized, high throughput analytical screening 
methods such as microarrays emerged in recent years.5,6,7  
 
The concept of the miniaturized assay in the form of microspots, was successfully applied 
for the first time around 15 years ago to study gene expression and to detect nucleic acids 
in the form of DNA chips (Figure 1).8 The simplicity of the DNA microarrays development 
was based on the ability to synthesize DNA chains in a controlled and fast manner. This 
technology was later extended to protein and glycan microarrays (Figure 1),9 which 
development raised together with the improvement of their ligands synthesis techniques. 
As mentioned in the Chapter 1, nowadays, the glycan libraries can be effectively prepared 
by chemoenzymatic strategies whereas some of the carbohydrates can be also purified 
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from natural sources.10,11 
 
 
Figure 1. Microarray-based technologies for applications to genomics, transcriptomics, proteomics 
and glycomics (Shin et al. Chem.Commun. 20085) 
 
The miniaturization of glycan-binding assays into a microarray format permits to reduce 
amount of both, carbohydrates and analyte employed in the screening. It also allows for the 
simultaneous analysis of hundreds ligands and multiple glycan binding proteins in a single 
assay. Arrays are created by immobilization of sugars on the solid support. Individual glycans 
are spotted in extremely small amount of femtomoles to create a microspot of an average 
diameter of 100-200 microns. Approximately 100 µL of protein solution (concentration 
usually vary between 1-10 µg.mL) can be further apply to analyse interactions with over 100 
glycans at this same time. Binding of molecules to glycans is usually visualized by 
fluorescence of directly labelled protein or by fluorescently tagged antibody directed 
against the analyte. 
In this Chapter, we will describe the design and preparation of glycan microarrays which will 
contain xylosylated N-glycans synthesized in Chapter 1 and show their utility towards 
screening of glycan binding proteins, such as plant lectins and C-type lectin receptors from 
mammals.  
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2.1.2 Surface chemistry and printing of glycan microarrays 
 
The immobilization of glycans on the microarray surface can be performed either by non-
covalent interactions or covalent coupling.7,9 For example, the non-covalent approach 
utilizes nitrocellulose as a support and the ligands are immobilized through hydrophobic 
forces. Wang et al. first demonstrated how large molecules including glycoproteins and 
polisaccharides can be directly printed on nitrocellulose-coated slide without any prior 
derivatization.12 Later on, Feizi and colleagues established a new system in which smaller 
molecules, oligosaccharides, were linked to lipids to form neoglycolipids (NGLs) which could 
be further immobilized on nitrocellulose-coated glass slides.7,13 The other example of non-
covalent attachment methods utilizes functionalized aluminum oxide or indium tin oxide 
(ITO) slides which surface is coated with a hydrophobic layer. Taking advantage from the 
transparency and conductivity of these slides, both platforms have been mostly exploited 
to monitor enzymes activity and specificity by on-chip mass spectrometry combined with 
fluorescence read-out.14 Alternatively, glycans can be functionalized with oligonucleotide 
tags and immobilized on a surface by hybridization to a printed complementary DNA 
sequence. Likewise, biotinylated glycans can be attached to streptavidin covered glass 
slides via non-covalent but very strong interactions.15 
The covalent immobilization of compounds on the array requires use of slides with 
functionalized surface (Figure 2). Free reducing glycans (Figure 2, A) can be directly printed 
on hydrazide or aminooxy-derivatized glass slides based on the hydrazone oxime formation, 
however, the resulting glycosidic linkage may be either cyclic or acyclic with beta or alfa 
configuration (Figure 2, A2-3).16 Additionally, this conjugation technique requires relatively 
high immobilization concentrations (mM range) for the efficient construction of 
microarrays.17 
Beside the aldehyde function of reducing sugars, most glycans lack selective, reactive 
functional group and therefore require chemical modifications to be subsequently 
immobilized on the surface-activated glass slides. For this purposes, a large variety of 
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coupling chemistry, including for example the thiol-maleimide, Diels-Alder reaction on gold 
surface or click chemistry between an alkyne functionalized surface with azide modified 
glycan have been developed and nowadays, many commercial slides are available.18 
However, the most frequently used microarray slides are N-hydroxysuccinimide (NHS)-ester 
and/or epoxy- activated surfaces, reactive for free amino groups (Figure 2, B).6,19 
 
Figure 2. Covalent immobilization of sugars into the microarray surface; A. direct immobilization of 
free reducing carbohydrates using: A2. aminooxy activated glass slides and A3. hydrazide activated 
glass slides; B. immobilization of carbohydrates modified at their reducing end with: B1. 2AA tag and 
its further immobilization of the epoxy glass slide and B2. aminolinker and its immobilization on the 
NHS-activated slide. 
 
NHS-slides are reacting very efficiently with primary amines and the immobilization leads to 
the formation of a very stable amide bond (Figure 2, B2). These arrays are widely used for 
chemically amine-modified glycans as well as for glycoproteins or proteins. Epoxy slides 
bind to secondary and aromatic amines with the formation of tertiary or secondary amines 
(Figure 2, B1) and are most widely used for the preparation of so called natural glycan 
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microarrays. Natural arrays contain ligands isolated from the natural sources usually tagged 
with either 2-aminobenzamide (2AB) or 2-aminobenzoic acid (2AA) which enable their 
purification by the HPLC.20 So isolated 2AB or 2AA-tagged glycans are subsequently spotted 
on the epoxy activated glass slides to create the natural glycan microarray.  
 
The microarray manufacturing always involves transfer of the glycans from a microplate to 
the solid surface, such as glass slide. In general, once the chemistry of immobilization is 
chosen, ligands can be either printed in a contact or non-contact manner.9 During contact 
printing a set of steel pins (up to 64) is dipped into the ligand solutions and a small quantity 
of the sample is transferred to the surface by direct contact with it. Amount of solution 
delivered into the slide depends strongly on the time that pin is in contact with its surface. 
Non-contact printing is more elaborate and precise. It is accomplished with a Piezo-electric 
printer ensuring consistent drop size using controlled electric signals and thus resulting in 
more homogenous morphology and size of spots compared to contact-printing. The major 
disadvantage of the Piezo-electronic printers, however, is a limited number of tips (4 or 8) 
which results in longer printing times compared to contact printing methodology. The 
piezoelectric effect was discovered in 1880 by two brothers, Jacques and Pierre Currie, 
when they were in their early twenties. They describe it as electricity resulting from 
pressure. Later on this phenomenon was used for a construction of Piezo-electric printers 
containing a glass capillary (nozzle) surrounded by a piezoelectric quartz crystal, which 
flexes when an electric current is applied. The deformation provides pressure on the nozzle 
filled with sample and forces the drop out of it. The remaining ligand solution can be return 
back to the source plate once its printing is accomplished.  
 
2.1.3 Detection strategies 
 
The most commonly used strategies for the detection of binding events of proteins or other 
biological samples to the glycan array are fluorescence-based methods. They are highly 
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sensitive, allowing for the detection of femtomoles of ligands and very convenient to read-
out with a high resolution microarray scanner operating with a resolution of 2-10 µm.5 In 
this procedure, carbohydrate arrays are incubated with fluorescently labeled protein (Figure 
3, A) or secondary reagents (usually antibody) that specifically recognize primary protein 
(Figure 3, B). The fluorescence intensity of individual spot is proportional to the amount of 
bound protein and is determined using a microarray scanner and quantified with specially 
designed softwares (for example ProScanArray Express from Perkin Elmer). Quantitation 
methods are used to construct a pixel by pixel map that indicates the property of each pixel 
in the image corresponding to spots and their background. The adaptive circle 
quantification method fits all spots in the image with circles which diameters are estimated 
separately for each spot on the array. So obtained data represents the intensity of each spot 
with the substracted background fluorescence for that spot. The histograms can be 
subsequently represented as a mean or median fluorescence intensity of spots with local 
background subtraction. 
 
Figure 3. Detection strategies used for the carbohydrate-protein interactions quantification; A. and B. 
fluorescence-based methods applying directly labelled proteins or secondary antibody directed 
against analysed protein; C. SPR-based methods; D. Mass spectrometry usually used for the 
detection of enzymatic reactions performed on the array.  
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There are also alternative label-free detection methods for the array-based screenings, 
including surface plasmon resonance (SPR, Figure 3, C) and mass spectrometry (MS, Figure 
3D). In the SPR imagining technology the real-time data on the affinity, specificity and 
kinetics of protein interactions can be measured. The approach is based on an optical 
detection system that monitors real-time changes in protein mass on the sensor surface. 
Binding events result in changes in protein mass that, in turn, alter surface plasmon 
resonance, an electro-magnetic phenomenon that dampens the intensity of light reflected 
off of the surface of the sensor chip at a specific angle. The change of resonance angle 
resulting from analyte-ligand interaction is measured in resonance units (RU) and plotted in 
sensorgrams as a function of time.21 Although in this method the protein does not have to 
be labelled (Figure 3,C) it requires a gold surface, which is suitable to control the surface 
plasmon phenomena and the modification of ligands with SH-linker to be afterwards 
directly conjugated onto gold chip via Au-S linkage. Mass spectrometry, on the other hand is 
usually applied to follow the modifications of sugars printed on the array but also can be 
used for the identification of protein bound to the certain ligand.7,14 For example, MALDI-
TOF MS is perfectly suitable to assign the specificity of carbohydrate processing enzymes, 
like glycosyltransferases or glycosidases directly on the array.14,22,23 The difference in mass 
spectrum acquired after the reactions and compared to the starting material indicates the 
outcome of reaction (Figure 3, D). 
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2.2 Design and construction of glycan microarrays 
 
All glycans prepared in our laboratory are modified with a C5-amino linker for 
immobilization. We have chosen commercially available (NHS)-activated glass slides as the 
most convenient microarray support for our purposes. Next, regarding number of all glycans 
available in our lab we established the right array design and finally, we spotted 
carbohydrates with Piezo-electric robotic non-contact printer (Figure 4). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4. Preparation of the N-glycans microarrays; A. Piezo-electric printing of carbohydrates 
microarray; B-C. Schematic representation of the immobilization of glycans onto the NHS-activated 
glass slide; D. Final glycan array. 
 
We have built a library of over hundred glycan structures, including 39 xylosylated N-glycans 
(G1-G39) prepared in Chapter 1 of this thesis24, combined with diverse carbohydrates 
synthesized earlier in our laboratory and commercially available O-glycans (Figure 5).  
The glycan library of 126 structures was printed in a 7x1 microarray format (Figure 6) which 
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is consisted of seven identical subarrays (Figure 6, A-B) representing copies of same N-
glycan library. 
 
Figure 5. Total number of glycans printed on the glycan array; G1-G39 xylosylated N-glycans prepared 
in Chapter 1; G40-G103 structures prepared in our laboratory; G104-G126 commercial glycans. 
  
 
 
130 
Each subarray is designed to fit maximum of 648 spots with 36 spots per row and 18 spots 
per column (Figure 6, C). We have printed all glycans in 4 replicates, what resulted in 9 
glycans per row of each subarray (Figure 6, C) and a total of 3528 spots on every slide. The 
average spot diameter was 195 µm, with a pitch (distance between spots) of 400 µm in 
both, x and y axes (Figure 6, D).  
 
 
Figure 6. Design of glycan microarray used during our study; A. Real picture of the array taken 
directly after glycans printing; B. NHS-activated glass slide consistent of seven identical subarrays; C. 
subarray with 18x36 dots printed on its surface; D. distances between the spots and their average 
diameter. 
 
Glycan spotting solutions were prepared from 1mM stock solutions by dilution with sodium 
phosphate buffer (pH 8.4, 300 mM, 0.005% Tween 20) to a final spotting concentration of 
50 µM. The concentration of printing glycan solutions had been established in our 
laboratory and was supported by the data found in the literature.6 This concentration result 
in a spot saturation. Glycans were immobilized by the robotic printing by spotting of 5 drops 
of glycan solution per every spot on the array. Taking into account that each drop has an 
average volume of 250 pL (1.25 nL/spot) the final amount of each glycan used for the 
printing of one spot is about 0.62 fmol/spot. The microarray strategy is an extremely 
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powerful tool, which allow for a miniaturization of the binding assays and use of very small 
quantities of glycans and simultaneous screening of several samples on one slide. To 
demonstrate the big advantage of the microspot-strategy over usual techniques (like ELISA), 
a calculation was performed. With our glycan microarray, we use 1.25 nL/spot of each 
glycan. Taking into account that each sugar is printed in 4 replicates on each subarray and 
that there are 7 copies of subarrays on the slide, it gives total volume of 35 nL per array, 
equal less than 1 µL per 25 arrays. Usually, amounts of synthesized compound vary between 
0.5-1 mg, which allows for its good characterization, by both NMR and high resolution mass 
spectrometry. In order to prepare 50 µM printing solutions of each glycan (average mass of 
1200 g/mol) starting with 0.5 mg of compound, we would potentially prepare 7 mL of 
printing solution. As 1 µL would be used to print 25 microarrays, above volume would allow 
us for a screening of roughly 175 000 arrays. 
This theoretical calculation shows, how many binding studies can be done, regarding 
amount of synthesized glycan. Additionally, screening of different carbohydrates binding 
proteins can be done simultaneously on one slide reducing the amount of the required 
sample and of time needed for the experiment. Using multiple fluorescent probes, we can 
also measure different interaction patterns in one subarray format, what can be done for 
example for an antibody isotype class differentiation.   
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2.3 Screening of carbohydrate binding proteins using glycan arrays 
 
In this section of the Chapter the microarray-based studies of carbohydrate-protein 
interactions will be described.  
 
2.3.1 Carbohydrate binding proteins. Introduction 
 
Lectins are a family of proteins capable of binding to carbohydrate moieties. They form a 
heterogeneous family of mono- and multivalent proteins which are widely distributed in 
different species, including microorganisms, plants and animals.25 Lectins have diverse 
functions and play a crucial role in both physiological and pathological processes, like 
fertilization, pathogen recognition and endocytosis or immune defence. Animal lectins, 
called galectins for example, modulate the turnover of glycoproteins26 whereas selectins 
promote the migration of leukocytes to the site of injury in the inflammation process.27 
Through the interactions with leukocytes surface glycoproteins, selectins expressed by the 
inflamed endothelium of the blood vessel wall, ensure the contact between the 
endothelium and circulating in the blood stream leukocytes.  
Nowadays, lectins with well characterized specificity are commercially available and have 
found many applications in biochemistry, like in glycan profiling or in glycoprotein 
purification and characterization.28  The two groups of lectins described and analyzed in this 
Chapter are plant and fungal lectins and animal C-type lectins receptors (CLRs). 
The first plant lectin was discovered by Stillmark in 1888, he described the hemagglutinin 
activity of the castor beans extracts and this activity was assigned to ricin. Since then, 
several hundreds of proteins have been isolated from plants and fungi and characterised 
regarding their carbohydrate specificity. Nowadays, the term-lectin, is used for proteins 
which possess at least one non-catalytic domain which reversible bind to mono- and/or 
oligosaccharides. The physiological roles of plant lectins have been extensively studied over 
the years. It is believed, that they might have a dual functions: act as storage proteins and 
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have a role in the plant defence against various plant eating organisms.29–31 This theory was 
supported by the observation, that some of plant lectins possess sugar specificity towards 
carbohydrates present outside the plant kingdom. They are extremely stable in unfavorable 
conditions like harsh pH, heat or insect/animal proteases and they are associated with the 
survival of plant tissues. Additionally, the high cytotoxicity of some of these lectins (ricin) 
seems to assure good protection against predators like animals (herbivores), insects or 
some fungi.  
Other group of carbohydrate binding proteins are C-type lectins receptors which are present 
in animal organisms. They create group of over 1000 proteins, in either soluble or 
membrane bound form (Figure 7). C-type lectins are characterized by presence of at least 
one carbohydrate recognizing domain (CRD) which is a conserved structural motif 
containing two protein loops stabilized by two disulfide bridges.25,32 Because the second 
loop is more flexible than the first one, it is usually the place where ligands are bound.  
 
Figure 7. C-type lectins receptors belonging to transmembrane (type I and type II) and soluble 
subfamilies of proteins. 
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Furthermore, the carbohydrate specificity of CLRs depends on the conserved motifs present 
in the CRD, either EPN that could bind to mannose, N-acetylglucosamine, fucose and 
glucose or QPD that could bind to galactose and N-acetylgalactosamine moieties. C-type 
lectins are usually associated with calcium mediated binding of exo- and endogenous 
carbohydrates, however, less often they can also bind to sugars in calcium independent 
manner or recognize other ligands, including lipids. 
Membrane bound C-type lectin receptors can be further divided into two groups, type I 
(e.g. Mannose receptor, DEC-205) or type II transmembrane CLRs (e.g. DC-SIGN, MGL, 
DCIR).33 Proteins of the first group have their N-terminus tail pointing outside the 
cytoplasm, they contain an amino-terminal cystein-rich region (S-S) and between eight to 
ten CRDs. Type II C-type lectins on the other hand are characterized by the single CRD facing 
outside the cell with the N-terminus tail placed inside the cell. 
C-type lectins play important function in the immune system by acting as both an adhesion 
protein and pattern recognizing receptor (PRRs).25,33–35 The adhesion protein ensures the 
cell-cell contact (selectins) while the PRR are involved in pathogen recognition, uptake and 
further presentation (mannose receptor). Pattern recognizing receptors bind pathogen-
associated molecular patterns (PAMPs) and are able to further modulate the immune 
response. Depending on the intracellular internalization motifs present in the cytoplasmic 
domains of C-type lectins, ITAM-immunoreceptor tyrosine-based activation motif or ITIM-
immunoreceptor tyrosine-based inhibition motif, C-type lectins can have potential immune-
suppression or immune-activation functions.36 Because of these properties, C-type lectins 
have become important target for carbohydrate based vaccine candidates and the 
identification of their natural ligands emerged in recent years. One of a good example 
whene glycan arrays were utilized for the identification of the exact glycan binding motifs of 
C-type lectins has been given by Skerra and coworkers.37 They have characterized two 
homologues C-type lectins, DC-SIGN and Langerin, express on the surface of different 
dendritic cells. Both proteins, were found to play a role in HIV-1 infection, with DC-SIGN 
facilitating virus survival and transmission, whereas Langerin promoting HIV-1 uptake and 
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subsequent degradation. Even though, both C-type lectins share a common tripeptide 
sequence (EPN) and thus bind towards mannose and fucose containing structures, 
microarray analysis revealed more specific binding epitope of each protein. DC-SIGN was 
found to bind internal mannose residues of high mannose structures and fucose-containing 
blood type antigens, while Langerin was identified to recognize more preferentially terminal 
mannose moieties, N-acetylglucosamine and some of the blood type structures. This 
information may aid for the future design of HIV-1 vaccines candidates that specifically 
affect the virus interactions with DC-SIGN receptor while not compromising the protective 
function of Langerin. 
 
2.3.2 Characterisation of plant lectins 
 
To demonstrate the functionality of printed glycan structures on the microarray, we 
incubated different subarrays in parallel with fluorescently tagged lectins (Table 1) including 
Galanthus nivalis, Wisteria floribunda, Aleuria Aurantia, Bandeiraea simplicifolia, Canavalia 
ensiformis and Ricinus communis agglutinin, expressing different glycan specificities 
resumed in Table 1.38 
Entry Lectin Acronym-Label Specificity 
1 Galanthus nivalis agglutinin GNA-555 
High mannose-type N-glycans, 
preference to α-1,3 mannose 
2 Concanavalin A ConA-647 High mannose-type N-glycans 
3 Aleuria aurantia lectin AAL-555 Fucose 
4 Bandeiraea simplicifolia lectin II BSLII-647 
Terminal non-reducing α- or β-
linked N-acetyl-D-glucosamine 
5 Wisteria floribunda lectin WFL-555 N-acetyl-D-galactosamine 
6 Ricinus communis agglutinin-120 RCA-555 β−galactose residues 
Table 1. Lectins probed on the glycan arrays (column two) with the given acronym and fluorescent 
label (column three) as well as its previously described specificity38  (column four).  
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Lectins were fluorescently labelled on primary amino groups of lysines and the N-terminal 
with commercial Alexa Fluor® 555 NHS ester (sulfonated xanthene) and Alexa Fluor® 647 
NHS ester (sulfonated castasteron). Solutions of lectins in sodium carbonate buffer (pH=9.0) 
were incubated in the dark for 1 hour with the corresponding fluorescent dye NHS ester. 
Excess of dye was removed by dialysis or by ultracentrifugation. Subsequently lectins 
dilutions in PBS containing 5 mM CaCl2, 5 mM MgCl2 and 0.01% Tween-20 were incubated 
on glycan microarrays in the dark at room temperature for 1 hour. The slides were washed 
with PBS containing Tween-20 followed by water and scanned in a microarray scanner. The 
fluorescence bound to the surface was quantified and represented as histograms. 
Figures 8-10 show the histograms corresponding to incubation of lectins conducted on the 
glycan arrays. As a result, we could observe the carbohydrate specificity previously 
described for the lectins employed but also identify new features regarding for example 
influence of xylose modification on the recognition of glycans by the mannose binding 
lectins. Even though the general glycan specificity of analysed plant lectins is already 
known, in some cases it is based on simple inhibition assays performed with mono- or 
disaccharides and does not provide additional information about the specificity in context 
of larger, more complex glycans. Having on our arrays various, well-defined structures of 
plant, parasitic but also mammalian origins, the microarray-based screenings could not only 
confirm functionality of the array but also reveal more biological relevant ligands of 
analysed lectins and allow us to study the effect of differentiated epitope presentation on 
glycan-protein interactions.  
The glycan array probed with Ricinus communis agglutinin-120 (RCA-555) and with Wisteria 
floribunda lectin (WFL-555) (Figure 8), showed binding towards terminal N-acetyl 
lactosamine and towards terminated N-glycans with terminal N-acetyl-D-galactosamine 
respectively (Figure 8). The analysis of fluorescence further revealed, that the multivalent 
presentation of galactose moiety on the antennae of N-glycans, have an influence on the 
binding affinities of tetrameric RCA lectin towards mono-, di-, tri- and tetrantenary 
compounds. The latter two N-glycans were giving the highest fluorescence intensity values 
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indicating strengthen of the protein binding towards N-glycans presenting multiple 
galactose moieties. In this context, the multiantennary N-glycans can be seen as miniature 
analogues of dendrimers that present multiple copies of a terminal motif in a very define 
space.39,40  
The WFL, on the other hand was found to bind to the LDN glycan element, in a context of 
larger N-glycans but also to a simple disaccharide directly conjugated to the array surface. 
No significant difference of the LDN presentation on the affinity to the lectins was observed.  
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Further screening of two other lectins, BSLII-647 and AAL-555 revealed that specificity of 
both proteins follows previously described trends, with Bandeiraea simplicifolia recognizing 
the terminal N-acetyl-D-glucosamine moieties and Aleuria aurantia lectin L-fucose 
decorated glycans (Figure 9). A more detailed analysis of the carbohydrate binding profile of 
BSL-II showed the strongest affinity towards complex tri- and tetraantennary N-glycans with 
terminal GlcNAc moieties and slightly lower interactions with the biantennary compounds. 
Hybrid N-glycans, with only one GlcNAc substituted antennae were still bound, however, to 
the lower extent. It is also worth mentioning about the strong interactions of BSL-II with 
chitobiose core, what can be easily correlated with the role of Bandeiraea simplicifolia 
lectin in nature. This plant protein defends against certain insects by binding to the chitin or 
the glycoproteins of the epithelial cells of the incest.41   
Next, following the binding profile of AAL, we could observe specificity towards compounds 
containing fucose, regardless the position (α-1,3 or/and α-1,6) or presentation (core fucose 
of Lewis X-type of structures). Additionally, a simple fucose was also a good ligand.  
Binding of RCA-555, WFL-555, BSL-II-647 and AAL-555 to glycans was not affected by the 
presence of core xylosylation. The incubation of glycan microarray with mannose 
recognizing lectins, such as Concanavalin A (ConA-647) and Galanthus nivalis agglutinin 
(GNA-555) followed the general specificity of both proteins (Figure 10). However, an 
interesting influence of the presence of core β-1,2-xylose on the interaction was observed. 
In the case of Concanavalin A, the presence of core β-1,2-xylose strongly reduced the 
binding when compared to the non-xylosylated counterparts (Figure 11, A,B). We could also 
observe that core fucosylation also reduced binding to ConA but to a lower extent (see 
ligand pairs G66/G49 and G42/G75) and not in all cases (G50/G67). In the case of Galanthus 
nivalis agglutinin the presence of β-1,2-xylosylation completely abolished binding (Figure 
11, A, C). ConA is known to have broad specificity and bind high mannose as well as 
complex-type N-glycans.42  Microarray-assisted study showed, that it can recognize even in 
the context of a biantennary N-glycan with two bulky terminal LDN or Lewis X groups 
(Figure 11, A), however, the analyzed fluorescence intensities are approximately half of 
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those found for high mannose N-glycans.9 
 
Figure 11. Glycan array incubated with mannose recognizing fluorescently labeled lectins ConA-647 
and GNA-555; A,C. Selected ligands in the interaction with lectins. B. Decrease of binding for 
xylosylated (grey bars) and non-xylosylated structures (green bars) in the interaction with ConA-647; 
D. Lack of recognition of xylosylated structures compared to the corresponding non-xylosylated N-
glycans (green bars) after incubation with fluorescently labeled GNA-555. 
 
GNA on the other hand, binds to terminal α-1,3 and α-1,6 linked mannose residues and 
unlike ConA tolerates further extension of the β-mannose with GlcNAc but not with LN or 
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LDN residues. As these lectins could be involved in plant defense against predators31,43, this 
could be presumably achieved by attaching to insect or vertebrate type glycans lacking the 
core xylose motif representative of plant glycans. The strongly reduced binding affinity of 
ConA and GNA towards core-xylosylated plant glycans could be explained as a tolerance 
mechanism to avoid interference with self proteins.  
 
Overall, the incubation of printed glycan microarrays with plant lectins confirmed the high 
specificity of these proteins towards certain carbohydrates and showed the potential 
application for multiple analyte characterization. Moreover, taking advantage of the unique 
structures having on our array, we could further detailed the specificity of analyzed plant 
lectins in the context of larger N-glycans. It was demonstrated, that microarray-assisted 
binding studies with well characterized, chemo-enzymatically prepared ligands allow for a 
very precise insight into the protein specificity and the structural requirements of glycans 
for effective binding.  
 
2.3.3 Screening of C-type lectin receptors 
 
After the characterization of plant lectins, we screened a selection of human and murine C-
type lectins receptors. Glycan binding patterns for seven recombinant murine Fc fusion CLRs 
were studied with the glycan array: DC immunoactivating receptor (DCAR), DC 
immunoreceptor (DCIR), Clec-2, Clec-9A, Macrophage inducible C-type lectin (Mincle), 
Macrophage-galactose-type lectin (MGL-1) and the murine DC-SIGN homologue SignR3. 
CLR-Fc fusion proteins were produced in a mammalian expression system in the laboratory 
of Prof. Bernd Lepenies. They were expressed as fusion proteins containing the extracellular 
part of CLR and the Fc part of human IgG1 antibody.44 We additionally included in the 
screening three commercially available human Fc fusion proteins: Dectin-2, DC-SIGN and 
MGL-1. The previously described specificity and some general information about the 
function of these CLRs is listed in Table 2.  
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We have tried two different detection modes for C-type lectins on the glycan array, the so-
called sandwich assay and a single step incubation. In the first strategy, C-type lectins were 
diluted with TSMT binding buffer pH=7.5 (20 mM Tris·HCl, 150 mM NaCl, 2 mM CaCl2, 2 mM 
MgCl2, 1% BSA and 0.005% Tween-20) to a final concentration of 10 μg/mL and incubated 
on the glycan array overnight at 4 °C. Unbound proteins were washed off and the arrays 
were subsequently incubated with anti-human IgG1 (Fc specific)-Cy3 antibody for 1h. The 
slides were washed and scanned in a microarray scanner. In the one step incubation, fusion 
C-type lectins were premixed with anti-human IgG1-Cy3 antibody prior overnight 
incubation at 4 °C on the glycan array. In this strategy, one washing step is avoided but more 
importantly complexing of the protein with antibody could result in its dimerization and 
thus strengthen avidity. Results of both screenings were similar, although slightly lower 
fluorescence intensities where observed applying the single step incubation. Therefore, 
results presented in this Chapter are obtained by the sandwich incubation of C-type lectins 
on the glycan array.  
First, we determined carbohydrate recognition profiles of two closely related lectins: human 
macrophage galactose-type lectin MGL-1 and its murine homologue, mMGL-1 (Figure 12). 
Both proteins belong to family II transmembrane lectins and are expressed on the surface of 
immature macrophages and dendritic cells where are involved in pathogen and tumor 
antigens recognition.46 Humans and murine MGL-1 carbohydrate recognizing domains 
predict binding towards galactose-related structures; however their exact carbohydrate 
specificity differs.62 It has been described that human MGL-1 recognizes Tn-antigens 
(GalNAcα-Ser/Thr) which are expressed by adenocarcinoma cells, but they are also part of 
the parasite Schistosoma mansoni egg glycome.61 On the other hand, murine MGL-1 binds 
to Lewis X related structures, found in a high abundance in tumor cells (for example colon 
carcinoma) and in helminths organisms. In our glycan microarray screening, the known 
specificities of both human and murine MGL-1 were confirmed. The murine lectin bound to 
LeX decorated glycans, as well as tri- and tetra-antennary compounds with terminal 
galactose.40 Taking advantage from the collection of multiantennary N-glycans on our 
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synthetic array, it was interesting to see the impact of a multivalent presentation of 
galactose on the binding strength to the lectin. Murine MGL-1 bound higher towards tetra-
antennary compound compared to triantennary40 and no binding for galactosylated 
biantennary N-glycan was detected. Human MGL-1 was giving binding towards GalNAc 
terminated structures, both in LDN and LDNF epitopes. Also simple di- and trisacharides 
were recognized by the lectin and we could not observe any effect of epitope presentation 
in the context of larger N-glycans on the binding strength to the MGL-1. There was also no 
significant influence of core xylose or fucose on the interactions with protein.  
Next, we studied carbohydrate specificity of DC-SIGN to core-modified structures (Figure 13, 
14)24. This C-type lectin signaling receptor expressed by human dendritic cells can bind and 
internalizes several antigens some of which may be mannose- or fucose-containing 
glycans.60 DC-SIGN targeting is an efficient strategy of pathogens like human 
immunodeficiency virus (HIV), Hepatitis virus, Ebola virus or Mycobacterium tuberculosis to 
evade the immune system.24,63,64 DC-SIGN is also one of the receptors for recognition and 
uptake of Schistosoma mansoni antigens via LeX, LDNF and mannosylated and fucosylated 
N-glycan motifs.60,65,66  
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Incubation of DC-SIGN in our glycan microarray confirmed the known specificity towards 
high-mannose, LDNF, blood type antigens and perhaps less known, complex glycans with 
terminal GlcNAc on the 3-arm. Best binders in terms of fluorescence signal intensity were 
LeX presenting N-glycans (G27-31, G33, G88, G89) (Figure 13). 
Interestingly, at this point we could observe that the presence of core xylose in N-glycan 
structures completely abolished binding to the GlcNAc terminal (3-arm) oligosaccharides 
including biantennary and hybrid N-glycans (Figure 14). The binding pattern is similar to that 
of other mannose binding proteins observed previously, ConA and GNA. The presence of 
xylose residues seems to distort the glycan conformation in such a way that the lectin can 
no longer make favorable contacts with the binding epitope. No significant effect of xylose 
on binding to the Lewis X presenting N-glycans structures was observed (G30, G33), the 
conformation and accessibility of the Lewis X branches is clearly not compromised by the 
additional core xylose modification.67 Xylosylated glycans which do not bind DC-SIGN but 
conserve binding to other C-type lectins could become lead structures for glycan mediated 
specific targeting of antigens to C-type lectin receptors on dendritic cells in immune 
therapy. 
 
Figure 14. Interactions of DC-SIGN with xylosylated (grey histograms) and non-xylosylated glycan 
series of bi-antennary compounds (green histograms). 
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The other C-type lectins tested on the glycan microarray did not give binding towards any 
structure presented. Several reasons could be argued to explain this behavior, one of the 
most obvious is that we might simply lack the natural ligands of the proteins or that the 
glycan fragments available on the array have to be presented in the context of a larger 
structure, like protein or lipid. The other important issue could be the presentation and the 
accessibility of the C-type lectins CRD which might not be sufficient for effective binding of 
glycans. Further explanation will be given in the Chapter 4, where the protein G-coated C-
type lectin microarray was successfully prepared and probed with different fluorescently 
labeled glycoconjugates.  
 
2.4 Summary 
 
Including the newly synthesized 39 core-xylosylated N-glycans which preparation was 
presented in the Chapter 1, a large microarray containing non-xylosylated glycan structures 
and smaller glycan fragments was designed and prepared for the array-based analysis of 
glycan binding specificities of series of plant, fungi and animal lectins. In total 126 
carbohydrates were printed on NHS-activated glass slide using a Piezo-electric robotic non 
contact printer. We have shown the first functionality screenings of glycan array with plant 
and fungi lectins, specifically recognizing certain glycan elements. Already here, we could 
observe a great potential of our synthetic array towards identification of the ligands of 
carbohydrate binding proteins in the context of larger N-glycan structure and have an 
insight into the finer specificity of analyzed lectin. We discovered the influence of the core 
xylose on the interaction of N-glycans with mannose binding lectins, Concanavalin A and 
Galanthus nivalis. The presence of core xylose reduced the interactions with ConA and 
completely abolished binding towards GNA. Taking into account that the β-1,2-xylose is a 
common modification of plant N-glycans, above mentioned impact of xylose moiety on the 
lectins specificity could be rationalized by a tolerance mechanism avoiding interactions 
between plant lectins and self-glycans. 
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Further, we have performed a screening of murine and human C-type lectins receptors, 
paying a special attention on the proteins which may be involved in the host-pathogen 
interactions during curse of S. mansoni infection. As a result, we could observe binding of 
human MGL-1 receptor to the LDN and LDNF glycan elements and the Dendritic Cell-
Specific Intercellular adhesion molecule-3-Grabbing Non-integrin (DC-SIGN) to set of Lewis 
X terminated glycan structures. Our results confirmed the previous reports describing MGL 
as a pattern recognizing receptor for S. mansoni binding to the soluble egg antigens (SEA) 
expressing LDN and LDNF glycoconjugates and the DC-SIGN binding the Lewis X type of 
glycans that have been found on the glycoconjugates from all life cycle stages of S. mansoni. 
Interestingly, as it had place during the GNA characterisation, we noted the differences in 
the binding of DC-SIGN receptor towards xylosylated and non-xylosylated biantennary N-
glycans. Similar to the plant lectin, the presence of core xylose completely abolished 
binding towards DC-SIGN studied on the glycan microarray. Inspired by the influence of the 
xylose moiety on the recognition of biantennary compound by the DC-SIGN receptor, we 
have further design an in vitro assay employing OVA glycoconjugates containing above 
mentioned sugars (G6 and G50) to compare their abilities towards targeting of murine 
dendritic cells. The study will be described in details in the Chapter 4. 
 
2.5 Experimental Part  
 
General Methods 
 
Materials: Canavalia ensiformis lectin (ConA), Wheat germ agglutinin (WGA), Ricinus 
communis agglutini -120 (RCA-120), Aleuria aurantia lectin (AAL), Pisum sativum agglutinin 
(PSA), Galantus nivalis agglutinin (GNA), Griffonia (Bandeiraea) simplicifolia lectin II (BSL-II) 
and Wisteria floribunda lectin (WFL) were purchased from VectorLabs. Lectins were labeled 
with Hilyte PlusTM 647 and Hilyte PlusTM 555 protein labeling kits from AnaSpec, Freemont, 
USA. Recombinant human DC-SIGN, MGL-1 and Dectin-2 Fc chimeras were purchased from 
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Sino Biological Inc., Beijing, P. R. China. Murine-hFc C-type lectins were provided by Prof. Dr. 
Bernd Lepenies.44 Anti-human IgG (Fc specific)-Cy3, developed in goat, was purchased from 
Sigma-Aldrich. Glycan arrays were compartmentalized with 8 Well ProPlate Module 7 x 16 
mm Well from Electron Microscopy Sciences. NHS activated glass slides, Nexterion® H were 
purchased from Schott AG, Mainz, Germany. All aqueous solutions were prepared from 
nanopure water produced with a Diamond UV water purification system (Branstead 
International, IA, Madrid, Spain). Microarrays were printed employing a robotic non contact 
piezoelectric SciFLEXARRAYER spotter S11 (Scienion, Berlin, Germany). Arrays were imaged 
on an Agilent G2565BA fluorescence scanner system (Agilent Technologies, Santa Clara, 
USA) at 10 µm resolution, using 2 lasers (532 nm, 633 nm). Quantification of fluorescence 
was achieved by ProScanArray® Express software from Perkin Elmer, Shelton, USA. A 
quantification method using an adaptive circle with minimum diameter of 50 µm and 
maximum diameter of 200 µm was employed. Each histogram represents the average of 
mean fluorescence from four replicates with local background subtraction. 
 
Immobilization of the ligands and test for biofunctionality of the printed ligands 
 
Ligand solutions were prepared from stock solutions (1 mM in water) by dilution with 
sodium phosphate buffer (300 mM, pH 8.4, 0.005% Tween 20) to a final concentration of 50 
µM. 40 µL of each glycans spotting solution was placed into a 384 well source plate 
(Scienion, Berlin, Germany) which was stored at -20°C and reused if necessary. These 
solutions (1.25 nL, 5 drops of 250 pL) were spatially arrayed onto NHS functionalized glass 
slides (Nexterion® H, Schott AG, Mainz, Germany) with a distance of 400 µm. 126 glycans 
were spotted in 4 replicates (9 different N-glycans/row), establishing the complete 36x18 
array which was printed in 7 copies onto each slide. After printing, the slides were placed in 
a 75 % humidity chamber (saturated NaCl solution) at 25°C for 18 hours. The remaining NHS 
groups were quenched by placing the slides in a 50 mM solution of ethanolamine in sodium 
borate buffer 50 mM, pH 9.0, for 1h. The standard washing of the slides was performed 
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with PBST (PBS solution containing 0.5% Tween 20), PBS and water. The slides were dried in 
a slide spinner. 
 
Interaction with plant lectins 
 
Each subarray was incubated with a solution of fluorescently labelled lectin. Solutions of 
Galanthus nivalis agglutinin (GNA-555, 22 µg/mL), ConcanavalinA (ConA-647, 22 µg/mL), 
Aleuria aurantia lectin (AAL-555, 20 µg/mL), Bandeiraea simplicifolia lectin (BSL-II-647, 24 
µg/mL) (Figure X), Wisteria floribunda lectin (WFL-555, 10 µg/mL) and Ricinus communis 
agglutinin (RCA-120-555, 1 µg/mL), were prepared in PBS, 2 mM CaCl2, 2 mM MgCl2 
containing 0.01% Tween-20. For incubations, 200 µL of each lectin solution was applied to 
each subarray and incubated in the dark for one hour at room temperature. The slides were 
washed under standard conditions, dried and the fluorescence was analyzed with a 
microarray scanner. 
 
Glycan binding analysis of C-type lectins 
 
mMGL-1, MGL-1 and DC-SIGN solutions were prepared from stock solutions (0.25 mg/mL in 
PBS) by dilution with TSMT binding buffer (20 mM Tris·HCl, 150 mM NaCl, 2 mM CaCl2, 2 
mM MgCl2, 1% BSA and 0.005% Tween-20 pH=7.5) to a final concentration of 10 μg/mL 
whereas the Dectin-2 to the final concentration of 10, 20, 75 and 100 μg/mL. The murine C-
type lectins Clec-2, Mincle, Clec-9A, DCAR, DCIR, SignR3 were diluted with TSMT binding 
buffer to a final concentration of 10 and 20 μg/mL.  Lectins solutions (200 µL) were 
incubated overnight at 4 °C with gentle shaking. Solutions containing protein were removed 
and each subarray was washed with TSMT binding buffer, followed by 1h incubation with 
anti-human IgG (Fc specific)-Cy3 in TSM binding buffer (1:1000). The washing of slides was 
performed with TSMT (TSM containing 0.005% Tween-20), TSM and water. Slides were dried 
in a slide spinner. The fluorescence was analyzed with a microarray scanner. 
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3.1 Introduction 
 
3.1.1 Glycan arrays as a tool for antibody profiling 
 
Carbohydrates found on pathogens are often significantly different from the mammalian 
set of glycans and may induce important immune responses. In recent years, carbohydrate 
antigen arrays have become an excellent tool for high-throughput screening of anti-glycan 
antibodies and have been applied for the carbohydrate-based vaccines development.1–4 In 
general, glycan array can be used in the discovery and characterization of antigens but also 
to evaluate the immune response to vaccine candidates.  
Arrays of microbial carbohydrates have been used for the identification of bacterial 
antigens and for diagnosis by analyzing serum samples from infected patients. For example, 
Wang and coworkers were able to identify an antigenic sugar structure from gram positive 
bacteria Bacillus anthracis, using a glycan array composed of carbohydrates from the major 
surface glycoprotein (Bcla) of bacterial spores.5 In the other study, glycan arrays have been 
successfully applied for the characterization of carbohydrate specificity of broadly 
neutralizing antibodies (bnAbs) in HIV infection. The binding profile of the HIV-1 2G12 bnAb 
isolated from an asymptomatic HIV-positive patients6,7,8,9 was analyzed by screening of a 
glycan array composed of oligomannose structures found on HIV viral coat glycoprotein 
(gp120). The study revealed that the antibody was capable to bind high mannose type N-
glycans bearing Manα-1,2-Man residues.6 Further investigation defined the minimal 
epitope required for antibody to bind and identified the structure with highest affinity 
towards 2G12 bnAb, which was Man4 oligomannoside.7 In a more recent study, Wong and 
colleagues compiled several bi-, tri- and tetra-antennary sialylated complex 
oligosaccharides to a focused glycan array which was subsequently probed with the HIV-1 
bnAbs, PG9 and PG16. The authors identified natural and un-natural glycan ligands of PG16 
on their array, which were then conjugated to the diphtheria toxin and analysed in a dose 
  
 
 
162 
dependant manner with the antibodies as a first step towards a novel HIV vaccine 
candidate.10  
Beside the bacterial or viral infections, identification and characterization of glycan antigens 
can be also important for the development of new treatment or diagnostics towards 
cancer. Cancer cells express numbers of tumor-associated carbohydrate antigens, such as 
sialyl Lewis A ((Neu5Acα1-3)Galβ1-3(Fucα1-4)GlcNAc), Tn (GalNAcα-Ser/Thr) , Lewis Y ((Fucα1-
2)Galβ1-4(Fucα1-3)GlcNAc) or GloboH, which may be used as a biomarker of disease but also 
can become a target for the treatment development.11 GloboH is a glycolipid 
hexasaccharide expressed on several tumors including breast, colon, lung, prostate and 
ovary and thus this glycan with conjugation to antigenic protein has become a good starting 
point for anti-cancer vaccine development.1 Screening of anti-GloboH monoclonal 
antibodies and polyclonal antibodies from cancer patient sera on glycan microarray defined 
the minimal epitope of GloboH required for antibody recognition12. A tetrasaccharide was 
found to bind anti-GloboH antibodies with same affinity as larger hexasaccharide and 
because of reduced synthetic steps became a better candidate for the development of 
potential anti-cancer vaccine.  
There are also several examples where glycan arrays have been used for the study of 
biological functions of glycans during the course of parasite infections. Hokke and 
coworkers profiled the monoclonal and polyclonal antibodies from Schistosoma mansoni 
infected mice and humans employing natural shotgun glycan microarrays.13,14 
Schistosomiasis is a chronic and potentially deadly parasitic disease, which can be treated 
with praziquantel (PZQ)15, however the drug does not prevent from re-infection and thus 
the need of vaccine development emerged in recent years. It is known that the host 
immune response induced against parasite is directed towards its certain carbohydrates.16 
Their identification and further characterization can be performed on the shotgun array 
comprises N-glycans and lipid-glycan structures directly isolated from the four life stages of 
S. mansoni: larvae (cercariae), male adult worm, female adult worm and eggs. The 
microarray-based studies allow for the detection of serum antibodies towards the whole 
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natural glycome of parasite, including many unique glycan structures still not available 
synthetically. Screenings performed on the natural glycan array containing glycans or the 
glycan mixtures from the whole glycome of the parasite, is a good method to identify 
antigenic elements and to narrow the number of potentially important structures when no 
previous data is available. However, because some of the ligands printed on the shotgun 
array contains mixture of different glycan elements and structures, in some cases it may be 
difficult to speculate which specific responses occur to which glycan element. 14 
In this chapter we will describe use of our focused, synthetic glycan array as a 
complementary tool towards studying the biological role of glycan in S. mansoni infections. 
This work was performed in collaboration with Dr. C.H. Hokke from the Leiden Parasite 
Glycobiology Group (Leiden University Medical Center, the Netherlands) and brings 
together results of monoclonal antibody incubation with the screening of serum samples 
from S. mansoni infected patients. 
 
3.1.2 Glycome of Schistosoma mansoni 
 
Schistosomiasis also known as bilharzia, is a tropical disease caused by trematode worms, 
which infect over 200 millions of people worldwide according to the WHO organization 
(Figure 1, A). It is particularly abundant in the developing countries with inadequate 
sanitation where parasite is transmitted to the humans in a contact with excreta 
contaminated water.17,18 There are three main disease-causing species, S. haematobium, S. 
japonicum and S. mansoni, with the latter one being the interest of this Chapter. Human S. 
mansoni has a very complex life-cycle (Figure 1, B) involving a definitive host (mammalian) 
where sexual worm reproduction takes place and a freshwater snail where the parasite 
multiplies in an asexual manner. The infection is initiated by cercaria which are released by 
the snail into the water and which can penetrate through even intact skin of human host. 
During the skin penetration, cercariae loses its tail and transforms into schistosomula which 
migrates to the portal blood system and maturate into male and female adult worms. 
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Adult worms form male-female pairs and migrate to the blood vessels in the lower 
intestine. Adult females deposit eggs in the bloodstream (up to 200 eggs per day), many of 
which embolize in smaller blood vessels or capillaries of diverse organs, including urinary 
bladder or intestine. From there, eggs can be transported to the liver or are excreted in 
feces or urine.  
 
Figure 1. Schistosoma mansoni; A. Worldwide distribution of parasite (2012) showing the national 
prevalence [%] (data source: World Health Organization WHO); B. Life cycle of S. mansoni.  
 
Eggs from feces or urine hatch in fresh water and release miracidia which subsequently 
penetrate snail tissues and successively generate the free-swimming cercariae to complete 
the developmental cycle of parasite.19 
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There are two immunological phases of schistosomiasis infection, the acute and chronic 
phase.20 The acute phase starts when the cercariae penetrates the host skin and lasts until 
the deposition of eggs by the adult female (usually sixth week after infection). It is 
dominated by the Th1 pro-inflammatory immune response. The chronic phase of 
schistosomiasis is characterized by the spontaneous down modulation of the initial 
inflammatory response and switch from Th1 into Th2 immune response. It is also 
characterized by high levels of IgE antibodies. In this state, Schistosoma may resist in the 
host for years and even after PZQ drug treatment, reinfection usually occurs. The progress 
of the disease depends on the individual and in some cases, it might lead to life-threatening 
inflammatory and obstructive conditions.18 It has been demonstrated that infected 
individuals living in endemic areas acquire certain level of immunity towards the parasite. 
However, it takes many years of exposure, several reinfections and drug treatments for the 
development of a protective immune response. Possibly, when humans are treated with 
PZQ the parasite dies, it falls apart and exposes antigens which further induce more 
effective immune responses in the host. It may subsequently lead to maturation of immune 
system and in some cases produce immunity against the parasite.13,20 
During its life cycle, S. mansoni express a high number of glycans as a part of its 
glycoproteins and glycolipids. The detailed glycomic spectrometric analysis of the parasite 
extracts at different developmental stages revealed that S. mansoni express very complex 
and stage-specific sugars (Figure 2) and some of them, markedly differs from the 
mammalian ones (Figure 2).21,22,23 In a typical experiment N-glycans are released from the 
total protein extracts by treatment with PNGase-F to cleave off all asparagine-linked 
complex, hybrid, or high mannose oligosaccharides unless their core contains an α-1,3-
fucose. Fractions are subsequently incubated with trypsin and then treated with PNGase-A 
to cleave remaining α-1,3-fucose containing glycans. Released glycans are purified, labeled 
and fractionated by hydrophobic interaction liquid chromatography with fluorescent 
detection.21 Collected fractions are subsequently analyzed by MALDI-TOF MS.   
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Figure 2. Profiles of PNGase F (a-e) and PNGase A (f-g) released N-glycans from different S. mansoni 
life-cycle stages and measured by MALDI-TOF-MS in the positive ion-reflector mode (taken from 
Hokke at al.21) 
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It was shown that the majority of cercarial N-glycans are modified with β-1,2-xylose and 
core α-1,6-fucose while no core α-1,3-fucose is observed. Additionally, several truncated 
mannose terminated N-glycans appears and sugars presenting Lewis X antigen (Figure 2, a). 
Schistosomula express lower amounts of terminal Lewis X sugars and core xylosylated 
compounds compared to cercariae but the presence of truncated di- or trimannosidic N-
glycans is more pronounced (Figure 2, b).  
In adult worms, β-1,2-xylose completely disappears and Lewis X elements become less 
abundant compared to schistosomula N-glycans. N-glycosylation of adult parasites is mostly 
characterized by the presence of mono- and biantennary glycans with LDN termini and core 
α-1,6-fucosylation (Figure 2, c). 
In eggs, the N-glycan profile changes again and β-1,2-xylosylated, α-1,3-fucosylated and 
difucosylated (core α-1,3/α-1,6) structures can be now detected (Figure 2, d,f). The 
truncated N-glycans with terminal mannose residues reappears at high abundance; the 
antenna of remaining complex N-glycans are decorated with LDN termini, including Lewis X 
and LDNF moieties. Another characteristic of egg glycans is the multi-fucosylation of GlcNAc 
antenna and the presence of unusual multifucosylated motifes like, Fuc(α1-2)Fuc(α1-
3)GlcNAc motif or Fuc(α1-2)Fuc(α1-3)GalNAc(β1-4)[Fuc(α1-2)Fuc(α1-3)]GlcNAc (DF-LDN-
DF). N-glycans from miracidia show comparable N-glycan profile to eggs. (Figure 2, e,g). 
Even though S. mansoni expresses multiple and often unique glycans, their role during the 
parasite infection in the host is still not completely understood. It is well known that high 
levels of anti-carbohydrates antibodies are generated during the course of infection, 
however, they might be involved either in host protection or act like a smoke screen that 
could be beneficial for the parasite rather than for the host.20,24 The smoke screen theory 
refers to the subverting of the immune system away from epitopes that could provoke 
protective immunity by the high antibody responses induced against other carbohydrate 
elements.20 Generally, during the course of S. mansoni infection, high levels of IgE and IgA 
antibody responses are associated with increased resistance to re-infection. Two IgG 
subclasses, IgG1 and IgG3 are correlated with protection while IgG2 can have dual functions 
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and act as protective or blocking antibody. IgG4 on the other hand can block protective IgE 
functions and high IgG4/IgE ratio is associated with susceptibility to re-infection similar to 
high levels of IgM. 20  
In this Chapter, we will evaluate functionality of our glycan arrays towards profiling of anti-
glycan antibodies using anti-glycan monoclonal antibodies (mAbs) of S. mansoni infected 
mice and compare acquire results of specificities in a context of complex N-glycans printed 
on our array with previously published studies. Later we will focus on the characterization 
of polyclonal antibodies from the sera of infected individuals from schistosomiasis endemic 
areas. We will study the age-related anti-carbohydrate IgG and IgM responses in sera of 
infected children and adults and compare our results with the data obtained from the 
shotgun arrays. Finally, we will try to evaluate potential role of sugars during the course of 
infection. 
 
3.2. Glycan array assisted characterization of S. mansoni specific monoclonal antibodies 
 
To test the functionality of our glycan array towards characterization of anti-carbohydrate 
antibodies but also to characterize the specificity of antibodies in the context of glycans 
present on the array, we first probed a group of 17 monoclonal antibodies (mAbs) 
generated from serum of S. mansoni infected mice.25 
Monoclonal antibodies are single type antibodies secreted by immortal hybridoma cells 
that have been created by fusion of antigen activated B-cells isolated from the spleen of 
immunized mice with a non-secreting myeloid cell line (Figure 3).26 Hybridomas can grow in 
culture media indefinitely and secrete antibodies of desired specificity what makes them 
especially attractive for research. Nowadays, monoclonal antibodies have found multiple 
applications in the diagnosis and treatment of many diseases, like rheumatoid arthritis 
(Rituxan) or certain cancers (Cetuximab).27 
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Figure 3. Production of monoclonal antibodies (taken from Sefik S. Alkan at al.26) 
 
The available library of mAbs specific for schistosome antigens has included two 
immunoglobulin isotypes, immunoglobulin M (IgM) and G (IgG). Pentameric-IgM is the 
largest antibody with five complement-binding sites and plays a major role in the 
intravascular neutralization of for example certain viruses. IgM is produced immediately 
after exposure to the antigen, disappears few weeks later and thus usually indicates acute 
or current infections. IgG on the other hand is the most abundant immunoglobulin isotype, 
smaller than IgM and thus able to penetrate into human tissues. It is also the most 
important antibody of the humoral immune response, which is associated with the 
acquisition of long term immunity, induction of opsonization or antibody dependent cell 
cytotoxicity (ADCC).28,29 
The specificities of several IgG and IgM mAbs have been previously studied based on the 
screening against a small panel of synthetic glycoconjugates25,30 or applying shotgun 
arrays31 and were generally divided into four groups, based on the recognition either to 
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Lewis X, LDN, LDN-DF or both LDNF and LDNDF motifs. Here we will to study the 
specificities of mAbs in the context of structures presented on our synthetic array, taking a 
closer insight into the structural requirements of antibodies to bind. 
We have analyzed the supernatants of hybridoma culture media containing mAbs. First, the 
media was diluted in PBS to be subsequently incubated on the glycan array at room 
temperature during one hour. Slides were washed and subsequently incubated with anti-
mouse IgG-647 and anti-mouse IgM-555 (1:1000 dilution) for one hour in the dark. Arrays 
were washed from unbound antibodies, dried and fluorescence was analyzed in a 
microarray scanner. 
The majority of antibodies bound only to the tri- or tetrasaccharide glycan fragments, Lewis 
X, LDN and LDNF but with subtle differences regarding their presentation (Figure 4-5). Five 
of the mAbs, including 291-2G3, 128-4F9, 114-4D12, 291-4D10 and 99-16325,30 were specific 
for Lewis X motif, three of which (291-2G3, 128-4F9, 114-4D12) were found to bind 
exclusively the monovalent trisaccharide, showing no recognition of Lewis X terminated N-
glycans (Figure 4, A-C). 291-4D10 IgM recognized trisaccharide Lewis X in its monovalent 
form and within the context of the oligosascharides only on the arm 6 of N-glycans (Figure 
4, D). In contrast, 99-1G3 IgM recognized Lewis X motif exclusively when presented on the 
arm-3 of truncated N-glycans lacking α-1,6-mannose on the pentasaccharide core. (Figure 
4, E).  
MAbs 114-4E8 IgG332 and 290-2E6IgM had been previously characterized as anti-LDNF 
antibodies. We could observe binding of both antibodies against LDNF (Figure 5 A, B). 
However, due to the lack of N-glycans presenting this epitope on the antennae, it was not 
possible to determine if the presentation of LDNF in the context of larger oligosaccharide 
would improve binding. MAbs 259-2A1 IgG325 and 114-3A5 IgG3 had been previously 
described as LDN binding antibodies. We could observe that both mAbs bound the simple 
disaccharide fragment (Figure 5 C, D). While 259-2A1 IgG3 exclusively recognized simple 
LDN structure, 114-3A5 IgG3 also showed binding towards N-glycans containing terminal 
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LDN on truncated N-glycans with LDN on arm-3, on hybrid N-glycans with LDN on arm-3 
and on biantennary LDN terminated compounds.  
 
Figure 4. Glycan array screening of five monoclonal antibodies, showing carbohydrate specificity 
towards Lewis X. A-E. Fluorescence intensities after incubation with mAbs followed by anti-IgG-
647/anti-IgM-555. Each histogram represents the average RFU values for four replicates (mean±SD).  
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Figure 5. Glycan array screening of four monoclonal antibodies, showing carbohydrate specificity 
towards LDN or LDNF. A-D. Fluorescence intensities after incubation with mAbs followed by anti-IgG-
647/anti-IgM-555. Each histogram represents the average RFU values for four replicates (mean±SD).  
 
Lewis X, as well as LDN motif either with (LDNF) or without fucose are major antigens 
responsible for anti-carbohydrate immune response upon S. mansoni infection, although 
both motifs are also found to a minor extent in mammalian glycome. The consequences of 
the cross-reactivity for schistosomal induced antibodies with host structures are still not 
fully understood but could be part of a strategy to evade recognition by molecular 
CHAPTER 3 Anti-carbohydrate Abs 
 
 
173 
mimickry.33 Additionally, we could observe that the binding of several mAbs depended not 
only on the presence of particular recognition element but also on its structural context. 
These results are supported by the fact that S. mansoni expresses different structural forms 
of Lewis X or LDNF motifs during its development stages and which result in induction of 
context-specific antibodies against structurally related but not identical presentations of 
these elements. For example, in Schistosoma glycome Lewis X can be present as a 
monomeric but also oligo- or polymeric structures, it can decorate glycoproteins both 
through N-linkage or O-linkage and it could also decorate glycolipids.20 Monoclonal 
antibodies which are specific exclusively against simple trisaccharide Lewis X might suggest 
the specificity towards structures expressed for example in O-glycans or glycolipids. LDN 
and LDNF-based structures are present in all life stages of S. mansoni including cercarial O-
glycocalyx, the surface of schistosomula, adult worms and the egg-shell and sub-shell 
areas.23 Fucosylated and non-fucosylated LN and LDN motifs can be part of parasite N- or 
O-glycans or glycolipids.  
Finally, we have characterized the specificity of 100-4G11 IgM monoclonal antibody34 
(Figure 6) which has been described to cross-react with S. mansoni and allergens present in 
plant and insect glycoproteins. It has been demonstrated that 100-4G11 IgM is able to 
recognize horseradish peroxidase (HRP), a plant glycoprotein and phospholipase A2 (PLA2) 
from honeybee venom. The most abundant N-glycans which are shared by both 
glycoproteins and parasite glycans are classified as paucimannose N-glycans modified with 
core α-1,3-Fuc/α-1,6-Fuc, but in contrast to HRP (Figure 6B, G37), PLA2 does not present β-
1,2-xylosylation (Figure 6B, G73, G75).  
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Figure 6. Anti-carbohydrate specificity of 100-4G11 IgM monoclonal antibody; A. Fluorescence 
intensities after incubation of glycan array with mAb 100-4G11/anti-IGM-555. Each histogram 
represents the average RFU values for four replicates (mean±SD). B. Fluorescence images and 
quantification of glycans recognized by 100-4G11 IgM; C. Comparison between structurally similar N-
glycans which are recognized (green tick) and not (red cross) by 100-4G11 IgM.  
 
We have screening the anti-carbohydrate specificity of 100-4G11 IgM mAb on our glycan 
array. Our results strongly suggested that 100-4G11 IgM mAb recognizes paucimannose N-
glycans as reported before34, but also binds to other structurally similar N-glycans carrying 
additional core modifications (Figure 6, B). Recognition of certain hybrid compounds (Figure 
6B; G4, G16, G20, G29) was comparable to paucimannose mannose structures. On the 
other hand, analogues isomeric compounds G5, G55 (Figure 6C) and biantennary complex 
type N-glycans G6, G50 were not recognized by the mAb. Those data demonstrate that 100-
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4G11 antibody requires a free terminal α-1,3-linked mannose, but it can also tolerate 
different substitutions on the 6-arm. Based on glycan array results, the minimum epitope 
required for antibody binding consist of Manα-1,3-Manβ-1,4-GlcNAc-β-1,4-GlcNAc epitope 
and α1-6-linked mannose is not required as suggested in earlier study34 (Figure 6B, 
compounds G2, G41, G10, G72, G35, G38). The presence of a core α-1,3-Fuc and α-1,6-Fuc 
linked to the proximal core GlcNAc as well as β-1,2-xylose does not affect the binding. The 
presence of core α-1,3-linked fucose in the distal GlcNAc of the chitobiose core completely 
abolishes binding of mAb (Figure 6C; G81, G84). In Table 1, a summary of anti-carbohydrate 
mAbs specificities established during our glycan array study and previous reported data is 
compiled.  
 
Entry MAb Isotype Reported ligand Glycan array 
1 291-2G325 IgG1 Lewis X Simple LeX 
2 291-4D1025 IgM Lewis X Simple LeX, LeX (arm-6) 
3 128-4F925 IgM Lewis X Simple LeX 
4 99-1G325 IgM Lewis X LeX (arm-3) 
5 114-4D1230 IgG1 DF-LDN-DF Simple LeX 
6 114-4E832 IgG3 LDNF Simple LDNF 
7 290-2E625 IgM LDN-DF+ LDNF Simple LDNF 
8 114-3A5 IgG3 Unknown? Simple LDN, LDN (arm-3), G0 
9 259-2A125 IgG3 LDN Simple LDN 
10 100-4G1134 IgM Man3GlcNAc Manα-1,3-Manβ1,4-GlcNAc 
 
Table 1. Binding specificity of monoclonal antibodies against S. mansoni. Comparison between 
reported data and results obtained employing our synthetic N-glycan array. 
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In conclusion, we have evaluated the utility of our synthetic N-glycan array for the 
characterization of mAbs generated in serum of S. mansoni infected mice. Ten of the 
seventeen analyzed mAbs found to recognize specific elements presented on the glycan 
array, including Lewis X, LDN, LDNF and paucimannose N-glycan structures. The remaining 
seven mAbs did not bind to any structure on the arrays, suggesting a different specificity of 
these. The reactivity of monoclonal antibodies towards ligands presented on the glycan 
array directly confirmed that these carbohydrate elements are present in S. mansoni 
glycome and that during the course of infection, they are presented to the immune system 
leading to the generation of anti-carbohydrate antibodies. It is important to highlighted 
that the use of glycan arrays with large numbers of glycans showing very subtle structural 
differences can contribute to the definition of a precise sugar recognition epitope and help 
to understand the impact of the structural context in which the carbohydrate epitope is 
presented.  
More importantly, having in hands structures found not only in helminths but also being 
shared with food allergens (cross-reactive antigens), we could potentially apply our glycan 
array as a tool for example in allergy diagnosis. Recently our glycan arrays attracted 
attention of the Yazdanbakhsh group at Leiden Medical Center and could be possible used 
for a project discussing link between helminths infection and protection against peanut 
allergies in the Ghanese population. It has been reported35,36, that in Europe and North 
America the incidence of peanut allergy has increased recently, while the prevalence is 
much lower in many developing countries. This phenomenon was linked to the “hygiene 
hypothesis” and to the much higher prevalence of parasitic infections in developing 
countries.27 There are several proposed mechanisms by which helminths are believed to 
protect against allergies, including the activation of regulatory mechanisms, the modulation 
of innate immune cells as well as cross-reactivity between parasite antigens and allergens 
and their role in IgE sensitization. The array screening of possible cross-reactive antigens 
will potentially help in characterization and identification of glycan structures being the 
main players in the helminth infections and allergies. 
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3.3. Identification of anti-carbohydrate antibodies in sera of S. mansoni infected patients 
 
In this section, we will describe the screening of sera from S. mansoni infected individuals 
living in the endemic area of Piida fishing community at Butiaba, along Lake Albert in 
Uganda employing our glycan arrays. Pooled serum samples from children (age 5 to 11) and 
adults (age 26 to 46)37 were analyzed. We measured total IgG and IgM polyclonal antibody 
responses and we have compared the results between both age groups. In addition, sera 
from three healthy European adults were analyzed and used as negative controls.  
 
3.3.1 Natural antibodies of healthy individuals 
 
We began the serum antibody analysis with the sera from three healthy individuals 
employed as negative controls in our schistosomiasis study. Total IgG and IgM glycan 
binding profiles were recorded and compared for each donor.  
The majority of antibodies in human sera are the result of natural immunizations.38 
However, during the life-time healthy individuals acquire a variety of so-called natural 
antibodies (nAbs) many of which are directed towards carbohydrate antigens present in 
normal, healthy tissues (xeno-autoantigens).39 Natural antibodies are present in the sera of 
all individuals in the absence of an antigenic stimulus and they form part of the innate 
immune response. The best known and studied nAbs are against blood group antigens, 
group A (GalNAcα-1,3(Fucα-1,2)Gal) and group B (Galα-1,3(Fucα-1,2)Gal), α-Gal-epitope 
(Galα-1,3-Gal) first identified by Galili et. al and Hanganutziu-Deicher (H-D) antigen 
(Neu5Gcα2-3Galβ1-4Glc)(Figure 7).38–41 The natural blood-group specific xenoactive 
antibodies are responsible for agglutination due to mismatched blood transfusions while 
anti-Galα-1,3-Gal antibodies are the major obstacle associated with pig-to-human organ 
transplants. Unlike humans, non-primate mammals and new world monkey possess in their 
tissues the Galα-1,3-Gal epitope and lack natural antibodies directed against it. Thus the 
transplant of organs from these species to human can caused hyperacute rejection of 
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transplanted tissues.41,42 On the other hand, anti-Neu5Gc antibodies can be also found in 
humans, however, their levels strongly depend on the individuals. Neu5Gc can be 
metabolically incorporated into tissues from dietary sources, like red meat by certain 
commensal bacteria and may lead to generation of antibodies which are cross-reactive 
against Neu5Gc-containing glycans in healthy human tissue.43 Experiments performed on 
the human-like Neu5Gc-deficient Cmah-/- mouse model have demonstrated that the 
inflammation caused by the antigen-antibody interactions can promote tumor progression, 
suggesting a link between red meat consumption and carcinoma risk. 
 
 
Figure 7. Blood type and Galili/isoglobo/xeno antigens of healthy human sera.  
 
In our experiment, sera from healthy individuals were diluted in PBS (containing 1% BSA 
and 0.01% Tween-20) and incubated on glycan array at room temperature for 1h. Slides 
were washed and subsequently incubated with anti-human IgG(Fc specific)-Cy3 and anti-
human IgM(µ specific)-Alexa fluor 647 simultaniously for 30 minutes in the dark. Arrays 
were washed from unbound secondary antibodies, dried and fluorescence emission was 
measured in a microarray scanner. The anti-carbohydrate IgG responses were showing 
generally higher fluorescence intensities (Figure 8, A) and were much more specific 
compared to IgM patterns (Figure 8, B). Overall IgG response recorded for each donor 
created a unique anti-carbohydrate “finger print” for a single, analyzed person.  
The general binding tendencies were in a good agreement with the literature39,40, the 
profile of human anti-glycan antibodies detects α-Gal-related structures, blood group 
antigens ABH (variously represented in different individuals, mainly IgM response), Lewis 
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and related structures (IgM response) and smaller O-type glycans. The anti-carbohydrate 
IgG responses of healthy donor 1 and 2 were directed towards Galili-type of structure38 
G112 and/or G113 with donor 2 exhibited additional responses towards Galα-1,2Gal 
disaccharide G107, blood group antigen H6 G116 and human milk 3’sialyllactose G120 
(Neu5Acα2-3Galβ1-4Glc). The natural antibodies towards structure G107 as well as H-type 
blood antigens G116 were also observed by Bovin and coworkers, who employed glycan 
array to profile blood of healthy individuals and reported the presence of these common 
antibodies in analyzed sera.39 
  
Figure 8. Anti-carbohydrates IgG (A) and IgM (B) responses in three (1-3) healthy individuals. 
 
  
 
 
180 
Additionally, individuals 2 and 3 possess IgG antibody responses towards trimannosyl 
structure G107 (Manα-1,2Manα-1,2Man) and G82 and G84 N-glycans (Figure 8, 1-2). The 
Manα-1,2Man linkages are present in the branches of the pathogenic fungi44 and in the arm 
3 of Man9 high mannose N-glycans while core α-1,3 bisfucosylation is a characteristic 
feature of certain nematodes glycans45. Antibodies directed towards these sugars might 
suggest possible recent infection-related disease of these healthy donors. 
As mentioned before, the anti-carbohydrate IgM responses were of much lower intensities 
and are less specific. As most of the natural antibodies directed against blood group 
antigens are of the IgM class it could suggest that some of them could bind to these 
structures on the array. Additionally, smaller O-glycans, including chitobiose-type structure 
G40 and G93 were recognized by anti-glycan IgM antibodies. 
Summarizing, natural antibodies against several self-glycans as well as carbohydrate 
antigens encounters during the human life-time are present in the sera of every healthy 
individual. More importantly for our study, healthy donors with no previous history of the 
S. mansoni infection, do not elicit antibodies against any of N-glycans present on the array 
(with exception to compounds G82, G84) and can be further used as the negative controls 
for the screening of the sera of Schistosoma infected patients. In the next study, we used 
the pooled sera of healthy individuals, and compared the anti-carbohydrate responses 
directed against N-glycans excluding glycan fragments G91-G126. 
 
3.3.2 Glycan binding analysis of anti-carbohydrate antibodies from sera of S. mansoni 
infected children and adults 
 
Shotgun microarrays covering structures from the entire S. mansoni glycome, including 
natural N-glycans and glycolipids harvested at different parasite life stages are key tools to 
match antibody responses to parasite glycan structures. Recent studies revealed a 
differential glycan recognition profiles characteristic for two different age group, children 
and adults.13 However, due to the nature of the shotgun array, it is difficult to identify the 
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responsible antigen from the mixture of the printed fraction. Here, we used our synthetic 
glycan array as a complementary tool, to evaluate whether an age-related differentiation of 
sera can be defined on the basis of antibody reactivity to our array of parasitic N-glycans. 
Sera were diluted 1:100 with PBS and incubations were performed as previously described 
in section 3.3.1 (Figure 10).  
 
Figure 10. Fluorescence read-out of anti-carbohydrate IgG (green) and IgM (red) responses in sera of 
Schistosoma infected children and adults probed with anti-human IgG(Fc specific)-Cy3 and anti-
human IgM(µ specific)-Alexa fluor 647 antibodies respectively. 
 
The IgM responses to the glycans on our array (Figure 11) were of weak to moderate 
intensity and of low specificity in both age groups. Generally, we observed a higher anti-
carbohydrate response for children than for adults but no significant differences in bound 
structures could be detected between the age-groups. 
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 For IgG binding, however, we found a more pronounced binding pattern and a strong 
differentiation between the two age groups based on core β-1,2 xylosylated and core α-1,3 
fucosylated glycan structures (Figure 12). The major children derived anti-carbohydrate IgG 
antibody response was found to be directed towards both, core β-1,2-xylosylated and core 
α-1,3-fucosylated structures of high mannose, hybrid and complex type N-glycans. 
Interestingly, the pooled adult IgG antibodies only bound to certain core β-1,2-xylosylated 
compounds, but not to core α-1,3-fucosylated structures lacking xylose. Importantly, the 
glycans recognized by either the adults or children were bound at only very low levels by 
serum antibodies from individuals uninfected with S. mansoni (Figure 11, 12 C) suggesting a 
specific response to S.mansoni infection. Structures which were truncated on the 3-arm 
and presenting substituents no larger than a single α-1,3 mannose residue were best bound 
both for children and adults. Core-xylosylated structures presenting more sterically 
demanding substituents on the 3-arm were still bound by the children serum pool, 
however, with lower intensity. In adults no antibodies against these glycans were detected.  
Altogether, we were able to detect with our array an important number of anti-
carbohydrate Abs in the blood of S. mansoni infected patients as demonstrated above, their 
protective potential or specific function, however, remains unclear.  
Since the parasite has to developed mechanisms to evade or resist the immune response of 
the host in order to remain in the host for a long period of time, certain carbohydrates may 
down regulate immune responses in the chronically infected patients and act as a "smoke 
screen" subverting the immune system away from the epitopes that could provoke 
protective immune responses.20 It has been demonstrated that children are generally far 
more susceptible to infection and re-infection than adults, even if in the area of study 
adults are much more exposed to the parasite. It has been shown that the acquisition of 
immunity against parasites is age-dependent and require maturation of the immune system 
by multiple infections and treatments.20 This might suggest that certain parasitic glycans 
which are recognized by the children immune system during the infection are ignored by 
adult immune system that had been exposed to the parasite previously.  
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For the selection of glycan structures as antigens of a glycoconjugate vaccine one should 
also consider the specificity of the encountered hits in the glycan array screen for the 
targeted species. A further interpretation of the serum antibody binding profiles to identify 
structures as potential vaccine candidates or for specific diagnostic purposes has to be 
made with caution, as core β-1,2-xylosylated and core α-1,3 fucosylated glycans are not 
unique in S. mansoni glycome but they are also present on several other helminths 
parasites, plants and insects. Nevertheless, the fact that we see strong IgG binding to core-
xylosylated glycans in schistosomiasis sera and not in controls indicates that this response is 
indeed directed against the parasite. A protective function of the elicited antibodies can, 
however, not be determined by glycan array screening alone. We require additional 
immunological studies and an immunization trial with putative glycan conjugate vaccine 
candidates in a relevant animal model. Additionally, a protective immune response against 
S. mansoni may be formed by the combined action of multiple antibodies against various 
glycans, glycoproteins and/or glycolipids rather than against a single antigen. 
 
3.4 Summary 
 
This chapter described the successful application of the synthetic glycan arrays towards 
screening and characterization of anti-carbohydrate antibodies. We have probed a group of 
monoclonal antibodies induced in S. mansoni infected mice and evaluated their specificity 
towards structures present on the microarray. Subsequently, we have probed the sera of 
healthy Europeans and recorded their unique IgM and IgG binding profiles which were 
directed mostly towards blood group and possible environmental antigens. Finally, we have 
compared the IgG and IgM antibody responses in serum samples in S. mansoni infected 
individuals divided into two age-groups, children and adults. The overall IgM response 
patterns were similar for children and adults, but showed higher intensity for younger age 
group. For the IgG binding profile, we found a more pronounced binding pattern and an 
important age-related differentiation. These difference appear to be based on core β-1,2 
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xylosylation and core α-1,3 fucosylation as major denominators. This observation highlights 
the antigenic nature of both these motifs as well as the value of our synthetic core-
xylosylated structures to detect specific antibodies in different serum cohorts. However, if 
this glycan structures might induce protective immunity during the parasitic infections 
cannot be still clearly evaluated. These glycan array screening of serum is ongoing and it 
will be focused in classifying the immunoglobulin isotype and subclass. This will help to 
clarify the functional role of the detected antibodies.  
 
3.5 Experimental Part 
 
General methods 
 
Materials: Bovine serum albumin BSA (globulin free) was purchased from Sigma Aldrich. 
Anti-mouse IgG (H+L specific) Alexa fluor 647 produced in rabbit, and anti-mouse IgM- 
Alexa fluor 555 (µ specific) produced in goat, were purchased from Invitrogen. Secondary 
anti-mouse antibodies were used in 1:1000 dilution in PBS containing 1% BSA and 0.01% 
Tween-20. Anti-human IgG (Fc specific)-Cy3, produced in goat, was purchased from Sigma-
Aldrich and Anti-human IgM-Alexa fluor 647 (µ specific) was purchased from Invitrogen, 
Breda, the Netherlands. Anti-human antibodies were used in 1:1000 dilution dilution in PBS 
containing 1% BSA and 0.01% Tween-20. 
Glycan arrays (36x18) were prepared and fluorescence was analyzed as indicated in 
Chapter 2.  
 
Mouse mAbs reactive to schistosome glycans were provided by Dr. C.H Hokke from the 
Leiden Parasite Glycobiology Group (Leiden University Medical Center, the Netherlands). 
They were generated from S. mansoni infected mice as described previously25. Human sera 
were obtained from 41 Schistosoma mansoni infected individuals living in the Piida 
community, Butiaba in Uganda where S. mansoni is endemic. Ethical approval for the Piida 
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study was obtained from the Uganda National Council for Science and Technology (UNCST). 
Sera were made available by Dr. Dunne, Cambridge University, United Kingdom and by N. 
Kabatereine, Vector Control Division, Uganda Ministry of Health, Kampala. 
 
Incubation of S. mansoni specific monoclonal antibodies 
 
Culture supernatants containing mAbs were diluted 1:50 in PBS containing 1% BSA and 
0.01% Tween-20, and aliquots (180 µL per array) were used to incubate individual wells on 
a glycan array slide at room temperature for 1h. The slides were washed with PBST (PBS 
containing 0.01% Tween-20) followed by PBS. Slides were then incubated with anti-mouse 
IgG-647 and anti-mouse IgM-555 (1:1000) in PBS containing 1% BSA and 0.01% Tween-20 
for 1h in the dark. Arrays were washed from unbound secondary antibodies with PBST, PBS 
and water. Microarrays were dried and scanned for the fluorescence emission in a 
microarray scanner.  
 
Incubation of pooled serum samples from S. mansoni infected patients 
 
Previously collected selected sera of schistosomiasis patients were pooled into two age-
groups: children (21 individuals, age between 5 to 11 years) and adults (20 individuals, age 
between 20 to 46 years). In both groups,the ratio female/male ratio was 3:2. In addition, 
sera from 3 healthy Europeans was analyzed and used as negative control. Sera were 
diluted 1:100 with PBS containing 1% BSA and 0.01% Tween-20, and aliquots (180 µL per 
array) used to incubate individual wells on a glycan array slide at room temperature for 1h. 
The slides were washed with PBST (PBS containing 0.05% Tween-20) followed by PBS. Slides 
were then incubated with anti-human IgG(Fc specific)-Cy3 (Figure 12) and anti human-
IgM(µ specific)-Alexa fluor 647 (Figure 11) in PBS containing 1% BSA and 0.01% Tween-20 
for 30 minutes in the dark. Slides were washed subsequently with PBST, PBS and H2O and 
dried in a slide spinner prior to scanning the fluorescence emission in a microarray scanner. 
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4.1 Introduction 
 
Targeting antigens to dendritic cell (DC) subsets is a promising strategy to enhance the 
efficacy of vaccines. DCs are highly specialized antigen-presenting cells (APCs) that constantly 
sample their environment in the search for foreign molecules.1 Once DCs encounter an 
antigen, they are able to capture it, further process it and present antigen fragments to T 
cells (Figure 1). Since DCs stimulate T cell responses but are also capable of inducing 
tolerance, they are an attractive target for immunotherapy2 and have been exploited to 
improve vaccine candidate efficacy.3,4,5  
 
Figure 1. Dendritic cell recognizes the pathogen through the pattern recognizing receptor (PRR), 
uptake it, process and the fragments are presented by the major histocompatible complex (MHC-II) to 
the CD4+T cells. Peptides presented by the MHC-II molecule are recognized by the T cells receptors 
(TCR) along with binding of the co-stimulatory molecules CD80 or CD86 by CD28. 
 
Some DC-targeting vaccines are generated ex vivo using antigen-loaded monocyte-derived 
DCs that are further re-administered to the patient.6,7 More direct methods involve the in 
vivo targeting of specific DC receptors, including C-type lectin receptors which were 
mentioned in Chapter 2. CLRs represent a large family of receptors specialized in the 
recognition of carbohydrates on pathogens and self-antigens through their extracellular 
carbohydrate recognition domain (CRD).8,9,10 Since CLRs exhibit a differential expression on 
DC subsets and a number of them act as endocytic receptors, they are attractive candidates 
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for an efficient antigen targeting to DCs.9,9 Still, most of the efforts towards CLR targeting 
utilize monoclonal antibodies11 (for example, anti-DEC20512,12, anti-mannose receptor mAbs) 
and far less examples are available for glycan-based CLR targeting.13 However, glycan-based 
CLR targeting offers some advantages compared to antibody-mediated targeting, such as a 
low immunogenicity and the possibility to target several CLRs simultaneously. Furthermore, 
targeting CLRs with glycans resembles the natural CLR-ligand interactions and allows 
modulating binding strength by adjusting ligand densities and spatial orientation.14 Finally, 
glycans show a potentially more favorable pharmacokinetic profile when compared to large 
protein drugs 15,15 and as described in Chapter 1, they can be prepared relatively fast and with 
good yields applying chemoenzymatic synthesis.16,17 The inherently weak interactions 
between single carbohydrates and proteins can be substantially increased by a multivalent 
glycan presentation. To this end, nanoparticles, liposomes, and dendrimers have been used 
as different display systems for multivalent CLR targeting.8  
The Chapter 2 described how the presence of core β-1,2-xylose disrupted the interaction of 
several N-glycans with mannose binding plant lectins such as Galanthus nivalis agglutinin 
(GNA) and Concanavalin A (ConA). More importantly, the presence of core xylose on the N-
glycan G6 completely abolished binding to the human Dendritic Cell-Specific Intercellular 
adhesion molecule-3-Grabbing Non-integrin (DC-SIGN)16, a CLR involved in the recognition of 
many pathogens such as HIV, Schistosoma mansoni or Ebola virus.18,19,20  In this Chapter, 
based on the glycan array screening of DC-SIGN, we will describe the preparation of two 
glycoconjugates (G0-OVA and XG0-OVA) which were synthesize by conjugating the 
biantennary N-glycan (G50=G0) and its O-2 core xylosylated analogue N-glycan (G6=XG0) to 
the model protein antigen ovalbumin (OVA). We will analyze their binding to a set of murine 
CLR-Fc fusion proteins (including homologues of human DC-SIGN) using lectin microarray and 
further evaluate whether the differential binding of G0 and XG0 to CLRs will have an impact 
on dendritic cell targeting. We will perform uptake studies using Alexa Fluor® 647 labeled 
glycoconjugates and murine dendritic cells and finally, we will measure the effects of 
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ovalbumin glycoconjugates on T cell activation in a dendritic cell/T cell co-culture assay 
(Figure 2). 
 
Figure 2. Schematic representation of the DCs/T cells co-culture assay applying two, chosen 
glycoconjugates, XG0-OVA and G0-OVA as a targeting molecule of DCs CLRs. 
 
In the second part of the Chapter 4, inspired by the results obtained from the DCs and Alexa 
Fluor ® 647 labeled glycoconjugates uptake study, we will describe the preparation of an 
alternative to the organic dye labeled glycoproteins system, glycoprotein coated gold 
nanoclusters (AuNCs). AuNCs exhibit a size-dependent fluorescence and are considered to 
be a novel ultra-small, bio-labels.21 Based on the progress in the macromolecule directed 
synthesis of clusters, we will use glycoconjugates for the generation of glycan-OVA-AuNCs. 
So created system will combine DCs targeting properties of glycan with antigenic properties 
of the protein and the imaging capability of fluorescent gold nanoclusters. An introduction 
describing gold nanomaterials in general illustrated with examples of synthetic strategies 
previously found in literature will be given. Finally, in the last part of the Chapter we will show 
a first example for the use of glycoprotein-based gold nanoclusters in DCs targeting. 
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4.2 Generation and characterization of ovalbumin glycoconjugates, XG0-OVA and G0-OVA 
 
N-glycan structures (G0 and XG0) equipped with a C5 amino linker for further conjugation 
were chemically synthesized as described in Chapter 1.16,17 The corresponding OVA 
conjugates were generated by first activating glycan-amino linker with disuccinimidyl 
suberate ester (DSS) (Figure 3) and then crosslinking accessible OVA lysine residues in a 
second step.22 The glycoconjugates G0-OVA and XG0-OVA were characterized by gel 
electrophoresis (Figure 3, B) and by MALDI-TOF mass spectrometry (Figure 3C).  
The mass shift upon conjugation of OVA with activated glycans G0-DSS and XG0-DSS (Figure 
3C) indicated an average conjugation of 3-4 glycans per OVA molecule. To evaluate the 
influence of core xylose on the recognition by CLRs and DC targeting, a similar glycan valence 
was required for both, XG0-OVA and G0-OVA. By carefully adjusting the glycan/OVA ratio and 
the protein concentration during the conjugation reaction, we were able to produce both 
OVA glycoconjugates displaying equal numbers of glycan moieties. 
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Figure 3. A. Synthesis of OVA glycoconjugates employing disuccinimidyl suberate ester (DSS) as a 
linker; I. mono-substituted NHS-activated suberate ester; II. Addition of activated N-glycan to OVA 
solution. Evaluation of the glycoconjugate synthesis; B. SDS-PAGE (10% acrylamide) stained with 
Coomassie Blue G-250; C. MALDI-TOF spectra of OVA (violet), XG0-OVA (green) and G0-OVA (yellow). 
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4.3 Binding of OVA neoglycoconjugates to CLRs printed on the array 
 
To identify CLRs involved in the recognition of the glycoconjugates G0-OVA and XG0-OVA by 
murine DCs, we performed binding studies using lectin microarray technology. To this end, a 
library of CLR-Fc fusion proteins consisting of the extracellular part of the respective CLR and 
the Fc part of human IgG1 molecules was used.23 We analyzed binding of G0-OVA and XG0-
OVA towards eight recombinant murine CLRs: DC immunoactivating receptor (DCAR), DC 
immunoreceptor (DCIR), Dectin-2, Macrophage inducible C-type lectin (Mincle), 
Macrophage-restricted C-type lectin (MCL), Clec12b and the murine DC-SIGN homologues 
SignR1 and SignR3.  
To achieve a more uniformly oriented presentation of the CLR extracellular CRDs on the 
microarray surface, NHS-slides were first coated with protein G before the CLR-Fc fusion 
proteins were subsequently spotted on top (Figure 4).  
 
Figure 4. Schematic representation of the protein G coated lectin array-assisted binding studies with 
glycoconjugates and unconjugated OVA. In the zoomed view illustration of the protein G recognizing 
Fc part of the IgG1 antibody fused with extracellular domain (ECD) of C-type lectin receptors (CLR). 
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Protein G binds to the Fc region of the CLR-Fc fusion proteins thus improving the orientation 
of the CLR on the microarray surface.24,24 Human Fc was included as negative control. 
Glycoconjugates and OVA were fluorescently labelled in primary amino groups from lysines 
and N-terminal employing commercially available Alexa Fluor® 647 NHS ester. Solutions of 
XG0-OVA, G0-OVA and OVA in sodium carbonate buffer were incubated in the dark for 1 hour 
with the fluorescent reagent. Excess of dye was later removed by dialysis and 
ultracentrifugation. The reaction conditions were adjusted to obtain a comparable degree of 
substitution (DOS) of dye for each glycoprotein and unmodified OVA, which was further 
estimated based on absorbance of dye and protein. An average of 11 dye molecule was 
assigned per each construct (a detailed calculation is given in the Experimental section). 
Subsequently glycoconjugates and OVA dilutions in PBS were incubated in the dark on the 
CLR microarrays at 4°C overnight. The lectin microarray was washed and the fluorescence 
was measured in a microarray scanner (Figure 5).  
 
Figure 5. C-type lectin microarray-based analysis of binding of CLR-hFc fusion proteins to 
glycoconjugates XG0-OVA (grey) and G0-OVA (black) compared to unmodified OVA (white). Statistical 
analysis was performed with an unpaired student's t test, ***p<0.0001,**p<0.01, *p<0.05,   ns-not 
significant. 
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Binding studies revealed that glycoconjugates bound strongly to three of the eight analyzed 
CLR-Fc fusion proteins: Mincle, and both DC-SIGN homologues, SignR1 and SignR3. Lower 
binding but still significant binding was detected for Clec12b and DCIR. While the presence 
of a core xylose in XG0-OVA showed no significant effect on glycoconjugate binding towards 
Mincle and SignR1, it strongly reduced the interaction with SignR3 compared to the non-
xylosylated homolog G0-OVA. Unconjugated OVA was used as a control in all experiments to 
evaluate the impact of background glycosylation and potential protein-protein interactions 
on binding. With the exception of SignR1, with a known specificity towards high-mannose 
structures25, we did not observe any significant binding of the control protein. Although 
native chicken OVA contains a single N-linked glycosylation site (Asn-292) which is 
predominantly substituted with high mannose (Man5GlcNAc2/Man6GlcNAc2) or less 
abundant hybrid (Man5GlcNAc4/Man5GlcNAc5) glycans,26 this sugar modification seems to 
play a minor role in the recognition by CLRs, probably due to the monovalent presentation. 
Thus, the G0/XG0 N-glycans seem to be exclusively responsible for recognition by the CLR-Fc 
fusion proteins tested on our array.  
A significantly reduced binding of XG0-OVA compared to G0-OVA was observed for SignR3. 
We have shown previously that the xylose modification completely abolishes binding of XG0 
towards DC-SIGN16. The murine DC-SIGN family consists of several homologous type II 
transmembrane proteins of which each displays a single carboxyl terminal CRD.27 Previously, 
it had been shown that the dominant specificities found for the DC-SIGN homologues SignR1 
and SignR3 preferentially bind to mannose- and fucose motifs found in on high mannose type 
N-glycans and in Lewis A/B and Lewis X/Y moieties.28 The differential carbohydrate 
specificities of both DC-SIGN homologues have been previously exploited for cell targeting 
with glycoliposomes.29 SignR3 has been reported to bind to bacterial pathogens such as 
Mycobacterium tuberculosis, but also glycans of commensal microbiota.30,31 Since SignR3 is 
considered to be the biochemically closest murine homolog of the human DC-SIGN 
receptor,32,33 it might exhibit a similar glycan binding pattern as DC-SIGN thus explaining the 
differential binding of G0 and XG0 by SignR3. 
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4.4 DCs binding and uptake assays of glycoconjugates 
 
4.4.1 Purification of DCs and T-cells by Magnetic Assisted Cell Sorting (MACS) 
 
CD11c+ splenic DCs as well as OT-II T cells used in the section 4.4.2, 4.4.3 and 4.10 were 
purified by magnetic-activated cell sorting (MACS) as shown on Figure 6. To isolate 
splenocytes, spleens were flushed with cell culture medium and the cell suspension was 
filtered through a cell strainer to remove cell aggregates. After centrifugation cell pellets 
were re-suspended in erythrocyte lysis buffer, washed and re-suspension in MACS buffer 
(PBS, 0.5% BSA, 2mM EDTA). Dendritic cells (CD11c+ cells) were isolated from suspension of 
C57BL/6 murine spleen cells by positive sorting applying microbeads containing antibody 
directed against CD11c+ surface marker of DCs (Figure 6, B). 
 
 
Figure 6. A. Magnetic Assisted Cell Sorting-(MACS) principles; 1. Cells in a single-cell suspension are 
magnetically labeled with MACS microbeads; 2.The sample is applied to a MACS column placed in a 
magnet and the unlabeled cells pass through the column; 3. The column is removed from the 
separator, and the magnetically labeled cells are eluted from the column; B. Positive selection: target 
cells type (DCs) are magnetically labeled and are retained within the column; C. Untouched isolation: 
target cells type (OT-II T cells) are unlabeled and collected in the flow-through fraction. Figure A was 
taken from: http://www.miltenyibiotec.com. 
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Cells incubated with magnetic microbeads were loaded onto a MACS column placed in a 
 magnetic field. Unbound cells passed through the column, while remaining CD11c+ cells 
were washed with MACS buffer and eluted from the column by removing the magnetic field. 
To increase DC purity, the CD11c+ cell purification was repeated. The cell suspension was 
centrifuged, resuspended in IMDM complete medium and counted. Subsequently, T cells 
were isolated from spleen of OT-II transgenic mice using the Pan T Cell Isolation Kit II (Figure 
6, C). Non-target cells were magnetically labeled with a cocktail of biotin-conjugated 
antibodies followed by anti-biotin monoclonal antibodies conjugated to MicroBeads. Non-
targeted cells were retained on the MACS column, while the untouched T cells passed 
through the column in the first fraction. As in a case of DCs, to increase T cell purity, the T 
cell purification was repeated. The purities of MACS-isolated DCs and T cells were analyzed 
by flow cytometry (Figure 7).  
 
Flow cytometry (FC) is a technology that allows for the simultaneous measurements of 
multiple physical properties of particles (here cells) which flow in a fluid stream through a 
beam of light.34 The characteristic cells features which can be assigned from a single FC 
measurement include their relative size, granularity or internal complexity and relative 
fluorescence intensity. These characteristics are determined using an optical-to-electronic 
coupling system that records how the cell scatters incident laser light and emits fluorescence. 
Forward-scattered light (FSC) is proportional to the cell-surface area or size while the side-
scattered light (SSC) indicates the cell granularity or internal complexity. Correlated 
measurements of FSC and SSC can be used to differentiate cell types in a heterogeneous cell 
population.34 On the other hand, fluorescently labeled monoclonal antibodies directed 
towards certain cell surface markers are employed to identify a particular cell type in a mixed 
population of cells, as well as to distinguish isolated subpopulations of cells. FSC and SSC data 
combined with the immunofluorescence staining pattern can be used for identification of 
cells present in a sample and to count their relative percentages.  
CHAPTER 4 Targeting of DCs 
 
 
203 
Figure 7 shows scatter plots of MACS-purified DCs and T cells with correlated SSC and FSC 
data and fluorescence emission of mAbs-labeled surface markers. CD11c+ DCs were stained 
with anti-CD11c APC-labeled antibody while the OT-II T splenic cells with APC-eFluor780-
labeled antibody, that targets a T cell receptor associated molecule CD3e (Figure 7A-B, 
second and third column). The FACS analysis of MACS-purified DCs and T cells demonstrated 
a purity of 85.1% and 90.3% respectively. The control measurement of flow through collected 
during CD11c+ DCs purification was also recorded (Figure 7A, first column).  
 
 
Figure 7. Representative dot plots of MACS-purified DCs and T cells A. splenic CD11c+ cells from wild-
type C57BL/6 mice and B. splenic T cells from transgenic OT-II mice. 
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4.4.2 DCs binding and uptake assay followed by confocal microscopy and FACS 
 
We then studied the uptake of fluorescently labeled G0-OVA, XG0-OVA and unconjugated 
OVA by murine DCs isolated from C57BL/6 mice by confocal microscopy (Figure 8A). Purified 
DCs were seeded on poly-D-lysine-coated glass cover-slips overnight, incubated with either 
fluorescently labeled OVA, G0-OVA or XG0-OVA, washed to remove unbound proteins and 
fixed.  
 
Figure 8. Uptake of the Alexa Fluor®-647 labeled glycoconjugates XG0-OVA and G0-OVA and OVA by 
murine DCs; A. Internalization of compounds measured by confocal fluorescence microscopy; B. 
Uptake of glycoconjugates and OVA analyzed by flow cytometry (data are representative for three 
independent experiments). 
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In all cases, we could observe a rapid internalization within 10 minutes (Figure 8A). To 
quantify potential differences in glycoconjugate uptake, which could indicate a possible 
influence of the core xylose modification on internalization, we analyzed the uptake by flow 
cytometry (Figure 8B). Purified DCs were pulsed with fluorescently labeled OVA and 
conjugates G0-OVA and XG0-OVA, incubated and subsequently washed to remove non-
internalized fluorescent conjugates.  
We observed that both sugar modifications increased OVA uptake by DCs. After 10 minutes 
of incubation, OVA was detected in about 17% of the murine DCs, while a slight increase was 
observed upon incubation with conjugate XG0-OVA (22.6%). However, incubation with the 
non-xylosylated glycoconjugate G0-OVA led to a marked increase in glycoconjugate 
internalization (in 37% of the murine DCs) indicating that the respective glycan modification 
indeed markedly impacted DC targeting efficacy. 
 
4.4.3 In vitro stimulation and DCs/T cells co-culture 
 
Upon internalization into DCs, antigens are processed and peptide fragments can be 
presented on major histocompatibility complex (MHC-II) molecules to T cells. However, 
besides activating T cells, DCs may also shape T cell responses, for instance by inducing CD4+ 
T cell differentiation into Th1, Th2, or Th17 cells.35 To analyze whether the differential DC 
targeting capability of the OVA glycoconjugates also impacted subsequent T cell activation, 
a DC/T cell co-cultivation assay was performed. To this end, CD11c+ splenic DCs were pulsed 
with the OVA neoglycoconjugates or OVA alone and then incubated with purified CD4+ T cells 
from OT-II transgenic mice. This transgenic system allows to evaluate antigen presentation 
and subsequent T cell activation since OT-II CD4+ T cells have a T cell receptor specific for the 
OVA323-339 peptide presented by the MHC-II molecule I-A.36 
As a read-out, the expression of the early activation marker CD693738 was measured by flow 
cytometry. Indeed, we found a higher frequency of OT-II CD4+ T cells expressing CD69 on 
their surface upon stimulation with the OVA glycoconjugates compared to the unconjugated 
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OVA (Figure 9A, B). Importantly, a signiﬁcantly higher frequency of CD4+ T cells expressed 
CD69 when DCs had been pulsed with G0-OVA compared to the xylosylated analogue XG0-
OVA (Figure 8A, B). This finding indicates that the differential DC targeting efficiency of the 
OVA glycoconjugates observed in the DC uptake assay also correlates with subsequent T cell 
activation.  
 
 
Figure 9. Frequencies of OT-II CD4+ T cells expressing the early activation marker CD69 upon 
stimulation with glycoconjugates (G0-OVA, XG0-OVA) and OVA; A. Representative dot plots after 48 
h; B. Statistical analysis for the incubation over 48 h and 72 h (data are representative for three 
independent experiments). Statistical analysis was performed with an unpaired student's t test, 
*p<0.05, ns-not significant.  
 
Besides the expression of activation markers, activated T cells produce cytokines with 
different effector functions. Thus, as an additional functional read-out, we measured the 
concentrations of interleukin 239 (IL-2) and interferon gamma40 (IFN-γ) produced by the OT-
II CD4+ T cells. While IL-2 is produced by activated T cells and further promotes T cell 
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proliferation, IFN-γ is an effector cytokine mainly produced by Th1 cells. Indeed, significantly 
higher levels of IL-2 were produced by T cells that had been stimulated with the OVA 
glycoconjugates compared to the unconjugated OVA (Figure 10A). While both 
glycoconjugates induced a higher IL-2 production than unconjugated OVA, the presence of 
the xylose modification in XG0-OVA resulted in a lower IL-2 level than for G0-OVA. A similar 
trend was observed for IFN-γ production (Figure 10B). Thus, the results obtained for 
glycoconjugate-dependent cytokine production are consistent with the CD69 expression 
data (Figure 9) and indicate that glycan-based DC targeting may be used to elicit subsequent 
T cell responses. 
 
Figure 10. Cytokine production by OT-II CD4+ T cells with CD11c+ DCs pulsed with OVA, XG0-OVA and 
G0-OVA; A. Interleukin-2 (IL-2) production after 48 and 72 h of incubation; B. Interferon-γ (IFN-γ) 
production after 48 and 72 h (data are representative for three independent experiments). Statistical 
analysis was performed with an unpaired student's t test, *p<0.05, **p<0.01, ***p<0.0001, ns- not 
significant.  
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4.5 Summary 
 
The use of protein or peptide antigens alone may not always induce an effective 
internalization by DCs and subsequent T cell activation. In this context, the use of glycan-
modified antigens and their targeting via CLRs is a promising strategy to enhance the uptake 
of the construct. Recent studies indicate that different carbohydrates may even initiate 
differential signalling processes by engagement of the same CLR as has been shown for 
fucose-based DC-SIGN targeting.41,42,43 However, targeting CLRs with glycans is still hampered 
by incomplete knowledge of CLR binding specificities.44 In this Chapter, we demonstrate the 
utility of CLR microarrays to identify natural glycan ligands. N-glycans conjugated to the 
model antigen OVA were targeted to murine DCs in vitro. We showed that xylosylated and 
non-xylosylated biantennary N-glycans enhanced the uptake and presentation of OVA and, 
more importantly, we could demonstrate that even small structural glycan modifications can 
have a marked impact on uptake by DCs and subsequent T cell activation. In line with our 
glycan array based binding study, we found that the non-xylosylated G0-OVA glycoconjugate 
bound with higher affinity to SignR3 than XG0-OVA and unconjugated OVA. Consequently, 
G0-OVA was preferably internalized by murine DCs and led to enhanced T cell activation as 
demonstrated by CD69 staining. Finally, the production of IL-2 and IFN-γ measured after 48h 
was elevated further underlining an increase of T cell activation as well as their differentiation 
towards a Th1 phenotype. Ultimately, our study highlights the utility of glycan-based CLR 
targeting and may open up new possibilities for the specific delivery of vaccine antigens into 
DCs.  
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4.6. Glycoconjugate OVA-Gold Nanoclusters  
 
In the second part of this Chapter, we will use G0-OVA glycoconjugate, which exhibited the 
highest DCs targeting, for the preparation of protein-derived gold nanoclusters, G0-OVA-
AuNCs. This novel system combines the targeting properties of N-glycan with potential 
antigenic properties of the protein and bioimaging capabilities of fluorescent AuNCs (Figure 
11).  
 
 
Figure 11. Schematic representation of the G0 glycan-derived OVA-AuNCs preparation with the 
properties assigned to each component of the system. 
 
OVA-G0-AuNCs can be considered as an alternative system to fluorescently labeled OVA-G0. 
AuNCs are characterized by their biocompatible properties, like water solubility or low 
toxicity in a broad range of concentrations.45 The size-tunable fluorescence of AuNCs falls 
into the near-IR window which is particularly well suited for in vitro and in vivo imaging as 
with this emission wavelength the minimal biological auto-fluorescence is induced. In 
addition, the presence of a gold core opens the possibility of in vivo X-ray computed 
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tomography (CT) imaging and radiotherapy application, as certain AuNCs have been found 
to act as radiosensitizers.46  
 
4.6.1. Introduction to Gold Nanoclusters 
 
The word nano is derived from Greek nanos, meaning dwarf and is used to describe materials 
or properties which occur on a nanometer scale (10-9 m).47 The science dealing with 
nanomaterials, called nanoscience, combines multiple fields of research, including chemistry, 
physics, biology and medicine. One of the exciting branches of this multidisciplinary field is 
the generation of new (bio)materials and investigation their interaction with biological 
systems. The knowledge obtained can be further applied for therapy, drug delivery, imaging, 
biosensing and cell labeling.21  
Among different metals, gold is one of the most extensively studied material in nanoscience. 
This nobel metal in its bulky state is highly unreactive and mostly associated with the jewelry 
or electronic industry48 whereas in the nano scale form it has found entry into a variety of 
biomedical applications.47 Gold nanomaterials can be categorized according to their 
dimensions, into gold nanoparticles (NPs) and gold nanoclusters (NCs).21,49 Gold 
nanoparticles with sizes close to the wavelength of light (3-100 nm) exhibit distinctive 
properties which differs from others NPs, such as surface plasmon resonance (SPR) and their 
photothermal properties. Gold nanoclusters (AuNCs) on the other hand, are smaller than 3 
nm in diameter which is consistent with ten to hundred gold atoms. Their ultra-small 
dimensions approach to the Fermi wavelength of electrons (0.7 nm), which places them 
between metal atoms and larger nanoparticles.47 AuNCs exhibit molecular-like behavior and 
optical, electrical and chemical properties distinctive from the GNPs. Due to strong quantum 
confinement effects, AuNCs are too small to support surface plasmon resonance but can emit 
size-dependent fluorescence. Nowadays, the use of labeling agents, especially for the tagging 
of biomolecules has been demonstrated to be indispensable in many biological studies.50 In 
this Thesis we have discussed how the fluorescence can be used to follow complex biological 
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processes, like carbohydrate-protein interactions, where the fluorescently-tagged lectin is 
required to evaluate its binding towards ligands printed on the microarray (see Chapter 2). 
In the first part of this Chapter, we used commercialized fluorescently-labeled antibodies to 
differentiate between the cell subclasses by FACS analysis and finally followed the uptake of 
Alexa Fluor®-647 glycoconjugates by DCs.  
The fluorescent labeling commonly uses conventional organic dyes, like fluorescein and 
rhodamine, which are considered to be the earlier classes of fluorescent labeles.50 They are 
easy to use because of the well-established standard protocols for conjugation and their 
availability. In spite of the popularity of organic dyes, some of them can have certain 
limitations, like poor photochemical stability and a low photobleaching threshold which 
decreases their sensitivity and limits the trafficking lifetime.51 Stokes shifts of organic dyes, 
measured as a difference between the maximum of excitation and emission peaks, normally 
range between <50 nm.52 The poor separation of the absorption and emission spectra 
together with their broad profiles may favour the cross-talk between different dye 
molecules. The small size of organic dyes minimizes possible steric hindrance which could 
interfere with the function of a labeled biomolecule. However, in the biological environment, 
some of even small organic dyes cause aggregation due to their high hydrophobicity. The 
latter issue of rhodamine or cyanine dyes was overcome via their sulfonation and generation 
of more hydrophilic, relatively new fluorescent molecules called Alexa dyes.53,54  
Together with the development of the material science, new labeling agents have evolved 
and started gaining the popularity due to their better optical properties compered to organic 
dyes.51 For example, fluorophore-tagged latex/silica nanobeads have become a good 
alternative to commonly used fluorophores.55 By encapsulation of thousands of the organic 
dye molecules in a polymer shell, the labeled agents are less affected by environment and 
more stable to photobleeching. Still, several limitations can be associated with such a system, 
like leaking of the fluorophores through surface defects or particle agglomeration.56 
Nowadays, gold nanoclusters are considered to be another, novel ultra-small fluorophores 
with high biocompatible properties. They are much smaller than biological molecules in 
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which are entrapped and thus may have just a little effect on their functions and on their 
interaction with targeted biomolecules. Moreover, while entrapped by the biomolecule, gold 
clusters are isolated from the external environment and thus might have just a limited 
interplay with other molecules. Another advantage of AuNCs is their water solubility and 
simple preparation which follows green synthetic strategy, avoiding harmful chemicals or 
heavy metals. AuNCs exhibit good photostability, strong photoluminescence, large Stokes 
shift and size-dependent tuneable fluorescence.21 Moreover, the long emission wavelength 
of AuNCs from the red visible region to the near-infrared (IR) is highly favorable in bioimaging 
because it overlaps the tissue transparency window (650-950 nm). 
 
Template-based synthesis of gold clusters had been introduced in early 2000 which described 
the use of several biological macromolecules including dendrimers, polymers, proteins or 
even DNA for clusters formation. The first protein-directed synthesis of gold nanoclusters 
was reported by Xie and co-workers in 2009.57 In this report, commercial bovine serum 
albumin (BSA) was used as a template and led to the development of a one-pot synthesis for 
BSA-AuNCs generation. As a result, red emitting, small clusters consistent of 25 gold atoms 
were obtained with a photoemission peak at around 640 nm. Based on this strategy several 
other groups prepared BSA-AuNCs and demonstrated examples of their possible 
applications.21 Dong’s group for example, showed the utility of as synthesized BSA-AuNCs as 
a fluorescent probe for the detection of glucose58, while Huang and coworkers further 
functionalized BSA-AuNCs with folic acid for in vitro and in vivo tumor-targeted imaging.59  
The ease of the synthesis and the attractive, potential bio applications of BSA-derived gold 
nanoclusters promoted the investigation of alternative proteins for the protein-template 
assisted synthesis of AuNCs. Geckeler60 and one year later Yu-Chie Chen45 prepared gold 
nanoclusters (AuNCs@ew) with inexpensive chicken egg white proteins (CEW) directly 
separated from egg and the latter have successfully applied them for the sensing of 
polyphosphates and Concananalin A (ConA). At this point it is known, that the preparation of 
nanoclusters is mainly dependent on the amino acid composition of the protein which is used 
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as a template. It acts as both, reducing and stabilizing agent but also restricts the size of the 
gold nanoclusters by preventing their further growth and expansion into larger 
nanoparticles.61 Template protein which can be successfully applied for the generation of 
AuNCs with red photoluminescence have to carry sufficient numbers of certain amino acids, 
such as cysteine and tyrosine residues which are able to reduce Au (III) into Au (I) and Au (0) 
and thus promote cluster formation. 59,45  
 In the first part of this section we will discuss the synthesis of OVA-derived AuNCs and their 
detailed characterization, including UV-Vis and fluorescence spectroscopy, dynamic light 
scattering (DLS) or transmission electron microscopy (TEM). Finally, based on the knowledge 
acquired during the OVA-AuNCs synthesis we will present the synthesis of first glycoprotein 
gold nanoclusters (OVA-G0-AuNCs) and discuss possible biological applications of glycan 
derived clusters exemplified by the DCs uptake study analyzed by confocal microscopy. 
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4.7. Synthesis of OVA-AuNCs 
 
Here the preparation of G0-OVA-AuNCs based on prior experiments employing native OVA 
are described.  
In a typical experiment, protein-derived gold nanoclusters are generated by the addition of 
tetrachloroauric (III) acid (HAuCl4. 3H2O) to a highly concentrated aqueous solution of protein 
under vigorous stirring. After several minutes, the pH of reaction is adjusted to 10 or higher 
with sodium hydroxide (NaOH) and the mixture is incubated in the dark at 37 °C (Figure 12). 
Generated AuNCs are subsequently dialyzed over water to remove excess of reagents.57 62 
 
 
Figure 12. Schematic representation of OVA gold nanoclusters (OVA-AuNCs) synthesis starting with 
OVA protein and HAuCl4. 3H2O followed by addition of sodium hydroxide; the bottom left picture 
correspond to OVA protein and bottom right picture to OVA gold nanoclusters, both under UV lamp 
irradiation (365 nm). 
 
After revision of the literature we studied several synthetic strategies for the generation of 
OVA-AuNCs.57,59,60,63 A major aim in the optimization of an experimental protocol was to 
reduce amount of protein or more importantly precious OVA glycoconjugates required for 
the efficient formation of fluorescent clusters.  
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To this end we investigated the effect of different OVA concentrations (15, 10, 5, 2.5, 1.25 
and finally 0.65 mg mL-1) on protein gold cluster formation. The final concentrations of 
HAuCl4. 3H2O (4.2 mM) and NaOH (150 mM) as well as the reaction temperature (37 °C) were 
kept unchanged. After overnight incubation at 37 °C in the dark, the fluorescence of the 
reaction mixtures was measured as an indicator of clusters formation (Figure 13). The highest 
fluorescence intensity was recorded at 15 mg.mL-1 of OVA concertation, followed by 10 
mg.mL-1, which was further considered to be the minimal amount of protein required to 
generate fluorescent clusters. Unlike samples 1-2 (Figure 13B), OVA-AuNCs synthesized at 5 
mg.mL-1 OVA concentration exhibited no visible or very low fluorescence emission (Figure 
13C, pink line). 
 
Figure 13. Optimization of the OVA-AuNCs synthesis; A. Picture of the OVA-AuNC solutions under UV 
light illumination (365nm); B. Amounts of OVA used during the synthesis; C. Fluorescence emission 
spectra of OVA-AuNCs at six different concentrations of OVA used.  
 
Knowing that gold clusters exhibit size-tunable fluorescence which disappears with increased 
size of the gold core we have recorded the UV-vis spectra of three reactions (Figure 14). 
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Unlike AuNCs, the larger gold nanoparticles interact with incident electromagnetic fields 
resulting in the excitation of localized surface plasmon resonance (LSPR) that prompts light 
scattering and absorption at ~520 nm.  
 
Figure 14. A. UV-visible spectra of OVA clusters generated with different amounts of protein; B. 
Zoomed view in the region of 400-600 nm shows the plasmon band at 520 nm for molecules generated 
with 5 mg.mL-1 of OVA (pink line).  
 
The presence of LSPR observed only in the sample at 5 mg.mL-1  (Figure 14B) can explain the 
absence of fluorescence due to the increased gold core size from cluster (up to 3 nm) into 
nanoparticle range.  
Finally, analyzed samples formed with less amount of OVA (2.5-0.65 mg.mL-1) lack the 
fluorescence suggesting no cluster formation. Moreover, after freeze-drying and re-
suspension in water an important precipitate was observed, indicating lack of stability of 
created systems. 
 
In order to accelerate the synthesis of OVA-AuNCs, its preparation has been alternatively 
investigated applying the microwave irradiation.45,63 Based on the previous experiment 
(Figure 13) we have investigated the influence of the temperature, reaction time and the 
amount of gold (III) chloride trihydrate added to the 15 mg.mL-1 solution of OVA (Figure 15A, 
entries 1-5). Solution of protein in water was placed in a microwave vial followed by addition 
of 0.1M HAuCl4. 3H2O (different concentrations, see Figure 15A). The reaction mixture was 
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allowed to incubate under vigorous magnetic stirring at 37 °C for 5-10 minutes. After this 
time 1M NaOH (150 mM) was added and the vial was placed in the microwave for 6 minutes 
at either 100 °C or 70 °C.59 After heating, the fluorescence emission of different reaction 
mixtures was measured. As a result, the strongest fluorescence intensity was recorded in the 
sample 1 (Figure 15, B-C) containing 4.2 mM HAuCl4. 3H2O and heated to 100 °C. 
Subsequently, in order to establish the optimal time of the microwave-assisted reaction, we 
have employed heating cycles of 3, 6, 9 and 18 minutes (Figure 15, D). 
 
 
Figure 15. Microwave assisted synthesis of OVA-AuNCs, A. Table with conditions used during the 
study; B. Picture of the OVA-AuNCs solutions under UV light illumination (365nm); C. Fluorescence 
emission spectra recorded for six reactions with different conditions applied; D. Fluorescence emission 
spectra recorded at different reaction times. 
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Already after 3 minutes the fluorescence intensity reaches maximum and after another 3 
minutes it shifts from 650 nm to longer wavelengths (670 nm) while the intensity remains 
unchanged. It is reported in the literature by Xie and coworkers, that a shift of the 
fluorescence emission maximum into shorter wavelengths correspond with formation of 
larger size AuNCs.64 When longer time of heating was applied (Figure 15D, 18 minutes) partial 
decrease of the fluorescence was observed which could be associated with overheating and 
decomposition of part of clusters or to the partial generation of larger gold nanoparticles. As 
a result, in order to obtain the maximum of fluorescence and the smallest clusters possible 
we have chosen heating cycle of 6 minutes for the next experiments.  
A mechanism of AuNCs formation has been proposed by Xie and coworkers57 who postulated 
that upon addition of Au (III) ions to the aqueous protein solution, the protein molecules 
sequesters Au ions and entraps them. The reduction ability of protein is activated by the 
addition of NaOH, and the entrapped Au ions undergo progressive reduction to form AuNCs 
in situ. The amino acid involved in the gold clusters formation have been suggested to be 
cysteine, threonine and tryptophan.60 It has been reported that tyrosine reduces Au(III) to 
Au(I) by their phenol groups and their reduction capability can be strongly improved by 
adjusting of reaction pH above the pKa of tyrosine (~10).65 Tryptophan moieties can also 
reduce metal ions in alkaline medium, after deprotonation of its indole group and they have 
been found to be the strongest reducing amino acid for gold in protein AuNCs formation.66 
On the other hand, cysteine residues have been reported to facilitate the formation of Au(I) 
thiolate polymers based on their reduction capability of thiol groups.64 But additionally thiol 
groups of cysteine residues have been suggested to play important role as stabilizer for the 
nanocluster due to the known interaction between gold and sulfur atoms. 
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4.8 Characterization of OVA-AuNCs 
 
In this section the detailed characterization of AuNCs will be described. The optical properties 
of AuNCs were characterized by UV-vis absorption and fluorescence emission 
measurements. Additionally, the size of AuNCs was determined using transmission light 
microscopy (TEM), dynamic light scattering (DLS) and MALDI-TOF spectrometry. 
 
In the daily light OVA-AuNCs exhibit pale brown color and under UV light illumination (365 
nm) emit an intense fluorescence (670 nm). The spectral characteristics of OVA-AuNCs are 
given in the Figure 16. UV-vis spectrum of OVA-AuNC lacks LSPR at 520 nm suggesting the 
absence of gold nanoparticles larger than 3 nm. The solution of clusters exhibits an 
absorbance shoulder at 278 nm, which correspond to the absorption from the aromatic 
residues (tryptophan and tyrosine) and disulfide bond of native protein (Figure 16, A).67,58 In 
comparison to OVA the absorbance band of OVA-AuNCs slightly differs by more monotonous 
increase towards shorter wavelengths, which can be explained by the conformational 
changes of OVA during OVA cluster generation.68 
 
The emission spectrum of OVA-AuNCs (Figure 16, B) displays a maximum around 670 nm 
approaching the near-IR region (range between 700 nm to 1.1 µm) upon excitation at 350 
nm. It is worth mentioning that the excitation peak of AuNCs is quite broad and the Stoke 
shift large (above 200 nm). These spectral properties allow for the simultaneous excitation 
of AuNCs with other fluorescent probes at single excitation wavelength and their further 
discrimination based on the different fluorescent emission spectra.69 This spectral multicolor 
detection is also known as multiplexing.52 With a violet laser diode for example, blue-
fluorescent dye Alexa Fluor ® 405 and red-fluorescent OVA-AuNCs could be both excited at 
~400 nm and would emit at 421 and 670 nm respectively with no spectral overlap. 
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Figure 16. A. UV-visible spectra of OVA (green line) and OVA-AuNCs (violet line) and image of OVA and 
OVA-GNCs solutions under visible illumination (left) and UV light illumination (365 nm) (right); B. 
Fluorescence excitation (blue line) and emission (violet line) spectra of OVA-AuNCs; C. Agarose gel 
(0.75%) of a) OVA protein stained with Coomassie Brilliant Blue G-250; b) OVA-AuNCs under the UV 
light illumination. 
 
OVA-AuNCs were further analyzed by agarose gel electrophoresis using as standard a 
solution of OVA protein. The band corresponding to OVA was stained by Coomassie Brilliant 
Blue G-250 and exhibited very similar electrophoretic mobility that OVA-AuNCs band 
visualized under UV lamp illumination (Figure 16C). This feature indicates that both OVA and 
OVA-AuNCs have similar size and as they migrate to the positive pole, both samples are 
negative in charge.  
 
 
CHAPTER 4 Targeting of DCs 
 
 
221 
A size estimation of synthesized OVA-AuNCs was achieved by different techniques, as 
summarized in Figure 17. Dynamic light scattering (DLS) has been used to measure the 
hydrodynamic radius of OVA-AuNCs, which includes the inorganic gold core, protein coating 
and the solvent layer (Figure 17, A). 
 
 
Figure 17. Characterization of the OVA-AuNCs; A. DLS of OVA protein (green line) and OVA-AuNCs 
(violet line); B. TEM image of OVA-AuNCs; C. MALDI-TOF spectrum of OVA-AuNCs with the zoom view 
in the region 1800-2400 m/z. 
 
Remarkably, the size difference between OVA (6.5 nm) and OVA-AuNCs (8.7 nm) of about 2 
nm corresponds well with the expected size of the gold core. This also suggests that the ratio 
of gold core to OVA is around 1:1. The samples were measured at high salt concentrations 
(0.1 M NaCl) and adjusted protein concentration (5 mg.mL-1) in order to avoid OVA 
aggregation. 
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The size of the inorganic core was further confirmed by transmission electron microscopic 
(TEM) image, giving an average size of gold clusters of 1.91 ± 0.76 nm (Figure 17, B). 
Additionally, OVA-AuNCs were studied by MALDI-TOF spectrometry (Figure 17, C) using 
sinapic acid as matrix and the spectra were acquired in reflection mode. MALDI-TOF 
spectrum showed signals with m/z values between 985.5 to 4334.4 corresponding up to 22 
gold atoms per gold cluster, stabilized by cysteine thiolate groups of the protein (Figure 17, 
C). The gold core size corresponds to the described “magic number“ sizes for AuNCs, with 2, 
3, 5, 8, 10, 15, 18, 22, 25, 29, 33, etc. gold atoms/cluster depending on the synthetic strategy 
applied.67 Intact OVA-AuNCs could not been detected by MALDI-TOF, suggesting that the 
protein may be detached from the core upon ion formation. This behavior of the protein-
derived AuNCs had been reported on the example of clusters generated with molecules 
containing low numbers of cysteines like RNAse (8 Cys).67 In contrary, AuNCs stabilized with 
BSA carrying 35 cystein residues have been previously detected by MALDI-TOF.59 OVA 
contains four free cysteine residues and one disulfide bond, perhaps an insufficient number 
to stabilize the OVA-AuNCs during ion formation. 
 
To clarify the binding between OVA protein and gold cluster as well as to establish the 
oxidation state of the inorganic gold core of the clusters, X-ray photoelectron spectroscopy 
(XPS) was performed (Figure 18). This technique allows the measurement of binding energies 
for all elements present in the cluster and the comparison with binding energies of reagents 
used during the reaction, such as HAuCl4. 3H2O and native OVA. Figure 18 shows XPS spectra 
of HAuCl4. 3H2O (A) and OVA-GNC (B). As expected, HAuCl4. 3H2O shows the typical binding 
energy for gold 4f Au(III) at 85.5 eV (Figure 18, A). Once OVA-stabilized AuNCs are formed, 
the binding energy of gold 4f Au(III) shifts to 84.3 eV indicating reduced state of gold in OVA-
AuNCs (Figure 18, B). According to the literature this value can be assigned to a mixture of 
Au (I) and Au (0) species.57,70  
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Figure 18. X-ray photoelectron spectra (XPS) of HAuCl4. 3H2O, OVA solution and OVA-AuNCs A. Au 4f 
region for solid HAuCl4. 3H2O B. Au 4f region of OVA-AuNCs solution C. S 2p region of OVA solution D. 
OVA-AuNCs solutions.  
 
Regarding the protein alone, sulfur S 2p region in native OVA (Figure 18, C) is resolved into 
two species: one with binding energies at 163.4 eV assigned to S-H (S-C) groups of cysteines 
and other at 166.7 eV, which corresponds to the oxidized sulfur species, like disulfide bound 
(S-S).71 For AuNCs (Figure 18, D) there is a visible shift observed in the binding energy assigned 
to the first species (S-H) into the lower values of 162.3 eV which can indicate Au-S-C-S bound 
formation.67,72,73 The maximum corresponding to the oxidized sulfur species stays 
unchanged. To summarize, the XPS analysis revealed the presence of Au(I) and Au(0) atoms 
and an involvement of the thiol groups of cysteine moieties in reducing Au during formation 
of AuNCs. 
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Knowing that OVA protein is attached to the gold core of clusters via cysteine resides as 
suggested by MALDI-TOF and XPS analysis, we have investigated a potential influence of the 
cluster generation on the secondary structure of OVA protein by circular dichroism (CD, 
Figure 19). Each regular secondary structure found in the protein has its own characteristic 
CD spectrum.74 The broad negative band recorded for native OVA contains two peaks at 
around 208 and 222 nm characteristic for the alpha-helical structure of protein. Generation 
of OVA-AuNCs (Figure 19, violet line) causes irreversible changes in the structure of OVA 
demonstrated by a blue shift in the CD spectrum, a very low ellipticity above 210 nm and 
negative band around 195 nm.75 Upon gold reduction and cluster formation OVA adopts a 
more irregular and disordered structure.  
 
Figure 19. Circular dichroism (CD) spectra of OVA 
solution (green line) and OVA-AuNCs (violet line) 
indicating conformational changes in the native 
protein compared to the OVA bound and 
stabilizing gold clusters. 
 
Previous studies on gold nanoparticle have also reported a partial loss of the albumin 
secondary structure upon absorption on the surface of nanoparticle.68,67 Thus the observed 
changes in the CD of OVA-AuNCs might indicate an attachment of protein to the gold surface 
but also could be caused by the harsh reaction conditions involving 1M NaOH and heating 
for clusters formation. Recently, a preparation of protein stabilized gold nanoclusters under 
mild reaction conditions that maintains the secondary structure and functionality of proteins 
attached to gold core was reported, which opens new possibilities regarding synthesis of OVA 
stabilized AuNCs.76  
In this section, we have optimized the synthesis and characterized OVA-AuNCs using different 
techniques. Spectroscopic characterization of OVA-AuNCs was performed by UV-vis and 
fluorescence measurements. The size of OVA-AuNCs was estimated by agarose gel and DLS. 
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The size of gold core was assigned by TEM and MALDI-TOF. Oxidation state of gold core was 
assigned to a mixture of Au(I) and Au(0) species based on XPS measurements. Protein 
secondary structure and protein oxidation state was studied by CD and by XPS, respectively.  
 
4.9 Preparation of glycoconjugate OVA-AuNCs 
 
Having in hands fully characterized OVA-AuNCs and having established a synthetic strategy 
towards their generation, we investigated the preparation of AuNCs with OVA 
glycoconjugates. Based on the DCs cell uptake studies described in the first part of this 
Chapter, we have chosen G0-OVA conjugates as first candidate towards glycoprotein-based 
AuNCs generation (Figure 20). Applying microwave-assisted synthesis optimized in section 
4.7, we efficiently synthesized sufficient amount of G0-OVA-AuNCs on a mg scale which 
allowed further characterization and a first biological assay. 
 
 
Figure 20. Schematic representation of the G0 glycan-derived OVA-AuNCs generation. 
 
To investigate a possible influence of the sugar on the physical properties of G0-OVA-AuNC, 
we have measured its UV-visible absorption spectrum, the fluorescence emission spectrum 
and determined the gold core size by TEM. The results are summarized in Figure 21.  
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Figure 21. Characterization of G0-OVA-AuNCs; A. UV-visible spectra of OVA-AuNC (violet line) and G0-
OVA-AuNC (blue line); B. Fluorescence emission spectra of OVA-AuNCs (violet line) and G0-OVA-AuNCs 
(blue line); C. TEM image of G0-OVA-AuNCs D. Size distribution of gold core diameter of G0-OVA-
AuNCs. 
 
The absorption UV-vis and fluorescence emission of G0-OVA-AuNCs were identical to OVA-
AuNCs with characteristic absorbance at 278 nm and red fluorescence emission with 
maximum around 670 nm (Figure 21 A-B). The size of G0-OVA-AuNC gold core was 
established based on TEM image showed an average diameter of 1.61 ± 0.49 nm (Figure 21 
C-D) comparable to the size of OVA-AuNCs (1.91 ± 0.76 nm). The spectral characteristics and 
size of glycan derived AuNCs demonstrated that the glycan conjugation to OVA did not 
influence gold nanocluster formation.  
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To further investigate possible impact of the sugar structure and/or the number of glycan 
attached to OVA on the generation and optical properties of protein stabilized gold 
nanoclusters, we performed the synthesis with different numbers of G0 glycan conjugated 
to OVA protein (2-3 or 5-6 copies) and applying XG0-OVA glycoprotein, with the same ligand 
valency as starting G0-OVA (3-4) but with additional 2-O-xylose core modification on N-
glycan (Figure 22).  
 
Figure 22. Spectral characterization of glycan modified OVA-AuNCs; A. Excitation (blue lines) and 
emission spectra of XG0-OVA-AuNCs (pink), G0-OVA-AuNCs with 3-4 sugars (green) and G0-OVA-
AuNCs with 5-6 sugars (orange); B. Comparison of UV-visible spectra of glycan modified OVA-AuNCs. 
 
As shown on Figure 22 we did not observe any measurable effect of the sugar structure or 
its valency (measured up to 6 ligands) on the formation and optical properties of the gold 
nanoclusters. It can be speculated that the glycan moieties which are conjugated to OVA by 
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DSS linker through the free amine groups of either lysine moieties or OVA N-terminus do not 
affect the reduction properties of glycoproteins which, as mentioned before, are based on 
tryptophan, tyrosine and cysteine residues. Additionally, sugars seem not to hamper 
formation of S-Au bond even while presented in higher number (5-6 copies). 
It is also important to remember that beside N-glycans occupied lysine moieties, other 
important functional groups, like hydroxyl, carboxylic and remaining amino groups are still 
available for site-specific labeling. It opens whole new possibilities of conjugations other 
components to the system and its further evolution and improvement. 
 
Similar to protein-derived AuNCs, glycan-OVA-AuNCs generated during the study are highly 
fluorescent and biocompatible due to their size, water solubility and emission in the range of 
near-IR. Interestingly, unlike the purely protein-stabilized clusters, glycoprotein-AuNCs can 
potentially benefit from the presence of sugar moieties by exhibition of intracellular 
targeting properties mediated through the C-type lectin receptor endocytosis. The ability to 
track the biomolecule inside the cell is an important property for any fluorescent dye. 
Additionally, use of glycan containing AuNCs can find a direct application as a sensing probes 
for glycan binding proteins, like plant lectins. A first successful example of use AuNCs as a 
sensing probe for plant lectins was given by Chen and co-workers who described the 
quantitative analysis of ConA applying OVA-AuNCs by measuring the loss of fluorescence 
upon creation of the OVA-AuNCs-ConA complexes.45 ConA is specific towards high mannose 
structures which predominantly substitute the Asn-292 glycosylation site of OVA protein.26 
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4.10 Biological application of glycoconjugate OVA-AuNC. Targeting of DCs 
 
Prior to biological assays the stability and solubility of OVA-AuNCs were evaluated in a 
solution of fetal bovine serum (FBS), the most common used serum-supplement for in vitro 
cell culture. Freeze-dried OVA-AuNCs were easily re-suspended in 10% solution of FBS in PBS 
buffer and left overnight at 37 °C. After this time, fluorescence emission was recorded (Figure 
23). The spectrum of OVA-AuNCs did not show any significant change in the emission, neither 
in the fluorescence peak maximum nor in the fluorescent intensity when compared to 
starting OVA-AuNCs, suggesting that cluster are stable over the studied time in the presence 
of FBS. 
 
 
Figure 23. Fluorescence emission spectra of OVA-AuNC 
(violet continuous line) and OVA-AuNCs after incubation 
with 10% FBS (violet dashed line). 
 
 
 
 
Taking advantage of the good bio-stability of OVA-AuNC in FBS solution, their imaging 
properties and previously demonstrated DCs targeting capability of G0 N-glycan, we were 
encouraged to study a possible in vitro biological application of G0-OVA-AuNCs by their 
uptake by murine DCs. 
We have isolated murine CD11c+ DCs from C57BL/6J mice following procedure described in 
section 4.4.1, seeded them on poly-D-lysine-coated glass cover-slips and pulsed with G0-
OVA-AuNCs. The glass slide was washed to remove unbound clusters, DCs were fixed and the 
confocal measurements were performed. Figure 24 shows fluorescence images taken after 
40 minutes of incubation. A negative control representing CD11c+ DCs was also included. 
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Strong fluorescence could be clearly observed in the sample incubated with G0-OVA-AuNCs, 
suggesting their uptake by murine DCs. Similar results had been obtained with analogue, 
Alexa Fluor ® 647 labeled glycoconjugate. In this study, it was demonstrated that the 
developed system is suitable for in vitro uptake assays and that the glycoprotein gold 
nanoclusters are an interesting alternative to the use of organic dyes in cell assays. 
 
Figure 24. Uptake of fluorescent G0-OVA-AuNCs by murine DCs measured by confocal fluorescence 
microscopy. 
 
Changes in the secondary structure of OVA protein during the AuNCs formation (CD) did not 
influence the DCs targeting capability of G0-OVA-AuNCs. Native OVA can be internalized by 
the DCs through receptor-mediated endocytosis, including mannose receptors recognizing 
sugars on OVA surface and through scavenger receptors which recognize negatively charged 
proteins.77 Moreover, sugar modified clusters G0-OVA-AuNCs are targeted to the murine DCs 
through C-type lectins receptors described in the section 4.3 of this Chapter and thus 
conformational changes of protein should not play a role in the cluster internalization. 
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4.11 Summary 
 
In this Chapter, we have shown the utility of glycoconjugates decorated with sugars selected 
on the basis of the microarray study described in the Chapter 2 (section 2.3.3, screening of 
DC-SIGN) for DCs targeting. A biantennary N-glycan G0 and its analogous O-2 core xylosylated 
N-glycan XG0 were synthesized, covalently conjugated to the model antigen ovalbumin 
(OVA) and analyzed for binding to a set of murine CLR-Fc fusion proteins using lectin 
microarray technology. We further evaluated if the differential binding of G0 and XG0 to 
murine SignR3 receptor has an impact on dendritic cell targeting. First, the uptake of 
fluorescently labeled glycoconjugates by DCs was followed by confocal microscopy and 
second, effects of the ovalbumin glycoconjugates on T cell activation were measured in a 
DC/T cell co-cultivation assay. Our results showed that both xylosylated and non-xylosylated 
biantennary N-glycans enhanced the uptake and presentation of OVA and, more importantly, 
G0-OVA conjugates were internalized better than the other two. This demonstrates that even 
small structural glycan modifications can have a marked impact on uptake by DCs and 
subsequent T cell activation. Knowing that the G0-OVA glycoconjugates enhanced the uptake 
by DCs, in the second part of this Chapter, we described the preparation and characterization 
of OVA-G0 AuNCs that combine glycan mediated targeting, the immunogenic properties of 
OVA protein and imaging properties of fluorescent gold clusters in a single entity. The 
preparation and characterization of AuNCs was optimized using unconjugated OVA protein 
as a reducing and stabilizing agent. Later, the optimized conditions were applied to G0-OVA-
AuNCs generation. We have subsequently synthesized three other OVA-glycan-derived 
AuNCs, applying XG0-OVA and G0-OVA with different sugar valency. We did not observe an 
influence of the glycans on the measured optical properties of the clusters. Finally, we had 
successfully applied G0-OVA-AuNCs as a fluorescent probe in an in vitro uptake study utilizing 
murine DCs.  
Based on the C-type lectin receptors specifically recognizing certain glycan ligands, glycan 
modified AuNCs have a big potential as an efficient and specific targeting fluorescent probe 
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for in vitro and in vivo imaging.  Moreover, they can find an application as a sensing probes 
for glycan binding proteins, including plant lectins but also other biologically relevant 
molecules. 
 
4.12 Experimental Part 
 
General Methods 
 
Materials: LPS-free ovalbumin was purchased from Hyglos (Bernried, Germany). Gold (III) 
chloride trihydrate and sodium hydroxide were purchased from Sigma Aldrich. 
Glycoconjugates were labeled with Alexa Fluor® 647 NHS ester from Thermo Fisher Scientific. 
Dialysis of glycoconjugates was performed on Slide-Z-lyser TM dialysis cassettes (10K) from 
Thermo Fisher Scientific. All aqueous solutions were prepared with nanopure water 
produced won a Diamond UV water purification system (Branstead International, IA, Madrid, 
Spain). Murine-hFc C-type lectins were construct and expressed in the laboratory of Prof. Dr. 
Bernd Lepenies as previously described. 23 
MALDI-TOF mass spectrometry was controlled by FlexControl 3.3 software (Bruker 
Daltonics). Lectin microarrays were prepared using NHS activated glass slides, Nexterion® H 
(Schott AG, Mainz, Germany). Lectin microarrays were printed employing a robotic non 
contact piezoelectric SciFLEXARRAYER spotter S11 (Scienion, Berlin, Germany). Lectin 
microarrays were compartmentalized with 16 Well ProPlate Module 7 x 16 mm Well from 
Electron Microscopy Sciences. Fluorescence was measured using an Agilent G265BA 
microarray scanner system (Agilent Technologies) and quantification was performed with 
ProScanArray Express software (Perkin Elmer) with an adaptive circle quantification method 
(spot diameter: 50-300 µm). Histograms represent median RFU values with local background 
subtraction. 
IMDM medium was supplemented with 2 mM L-glutamine, 100 U/mL penicillin, 100-μg/mL 
streptomycin and 10% fetal calf serum (FCS) purchased from PAN Biotech. Dendritic cells 
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(CD11c+ cells) were isolated from a suspension of C57BL/6 murine spleen cells by magnetic-
activated cell sorting using CD11c+ MicroBeads (Miltenyi, Bergisch-Gladbach, Germany) and 
OT-II T cells using the Pan T Cell Isolation Kit II (Miltenyi Bergisch-Gladbach, Germany). 
Monoclonal antibodies against CD11c (APC), CD3e (APC), CD19 (PE), CD4 (FITC), CD8 (APC-
H7) were purchased from eBioscience. Fluorochrome-conjugated monoclonal antibodies 
against CD69 (PE), CD4 (Alexa Fluor 700) were purchased from eBioscience and BD 
Pharmingen (Cowley, UK), respectively. The flow cytometric analysis was performed on a 
FACS Canto II flow cytometer (BD Biosciences, Heidelberg, Germany). Data were analyzed 
using FlowJo analysis software (Tree Star, Ashland, OR). Fluorescent images were taken using 
a Zeiss LSM 510 laser scanning confocal microscope (Carl Zeiss, Oberkochen, Germany) 
equipped with a red helium-neon (HeNe633) laser and UV laser (364 nm) and a 63×oil 
immersion objective. The measurement of cytokines IL-2 and IFN-γ in the supernatants after 
48 and 72h was performed according to the manufacturer’s instructions (PeproTech, 
Hamburg, Germany). Plates were developed with a solution of tetramethyl benzidine (Ultra 
TMB-Elisa Substrate Solution, Thermo Scientific). After a few minutes, 2M sulfuric acid 
solution was added to stop the reaction. Absorbance was measured at 450 nm using an ELISA 
reader (Tecan). 
 
Microwave-assisted synthesis of gold nanoclusters was carried out in a Biotage Initiator 
microwave reactor with microwave reaction vials of a total volume 0.2-0.5 mL. Fluorescence 
spectra of OVA-AuNCs and OVA-glycan-AuNCs were measured on a Varioskan Flash (Thermo 
Scientific) operating with a ScanIt Software, using NUNC MaxiSorp Polystyrene Black 96 or 
384 Well plates. UV-visible spectra were obtained on a NanoDrop ND-1000 
spectrophotometer. Circular Dichroism was recorded using Jasco J815 spectrometer. 
 
XPS Surface analysis by XPS was performed in a SPECS SAGE HR 100 system spectrometer in 
an ultrahigh vacuum (UHV) chamber. The X-ray sources employed for this analysis were an 
non monochromatic Mg Kα (1253.6 eV) and 250 W or Al Kα operated at 1.25 kV and 300W, 
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calibrated using the 3d5/2 line of Ag with a full width at half maximum (FWHM) of 1.1 eV. The 
take- off angle was fixed at 90º and the analysis was conducted at a pressure of ~10-6 Pa. 
Surfaces were brought into the XPS chamber within 5 min after cleaning/preparation. The 
selected resolution for the spectra was 30 eV of Pass Energy and 0.5 eV/step for the general 
survey spectra and 15 eV of Pass Energy and 0.15 eV/step for the detailed spectra of the 
different elements. Spectra were analyzed with the CasaXPS 2.3.15dev87 software. The 
analysis consisted of satellite removal, Shirley background subtraction, calibration of the 
binding energies related to the C 1s C-C peak at 285 eV, and asymmetric peak fitting with 
Gaussian-Lorentizan line shapes where the FWHM of all the peaks were constrained while 
the peak positions and areas were set free. Samples are prepared by dehydration on clean 
titania substrates where titania is selected as a substrate to avoid any possible overlap of 
gold signal with signal of silica coming from wafer or glass. HAuCl4 salt is measured as 
received in custom made powder holder. 
 
TEM imaging was conducted on a JOEL JEM-2100F field emission TEM with an accelerating 
voltage of 200 kV. AuNCs solutions were drop-cast onto copper TEM grids coated with 
ultrathin carbon support (Ted Pella, Redding, USA). The average gold nanoclusters diameter 
was quantify using ImageJ (Java). Dynamic light scattering (DLS) was performed at fixed 
scattering angle of 90º on a Malvern Zetasizer Nano ZS applying 0.1M NaCl and solutions 
were sonicated before measurement.  
 
Mice 
Dendritic cells isolated from C57BL/6 mice and T cells isolated from OT-II transgenic mice 
(own breeding at the Federal Institute of Risk Assessment (BfR), Berlin, Germany) were used 
in all experiments except for the confocal microscopy studies where dendritic cells isolated 
from C57BL/6J mice (CIC biomaGUNE, San Sebastian, Spain) were used. 
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Synthesis of ovalbumin-glycoconjugates 
 
G0-OVA: Disuccinimidyl suberate (DSS) linker (6.8 mg, 18.46 µmol, 13 eq.) was dissolved in 1 
mL of DMSO (18.4 mM) and activated with 15 µL of triethylamine. The biantennary N-glycan 
(2 mg, 1.42 µmol) was dissolved in 0.3 mL of DMSO and added dropwise to the linker solution. 
The reaction was stirred at RT for 90 min. The product was extracted with 800 µL PBS (pH 
7.4), washed 3 times with chloroform and centrifuged at 3000g to facilitate phase separation. 
Attachment of DSS linker to N-glycan was confirmed by MALDI-TOF mass spectrometry. G0-
DSS (40 eq.) was added to 1.25 mg of OVA and the reaction was incubated overnight at RT. 
Sample was concentrated in a 10K Amicon filter device and dissolved in sterile PBS.  
 
XG0-OVA: DSS linker (7.4 mg, 20 µmol, 17 eq) was dissolved in 1.1 mL of DMSO (22 mM) and 
activated with 15 µL of triethylamine. The xylosylated biantennary N-glycan (2.15 mg, 1.2 
µmol) was dissolved in 0.3 mL of DMSO and added dropwise to solution of linker. The 
reaction was stirred at RT for 90 min. The product was extracted with 800 µL PBS (pH 7.4), 
washed three times with chloroform and centrifuged at 3000g. The attachment of DSS linker 
to N-glycan XG0 was confirmed by MALDI-TOF mass spectrometry. XG0-DSS (40 eq.) was 
subsequently added to 1.25 mg of OVA and reaction was left stirring overnight at RT. The 
sample was concentrated in a 10 kDa Amicon filter device and dissolved in sterile PBS.  
 
Alexa Fluor®-647 labeling of ovalbumin and ovalbumin glycoconjugates 
 
400 µL of 10 [mg/mL] solutions of OVA, 70 µL of 10 [mg/mL] XG0-OVA and 86 µL of 10 
[mg/mL] G0-OVA in sodium bicarbonate buffer (100 mM, pH=9) were prepared. 
Subsequently 50, 12 and 15 µL of 10 [mg/mL] Alexa Fluor®-647 NHS ester were added and 
reaction mixtures were gently shaken at RT for a 1h (ovalbumin) or 2h (OVA-
glycoconjugates). Excess dye was removed by dialysis (10k) over water (12h) and 
glycoconjugates were concentrated by ultracentrifugation with 10kDa Amicon devices. The 
  
 
 
236 
ratio of Alexa Fluor®-647 to protein (degree of substitution, DOS) was estimated based on 
the absorbance of dye (ɛdye, 250 000 cm-1M-1) and OVA (ɛOVA, 35 900 cm-1M-1) and calculated 
based on the equation: 
 
 
Calculation of the DOS of OVA-647, G0-OVA-647 and XG0-OVA-647: 
 Amax A280 [Dye] [OVA] DOS 
OVA 7.98 0.48 6.38e-5 5.28e-6 12.1 
XG0-OVA 8.52 0.52 6.82e-5 6.12e-6 11.1 
G0-OVA 8.88 0.54 7.10e-5 6.25e-6 11.3 
 
 
Preparation of CLR microarray 
 
NHS-activated glass slides were incubated overnight with protein G solution (20 µg/mL) in 
PBS at 4°C. Each slide was washed three times with PBST (PBS containing 0.05% Tween-20), 
followed by PBS and water. Slides were dried in a slide spinner. CLR-Fc solutions were 
prepared by dilution with printing buffer (PBS, 0.01% Tween-20 and 0.1% glycerol) to a final 
concentration of 0.2 mg/mL and placed into a 384 well source plate (Scienion, Berlin, 
Germany). 0.6 nL of CLR-Fc solutions were spatially arrayed onto protein G functionalized 
glass slides in five replicate spots per C-type lectin. After printing, the slides were placed in a 
75 % humidity chamber (saturated NaCl solution) at 4°C for 2 hours. To reduce unspecific 
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binding, the slides were incubated with bovine serum albumin solution (3% BSA in PBS) for 
1h followed by the standard washing procedures with PBST, PBS and water.  
 
Incubation of microarrays with OVA and OVA glycoconjugates 
 
CLR microarrays were incubated with solutions of Alexa Fluor®-647 labeled OVA and 
glycoconjugates (XG0-OVA and G0-OVA) at a final concentration of 50 µg/mL in binding 
buffer (PBS, 0.01% Tween-20, 5 mM CaCl2, 5 mM MgCl2, 1% BSA). After overnight incubation 
at 4˚C, arrays were washed with PBS, water and dried in a slide spinner. Fluorescence was 
measured in a microarray scanner. 
 
Isolation of spleen cells subset 
 
To isolate splenocytes, spleens were flushed with IMDM medium supplemented with 2 mM 
L-glutamine, 100 U/mL penicillin, 100-μg/mL streptomycin and 10% fetal calf serum (FCS). 
The cell suspension was kept cold and filtered through a 40 μM cell strainer to remove cell 
aggregates. After centrifugation (300 g, 5 min, 4°C), cell pellets were resuspended in 5 mL of 
freshly prepared erythrocyte lysis buffer (10% 100 mM Tris pH 7.5 + 90% 160 mM NH4Cl), 
mixed gently and incubated at RT for 2 min. Cells were washed twice in complete IMDM 
medium and centrifuged before re-suspension in MACS buffer (PBS, 0.5% BSA, 2mM EDTA).  
Dendritic cells (CD11c+ cells) were isolated from suspension of C57BL/6 murine spleen cells 
by magnetic-activated cell sorting using CD11c+ functionalized MicroBeads. Cells incubated 
with magnetic microbeads were loaded on a MACS column placed in a magnetic field. 
Unbound cells passed through the column, while remaining CD11c+ cells were washed with 
MACS buffer and eluted from the column. To increase DC purity, the CD11c+ cell purification 
was repeated. The cell suspension was centrifuged, resuspended in IMDM complete medium 
and counted. T cells were isolated from spleen of OT-II transgenic mice using the Pan T Cell 
Isolation Kit II. Non-target cells were magnetically labeled with a cocktail of biotin-conjugated 
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antibodies against CD11b, CD11c, CD19, CD45R (B220), CD49b (DX5), CD105, Anti-MHC-class 
II, and Ter-119 markers followed by anti-biotin monoclonal antibodies conjugated to 
MicroBeads. Non-targeted cells were retained on the MACS column, while the unlabeled T 
cells passed through the column in the first fraction. To increase T cell purity, the purification 
procedure was repeated. Isolated T cells were subsequently centrifuged, resuspended in 
IMDM complete medium and counted. The purity of DCs and T cells isolated by MACS was 
analyzed by flow cytometry. Cells were pre-incubated with CD16/32 (Fc-Block, dilution 1:100) 
blocking antibody in 100 µL FACS buffer (PBS, 0.5% BSA, 2mM EDTA) at 4°C for 10 min. 
Subsequently, purified DCs and flow through were incubated with CD11c (APC) monoclonal 
antibody (1:100 dilution) for 30 min at 4°C in the dark. Purified T cells were incubated with 
anti-CD3e (APC) and anti-CD19 (PE) antibodies (1:100 dilution) for 30 min at 4°C in the dark. 
As a control, unstained samples were also prepared. Cells were washed with 1 mL of FACS 
buffer re-suspend in 100 µL FACS buffer and vortex before each measurement.  
 
Uptake of labeled glycoconjugates by DCs followed by confocal fluorescence microscopy 
 
DCs from C57BL/6J mice (2x106 cells) were seeded on poly-D-lysine-coated glass cover-slips 
and incubated at 5% CO2 at 37ºC overnight. Alexa Fluor®-647 labeled OVA, XG0-OVA and G0-
OVA were added to cells (10 µg/mL) and incubated for 10 min at 37°C. After incubation, cells 
were carefully washed with cooled PBS and fixed with 3% paraformaldehyde at RT for 20 
min. After washing with PBS and water, the cover-slips were mounted on slides using 
Vectashield® mounting medium (Vector Labs, Burlingame, USA) and the fluorescent images 
were taken.  
 
Uptake of labeled glycoconjugates by DCs followed by flow cytometry  
 
Purified DCs were seeded in 96-well round bottom plates (2x104 cells/well) in complete 
IMDM medium. After 30 min (37°C, 5% CO2), cells were pulsed with Alexa Fluor®-647 labeled 
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OVA, XG0-OVA and G0-OVA (10 µg/mL). After 10 min of incubation (37°C, 5% CO2), cells were 
carefully washed with cold PBS (2x) and resuspended in 100 µL FACS buffer containing 
CD16/32 (Fc-Block, dilution 1:100) blocking antibody at 4°C for 10 min. Subsequently, a 
control sample was incubated with CD11c (APC) monoclonal antibody (1:100 dilution) for 30 
min at 4°C in the dark. As a control, unstained sample was also prepared. Cells were washed 
with 1 mL of FACS buffer, resuspended in 100 µL FACS buffer and vortexed before each 
measurement.  
 
Co-cultivation of OT-II T cells with OVA-glycoconjugate pulsed DCs 
 
Purified DCs were seeded in 96-well round bottom plates (2x104 cells/well) in complete 
IMDM medium. After 30 min (37°C, 5% CO2), cells were pulsed with OVA, XG0-OVA and G0-
OVA (30 µg/mL). After 1h of incubation, 60 µL of purified T cells (7x104 cells/well) were added 
and incubated at 37°C, 5% CO2 for 48h. The expression of the early T cell activation marker 
CD69 and cytokine levels (IL-2, IFN-γ) in the supernatant were determined after 48 and 72 
hours of stimulation. 
 
Detection of CD69 by flow cytometry 
 
Expression of the T cell activation marker CD69 was analyzed by flow cytometry 48 and 72 
hours after stimulation. Fc receptors were blocked using anti-CD16/32 (dilution 1:100) in 100 
µL FACS buffer at 4°C for 10 min. Subsequently, cells were incubated with anti-CD4-AF700 
and anti-CD69-PE (1:100 dilution) for 30 min at 4°C in the dark. Cells were washed with 1 mL 
FACS buffer and analyzed in 100 µL FACS buffer. Data was analyzed using FlowJo analysis 
software. 
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Optimized synthesis of OVA-AuNCs and glycan-OVA-AuNCs 
 
General procedure for OVA-AuNCs synthesis:  
 
OVA-AuNCs: To a solution of OVA protein (15 mg/mL, 124 μL) in a microwave vial (0.1-0.5 
mL) 0.1 M HAuCl4.3H2O (5.4 μL, 4.2 mM) was added under vigorous stirring. After 5-10 
minutes, 1M NaOH was added (24 μL, 150mM) and the reaction mixture was heated under 
microwave irradiation for one cycle of 6 minutes at 100ºC. After the microwave heating 
reaction mixture turns pale brown. The solution of OVA-AuNCs was subsequently dialysed 
against water and freeze dried until use. 
 
G0-OVA-AuNCs were generated following the general procedure using a solution of G0-OVA 
glycoprotein (13.5 mg/mL, 78 μL), 0.1M HAuCl4.3H2O (2.6 μL, 4.2 mM) and 1M NaOH (15 μL, 
150mM). 
 
XG0-OVA-AuNCs were generated following the general procedure using a solution of XG0-
OVA glycoprotein (13.9 mg/mL, 98 μL), 0.1M HAuCl4.3H2O (4 μL, 4.2 mM) and 1M NaOH (19 
μL, 150mM).  
 
G0-OVA-AuNCs (2-3) were generated following the general procedure using a solution of G0-
OVA (2-3) glycoprotein (15 mg/mL, 25 μL), 0.1M HAuCl4.3H2O (1 μL, 4.2 mM) and 1M NaOH 
(4.8 μL, 150mM).  
 
G0-OVA-AuNCs (5-6) were generated following the general procedure using a solution of G0-
OVA (5-6) glycoprotein (15 mg/mL, 37 μL), 0.1M HAuCl4.3H2O (1.5 μL, 4.2 mM) and 1M NaOH 
(7.1 μL, 150mM).  
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Uptake of OVA-AuNCs and glycan-OVA-AuNCs by DCs followed by confocal fluorescence 
microscopy 
 
DCs from C57BL/6J mice (2x106 cells) were seeded on poly-D-lysine-coated glass cover-slips 
overnight. OVA-AuNCs, XG0-OVA-AuNCs and G0-OVA-AuNCs were added to cells (150 
µg/mL) and incubated for 40 min at 37°C. After incubation, cells were carefully washed with 
cooled PBS and fixed with 3% paraformaldehyde at RT for 20 min. After washing with PBS 
and water, the cover-slips were mounted on slides using Vectashield® mounting medium. 
Fluorescent images were taken using confocal microscope equipped with a UV laser (365 nm) 
and an 63× oil immersion objective.  
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Final Conclusions 
 
Glycans together with nucleic acids, proteins and lipids are one of the four fundamental 
macromolecular components of all cells. The tremendous complexity of glycans reflects 
their multiple and diverse biological functions as well as evolutionary fight between the 
host and the invading pathogen. From all possible glycan functions, their role in host-
pathogen interactions, by involvement in the host receptors binding and the modulation of 
the host immune responses were studied in this Thesis. We have focused our research on 
the development and use of glycan microarrays for studying the interaction of synthetic N-
glycans predominately found in parasites and plants with plant lectins, C-type lectins 
receptors and antibodies from S. mansoni infected mice and individuals living in 
schistosomal endemic areas, respectively. Based on the results obtained in the microarray 
screening, we have also explored the DC targeting potential of selected N-glycans 
conjugated to the model protein ovalbumin and studied the influence of xylose 
modification on the uptake and further activation of T cells. We have finally prepared first 
glycan modified gold nanoclusters as an attractive novel system for imaging of 
glycoconjugates.  
 
In the first part of this Thesis, we have demonstrated the chemoenzymatic synthesis of N-
glycans and showed the efficiency of this strategy towards the generation of complex and 
well defined ligands. The use of recombinant glycosyltransferases and glycosidases limited 
the numbers of required synthetic scaffolds to six structures (G1-G6) and allowed for the 
preparation of 39 core β-1,2-xylosylated N-glycans decorated with α-1,3 and/or α-1,6 core 
fucose and terminal structural elements, including LN, LDN and Lewis X motifes. 
 
In the second Chapter, we describe the construction of a focused, synthetic glycan 
microarray, containing 126 diverse glycans including core xylosylated structures 
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synthesized during this Thesis. This high throughput screening tool has allowed us to study 
carbohydrate-protein interactions using minimal amount of both, sugars and proteins in a 
relatively short time.  
The first microarray-assisted screening was performed using plant and fungi lectins of 
known general specificity but this screening already revealed the great potential of our 
glycan arrays. We could observe the influence of core xylose on the interaction of N-glycans 
with mannose binding lectins such as, Concanavalin A and Galanthus nivalis. The presence 
of core xylose reduced the interactions with ConA and completely abolished binding 
towards GNA. As this β-1,2-xylose is a common structure found on plant N-glycans, 
observed lack of binding could be rationalized by a tolerance mechanism avoiding 
interactions between plant lectins and self-glycans. 
 
Additionally, we have analyzed the carbohydrate specificity of murine and human C-type 
lectins receptors using glycan microarrays. Here, we were mainly interested in host immune 
receptors which are involved in the interactions with glycoconjugates of the helminth 
parasite S. mansoni.  We could clearly observe the binding of human MGL-1 towards LDN 
and LDNF glycan elements and DC-SIGN to set of Lewis X terminated glycan structures. Our 
results were with a good agreement to the previous reports describing MGL-1 and DC-SIGN 
as receptors able to bind S. mansoni soluble egg antigens (SEAs) expressing LDN, LDNF and 
Lewis X type of glycans. As a major result of the binding studies, however, we noted the 
difference in the binding of DC-SIGN receptor towards xylosylated and non-xylosylated 
biantennary N-glycans. Similar to the behavior of GNA lectin, the presence of core xylose 
completely abolished binding towards DC-SIGN on the glycan microarrays. Inspired by this 
finding, we have further constructed glycoconjugates bearing either xylosylated or non-
xylosylated N-glycans and analyzed their DCs targeting properties in vitro. The study was 
explored in the Chapter 4.  
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It is important to mention, that besides MGL-1 and DC-SIGN, other analyzed C-type lectin 
receptors did not show any binding towards ligands present on the microarray. Especially 
Dectin-2 which is believed to play a role in the host-S. mansoni interactions and was found 
to recognize components of SEAs. This behavior might be explained either by the absence 
of a relevant ligand on the array or by insufficient binding strength perhaps due to non 
optimal presentation of glycans and protein analyzed.  
 
In Chapter 3, we described the application of our glycan microarrays for the screening and 
characterization of anti-carbohydrate antibodies, as a complementary tool to shotgun 
arrays derived from natural glycans of different development stages of S. mansoni. The 
majority of antibodies generated during schistosomiasis are directed against antigenic 
parasite glycans. Therefore, their identification and characterization might be essential for 
the development of future carbohydrate-based vaccines or to understand the role of 
certain sugars in the course of parasitic infection. The protective immune responses may 
require action of multiple antibodies against wide range of glycan elements not tested so 
far. However, it is important to remember that high antibody titers against glycan elements 
do not certainly correlate with protection and some anti-carbohydrate Abs might block the 
protective functions of other antibodies or are simply part of the natural antibody 
repertoire of healthy individuals. Thus the comparison of the profiles of Ab responses 
coming from sera of infected, healthy and resistant individuals using the glycan arrays is 
believed to be a promising strategy towards the identification of important glycan antigens.  
First, we have evaluated the specificity of group of monoclonal antibodies induced in S. 
mansoni infected mice and confirmed the functionality of synthetic glycan arrays towards 
screening of antibodies. We have observed the known specificities of certain MAbs towards 
Lewis X, LDN or LDNF glycan motifs highlighting their antigenic character during the S. 
mansoni infection. Moreover, taking advantage of the nature of the synthetic glycan array 
we could additionally draw conclusions about the importance of the presentation of these 
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elements required for antibody recognition. Certain Lewis X or LDN glycan elements could 
be recognized as a simple tri- or disaccharide structures directly coupled to the array 
surface while other in the context of larger N-glycan structures. Additionally, we 
established the minimal epitope for100-4G11 IgM MAb binding and identified new good 
ligand structures.   
Next, we have recorded the anti-carbohydrate IgG and IgM profiles of healthy individuals 
with no previous history of S. mansoni infection. We observed the unique anti-
carbohydrate fingerprints for each individual reflecting the natural antibodies and 
antibodies raised against recent infections circulating in the blood stream of each donor. 
More importantly for our study, healthy donors did not elicit antibodies against any of 
relevant N-glycans present on the array and could be further used as the negative controls 
for the screening of the sera of S. mansoni infected patients. 
 
We have compared the anti-carbohydrate responses elicited from pooled sera of two age-
groups (children and adults) coming from the S. mansoni endemic area. It has been 
demonstrated in the literature that children are far more susceptible for the infection and 
re-infection compared to adults, in who the acquisition of the protective immune responses 
towards parasite occurs however it takes many years of exposure, multiple infections and 
treatments to develop.  
Applying the glycan microarrays, we have observed interesting differences in the profiles of 
anti-carbohydrate IgG antibody responses whereas the IgM did not significantly differ 
depending on the age-group. We found a more pronounced specific IgG binding pattern 
and important differentiation between children and adults based on core β-1,2-xylosylated 
and core α-1,3-fucosylated N-glycan structures, with the adult pool IgG antibodies 
bounding only to certain core β-1,2-xylosylated compounds and none of the core α-1,3-
fucosylated structures that lack xylose. This observation highlighted the antigenic nature of 
both motifs as well as the value of our synthetic arrays to detect specific antibodies in 
different serum cohorts.  
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Discovered differences in the IgG profiles of children and adults may raise a question about 
the role of certain glycans in the modulation of immune responses and acting as a smoke 
screen during the parasitic infections. While some of the glycans are ignored by the mature 
immune system of adults, they can still induce the anti-carbohydrate responses in the 
younger age group. However, based only on the performed microarray-assisted screening it 
is not possible to take clear conclusions about the exact glycan structures involved in the 
modulation or the induction of protective immunity during parasitic infections. However, 
our findings identified important antigenic structures and more importantly have raised the 
interest in continuing with glycan array screening of serum this time with a focus on 
immunoglobulin isotype and subclass that can help to clarify the functional role of the 
detected antibodies.  
 
In Chapter 4, we explored the use of glycans as dendritic cells antigen targeting molecules 
utilizing the endocytic C-type lectins receptors expressed on the cells surface. Targeting 
antigens to dendritic cell subsets is a promising strategy which may enhance the efficacy of 
vaccines and further stimulate antigen presentation and subsequent T cell activation. Based 
on the difference in the recognition of xylosylated versus non-xylosylated biantennary 
compounds G0 and XG0 by the DC-SIGN assigned by the microarray-assisted study 
mentioned before, we have covalently conjugated both N-glycans to the model antigen 
ovalbumin (G0-OVA, XG0-OVA) and studied their targeting properties to murine DCs in 
vitro. An initial binding screening was performed using C-type lectin microarrays. 
Subsequently, we studied the binding of glycoconjugates constructed with fluorescently 
labeled OVA bearing average of 3-4 copies of non-xylosylated and xylosylated biantennary 
glycan G0. As result, we recorded interactions with several C-type lectins, including 
homologues of DC-SIGN, SignR1 and SignR3 previously not detected on glycan microarrays. 
These results highlighted the importance of the multivalent presentation of glycans and 
proteins in the strengthening of the relatively weak interactions between single molecules 
  
 
 
254 
as well as importance of their special orientation and presentation. We also demonstrate 
the utility of CLR microarrays to identify natural glycan ligands. 
We demonstrated that both N-glycans, G0 and XG0 enhanced the uptake and presentation 
of OVA compared to unconjugated protein opening new possibilities for the specific 
delivery of vaccine antigens into DCs. Moreover, presence of the xylose modification had a 
marked impact on the uptake by DCs and subsequent T cell activation as demonstrated by 
CD69 expression and production of IL-2 and IFN-γ measured after 48h. In line with our 
glycan and lectin microarray binding studies, we found that non-xylosylated G0-OVA was 
preferably internalized by murine DCs and led to enhanced T cell activation. In the future, 
the use of this glycan could be explored as targeting molecule which in conjugation to 
model antigen structures could enhance the uptake of all construct by the internalization 
through the interaction of CLRs.  
Knowing that G0 N-glycan enhanced the uptake of glycoconjugate by DCs compared to the 
unconjugated protein or the XG0-OVA, in the last part of this Thesis we prepared gold 
nanoclusters utilizing G0-OVA as a stabilizing and reducing agent. Compared to the 
glycoconjugate alone, G0-OVA-AuNC combines targeting properties of glycan with the 
antigenic properties of OVA and the imaging properties of fluorescent gold clusters in a 
single construct. These glycoprotein gold nanoclusters are highly biocompatible and emit 
size dependent fluorescence in the red spectra. Additionally, the presence of the gold core 
opens the possibility of in vivo X-ray computed tomography (CT) imaging and radiotherapy. 
These nanostructures could be used as a promising candidates for dendritic cell targeting or 
as a specific fluorescent probes.  
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